Cerebral microbleeds as a marker of small vessel disease: new insights from neuro-imaging and clinical studies in stroke patients by Gregoire, SMF
Cerebral Microbleeds as a
Marker of Small Vessel
Disease: New Insights from
Neuro-imaging and Clinical
Studies in Stroke Patients
by
Simone M. GREGOIRE
A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor
of Philosophy in Neuroscience
UNIVERSITY COLLEGE LONDON
INSTITUTE OF NEUROLOGY
DEPARTMENT OF BRAIN REPAIR AND REHABILITATION
Supervisor: Dr David J Werring
2I, Simone M. Gregoire, confirm that the work presented in this thesis is my own. Where information
has been derived from other sources, I confirm that this has been indicated in the thesis.
Simone M Gregoire
3ACKNOWLEDGEMENTS
First of all, I would like to thank University College London for giving me the opportunity to study and
work in a fascinating research and clinical environment. Throughout my graduate studies I have had
the opportunity to attend multiple teaching sessions, ward rounds and seminars which have helped me
to improve my neurological and research skills.
I am indebted to Dr David J Werring, Honorary Consultant Neurologist at the National Hospital for
Neurology and Neurosurgery and Reader in Clinical Neurology at the Institute of Neurology, for his
guidance throughout my studies. His contribution has been invaluable, from designing the studies,
providing training on microbleed identification, and helping with the interpretation and arbitration of the
data. He supervised the writing and editing of our manuscripts and was principally responsible for the
supervision of this thesis, and I am very grateful for his expertise and wisdom.
I am also grateful to Dr Rolf H Jäger for his training in microbleed and white matter change ratings,
designing the studies reported in this manuscript, and providing feedback on the papers and abstracts
submitted. Professor Martin Brown also receives my special thanks for his guidance and support
throughout my studies. His feedback on the manuscripts and presentations given to national and
international conferences has been extremely useful.
I would like to extend my thanks to Dr Constantinos Kallis, statistician at the Institute of Neurology,
who has provided helpful advice on the statistical questions related to these microbleed studies. He
has also helped with revising our manuscripts on numerous occasions.
My thanks also go to the members of the neuropsychology department, Dr Lisa Cipolotti in particular,
and her research assistants, Kirsten Smith, Nava Sokolovsky and Benjamin Maxwell, for their helpful
input on the studies involving neuropsychological data, and their hard work in collecting, analysing and
interpreting the data. Kirsten and Nava also helped with drafting the longitudinal paper which was very
helpful. None of the studies on microbleeds and cognition would have been possible without their
contribution.
I would also like to thank Professor Tarek Yousry, Consultant Neuroradiologist, and John Thornton,
MR Physicist from the Lysholm department of Neuroradiology for sharing their ideas and experience,
and for their valuable feedback on the manuscripts. In the same department, Susan Wakeling,
superintendant, and the Neuroradiology secretaries, Adrienne Wallis in particular, also greatly
contributed to this work.
Our prospective study received contributions from talented and enthusiastic research nurses whose
hard work was greatly appreciated. Vanessa Bassan, who succeeded Olivia Brown, helped with the
recruitment and data collection of the CROMIS patients. Jennifer Godwin and Gillian Murphy provided
useful advice on matters related to the Thames Research Network. They are all to be thanked along
with our research assistant Phillip Rayson for his assistance with the CROMIS follow-ups.
Andreas Charidimou, my successor in the Stroke Research Group and PhD student, contributed to
finalise the paper on microbleeds and ischaemia, and helped in getting some of my last papers
published. I am very grateful for his help during the last stages of my research studies.
Finally I would like to address very special thanks to my previous mentors in Belgium, firstly Professor
Patrice Laloux, head of department of Neurology at CHU Cliniques UCL Mont Godinne in Yvoir, who
guided me throughout my first steps in stroke medicine; secondly, Dr Andre Peeters, head of the
stroke unit at Cliniques universitaires St Luc in Brussels, for sharing his passion for cerebrovascular
diseases and supporting my application for a research degree in the UK. Together, we set up a
multicentre collaboration which led to numerous publications, and still carries on today.
Financial support for the work undertaken was provided by the Stroke Association.
4PRINCIPAL SUPERVISOR: DR DAVID J WERRING
SUBSIDIARY SUPERVISORS: DR ROLF JÄGER
PROFESSOR MARTIN M BROWN
5ABSTRACT
Introduction: A portfolio of studies is presented aimed at understanding the clinical and
pathophysiological significance of cerebral microbleeds (CMBs) in stroke patients. CMBs are
the radiological marker of microscopic haemosiderin deposits on iron-sensitive MRI
sequences (mainly gradient-recalled echo [GRE] T2* MRI). They are common in patients
with cerebrovascular disease and are hypothesised to be a biomarker for brain small vessel
diseases, including hypertensive arteriopathy and cerebral amyloid angiopathy (CAA).
Important questions relating to CMBs include their use as a prognostic marker for
antithrombotic-related intracerebral haemorrhage (ICH) and cognitive impairment. Our
aims were to address the pathophysiological and clinical relevance of CMBs using
longitudinal, case-control and cross-sectional studies.
Methods: Patients were ascertained from prospective databases of admissions to the
stroke service at the National Hospital for Neurology and Neurosurgery and at University
College London Hospital’s (UCLH) NHS Trust. Magnetic resonance imaging data was
collected and analysed for markers of small vessel disease including CMBs. Clinical and
radiological associations of CMBs were determined using appropriate statistical tests.
Objectives: First, ways of improving microbleed detection and reporting were explored
through the development of a visual rating scale (the Microbleed Anatomical Rating Scale,
MARS) aimed at reliably rating CMBs. Second, the prognostic relevance of CMBs was
investigated for antiplatelet-related ICH in a case-comparison study. Third, the detection of
new CMBs over time and the factors that influence this were explored. Fourth, the impact
of CMBs on cognitive impairment was studied in a cross-sectional study. Finally, the
association between CMBs and acute silent ischaemia on diffusion-weighted MRI was
investigated via a multi-centre cross-sectional MRI study of patients with ICH.
Main findings: 1. MARS is a reliable scale with good intra- and inter-rater agreement for
rating CMBs presence and number in any brain location. 2. Lobar CMBs, especially if
numerous, are a risk factor for antiplatelet-related ICH independent of the extent of white
matter changes. 3. CMBs accumulate over time in stroke patients, and the risk is related to
baseline systolic blood pressure. 4. Lobar CMBs are an independent predictor of frontal
executive impairment; this suggests that CAA is a potential underlying contributor to
cognitive impairment. 5. Silent acute infarcts are frequent in patients within 3 months of
ICH, especially in those with probable CAA, and are associated with markers of small vessel
disease severity, including CMBs.
Conclusion: These studies provide new information on detection, clinical impact and
associations of CMBs in stroke patients. They suggest that CMBs have useful roles in
understanding pathophysiology, diagnosis and prognosis in patients with small vessel
diseases. Further studies are required to determine the direct therapeutic consequences of
CMBs, but the present work suggests several promising areas for future research.
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PREFACE
Research in recent years, including this work, suggests that cerebral microbleeds (CMBs)
may have a greater impact on ageing societies than previously thought. Rather than being
focused on one particular aspect or disease related to CMBs, this work covers multiple
aspects of CMBs in the context of cerebral small vessel diseases. I have therefore chosen to
summarise current knowledge on the considerable number of relevant topics in a
comprehensive and detailed introduction. The latter encompasses all relevant topics
covered in this thesis including the definitions and characteristics of the major small vessel
diseases, the radiological methods to detect CMBs, and their clinical implications. In such a
broad spectrum of overlapping topics, repetition is inevitable, but I have tried to keep it to
a minimum. The thorough and wide-ranging historical introduction aims to provide the
essential background to allow an understanding of current concepts of small vessel
diseases and CMBs.
The thesis is in 2 sections; the first is an introduction on small vessel diseases and CMBs,
and the second is a systematic report of the results of our main studies. I then discuss and
summarise our findings in the conclusion and suggest ideas for future research on CMBs. As
a final note, the terminologies used in the thesis are based on the most recent standards
for reporting small vessel diseases and are the most commonly used term to report
microbleeds, ‘cerebral microbleeds’ or CMBs. Like many authors, I used the term ‘cerebral
small vessel disease’ to indiscriminately describe both the neuroimaging correlates and the
underlying small vessel pathology, but created separate sections to describe these aspects
for ease of reading and understanding.
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PART 1: INTRODUCTION TO SMALL VESSEL DISEASE
AND CEREBRAL MICROBLEEDS
Chapter 1 - Small vessel disease: definition and clinical
relevance
The objectives of this chapter are to describe the different types of brain
small vessel diseases, to understand their neuropathology, neuroimaging
and clinical features.
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1.1 Small vessel disease: definitions and classification
The term cerebral small vessel disease refers to a group of pathological processes affecting
the small arteries, arterioles, venules and capillaries of the brain. Two main processes have
been identified: (1) age-related and hypertension-related small vessel arteriopathy
affecting the deep perforating small vessels, and (2) cerebral amyloid angiopathy (CAA),
affecting mainly superficial cortical and leptomeningeal small vessels. The consequences of
these processes on the brain parenchyma are mainly lesions located in the subcortical
structures and include lacunar infarcts, white matter lesions (WML, leukoaraiosis),
intracerebral haemorrhages (ICHs) and cerebral microbleeds (CMBs). Unlike large vessels,
small vessels are not easily visualised in vivo. Therefore, these parenchymal lesions are
used as surrogate markers of the underlying process, and the term small vessel disease has
been adopted to describe these lesions. They are easily detected by neuroimaging and their
characteristic imaging appearances have been extensively studied (Wardlaw et al., 2013).
Clinically, small vessel diseases have a range of presentations and are a leading cause of
cognitive decline and functional impairment in the elderly. They are one of the main targets
for preventive and treatment strategies and should be taken into account in clinical
practice and therapeutic trials.
Anatomically, cerebral arterial small vessels have two origins: superficially, they stem from
the subarachnoid circulation as the terminal vessels of medium-sized cortical and
leptomeningeal arteries, which originate from larger arteries; and at the base of the brain,
they stem directly from the large vessels as small arterial perforators or lenticulostriate
arteries (Pantoni, 2010). These two systems converge towards each other and after having
passed through the cortical layers and the deep grey structures, respectively, merge in the
deepest areas of the subcortical white matter where there is a ‘borderzone’ or watershed
area (Figure 1).
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Figure 1.The brain vasculature and the main disease processes.
A. Coronal post-mortem microangiogram
superficial arteries. Watershed infarcts are located in the parave
border between the lenticulostriate arteries and the short insular penetrating branches (line of dots). From
(Veglio et al., 2009).
B. Schematic representation of the brain vasculature showing the main disease processes that can affect
small vessels: CAA affects capillaries, small to medium
while arteriolosclerosis affects the deep perforating arteries. From
Small vessel diseases are systemic disorders that can affect various organs and areas of the
body. One approach to classify t
1. This thesis will mainly focus on those small vessel diseases where the brain is one of the
main targets and which are the most prevalent forms;
specific interest in the sporadic form of CAA. Both of the
the presence of CMBs in the brain which are the main focus of this work.
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-sized arteries of the leptomeninges and cerebral cortex,
Greenberg, 2006
he different types of small vessel diseases is
arteriolosclerosis and CAA, with a
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Table 1. Aetiopathogenic classification of cerebral small vessel disease
(adapted from Pantoni, 2010)
Type Characteristics Name(s)
Age-related and
hypertension related
arteriopathy (also termed
arteriolosclerosis or
‘hypertensive
arteriopathy’)
Age-related and vascular-risk-
factor-related, affects the deep
perforators. Loss of smooth
muscle cells, wall thickening
Fibrinoid necrosis
Lipohyalinosis
Microatheroma
Microaneurysms
Segmental arterial disorganisation
CAA Amyloid-β deposition in small 
arteries, capillaries and veins
(cortical and leptomeningeal)
Sporadic CAA
Hereditary CAA (Dutch type)
Familial non-Aβ CAA: British, Danish, Icelandic 
Inherited or genetic Inherited small vessel diseases
distinct from CAA
e.g. CADASIL, CARASIL
MELAS
Fabry disease
Small vessel diseases caused by COL4A1 mutations
Hereditary multi-infarct dementia of the Swedish type
Hereditary cereboretinal vasculopathy
Hereditary endotheliopathy with retinopathy
Nephropathy and stroke
Inflammatory and
immunologically
mediated
Heterogeneous, rare, usually
systemic, presence of
inflammatory cells in vessel
walls (vasculitis)
e.g. Wegener’s granulamatosis
Churg-Strauss syndrome
Microscopic polyangiitis
Henoch-Schonlein purpura
Cryoglobulinaemic vasculitis
Primary angiitis of the CNS
Venous collagenosis Pathological appearance of
veins and venules located next
to the lateral ventricles
Other small vessel
diseases
- e.g. post-radiation angiopathy
non-amyloid microvessel degeneration in Alzheimer’s
disease
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1.2 Historical background
1.2.1 History of lacunes and white matter lesions
Since the beginning of the 19th century, physicians and scientists have had great interest in
trying to understand the causes of ischaemic and haemorrhagic stroke. Post-mortem
examination of the brain, a common technique since the 17th century, was used by
pathologists to report neuropathological findings from patients who had died from what
was then called cerebral apoplexia. Amédée Dechambre, a French physician at the
Salpétrière Hospital in Paris, made breakthrough finding in 1838 which was a turning point
in the history of small vessel diseases. He first reported the presence of ‘lacunes’ in stroke
survivors, referring to the empty space or cavity (lacuna in Latin means tiny hole or cavity)
remaining after liquefaction and re-absorption of the core of a small stroke. This generated
a research boom in the field of small vessel diseases. In the following decades many people
reported their own observations of lacunes and other small vessels-related lesions which
set the foundation for our current understanding of small vessel disease pathology (Figure
2). Five years later, Maxime Durand-Fardel (1816-1899) confirmed Dechambre’s
observations and provided a more detailed description of lacunes as healed, small infarcts.
He also described the atrophie interstitielle du cerveau in elderly patients and coined the
term ‘état criblé’ (meaning ‘tissue riddled with holes’) to describe the dilatations of the
perivascular spaces associated with small vessel disease. In 1894, Alzheimer and
Binswanger both described the ‘arteriosclerotic brain atrophy’, a form of vascular dementia
(VaD) characterised by ‘miliary apoplexies’ (most likely multiple lacunar strokes) affecting
the basal ganglia, internal capsule and white matter of the centrum semi-ovale.
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Figure 2. Scientists who provided a significant contribution to the understanding of small
vessel disease, with associated descriptive terms
Pierre Marie (1853-1940) provided the best clinicopathological correlation study of lacunes
whilst working at the Hospice for the Elderly in Bic
famous paper Des foyers lacunaires de désintégration et les différents autres état
cavitaires du cerveau, in which he coined the term
describe a clinical picture characterised by recurrent episodes of motor deficit in the elderly,
often with partial resolution, and accompanied by pseudobulbar palsy, incontinence and
small-steps gait. These are still the hallmarks of
described in modern clinical
showed multiple lacunes as small softenings caused by atherosclerosis.
that the ‘arteriosclerotic brain atrophy’ observed by Alzheimer and Binswanger was
equivalent to Pierre Marie’s
two terms ‘état lacunaire’ and ‘état criblé’ created much confusion in subsequent works. In
the 1960s, Fisher provided illuminating clinicopathological studies describing lacunes as we
know them today: small deep cerebral infarcts seco
disease of small vessels.
Leukoaraiosis, a word derived from the Greek ‘leuko’ meaning white and referring to the
white matter, and ‘araiosis’ meaning rarefaction, was first coined by Vladimir Hachinski in
1987 to describe the radiological images of loss of density of the periventr
1842
Maxime
Durand-Fardel
‘état criblé’ ‘arterioscleroticbrain atrophy’
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être, near Paris. In 1901 he
‘état lacunaire’. This term was used to
the ‘small vessel disease syndrome’
studies (Basile et al., 2006). The brains of these patients
‘état lacunaire’ (Román, 2002). Nevertheless, the use of the
ndary to the hypertensive occlusive
1894 1901 1965
Otto
Binswanger
Pierre
Marie
Charles
Miller-Fisher
‘état lacunaire’ ‘occlusion of aperforating vessel
published his
s
It is highly likely
icular white
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’
‘leukoaraiosis’
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matter associated with hypertension as observed by computerised tomography (CT)
(Hachinski et al., 1987). The introduction of this terminology was aimed at preventing
confusion with a specific pathological process that had no criteria or definition consensus
(so called Binswanger’s disease) and to avoid attributing an explicit clinical cause or
significance to these WML. It is possible that the atrophie interstitielle du cerveau described
by Dechambre was the first description of what became known as leukoaraiosis.
Twenty-five years later, the amount of data on the clinical and pathological correlates of
small vessel disease has enormously increased. The introduction of new imaging
techniques of the brain — initially CT scanning then, since the 1980s, magnetic resonance
imaging (MRI) — has enabled the increasingly sensitive detection of WML in vivo. The use
of improved diagnostic techniques, e.g. diffusion-tension imaging (DTI) and functional MRI
(fMRI), has contributed to a deeper understanding of the pathophysiology of small vessel
diseases and their clinical correlates (Pantoni, 2010). These techniques have also
demonstrated that etiologies other than hypertension can cause lacunes and leukoaraiosis.
There are now a few high field studies showing that small vessels can be seen in vivo (Harb
et al., 2013; Schreiber et al., 2013). The improved definitions and characteristics of small
vessel-related lesions arising from these new developments will be detailed in the next
sections.
1.2.2 History of cerebral amyloid angiopathy
Amyloid is an in vivo material, with a protein fibrillar structure (seen on electron
microscopy), and typical x-ray diffraction pattern, an affinity for some histological stains,
especially Congo red. Disease associated with, or caused by, amyloid, is termed
‘amyloidosis’. Systemic amyloidosis is derived from a plasma protein, while localized
amyloid derives from proteins at the site of the disease. According to Belokrenitzky, the
first observations of dégénérescence amyloide date back from the 17th century and consist
of pathological studies of fragments of spleen, kidney and liver with a tissue aspect
described as waxy (Belokrenitzky, 1911). In 1853, Virchow created the term
dégénérescence amyloide because the substance coloured with iodine had a brown
mahogany colour that resembles the colour of starch (amidon, in French) when treated
with the same metalloid. Wild (Goldberg, 1950; Reddy, 1951) and Wilks (Goldberg, 1950;
Higgins and Higgins, 1950) provided the first descriptions of cases of ‘primitive
amyloidosis’. The proteinic nature of the substance is due to Kekule and Friedrich in 1859
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(Martin, 1947). The association with multiple myeloma was first reported by Askanazy in
1904 (Goltz, 1952).
In the early 20th century, several colorations and techniques were used to detect amyloid in
patients with ‘primitive amyloidosis’, based on the strong affinity of amyloid deposits for
silver and their property to enhance with red Congo and methyl or cresyl violet (Schwarz,
1970). These techniques had only been scarcely used to detect amyloid in the cerebral
tissue. The first reports of cerebral amyloid were made in patients affected by various types
of intracerebral tumours (Fischer and Holfelder, 1930; Morgenstern, 1935). Amyloid was
further detected in patients with Alzheimer’s disease (AD) using Bielschowsky’s silver
technique, based on the strong affinity of the substance for silver (Allsop, 2000). The
technique revealed dense bundles of fibrils within the nerve cells (neurofibrillary tangles)
and numerous focal lesions within the cerebral cortex that were subsequently called ‘senile
plaques’. Bielschowsky stated that the substance found in senile plaques represented
amyloid on the basis of its iodine reaction and metachromasia with methyl violet. In 1942,
Divry published a neuropathological series of 35 brains with dementia and 12 brains with
Alzheimers’ disease and demonstrated the presence of vascular amyloid (‘dyshoric
angiopathy’) within small cortical and/or meningeal vessels in 20 out of 35 demented
patients, with a predilection for the occipital lobes (Divry, 1941). The amyloid present
within vessels had the characteristics of the amyloid substance observed within senile
plaques (e.g. congophilia, birefringence under polarised light and a crystalloid nature). This
confirmed for the first time that the drusige Entartung of Scholz (dyshoric angiopathy)
(Scholz, 1938) and senile plaques were two processes involving amyloid (Divry, 1941). A
decade later, Pantelakis provided the first large clinico-pathological study of 82 patients
with various psychiatric conditions of which a third had vascular amyloid which he called
‘congophilic angiopathy’ (Pantelakis, 1954). In contrast with ‘primitive amyloidosis’,
vascular amyloid was absent in other organs. The amyloid substance was present within
the cortical and/or meningeal vessels and in senile plaques as in Divry’s cases. Pantelakis
noted that all his studies related to patients who had been elderly and demented, and that
the process was independent of the presence and severity of large vessel atherosclerosis.
Subsequent electron microscopic studies revealed that the amyloid in both senile plaques
and vessel walls was composed of extracellular fibrils identical to amyloid fibrils in other
organs (Schlote, 1965; Terry et al., 1964). However, amyloid was not detected in the blood
vessels or the interstitium of any other organs, suggesting a localised form of amyloidosis
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and confirming Pantelakis’ findings (Ishii et al., 1984). Except in rare circumstances (Benson
et al., 1977), amyloid deposition in this condition only affects the brain.
In light of these findings, there are now three recognised forms of amyloid deposition in
the central nervous system. These are the amyloid core of senile plaques, deposits in the
arterial and arteriolar walls (‘congophilic angiopathy’ of Pantelakis), and deposits in the
capillary and arteriolar walls with extension into the surrounding brain parenchyma
(drusige Entartung of Scholz, or dyshoric angiopathy) (Ishii et al., 1984). The latter two
conditions are not mutually exclusive and are together called ‘amyloid angiopathy’. It is
frequently observed in the cerebral vessels of elderly patients and is almost invariable in
AD. More recent immunocytochemical studies have shown that AD amyloid and vascular
amyloid were composed of two different forms of amyloid. The amyloid plaques of AD are
predominantly composed of a 42 amino acid residue fragment (Aβ42) whereas vascular 
amyloid is mostly composed of a more soluble 40 amino acid fragment (Aβ40), suggesting 
different pathophysiological mechanisms for its deposition (Charidimou et al., 2012b).
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1.3 Pathological features
1.3.1 Age-related and hypertension-related small vessel arteriopathy
Hypertensive small vessel disease affects arteries, arterioles of various sizes and capillaries.
Vascular changes induced by hypertension are associated with two recognised forms of
small vessel vasculopathy: (1) arteriosclerosis and (2) atherosclerosis. Both processes are
often combined. The former describes a generalised hardening of the arterial vessel wall
(also termed fibrohyalinosis); the latter is a form of arteriosclerosis with deposition of lipids
(atheroma) in the endothelium (Brandner, 2011). Theoretically, hypertension causes a
forced dilation of resistance vessels, resulting in a loss of autoregulation of the arteries.
This exposes smaller arteries and capillaries to excessive, unregulated blood pressure (BP)
and results in a disruption of the blood-brain barrier and vasogenic oedema (Ferrer et al.,
2008). Chronic hypertension and BP dysregulation causes structural alteration of the vessel
wall with deposition of plasma proteins including fibrin, and damage to the smooth muscle
cells in the media of small arteries. Chronic endothelial damage and platelet activation
trigger the coagulation cascade, the formation of microthrombi and small vessel ischaemia
(Brandner, 2011).
Typically, the vessels affected by small vessel disease are between 40 and 900 mm in size.
The arteries affected are superficial perforating vessels and basal (deep) perforating vessels
(Figure 1). Four types of structural change have been described in hypertension-related
small vessel disease, each of these affecting vessels of different size ranges (Figure 3).
First, atherosclerosis (analogous to a similar process in large arteries) affects distal vessels
of diameter 200-800 mm with atheromatous microplaques causing microocclusions.
Microocclusions can occur within proximal perforating arteries (microatheroma), at their
origin (junctional atheroma) or in the parent artery on the circle of Willis (mural atheroma).
These lesions may cause the lacunae originally described by Fisher (Ferrer et al., 2008).
Second, lipohyalinosis (also termed ‘complex’ small vessel disease) occurs in small, long,
scarcely branching arteries of diameter 40-300 mm (Lammie, 2000; Fisher, 1972). It causes
fibrinoid deposition in the walls of branches arising directly from large vessels e.g. the
lenticulo-striate perforating branches of the middle cerebral artery, the thalamo-
perforating branches of the proximal posterior cerebral artery, the perforating branches of
the basilar artery and the vessels in the periventricular white matter (Warlow et al., 2008).
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Lipohyalinosis is caused by the proliferation of smooth muscle cells from the tunica media,
with effusion of plasma proteins through damaged endothelium leading to thickening of
the basal lamina and deposition of fibro-hyaline material (Brandner, 2011). In addition, the
perivascular space is widened and the surrounding white matter appears gliotic. Finally
fibroblasts replace smooth muscle cells in the vascular wall and collagen is deposited
resulting in unequal resistance to pressure and irregular lumen diameter (Lammie, 2002;
Warlow et al., 2008). These vessel lesions may also be associated with lacunar infarcts.
Third, arteriolosclerosis (also referred to as ‘simple’ small vessel disease) affects vessels of
diameter 50-150 mm and causes hyaline thickening of vessel walls and concentric
fibrohyalinosis (arteriosclerosis). It occurs in the brain but has been observed in other
organs (e.g. kidneys, retinas). This form of microangiopathy is strongly associated with
ageing, diabetes and hypertension, and the microvascular changes of arteriolosclerosis are
likely the cause of WML (leukoaraiosis) in the elderly (Fisher, 1979; Takebayashi and
Kaneko, 1983; Furuta et al., 1991). The pathogenic events start with decreased cerebral
blood flow which induces the accumulation of fibrous collagen in the microvascular walls,
including those within the white matter. Massive collagen deposits accumulate within the
basement membrane and cause narrowing of the lumen and thickening of the
microvascular walls (Brandner, 2011).
Fourth, microaneurysms are lesions resulting from the destruction of the elastic interna of
smooth muscle cells by hyaline connective material. They occur at branching sites in vessels
of 100-300 mm diameter (Spangler et al., 1994). Their rupture causes small globular
haemorrhages which may correspond to CMBs. After rupture, repair processes involving
thrombosis and fibrosis occur, resulting in the creation of fibrocollagenous spheres.
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A B
C D
Figure 3. Pathological features of age-related and hypertension-related small vessel disease
revealed by haematoxylin-eosin staining
A. Microatheroma caused by atherosclerosis (basal ganglia x20) B. Lipohyalinosis (basal ganglia
x100). C. Arteriolosclerosis with fibrinoid necrosis (pons x20) D. Microaneurysm in the right thalamus
of a 70-year-old hypertensive patient who died after developing a massive ICH in the left thalamus.
Fibrinoid necrosis is visible in the aneurysmal wall.
Adapted from Pantoni, 2010
Finally, lacunes are small cavities in the deep brain parenchyma, adjacent to abnormal
small vessels. Three types of lacunae have been recognised on histological specimens
(Poirier and Derouesne, 1985) (Figure 4). Type 1 lacunae are small old infarcts typically
occurring in the putamen, caudate, thalamus, pons, internal capsule and hemispheric white
matter. They have been further subclassified into type 1a and 1b. Type 1a consists of small
cavities containing small vessels and scattered astrocytes while type 1b are incomplete
lacunar infarcts possibly resulting from transient or less severe ischaemia, with loss of
selective cellular elements and relative preservation of astrocytes causing patchy
astrogliosis (Brandner, 2011). Type 2 lacunes are lacunar cavities filled with numerous
haemosiderin-laden macrophages, assumed to have resulted from the re-absorption of
small haemorrhages. They are therefore highly relevant to CMBs, the main focus of this
work. They may result from haemorrhages within small lacunar infarcts or from primary
small haemorrhages. Type 3 lacunes are dilated perivascular spaces (enlarged Virchow-
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Robin space) which have attracted increasing attention as a potential neuroimaging marker
of small vessel disease (see 1.6.5).
1.3.2 Cerebral amyloid angiopathy
CAA is characterised by the progressive accumulation of congophilic immunoreactive β 
amyloid protein in the walls of small and medium-sized (10 to 500 μm) vessels located in 
the cortex and the leptomeningeal space (Corsellis and Brierley, 1954; Pantelakis, 1954;
Surbeck, 1961; Jellinger, 1977; Kemper, 1994). The process is also called congophilic
angiopathy, which refers to the Congo red stain classically used to demonstrate the twisted
β-pleated sheet fibrils of the amyloid substance, which appear with a characteristic ‘apple 
green’ birefringence on histological sections under polarised light (Chao et al., 2006;
Pantelakis, 1954; Richardson, 1985). An example in cerebral cortical vessels is shown in
Figure 5. The affected vessels are predominantly arteries and arterioles, to a lesser extent
capillaries, and very rarely venules (Attems et al., 2011). Intimal changes include fibrous
thickening, onion skin-like changes, and hyaline changes; an example in leptomeningeal
vessels is shown in Figure 6.
A B C
Figure 4. Histological classification of lacunes using haematoxylin-eosin staining
A. Type 1a. Small, old, deep infarct consisting of a small cavity containing occasional small vessels and scattered
macrophages. B. Type 1b. Incomplete infarct, comprising an area of perivascular rarefaction with loss of all
neurones and some oligodendroglia, with patchy astrogliosis. C. Type 2. Presumed small deep haemorrhage, in
which the cavity contains numerous haemosiderin-laden macrophages. The lesion is surrounded by an area of
incomplete infarction.
From Lammie, 2002.
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Figure 5. Histopathological appearance of β
vessels.
A. Congo red stain shows highlighted
stain obtained with polarised light shows the classic yellow
deposits. From Chao
Figure 6. Leptomeningeal vascular changes associated with CAA.
Hyalinous, onion skin
affected (arrows). Congo red staining
light (B) shows amyloid deposits in the media (arrow heads).
From Yamada et al., 1993
The precise origin of vascular amyloid has not been definitely established, the predominant
source appears to be n
by the sequential cleavage of the amyloid precursor protein (APP) by
(Charidimou et al., 2012b
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B
-amyloid deposition in cerebral cortical
Aβ deposits along the vessel walls.
-green birefringence of the
, 2006
-like changes are seen in the intima of the vessel
(A) and observation under polarised
euronal (Smith and Greenberg, 2009). Amyloid β (Aβ) is generated 
β-
). Mutations occurring in the gene encoding APP account for some
B. Congo red
Aβ 
 and γ-secretases 
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rare familial forms of the disease, including the CAA Dutch type. Mutations in other genes
also account for some rare non-Aβ forms of familial CAA. These familial forms of CAA have
provided new insights on how mutations in the APP encoding gene contribute to the
pathogenesis of the disease. In some families, APP gene mutations render Aβ highly toxic to 
vessel wall components and more resistant to proteolytic degradation or clearance from
the brain (Charidimou et al., 2012b). In the sporadic form of the disease, the mechanisms
leading to the deposition of Aβ are not as well understood. Recent studies using transgenic 
mouse models have demonstrated that Aβ is mainly derived from the neurons. Several 
potential mechanisms that may initiate and promote Aβ accumulation have been 
proposed, including: (1) the effects of certain factors that increase the Aβ40:Aβ42 ratio, 
leading to a shift of Aβ from the brain to the vasculature; and (2) an age-related failure of 
the mechanisms of  Aβ clearance, essentially the perivascular  pathways adjacent to 
cerebral small vessels. The failure of drainage along the perivascular drainage pathways
seems to be a key mechanism contributing to CAA pathogenesis (Weller et al., 2009).
Recent evidence suggest that perivascular spaces (also referred to as Virchow-Robin
spaces) may play a key role in the pathophysiology of CAA. Perivascular drainage may be
blocked by the amyloid β deposited in the walls of small arteries, causing dilation of 
perivascular spaces downstream in the underlying deep white matter, even in regions not
directly by CAA pathology (Charidimou et al., 2013c). This hypothesis is supported by the
presence of severe enlarged perivascular spaces (EPVS) in the centrum semi-ovale in CAA-
related ICH (Charidimou et al., 2013c). Certain genetic factors have been identified as
causing a higher risk of CAA and the most important factor is the ApoEε4 allele, which 
influences CAA risk and age of onset (Verghese et al., 2011).  Its effects on Aβ include a shift 
towards the vasculature and reduced clearance. For further information on the complex
pathogenesis of CAA, there is an excellent review article by (Charidimou et al., 2012b).
The reason for the anatomical predilection of Aβ deposition in the cortex and 
leptomeninges is unknown (Jellinger, 1977; Vinters, 1987). In a pathological series of 68
patients with CAA free of ICH, congophilic vessels were found within the cortex in 75.7%, in
the leptomeninges alone in 18.6%, and in the cortex alone in 5.7% (Vonsattel et al., 1991).
The cerebral cortex is constantly affected, with the basal ganglia and the thalamus slightly
affected in some cases. The brainstem, dentate nucleus, and white matter are usually
spared. Furthermore, the CAA process mostly involves the parieto-occipital regions. In a
pathological series of 17 brain specimens collected from patients with ICH and CAA, the
severity of CAA was slightly, but not significantly, more severe in both the parietal and
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occipital lobes than in the frontal lobe and was much less severe in the temporal lobe
(Vonsattel et al., 1991). Vinters and Gilbert also noted that the most severe degrees of CAA
were parieto-occipital (Vinters and Gilbert, 1983). This apparent predilection for the
occipital lobes is not well understood but one hypothesis is that the greater tortuosity of
occipital small arteries impairs perivascular drainage (Attems et al., 2011).
Three forms of amyloid deposition have been recognised in the central nervous system: the
amyloid core of senile plaques, deposits in the arterial and arteriolar walls, and deposits in
the capillary and arteriolar walls with extension into the surrounding brain parenchyma
(perivascular amyloid deposition). The latter two conditions are not mutually exclusive and
together are called amyloid angiopathy. The vascular alterations are progressive and have
been staged by Vonsattel into three grades: (1) mild, (2) moderate and (3) severe
(Vonsattel et al., 1991). In mild CAA, the vessel wall is intact and amyloid is present in the
abluminal aspect of the tunica media only, with amyloid deposition restricted to a
congophilic rim around normal or atrophic smooth muscle fibres. The moderate stage is
characterised by a degeneration of the media with replacement by amyloid and thickening.
Amyloid deposits are segmentally distributed with apparently normal segments of vessel
wall between the amyloid deposits and there are no microaneurysms. Isolated cortical
vessels show discrete transverse bands of amyloid, 10 to 20 µm wide, separated by 10 to
20 µm wide amyloid-free segments (Vonsattel et al., 1991). The amyloid-containing bands
become increasingly closer to one another as vascular bifurcations approach. As the
disease progresses, there is pan-mural accumulation of amyloid and the loss of smooth
muscle cells (Attems et al., 2011). In severe CAA, isolated cortical vessels show continuous
dense deposits of amyloid, especially thick near or at bifurcations (Vonsattel et al., 1991).
There is diffuse and extensive amyloid deposition, foci of fragmentation of the walls, the
presence of microaneurysms, and at least one focus of perivascular leakage with blood
extravasation (Vinters, 1987). Under light microscopy, the deposition of hyaline material in
the vessel wall can be seen causing splitting of the internal elastic lamina and resulting in a
‘double barrel’ appearance, typical of advanced stages of CAA (Pantoni, 2010; Yamada et
al., 1993). At this stage, about 10% of vessels show discrete microaneurismal dilatations,
and the diameter at this level is 50 to 100% greater than elsewhere. These aneurismal
dilatations contain fibrin clots, which arise at points of fibrinoid necrosis of the parent
vessel. Fibrinoid necrosis corresponds to discrete foci or segments of vascular wall
containing eosinophilic material of plasma proteins (Yamada et al., 1993). The exact
pathogenesis of fibrinoid necrosis in CAA is unknown. In severe CAA, breaks in the
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continuity of the vessel wall may allow the infiltration of the wall with blood plasma,
producing focal necrosis of the media (‘plasmatic necrosis’) and rupture of the vessel
(Vonsattel et al., 1991). Cortical vessels with necrotic walls are frequently accompanied by
perivascular fresh microhaemorrhages (haemosiderosis with gliosis), indicating that such
vascular changes could be the pathology underlying CAA-related ICH (Yamada et al., 1993).
These will be described in more detail in Chapter 2.
Figure 7. Histopathological changes of mild, moderate and severe CAA.
A1 – A3. Morphological changes of the vessel walls of leptomeningeal arterioles, as revealed by
haematoxylin-eosins staining. In mild (A1) and moderate (A2) CAA, only minimal structural changes
can be detected. The arrowhead points to amyloid deposition (A2). In advanced CAA (A3), there are
significant structural alterations, with visible double barrelling; the bracket represents the detachment
of the outer part of the tunica media (A3).
C1 – C3. Immunohistochemical detection of beta-amyloid (Aβ) in cortical arterioles. C2 shows 
moderate CAA with pan-mural deposition of Aβ along with Aβ deposition in the surrounding brain 
parenchyma (arrowhead).
From Charidimou et al., 2012a
The alterations to the vessel wall in CAA may occasionally produce stenosis of the lumen
resulting in obliteration and cortical infarcts (Vonsattel et al., 1991). However, in most
cases the lumen remains patent regardless of the severity of the involvement of the wall.
The presence of small infarcts in patients with CAA-related ICH will be studied in Chapter 8.
Mild Moderate Severe
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
38
Thal et al. described two types of sporadic CAA: type 1, associated with the existence of
capillary Aβ, and type 2, where capillaries are spared (Thal et al., 2002). A genetic 
component to these two types is likely, as apolipoprotein E (APOE) ε4 allele is associated 
with CAA type 1 while APOE ε2 is associated with CAA type 2. The location of Aβ deposits 
varies within capillaries and larger vessels; in the former, deposits are located at the outer
basement membrane, whereas in the latter, they occur in the media near smooth muscle
cells.
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1.4 Imaging spectrum of small vessel disease
In neuroimaging the term small vessel disease is often used to describe the radiological
features (in the brain parenchyma) of the underlying pathological process, appearing on
MRI as recent small subcortical infarcts, lacunes, white matter hyperintensities,
perivascular spaces, CMBs and brain atrophy (Pantoni, 2010). In this thesis, description of
the common MRI features will be based on the recent STRIVE standards for neuroimaging
in small vessel disease, an international collaboration aiming at providing Standards for
ReportIng Vascular changes on Neuroimaging (Wardlaw et al., 2013). These standards are
expected to reliably classify most manifestations of small vessel disease seen on
neuroimaging. Lesions with greatest relevance to our work are CMBs, lacunes and white
matter hyperintensities of presumed vascular origin. Their distinction is theoretical as the
occlusion of microvessels is likely to be involved in both processes and in many patients the
two conditions coexist. Lacunes and white matter hyperintensities are often found
together, but in some patients one type of imaging appearance may predominate. They will
be used in our studies as markers of the presence and severity of small vessel disease.
Before detailing the different imaging features associated with small vessel disease, the
important question of how well imaging findings correlate with the underlying pathological
processes need to be addressed. Several imaging-pathological correlation studies have
examined the neuropathological underpinnings of MRI markers of small vessel disease in
post-mortem brains. While in previous studies post-mortem MRI of white matter lesions
was less sensitive than pathology, more recent ones show that post-mortem MRI is a valid
tool for the assessment of subcortical pathologies (McAleese et al., 2012). McAleese and
co-authors demonstrated for the first time that T2-weighted MRI performed on the whole
fixed post-mortem brain provides an assessment of small vessel pathology that is
comparable to an extensive histological assessment of the entire white matter dissected at
7 mm intervals. Moreover, post-mortem MRI was more accurate than routine histological
assessment in frontal, parietal and occipital lobes (McAleese et al., 2012). MRI had lower
sensitivity for the evaluation of small vessel pathology in the deep grey matter and in the
temporal lobes, likely due to MRI scoring methods causing some small lesions (below 5
mm) to be scored in histological assessment and not in MRI assessment, and possibly to the
small volume of temporal lobes. Therefore at least in post-mortem brains, MRI is a valuable
technique for translating pathological findings to the clinical setting. The sensitivity of post-
mortem MRI for WML was evaluated at 86% (range 79-93%) and specificity at 80% (range
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72-88%) (Bronge et al., 2002; Fernando
histopathological correlations of SVD detected on MRI was recently published and showed
the large heterogeneity of
MRI for the detection of small vessel pathology
Common imaging features of small vessel disease according to the definitions and imaging
standards of the STRIVE collaboration are presented below. A summary of the main lesions
related to small vessel dise
1.4.1 Recent small subcortical
Recent small subcortical infarcts cause about 25% of all ischaemic strokes
al., 2013) (Figure 8), typically with a clinical ‘lacunar syndrome’ (see section 1.6.1 below on
ischaemic manifestations)
referred to as silent cerebral infarcts
always accompanied by visible small subcortical infarcts suggesting that MRI sensitivity is
suboptimal to detect these lesions. Recent small subcortical infarcts can evolve in different
ways; some develop into a lacunar cavity while others will become a hyperintensity without
apparent cavitation or, less commonly, will completely disappear. Rates of cavitation range
in studies: from 28% (Potter et al., 2010
their size can be up to 20 mm on axial sections, above the usual size limit (15 mm) for
lacunes of presumed vascular origin
it is not unusual that recent small subcortical infarcts exceed the 20 mm long mark. The
pathogenesis of these infarcts is unclear, but thought to be due associated with oc
of a small perforating artery.
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et al., 2004). A recent systematic review of the
pathological substrates (Gouw et al., 2011). The sensitivity of
in vivo remains to be establish
ase is provided in Table 3 at the end of this section.
infarcts
. They are not always symptomatic in which case they are
. By contrast, symptomatic lacunar strokes are not
) to 94% (Moreau et al., 2012). On MRI sequences,
(Wardlaw et al., 2013). On coronal or sagittal sections,
Figure 8. Recent small subcortical infarct.
The lesion is visible in the right centrum semi
ovale on diffusion-weighted imaging (DWI) MRI
in the axial plane.
ed.
(ISs) (Wardlaw et
clusion
-
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Proposed definitions for the diagnosis of such lesion are that (1) imaging features and
clinical symptoms should be consistent with a lesion occurring within the previous few
weeks (period including the hyperacute and acute stages), and (2) in the territory of one
perforating arteriole, and (3) the lesion should be less than 20 mm in its maximum
diameter in the axial plane. Lesions exceeding that size likely result from the occlusion of
several penetrating arteries and should be classified as striatocapsular infarcts (Wardlaw et
al., 2013). In contrast with lacunes of presumed vascular origin, recent small subcortical
infarcts have no lower size limit because they can be distinguished from perivascular spaces
using DWI MRI.
1.4.2 Lacune of presumed vascular origin
This terminology proposed by the STRIVE international group allows some uncertainty
about the ischaemic or haemorrhagic origin of the lesion and aims at differentiating
lacunes from presumed vascular origin from other small brain cavities. Some cavitated
small infarcts might be caused by non-small vessel disease mechanisms, such as emboli
from atherosclerotic plaques in the carotid arteries or aortic arch (Wardlaw, 2005).
According to the recent STRIVE standards, lacunes of presumed vascular origin are round or
ovoid, subcortical, fluid filled (similar signal as Cerebrospinal Fluid [CSF]) cavity, of between
3 mm and about 15 mm in diameter, consistent with a previous acute small deep brain
infarct or haemorrhage in the territory of one perforating arteriole (Wardlaw et al., 2013)
(Figure 9). On fluid-attenuated inversion recovery (FLAIR) sequence, lacunes of presumed
vascular origin have a characteristic CSF-filled core surrounded by a rim of hypertensity
(Brown et al., 1988; Offenbacher et al., 1996). Variations exist, e.g. absent rim or no
evidence of central cavity fluid (the lesion appears entirely hyperintense).
A B
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Figure 9. Imaging characteristics of a lacune of presumed vascular
origin on MRI
A. Typical appearance of a lacune on FLAIR imaging, consisting of a
hypointense CSF-containing hole (white arrow). B. Corresponding T2-
weighted MRI sequence showing a hyperintense area (white arrow)
surrounded by other smaller white matter lesions.
From Wardlaw, 2010 .
Of note, perivascular spaces entering an area white matter hyperintensity may mimic
lacunes of presumed vascular origin on FLAIR sequences. Perivascular spaces can be
distinguished from lacunes based on their very small size, below the 3 mm diameter cut-off
(Longstreth et al., 1998; Vermeer et al., 2003b). The maximum diameter of lacunes of
vascular origin is 15 mm, smaller than that of recent small subcortical infarcts, because of
tissue loss in old lesions and swelling in new lesions.
1.4.3 White matter hyperintensity of presumed vascular origin
WML are seen on T2-weighted MRI as bilateral, mostly symmetrical hyperintensities (Figure
10). They can appear isointense or hypointense but not as hypointense as CSF on T1-
weighted MRI, depending on the sequence parameters and severity of the pathological
changes. They can also occur in the subcortical grey matter structures (i.e. basal ganglia),
and in the brainstem, where they should be termed subcortical hyperintensities (Wardlaw
et al., 2013). Whether periventricular and deep white matter hyperintensities are part of
the same process and share similar or different pathogenesis, risk factors and clinical
consequences is a matter of debate. The term leukoaraiosis first coined by Vladimir
Hachinski describes the radiological appearance of periventricular attenuation on CT and
was later transposed to appearances on T1 weighted, T2 weighted and FLAIR MRI
sequences. The STRIVE collaboration proposed the term white matter hyperintensity of
presumed vascular origin to exclude WML of other causes (e.g. leukodystrophies, multiple
sclerosis, metabolic or inflammatory disorders). When using CT, the term white matter
hypoattenuation or white matter hypodensities can be used because of the appearance of
the lesions on CT.
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Figure 10. Radiological characteristi
presumed vascular origin
A. Periventricular lesions on CT are termed white matter hypoattenuation or
white matter hypodensities
compatible with white matter hyperintensities of presumed vascular origin
White matter hyperintensities
advancing age and strongly associated with cerebrovascular disease
factors. Their severity varies considerably across individuals from a single focus
extensive involvement
(Inzitari et al., 2009) (Figure 11).
and progression over time is of crucial importance for epidemiological studies to determine
the associations between WML, cognitive and clinical data; their causes and th
new treatments in randomised trials (
Contradictory results between studies exploring the frequency, clinical significance and risk
factors of WML result in part from difference in study m
patient populations, but also in differences in the methods used to evaluate the degree of
white matter damage.
and cognition has been inconsistent across studie
quantifying methods deterring their application (Gao
methods to measure WML developed over the recent decades, visual (qualitative) rating
scales and computational
clinical practice and research studies
Here, I will develop three scales of white matter hyperintensities on MRI scans that appear
most frequently in the literature: the scale by Fazekas, the age related white
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cs of white matter hyperintensity of
B. T2-weighted MRI showing hyperintensities
of presumed vascular origin are increasingly common with
and vascular risk
(focal areas to large confluent areas) of the subcortical white matter
Accurate measurement of WML burden at presentation
Scheltens et al., 1998; Valdés Hernández et al.,
ethods and heterogeneity of
For example, the correlation between white matter hyperintensities
s, possibly reflecting heterogeneity of the
et al., 2011). Among the many
volume measurement (quantitative) methods are used i
.
(mild) to
e effects of
2013).
n routine
matter scale
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by Wahlund and the Scheltens scale. Fazekas and colleagues proposed 2 different scores
for periventricular and white matter lesions on T2-weighted MRI, rated on a 3-point scale:
periventricular score = absent (grade 0), caps or pencil-thin lining (grade 1), smooth halo
(grade 2), irregular lesions extending into the deep white matter (grade 3); and white
matter score: absence (grade 0), punctuate foci (grade 1), beginning of confluence of foci
(grade 2), or large confluent areas (grade 3) (Fazekas et al., 1987). Reliability was tested by
Leys et al and found to be poor (Leys et al., 1990). The rating scale is easy to apply in most
cases, even on poor-quality MRI scans. The second scale is the scale by Wahlund et al, and
is the one used in this thesis (Wahlund, 2001). The degree of white matter changes and
periventricular lesions was jointly rated on a 4-point scale, with scores ranging from 0 to 3.
No anatomical information is provided. Examples of the different degrees of severity based
on this scale are illustrated in Figure 11. The Scheltens scale is a ‘Fazekas plus’ score that
provides 4 scores in a semiquantitative way: periventricular hyperintensities score (0 to 6);
white matter hyperintensities score (0 to 24), basal ganglia and infratentorial
hyperintensity scores (both 0 to 24). As number and size of hyperintensities are taken into
account, the score provides a surface-based volume score, and the detail of individual
regions adds extra anatomical information. The scale had good reliability for assessment of
white matter hyperintensities (Scheltens et al., 1993).
Table 2. Example of rating scale for age-related white matter lesions MRI and CT
From Wahlund et al., 2001
White matter lesions
0 No lesions (including symmetrical, well-defined caps or bands)
1 Focal lesions
2 Beginning confluence of lesions
3 Diffuse involvement of entire region (with/without involvement of U-fibres)
Basal ganglia
0 No lesions
1 1 focal lesion (≥ 5 mm)
2 ≥ 1 focal lesion
3 Confluent lesions
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Figure 11. Illustration of different severity of white matter hyperintensities of presumed
vascular origin on axial T2
(1) Focal lesions (2) starting confluence of lesions and
These images correspond to Wahlund scale grades 1, 2 and 3 respectively
Adapted from Wahlund et al., 2001.
As shown above, these visual scales vary greatly in the degree of complexity in regard to
morphology, size, number and anatomical distribution of WML.
previous comparisons of visual rating scales and quantitative WML volume measurements
showing inconsistent results (Valdés Hernández
volumetric methods of WML assessment were highly correlated in a recent study
comparing the most widely used and well
method using a validated a validated image
2013). WML rating scores and volumes provided near
burden. Therefore the autho
particular characteristics of the population or the circumstances of the data collection,
taking advantage of the strengths of each technique.
approaches have advantages and disadvantages. V
and easier to perform with relatively good reliability on scans from varied modalities or
qualities, and perhaps practically easier to use in clinical an
assisted quantitative volumetric measures are more objective and precise than the rating
scales, but are technically mo
research studies, a combination of qualitative and q
appropriate statistics are used.
total WML volume in volumetric methods, qualitative ratings should be used in studies of
WML in patients with stroke, and if volume
separated from stroke lesions (Valdés Hernández
45
2 3
-weighted MRI sequences.
(3) diffuse involvement of the entire region.
There have been
et al. 2013). Nevertheless, visual and
-validated scale (Fazekas scale) with a volumetric
-processing method (Valdés Hernández
-equivalent estimates of WML
rs suggested that either method can be used depending on the
Both qualitative and
isual rating scales are relatively quicker
d research settings
re demanding and time-consuming (Gao et al.,
uantitative methods is acceptable if
However, because stroke lesions are not separated from
s are measured, strokes will have to be manually
et al., 2013). In this thesis, when severity
four
et al.,
quantitative
. Computer-
2011). In
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of WML was measured, we chose to use the scale developed by Wahlund as a qualitative
method in agreement with these findings. The scale has been validated against volumetric
measurement (van Straaten et al., 2006) and has been widely used in recent studies. It has
provided similar scores on CT and MRI in various regions, with a fair intra-rater reliability (κ 
= 0.48) (Wahlund et al., 2001).
1.4.4 Perivascular space
Perivascular spaces, also known as Virchow-Robin spaces, type 3 lacune - or état criblé
when extensive and located predominantly in the basal ganglia - are visible on T2-weighted
and sometimes on T1-weighted MRI in the basal ganglia and hemispheric white matter.
They can also be seen in the midbrain but rarely in the cerebellum. They have been
recognised pathologically for many years and correspond to interstitial fluid filled spaces
that follow the typical course of a arteries, arterioles, veins and venules as they go through
grey or white matter. They are believed to function as the brain drainage system (Marin-
Padilla and Knopman, 2011; Ozturk and Aydingoz, 2002) and may play a key, previously
underestimated role in the pathogenesis of CAA (Charidimou et al., 2013c). They are
commonly microscopic, but larger spaces become increasingly apparent with increasing age,
especially when located at the basis of the brain (Wardlaw et al., 2013). On MRI, they can
be distinguished from lacunes because they are usually smaller (< 3 mm) and have an
isointense appearance with the CSF on all sequences (Hirabuki et al., 1994). They can
appear linear, when imaged parallel to the course of the vessel, and round or ovoid, when
imaged perpendicular. General enlargement of perivascular spaces is associated with
ageing and hypertension (Bokura et al., 1998), and with other markers of small vessel
disease such as white matter hyperintensities (Doubal et al., 2010)and lacunes (Kwee and
Kwee, 2007). As such, they are believed to be another expression of small vessel disease in
the brain (Doubal et al., 2010). However, the clinical consequences of increased size of
perivascular spaces are not fully understood, and their detection largely dependent on
imaging methods, therefore the term ‘enlarged’ or ‘dilated’ should be avoided (Wardlaw et
al., 2013). Their systematic study in patients with spontaneous ICH suggested that the
distribution of severe large perivascular spaces reflects the underlying arteriopathy type
(Charidimou et al., 2013c). Severe perivascular spaces in the centrum semi-ovale are more
often severe in patients with strictly lobar ICH (ie, probable or possible CAA) while in the
basal ganglia they are associated with markers of hypertensive arteriopathy including WML
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and deep CMBs (Charidimou et al., 2013c). A predilection of numerous visible perivascular
spaces in the centrum semi-ovale rather than the basal ganglia may therefore be an
indicator of CAA.
Figure 12. Axial T2-weighted MRI.
A. and B. Dot-like hyperintensities characteristic of perivascular spaces in the
basal ganglia in a patient with spontaneous deep intracerebral haemorrhage
(ICH). C. and D. Linear hyperintensities typical of perivascular spaces in the
centrum semiovale in a patient with CAA-related ICH. Note that deep brain
regions (e.g. basal ganglia) are not affected (D).
Adapted from Charidimou et al., 2013
1.4.5 Cerebral microbleeds
CMBs are small hypointense lesions that are visible on paramagnetic sensitive MR
sequences such as T2* weighted gradient recalled echo (GRE) or susceptibility weighted
sequences (Figure 13). They are generally not seen on CT, or on FLAIR, T1 weighted or T2
weighted sequences. They are most commonly located in the deep grey or white matter in
the cerebral hemispheres, brainstem and cerebellum, and in the cortico-subcortical
junction. Imaging pathology correlation studies suggest that they correspond to
haemosiderin laden macrophages in perivascular tissue, hypothesized to result from
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vascular leakage from abnormal, fragile small vessels
1999; Shoamanesh et al., 2011
spontaneous ICH because ICH tend to be larger, irregular with a cystic cavity, and are visible
on T1 weighted, T2 weighted or FLAIR sequences
for standardised imaging and reporting of
Study Group (Greenberg et al., 2009b
chapters: chapter 2 is dedicated to the understanding of the pathophysiology,
histopathology and detection of CMBs and Chapter 3 provides an overview of the clinical
implications of CMBs.
1.4.6 Brain atrophy
Brain atrophy is defined as a
macroscopic focal injury such as trauma or infarction
assumed from the enlargement of peripheral (sulcal) and central
relation to intracranial volume and other measures. It can be general or focal, symmetrical
or asymmetrical, or tissue selective (e
substrates of atrophy are neuronal loss, cortical th
arteriolosclerosis, venous collagenosis and secondary neurodegenerative changes
(Wardlaw et al., 2013). An association between the presence and severity of small vessel
disease and brain atrophy has been reported in many studies
Aribisala et al., 2013). Therefore, brain atrophy is a measure that should be included in
imaging studies assessing the effects of the vascular burden in the brain, and it is thought
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(De Reuck et al., 2011
). They can be differentiated from an old small deep
(Wardlaw et al., 2013
CMBs have been published by the Microbleed
). CMBs will be covered extensively in the next
Figure 13. Multiple CMBs in the cortex
and subcortex of a patient with probable
CAA, as shown on a gradient-recalled
echo T2* MRI sequence
reduced brain volume that is not related to a specific
(Wardlaw et al., 2013
(ventricular) CSF spaces in
.g. for the white matter). Neuropathological
inning, subcortical vascular pathology,
(Appelman et al.,
; Fazekas et al.,
). Recommendations
). Tissue loss is
2009;
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to mediate, at least partially, the effects of vascular lesions on cognition (Carmichael et al.,
2010; Mungas et al., 2001).
1.4.7 Other haemorrhagic brain lesions
Spontaneous ICH can be a manifestation of small vessel disease and a recommended term
is spontaneous ICH presumably due to small vessel disease (Wardlaw et al., 2013). These
haemorrhages are non-lobar haemorrhages, in contrast with lobar haemorrhages thought
to be caused by CAA. The Boston criteria for CAA should be used in assigning the likelihood
of underlying CAA in patients with lobar ICHs (see next section) (Knudsen et al., 2001).
Treatable underlying causes of haemorrhages (‘secondary’ haemorrhages’) have to be
identified before a haemorrhage can be classified as spontaneous. Detection of an
underlying arteriovenous malformation, aneurysm, dural arteriovenous fistula or
intracranial venous thrombosis is important because timely treatment can prevent
recurrent ICH. Furthermore, delayed MRI may help identify an underlying tumour or
cavernous malformation. The outcome after spontaneous ICH seems to be worse than after
a bleed secondary to an arteriovenous malformation (van Beijnum et al., 2009), which
justifies thorough investigation for all patients. Investigations into common causes of
secondary ICH include taking further history from patients and others (about trauma or
drug use), routine laboratory tests to search for vasculitis, cirrhosis or neoplasms,
coagulation studies, blood cultures, toxicology, CSF analysis, and imaging studies including
CT, CT angiography and venography, MRI, MR angiography and venography, and cerebral
catheter angiography (Josephson et al., 2010). However, despite the wide variety of
technologies for investigating ICH, there is a shortage of evidence and lack of consensus
about who, when and how to further investigate for a cause underlying ICH (Josephson et
al., 2010). From a systematic review and structured survey of clinicians in three different
countries, younger patient age was the strongest influence on the decision to further
investigate ICH (Cordonnier et al., 2010). Further studies of the diagnostic accuracy of non-
invasive investigations are required, but it is unlikely these techniques will replace the
intra-arterial digital subtraction angiography. Until then, clinicians will be guided by the
patient’s clinical characteristics and condition and their local healthcare resources.
Superficial cortical siderosis is the radiological correlate of the presence of chronic blood
products (haemosiderin) in the superficial layers of the cerebral cortex. It is visible on T2*
weighted GRE and other blood sensitive sequences as a linear hypointensity over the
cortex and should not be confused with the petechial cortical haemorrhagic transformation
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of an infarct. It is likely the radiological sequelae of repetitive bleeding in the subarachnoid
spaces or the chronic lesions following acute convexity SAH. Superficial cortical siderosis
has been included as an additional haemorrhagic lesion in the revised criteria for the
diagnosis of CAA, with potential diagnostic significance equivalent to lobar ICH (Linn et al.,
2010). It can be detected in up to 50% of patients with a clinico-radiological diagnosis of
CAA (Linn, Neurology 2010) and may be associated with transient neurological
manifestations (Charidimou et al., 2012a; Roch et al., 2005).
Convexity subarachnoid haemorrhage (SAH) results from the extension of a lobar
haemorrhage to the subarachnoid space over the cortical surface. The bleeding is localised
to up to several adjacent sulci and is frequently associated with CAA. In a report of 29
patients with atraumatic convexal SAH from a consecutive series of patients with SAH, 9 of
the 13 (69%) patients aged over 60 years had signs of superficial siderosis, white matter
hyperintensities and CMBs, all compatible with the diagnosis of CAA (Kumar et al., 2010).
Convexity SAH and cortical superficial siderosis are recently recognised imaging correlates
of sporadic CAA (Linn et al., 2008) and seem to be characteristic of the disease (Figure 14).
Figure 14. Susceptibility-weighted
imaging (SWI) showing the
coexistence of convexity SAH, cortical
siderosis and CMBs in a patient with
CAA.
The inset demonstrates the linear
hypointensities in the subarachnoid
space suggestive of convexity SAH
(green arrowhead) and focal cortical
siderosis in the adjacent sulcus (white
arrow) surrounded by some CMBs (red
circles).
From Charidimou et al., 2012a
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Table 3. Main lesions related to small vessel disease according to the definitions and imaging standards of the STRIVE collaboration (adapte
↑   Increased signal ; ↓  Decreased signal ; ↔  Iso-intense signal
Recent small
subcortical infarct
White matter
hyperintensity
Example image
Usual diameter ≥ 20 mm
Main characteristic Early identification on
DWI
Located in white matter
Presumed
mechanism of
formation
Occlusion of a small
perforating artery
Likely multifactorial
MRI findings:
DWI ↑
FLAIR ↑
T2 ↑
T1 ↓
GRE T2*-weighted ↔
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Lacune Perivascular space Cerebral microbleed
Variable 3-15 mm ≤ 2 mm
Usually have
hyperintense rim
Most linear without
hyperintense rim
Detected on GRE T2*
sequence,
blooming effect
Healed stage of a small
subcortical infarct or
small deep
haemorrhage
Fluid-filled space
following the course of a
vessel as it goes through
grey or white matter
Likely haemosiderin
macrophages in
perivascular tissue
consistent with vascular
leakage of blood cells
↔ ↔/(↓) ↔
↑ ↓ ↓
↑ ↑ ↑
↔/(↓) ↓ ↓
↑ ↔ (↓ if haemorrhage) ↔
d from Wardlaw, 2013)
≤ 10 mm
round or ovoid,
-laden
↔
↔
↔
↔
↓↓
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1.5 Mechanisms of small vessel disease
Clinical CT-correlated studies and pathological studies of the autopsied brain have found
that systemic hypertension is closely associated with ischaemic lesions such as lacunes or
white matter hyperintensities and with intracerebral haematomas (Fisher, 1972; Cole and
Yates, 1967; Cole and Yates, 1968; Fisher, 2003). The same type of hypertensive small
artery-disease (i.e. involving parenchymal small arteries and arterioles) can cause either
ICHs or ischaemic lesions, depending on the circumstances (Fisher, 1971a). Abnormally high
BP is associated with the increased occurrence of lacunes (Cole and Yates, 1968), and
favours the development of more extensive white matter hyperintensities (Awad et al.,
1986; Almkvist et al., 1992; Breteler, 2000; Wiszniewska et al., 2000; Hirono et al., 2000).
Other cardiovascular risk factors associated with white matter hyperintensities and lacunes
are diabetes mellitus and smoking (Yamauchi et al., 2002). However, in spite of the
recognised risk factors, the pathogenesis of age and hypertension-related small vessel
disease remains incompletely understood. It is unclear why some patients develop white
matter hyperintensities, whilst others also develop lacunes. Hypertension is the major risk
factor for all types of cerebral small vessel disease, but fails to account for all of the risk;
some of the risk remains unexplained by conventional risk factors. For example, CAA is
generally not considered to be related to conventional risk factors, apart from age.
Moreover, small vessel disease occur in normotensive, non-elderly and non-diabetic
patients, and the amount of lacunar infarcts is not directly related to the severity of
hypertension. Therefore, genetic predisposition has been widely speculated upon.
There is now evidence that genetic factors play an important part in the susceptibility of
vessels to damage. For example, a positive family history of stroke is a risk factor for
lacunar stroke. In lacunar stroke patients below the age of 65 years, a parental family
history of stroke is more frequent in patients with silent cerebral small vessel disease
compared with probands without silent small vessel disease, 59% versus 20%, respectively
(Knottnerus et al., 2011). The APOE ε4 allele may confer some risk of developing small 
vessel pathology, as there is evidence that amyloid beta peptide levels are associated with
an increased risk for lacunar stroke in carriers of the APOE ε4 allele (van Dijk et al., 2004). 
APOE ε4 was recently found to have a dose dependent association with sporadic CAA 
(Rannikmae et al., 2013). Furthermore, APOE ε4 carriers are at increased risk for the 
development of subcortical WML, if they are also hypertensive (de Leeuw et al., 2004).
These observations require further confirmation. Additional genetic factors that may play a
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role in the development of small vessel disease and lacunar stroke include homozygosity
for the T allele located at position -7351 within the enhancer region of the tissue
plasminogen activator gene (Jannes et al., 2004) and the D allele of the angiotensin
converting enzyme insertion/deletion genotype (Hassan et al., 2002). There probably are
other genes awaiting identification. The existence of inherited conditions characterised by
hereditary small vessel arteriopathy also supports the idea of a genetic contribution to
small vessel disease. These conditions have been identified in recent years and include
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL), Familial Cerebral Amyloid Angiopathy, Hereditary
Endotheliopathy with Retinopathy Nephropathy and Stroke (HERNS) and Cerebral
Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
(CARASIL). Likewise, mutations in the genes encoding for some vascular basement
membrane components, such as the type IV collagen, have recently been identified as a
cause of brain small vessel disease with haemorrhage (Gould et al., 2006; Vahedi et al.,
2007). All these conditions are of clinical and research interest as ‘pure’ forms of cerebral
small vessel disease, i.e. non-vascular risk factors related. While all of these conditions
affect small vessel and may theoretically manifest as a classic lacunar syndrome, CADASIL is
most likely to do so. CADASIL is a single gene disorder responsible for lacunar strokes and
severe white matter damage that result from a mutation in the NOTCH 3 gene, which
encodes for a transmembrane receptor protein (Joutel et al., 1996; Tournier-Lasserve et al.,
1993). NOTCH 3 is predominantly expressed in vascular smooth muscle cells and its protein
product, Notch-3, is critical for the structural and functional integrity of small arteries
(Viswanathan et al., 2011). Recent research suggests that a mutated gene may convey a
non-physiological and deleterious activity to the Notch-3 receptor or may result in a loss of
function in the receptor. The condition is associated with a systemic arteriopathy with
particularly severe involvement of the cerebral small vessels. The main clinical
manifestations include attacks of migraine with aura, mood disturbances, recurrent ISs and
progressive cognitive decline (Dichgans et al., 1998; Chabriat et al., 1995). The patients
have a combination of small lacunar infarcts, and more diffuse chronic ischaemic changes,
seen on imaging as white matter hyperintensities (leukoaraiosis) that is more extensive
than normal. MRI features highly suggestive of CADASIL are the confluent involvement of
the anterior temporal lobes, which is present in 90% of the patients with CADASIL and is
rare in hypertension-related small vessel disease (Markus et al., 2002). Genetic screening is
now available in many laboratories worldwide. We will end this section on inherited
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conditions or ‘pure’ forms of small vessel disease by describing Fabry disease, an X-linked
lysosomal storage disease with deficient α galactosidase causing endothelial vasculopathy 
and cerebral ischaemia. Up to 0.5% of cryptogenic strokes in patients aged 18 to 55 are due
to Fabry disease and therefore the diagnosis must be considered in all cases of unexplained
stroke in young patients (Rolfs et al., 2013). Active research in the diagnosis and treatment
of these conditions will help to improve our understanding of cerebral small vessel disease.
The mechanisms leading to parenchymal damage in cerebral small vessel disease are
complex and not entirely known, and may result from a combination of genetic and
environmental risk factors. A hypothesised cascade combining both mechanisms was
proposed by Pantoni (2010), and is shown in Figure 15. Pathophysiological events can lead
to haemorrhages, either microhaemorrhages (CMBs) or macrohaemorrhages, and to
ischaemia. The clarification of the pathological changes described above in hypertensive
arteriopathy and CAA allows a better understanding of the mechanisms leading to ICH.
However, the reasons why some vessel ruptures result in major haemorrhages while others
result in microhaemorrhages remains unknown. In CAA, it is believed that differences in
wall thickness are linked with haemorrhage sizes, with thicker walls possibly being more
susceptibole to small extravasations and thus associated with microhaemorrhages
(Greenberg et al., 2009a). With regard to ischaemia, the pathogenesis of ischaemic lesions
associated with small vessel disease remains hypothetical and several mechanisms have
been proposed. Firstly, the vessel lumen restriction leads to a chronic state of
hypoperfusion of the white matter, eventually resulting in the degeneration of the
myelinated fibres as a consequence of repeated selective oligodendrocyte death (Pantoni,
2010). White matter hyperintensities (leukoaraiosis) identified on neuroimaging is believed
to result from this putative mechanism. A second theory is that affected small vessels may
develop acute occlusions leading to acute and focal ischaemia, and tissue necrosis. The
microatheroma obstructs the vessel wall and may be the cause of lacunar infarcts visible on
brain imaging. This mechanism remains speculative due to little supportive pathological
data being available. Other mechanisms have been suggested and include: blood-brain
barrier disruptions (Wardlaw et al., 2003), endothelial dysfunction and a reduced capacity
for endothelial regeneration (Rouhl et al., 2009), oligodendrocyte apoptosis (Brown et al.,
2000), and local subclinical inflammation (Rosenberg, 2009; Simpson et al., 2007).
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Figure 15. Pathogenesis of brain damage resulting from small vessel disease, based on the
hypothesis by Greenberg and colleagues (2009)
From Pantoni et al., 2010
In CAA, the hallmark of the disease is the deposition of Aβ in the vessel walls. As shown in 
section 1.3.2, Aβ derived from the APP can deposit in the brain parenchyma to form senile 
plaques or can be carried into the perivascular space via the interstitial fluid to become
cerebrovascular deposits (Weller et al., 1998). Deposition within the vessel walls causes
injury to the vessel, which can give rise to small infarctions (Kimberly et al., 2009;
Soontornniyomkij et al., 2010) or to rupture of the vessel wall with leakage of blood, and
formation of small CMBs, microaneurysms or larger symptomatic ICHs. Possible
mechanisms to explain small cortical infarctions in CAA will be proposed in Chapter 8. ICHs
are of a subcortical or lobar type due to the predilection of Aβ for the cortical and 
leptomeningeal arteries. The predisposition for haemorrhage likely relates to structural
changes in the vessel walls, with the vessels becoming brittle, fragile and prone to
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microaneurysm formation and leakage (Mandybur, 1986; Vonsattel et al., 1991). Mild CAA
may cause no evident vessel damage, but in increasingly severe CAA, the progressive
degeneration of the tunica media with loss of smooth muscle cells, fibrinoid necrosis,
microaneurysms and leakage of blood products is responsible for haemorrhages
(Mandybur, 1986; Neumann, 1960; Torack, 1975; Okazaki et al., 1979). Risk factors that
predispose to ICH in CAA are the severity of CAA and the presence of fibrinoid necrosis
(Okazaki et al., 1979; Corsellis and Brierley, 1954; Dubas et al., 1985; Gray et al., 1985;
Mandybur, 1986; Regli et al., 1981; Vonsattel et al., 1991; Ferreiro et al., 1989). The
prevalence of CAA-related ICH is considerably lower than the overall prevalence of CAA.
This suggests that only the most severely affected minority of patients with CAA develop
ICH, indirectly supporting a link between CAA severity and ICH.
However, CAA does not necessarily result in ICH. In the study by Vonsattel and colleagues,
11 patients without ICH had severe CAA (Vonsattel et al., 1991). The majority of the brains
from patients with CAA were free of haemorrhage (Yamada et al., 1987), and in addition,
cerebral haemorrhage in CAA may occur without any evidence of vessel wall necrosis
(Julien et al., 1983). It is likely that CAA alone is not sufficient to explain the occurrence of
haemorrhage, thereby suggesting that other mechanisms may play a role. Acute trigger
factors, e.g. sudden increases in BP or minor trauma, may cause the rupture of these
abnormally weak, amyloid-laden vessels (Charidimou et al., 2012b). Other factors may also
interact with CAA to cause lobar ICH, e.g. hypertension, associated neurodegenerative
pathology, use of anticoagulant drugs. Other mechanisms of brain injury in CAA have been
suggested including impaired local regulation of cerebral blood flow (Smith and Greenberg,
2009) and impaired neurovascular unit function (Iadecola, 2004). Similarly to hypertensive
arteriopathy, blood-brain barrier disruption and active inflammation could also contribute
(Attems et al., 2011; Smith and Greenberg, 2009).
Several genetic polymorphisms have been associated with CAA and should contribute in
increasing our understanding of the mechanisms leading to CAA. Polymorphisms in the
APOE gene have been the most studied, but it is only recently that APOE polymorphisms
have been studied in histopathologically confirmed CAA (Rannikmae et al., 2013). An
association between APOE and ICH attributed to clinically confirmed CAA is well described
in case control studies of CAA-related ICH versus CAA-free controls but such studies were
not able to distinguish a genetic association with CAA from an association with ICH. APOE in
vitro influences Aβ conformation, fibril formation and toxicity (Lambert et al., 1998) and in 
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mouse models contributes in vivo to Aβ deposition, toxicity and possibly clearance 
(Holtzman et al., 2000). The APOE gene on chromosome 19 has 3 common alleles – ε2, ε3 
and ε4 – giving rise to 6 different genotypes:  ε2/2; ε2/3; ε2/4; ε3/3 (the wild type, 
occurring in just under two-thirds of people in most populations (Menzel et al., 1983), ε3/4 
and ε4/4. Alleles recognised for an implication in CAA pathogenesis are APOE ε4 and APOE 
ε2; it is believed that the former enhances amyloid deposition in cerebral blood vessel walls 
(possibly by increasing aggregation and/or impairing clearance) while the latter promotes
haemorrhage from amyloid laden blood vessels by increasing specific CAA related
vasculopathic changes including fibrinoid necrosis (Greenberg et al., 1998; Holtzman et al.,
2000; McCarron and Nicoll, 2000; McCarron et al., 1999). A recent meta-analysis of
published studies of the associations between any genetic polymorphism and
histopathologically confirmed CAA showed a significant association of APOE ε4 with CAA 
(Rannikmae et al., 2013); the odds of having CAA more than doubled for ε4+ genotypes 
independently of ethnicity and dementia status. More so, the risk of having CAA increased
with increasing dose of the ε4 allele (ε4-- versus ε4+- versus ε4++). There was no significant 
association between APOE ε2 and CAA. Preliminary evidence of other polymorphisms was 
also reported but results should be replicated in other studies (Rannikmae et al., 2013). It is
likely that both CAA and AD share this ‘mechanistic’ effect of APOE ε4. In Alzheimer’s, 
neurodegeneration may arise from additional causes, ie, via specific neurotoxic effects of
APOE, independent of interactions with Aβ (Verghese et al., 2011).  
With regards to ischaemia, white matter hyperintensities (leukoaraiosis) of presumed
vascular origin are very common in patients with CAA. The pathogenesis of leukoaraiosis in
CAA probably involves chronic hypoperfusion of the vulnerable periventricular white
matter and disruption of the blood-brain barrier due to amyloid in the overlying cortical
small vessels (Charidimou et al., 2012b). Another possible mechanism is the accumulation
of small ischaemic lesions or microinfarcts. Neuropathological studies have also
demonstrated the presence of small cortical infarcts in the brains of patients with CAA
(Olichney et al., 1995; Cadavid et al., 2000; Haglund et al., 2006b). These can be detected in
vivo using MRI, an imaging technique very sensitive to acute ischaemia. This has potential
implications for cognitive impairment and disability in patients with CAA and leukoaraiosis.
We conducted a neuroimaging study in patients with CAA-related ICH and other types of
spontaneous ICH to confirm this intriguing phenomenon in vivo (see Chapter 8). Possible
mechanisms to explain the presence of ischaemic lesions in CAA will be suggested.
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1.6 Clinical spectrum of cerebral small vessel disease
Cerebral small vessel disease can present as a stroke or cognitive decline, or can have few
or no symptoms (Wardlaw et al., 2013). Small vessel disease frequently coexists with
neurodegenerative disease and can exacerbate cognitive deficits, physical disabilities and
other symptoms of neurodegeneration. As such, it is a common, often insidious and
potentially devastating disorder and an important cause of morbidity and mortality,
particularly in the elderly. It accounts for up to a third of all ISs and for about three quarters
of all haemorrhagic strokes. It is also the predominant underlying cause of silent cerebral
infarcts. In this section, we will describe the ischaemic and haemorrhagic manifestations of
small vessel disease, detail the clinical spectrum of CAA and review the association
between small vessel disease and cognitive impairment.
1.6.1 Ischaemic manifestations
Manifestations of ischaemia related to small vessel disease are secondary to the
development of recent small subcortical infarcts, lacunes and white matter hyperintensities
of presumed vascular origin and perivascular spaces.
Recent small subcortical infarcts
Recent small subcortical infarcts attributed to small vessel disease, when symptomatic, will
cause a lacunar stroke syndrome. They are thought to account for around 25% of all ISs
(Wardlaw et al., 2009) and are associated with increasing age and hypertension. Infarction
occurs in the territory of one perforating arteriole with symptoms consistent with a
radiological lesion dating from the previous few weeks. They usually present with a sudden
onset of motor and/or sensory deficits involving at least two out of the three domains of
the ipsilateral face, arm or leg. As a general rule, lacunar syndromes lack findings such as
aphasia, agnosia, neglect, apraxia, or hemianopia (so-called ‘cortical’ signs). Monoplegia,
stupor, coma, loss of consciousness, and seizures also are typically absent. More than 20
lacunar syndromes have been described. Five have been validated as being highly
predictive for the presence of lacunes radiologically (Table 3). The commonest location for
each subtype is shown, although symptoms and location do not correlate well and it is not
possible to predict the location from the clinical presentation. Of note, larger striato-
capsular infarctions represent a separate catergory with distinct cause and should not be
attributed to small vessel disease. Similarly, infarcts in the anterior choroidal artery are
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aetiologically distinct, identifiable by their location in the caudate nucleus head, and by
their shape (mostly comma shaped). Nevertheless, a lacunar stroke syndrome can only be
diagnosed in a patient with a classical lacunar syndrome and compatible brain imaging
findings based on standardised criteria. Long-term deficits are possible and usually are
subtle, mainly in physical and cognitive function.
Table 4. Typical lacunar stroke syndromes verified by autopsy
Clinical Syndrome Commonest location Relative prevalence
Pure motor stroke Internal capsule, pons 45%
Sensori-motor stroke Thalamus, capsule 35%
Ataxic hemiparesis Pons, internal capsule 10%
Pure sensory stroke Lateral thalamus, corona radiata 5%
Dysarthria-clumsy hand Upper pons, corona radiata 5%
Lacunes and white matter hyperintensities of presumed vascular origin
Lacunes of presumed vascular origin are frequently seen on imaging in elderly patients with
no symptoms. Long-term imaging reveals that they are found in 8 to 28% of the general
population. Lacunes are associated with an increased risk of stroke, gait impairment, death,
and more than double the risk of stroke recurrence and dementia, including AD (Choi et al.,
2012; Santos et al., 2009; Snowdon et al., 1997; Vermeer et al., 2007; Norrving, 2008;
Arboix and Marti-Vilalta, 2009).
White matter hyperintensities of presumed vascular origin are seen in 7% of the normal
population aged between 50 and 69 years, and 17% of the population aged between 70
and 89 years (Barber et al., 1999; Breteler, 2000; Wiszniewska et al., 2000). In other
populations, they are seen in 7% of IS patients, 40% of patients with dementia and 60% of
patients with vascular dementia. They are more frequent and more severe in vascular
dementia and in stroke without dementia than in AD, Lewy Body dementia or controls
(Aharon-Peretz et al., 1988; Almkvist et al., 1992; Barber et al., 1999; Charletta et al., 1995).
For instance, Erkinjuntti et al. (1987) have found white matter hyperintensities in all their
patients with vascular dementia and only in a third of patients with AD. They are associated
with covert neurological and cognitive symptoms and physical difficulties such as gait
disturbance (de Laat et al., 2011; Windham et al., 2012; Saini et al., 2012; Haley et al., 2009;
Inzitari et al., 2009). Similarly to lacunes, white matter hyperintensities are a risk factor for
subsequent stroke. In a systematic review of 46 longitudinal studies and of 22 studies
included in a meta-analysis, white matter hyperintensities increased the risk of stroke by
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3.5-fold (Debette and Markus, 2010). The extent and progression of white matter
hyperintensities predicts the risk of a subsequent stroke resulting from arteriolosclerosis
(Yamauchi et al., 2002).
Patients with widespread small vessel disease often have severe white matter
hyperintensities, multiple lacunes and/or multiple perivascular spaces. The condition was
originally referred to as état lacunaire or état criblé (see section 1.2.1). Clinically, they have
recurrent episodes of motor deficit with gait apraxia, impaired balance, and an increased
risk of falls. Other symptoms include pseudobulbar palsy and incontinence. Global
intellectual deterioration and executive dysfunction are a characteristic feature. The
deterioration in gait is associated with the progression and severity of small vessel changes.
The mechanisms underlying the gait disturbance remain unclear, although a correlation
with frontal lobe atrophy and with WML could imply an interruption of circuits involving
the medial frontal lobe that are important in gait control. Physiotherapy to prevent falls has
been shown to improve gait and reduce the number of hospitalisations.
1.6.2 Haemorrhagic manifestations
Cerebral microbleeds
CMBs were originally thought to be asymptomatic markers of small vessel disease.
Extensive research in the past decade showed that they are associated with other
manifestations of small vessel disease and AD (Cordonnier et al., 2007; Vernooij et al.,
2008b), and as such, may play an important role in cognitive impairment. Their association
with cognitive impairment is increasingly recognised although the mechanisms of this
association, i.e by structural damage or dysfunction, are not clearly understood. When
confined to the cerebral lobes only, they are a key marker of the presence of CAA; the
presence or absence of strictly lobar CMBs has been included in the diagnostic criteria for
CAA (Knudsen et al., 2001). CMBs will be extensively studied in the next chapter.
Intracerebral haemorrhage
Major spontaneous haemorrhages are another correlate of brain small vessel diseases and
their location may be an indicator of the underlying microangiopathy. Deep haemorrhages
in the basal ganglia and deep white matter have been associated with hypertensive
microangiopathy (Fisher, 1971a), whereas lobar haemorrhages are more likely to represent
the consequences of the rupture of small vessels affected by CAA, especially in the
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However, the two types of microangiopathies may coexist, and the presence of a deep or
lobar macrohaemorrhage does not exclude the presence of one underlying
microangiopathy or the other.
described in section 1.6.3.
shown in Figure 16. Comprehensive guidelines for the diagnosis and management of ICH
have been published previously
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et al., 1984). In a review of 15 cases of AD, Mandybur found CAA in 13 cases and noticed a
correlation between the presence of amyloid-rich plaques and amyloid angiopathy
(Mandybur, 1975). Reported prevalences of CAA in AD vary from 88 to 92%. However, in
AD, there is no correlation between the formation of neurofibrillary tangles, the neuritic
plaques and the degree of CAA. Vascular amyloid seems to occur independently of plaque
formation (Haglund et al., 2006a). Furthermore, different amino acid residue fragments
compose neuritic plaques and CAA amyloid (Aβ42 and Aβ40, respectively), suggesting 
different mechanisms for their processing, accumulation and clearance (Vonsattel et al.,
1991).
Outside the context of AD, sporadic CAA is generally recognised in life by the occurrence of
lobar cerebral haemorrhages (Sveinbjornsdottir et al., 2008). Since the 1960s, CAA has
been suspected as a cause of ICH since not all cases of spontaneous ICH could be explained
by hypertension. Neumann was the first to report a fatal cerebral haemorrhage due to
amyloid angiopathy (Neumann, 1960). The case was a 46-year-old woman with severe
amyloid angiopathy and numerous peculiar senile plaques, who died of a lobar ICH in the
left parietal lobe. Fifteen years later, Torack cited two necropsied cases of amyloid
angiopathy with massive ICH (Torack, 1975). Jellinger found 8 cases of massive ICH due to
CAA among 400 cases of non-traumatic ICH (Jellinger, 1977); seven of them were lobar
haemorrhages and one was a basal ganglia haemorrhage, and all had senile plaques and
were demented. Okazaki et al. (1979) reported nine cases of massive lobar haemorrhage
due to amyloid angiopathy (Okazaki et al., 1979), with all of them associated with senile
plaques but only one was clinically demented. All of the cases reported were lobar
haematomas. In 1999, Tanaka and colleagues conducted an MRI-histology correlation study
of patients with and without intracerebral haematomas. They used T2-weighted MRI and
T2*-weighted EPI MRI to detect the ICH and small areas of chronic haemorrhage. Of the 30
patients with ICH, 16.7% were normotensive and normotensive patients also had a high
proportion of small chronic haemorrhages (10.3%). Therefore, the authors concluded that
other factors besides hypertension were involved in the pathogenesis of cerebral
microangiopathy and consequent haemorrhage and they suggested that CAA may be the
underlying cause. Nowadays, CAA is considered to be an important cause of lobar
haemorrhages and dementia in the elderly (Haglund and Englund, 2002). Based on
histopathological examination of 84 cases of spontaneous ICH, Hinton and colleagues
estimated that 5 to 10% of all spontaneous ICHs are due to CAA (Hinton et al., 1984). The
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haemorrhages are typically lobar and multiple (Gudmundsson et al., 1972; Neumann,
1960).
As demonstrated in the above studies, CAA haemorrhages are peripherally situated in the
cortex, subcortex and leptomeninges, reflecting the distribution of the underlying
microangiopathy. The disease is most likely to cause lobar (cortico-subcortical)
haemorrhages, especially in the occipital and temporal lobes (Rosand et al., 2005), less
commonly in the cerebellum (Bruni et al., 1977; Lee and Stemmermann, 1978) and rarely in
the deep or brainstem structures. There have been case reports of basal ganglia
haemorrhages in normotensive patients with CAA involving the leptomeninges and
parenchyma (Ferreiro et al., 1989). In most such instances, other causes such as
hypertensive vascular disease must be considered as a more likely cause of haemorrhage.
Another characteristic of CAA-related ICH is that the haemorrhages easily rupture into the
subarachnoid space (Yamada et al., 1993). SAH associated with CAA is usually secondary to
ICH (Yamada et al., 1993) and can be explained by the heavy infiltration of subarachnoid
leptomeningeal and cortical blood vessels common in CAA.
Clinically, patients with lobar haemorrhages present with an acute stroke syndrome, with
focal neurological deficits that may be associated with headache, nausea, vomiting,
seizures and/or an altered level of consciousness, especially in large lobar bleeds. This
presentation does not differ from the presentation of lobar haemorrhages secondary to
other causes, e.g. arteriovenous malformations, aneurysms and tumours. Patients with
secondary SAH due to CAA-related ICH have a higher incidence of headache, vomiting and
may have nuchal rigidity. First-ever ICHs in CAA may be clinically mild, but this is
counterbalanced by a high risk of recurrent lobar haemorrhages - often in the same lobe as
the initial bleed - and by a higher severity of subsequent haemorrhages (Passero et al.,
1995). The risk of recurrence in the long term is about 10% per year in elderly cohorts, a
higher incidence than in deep ICH (Passero et al., 1995). Negative prognostic factors for a
good recovery after lobar ICH are age and a larger haematoma size (Charidimou et al.,
2012b).
The relationship of CAA to ICH is not always certain even when CAA is suspected or when
its presence has been pathologically demonstrated. Reports have shown a surprising
paucity of parenchymal lesions in patients with CAA (Scholz, 1938), whilst in other reports
there was a lack of association between the sites of haemorrhage and the location of the
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most severe CAA lesions (Vinters and Gilbert, 1983). Multiple factors have been associated
with ICH in CAA, including: hypertension (Neumann, 1960; Okazaki et al., 1979), traumatic
brain injury (Greene et al., 1990), inflammatory vascular disease (vasculitis or
granulomatous angiitis) (Murphy and Sima, 1985; Probst and Ulrich, 1985; Shintaku et al.,
1986) and microaneurysms (Bruni et al., 1977; Okazaki et al., 1979; Vonsattel et al., 1991).
ICHs occuring in elderly patients may be due to CAA but also to causes other than CAA such
as coagulopathies, anticoagulant medications, vascular malformation, or neoplasms.
Therefore, in elderly patients without any identifiable vascular disease, it may be difficult to
attribute the bleeding to CAA unless specific diagnostic criteria are applied or pathological
findings prove the diagnosis.
The most commonly used criteria for CAA diagnosis are the Boston criteria (Table 5). The
diagnosis of probable or possible CAA is based on clinico-radiological criteria in the absence
of a neuropathological confirmation. The diagnosis of probable CAA requires all of the
following: age ≥55 years, the presence of multiple haemorrhagic cerebral lesions confined 
to cortical or cortical-subcortical (lobar) regions, and the exclusion of secondary causes of
ICH. The specificity and sensitivity of the Boston criteria were tested in a population of 39
patients with a clinical and radiological diagnosis of probable CAA against a
neuropathological diagnosis (Knudsen et al., 2001). In this study, the specificity of the
criteria was 100% (all patients with a probable CAA identified on clinical and imaging
grounds had a positive CAA pathology). However, the criteria missed the diagnosis of CAA
in 16 out of 29 patients, corresponding to a sensitivity of 44%. Unfortunately, the results of
this study are not generalisable to current clinical practice as an important fraction of the
patients included did not have a gradient-recalled echo (GRE) T2* MRI, and the severity of
the CAA pathology was therefore underestimated by imaging. Recently, the sensitivity of
the Boston criteria were improved in a study of Dutch-type hereditary CAA through the
greater use of GRE T2* MRI, especially when strictly lobar CMBs were included in the
criteria (van Rooden et al., 2009). Superficial siderosis and convexity SAH, both frequent in
CAA-related ICH and less common in other forms of ICH, have been shown to increase the
sensitivity of the Boston criteria without loss of specificity (Linn et al., 2010). A schematic
representation of the clinical manifestations of sporadic CAA is represented in Figure 17. Of
note, CAA also occurs in rare genetically transmitted diseases including hereditary cerebral
haemorrhage with amyloidosis as described in Icelandic and Dutch families (Esiri and
Wilcock, 1986; Gudmundsson et al., 1972; Vinters and Gilbert, 1983; Yamada et al., 1987).
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Table 5. Classic and modified Boston criteria for the diagnosis of CAA
1. Definite CAA
Full post-mortem examination
demonstrating:
Lobar, cortical or cortical-subcortical haemorrhage
Severe CAA with vasculopathy
Absence of other diagnostic lesion
2. Probable CAA with supporting pathology
Clinical data and pathological tissue
(evacuated haematoma or cortical biopsy)
demonstrating:
Lobar, cortical or cortical-subcortical haemorrhage
Some degree of CAA in specimen
Absence of other diagnostic lesion
3. Probable CAA
Clinical data and MRI or CT demonstrating: Multiple haemorrhages restricted to lobar, cortical or
cortical-subcortical regions (cerebellar haemorrhage
allowed)
*[OR single lobar , cortical or cortical-subcortical
haemorrhage and focalb or disseminatedc superficial
siderosis]
Age ≥ 55 years
Absence of other cause of haemorrhagea
4. Possible CAA
Clinical data and MRI or CT demonstrating: Single lobar, cortical or cortical-subcortical haemorrhage
*[OR focalb or disseminatedc superifical siderosis]
Age ≥ 55 years
Absence of other cause of haemorrhagea
a Other causes of lobar haemorrhages: head trauma, haemorrhagic transformation of an ischaemic
stroke, arteriovenous malformation, haemorrhagic tumour, warfarin therapy with INR >3, vasculitis;
b Focal siderosis: siderosis restricted to 3 or fewer sulci;
c Disseminated siderosis: siderosis affecting at least 4 sulci
As mentioned in section 1.5, it is also clear that CAA is related to cerebral infarcts (Jellinger,
2002) and white matter pathology (Gravina et al., 1995). Radiologically, amyloid deposition
has been associated with CMBs on MRI, and with the presence of cerebral ischaemic
changes such as WML and microinfarcts. This will be a specific topic in Chapter 8.
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Figure 17. Schematic representation of the spectrum of haemorrhagic and ischaemic
manifestations of sporadic CAA visible on MRI.
From Charidimou et al., 2012a
1.6.4 Cognitive impairment
Epidemiology
Cognitive impairment is one of the greatest challenges facing ageing societies. There are
currently about 800,000 people with dementia living in the UK and the disease costs the
economy £23 billion a year (Department of Health, 2013a). By 2040, the number of people
affected is expected to double and the costs are likely to treble. A quarter of hospital beds
are occupied by people with dementia. The department of Health’s Dementia Challenge
was launched in 2012 to achieve better awareness of dementia, increase early diagnosis
rates and high quality treatment (Department of Health, 2013b). There are two common
causes of dementia: (1) AD (causing up to 60% of cases of dementia) and (2)
cerebrovascular disease (causing up to 20% of cases of dementia). The latter is generally
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termed vascular cognitive impairment (VCI), a term coined by Hachinski to describe
individuals with cognitive difficulties arising from vascular causes (Hachinski, 2007; Rincon
and Wright, 2013). Following a stroke, two thirds of patients have some degree of cognitive
impairment (Hachinski et al., 2006), which reverses in some patients (Snaphaan and de
Leeuw, 2007) but progresses to frank dementia in about a third (Barba et al., 2000).
Therefore, early recognition and treatment of VCI are crucial to prevent progression from a
‘brain-at-risk’ stage, to ‘cognitive impairment-no dementia’ to the end stage of dementia
(Bowler, 2005). Without appropriate preventive measures there is a good chance that one
in three people will have a stroke and/or develop dementia during their lifetime (Seshadri
et al., 2006). Mounting evidence indicates that vascular and neurodegenerative processes
underlying AD and VCI are synergistic, and that the two conditions are probably not
separate entities. The frequent co-morbidity of lesions of Alzheimer’s disease and cerebro-
vascular disease suggests that neurovascular dysfunction could have a major role in the
pathogenesis of Alzheimer’s disease that by some authors, has even been considered a
primary vascular disorder (de la Torre JC, Stroke 2002). The interaction between vascular
and degenerative pathologies will be further explained later in this chapter (see pages 70-
71 and pages 132-134).
Pathogenic factors and mechanisms
Small vessel disease, which affects the brain diffusely, has been the subject of extensive
research as a cause of cognitive impairment, for several reasons: firstly, small vessel
disease is very common, and the commonest vascular cause of dementia; secondly, this
type of cognitive impairment has relatively homogeneous and clearly defined clinical and
radiological features that are potential targets for implementing therapeutic and
prevention strategies; and thirdly, with cerebrovascular risk factors as the main cause, early
therapeutic intervention might prevent its progression to dementia. Several vascular risk
factors (hypertension, hyperlipidaemia, diabetes) and behavioural factors (obesity,
sedentarity) have been associated with cerebrovascular disease and dementia in middle-
aged and older adults in some studies (O'Donnell et al., 2010). Diabetes and hypertension
alone predicted cognitive decline at 6- (Knopman et al., 2001) and 20-year follow-up
(Kilander et al., 1998) in otherwise healthy middle-aged individuals. Another study found
that diabetes type 2 affects the brain network by disrupting white matter brain
connectivity, leading to less efficient transfer of information between brain regions
(Reijmer et al., 2013). Several pathogenic mechanisms have been suggested including
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dysfunction through pathways mediated by Aβ, BBB alterations (Iadecola et al., 2009), 
microembolic complications from atrial fibrillation (AF) (Puccio et al., 2009) and potential
roles of inflammation (Yamamoto et al., 2005). Active antihypertensive treatment was
shown to reduce the risks of dementia (45%) and cognitive decline (34%) associated with
recurrent stroke (Tzourio et al., 2003), and the HYVET-COG trial findings support the finding
that antihypertensive treatment reduces the risk of dementia (Peters et al., 2008).
However, the complex interaction between risk factors severity, WML and load of small
vessel disease, VCI and dementia is such that the above associations have been
inconsistent between studies. Moreover, there are no unequivocal preventive studies that
have established a cause and effect between these. Therefore, it is possible that
therapeutic interventions aiming at reducing a person’s stroke risk may reduce their risk of
developing VCI, but this will need to be confirmed in large prospective studies.
Cerebrovascular lesions related to recent small infarcts, lacunes and white matter
hyperintensities cumulatively represent a major contributor to cognitive impairment and
physical disability in elderly persons (Thal et al., 2012). Mechanisms have been proposed to
understand the cumulative effect of these lesions on cognition, based on the concept of
neural nets and brain plasticity (Bowler, 2005; Saczynski et al., 2009). In rich neural
networks, disruptions in one circuit following a focal vascular injury may be compensated
for by the use of alternative neural connections. Consequently, an initial detriment in
efficiency and processing speed will be temporarily observed, and will improve with
practice, i.e., learning. As such, the ischaemic damage caused by a few early lesions
(particularly in the white matter) may go unnoticed in the absence of clinical deficits;
however, as the disease advances, the capacity of the neural net to compensate for the
continuing loss of connections decreases. This results in devastating consequences of
lesions that occur late in the disease process. Therefore, neural nets offer the potential for
recovery but this potential decreases with rising numbers of lesions (Bowler, 2005). The
burden of vascular lesions is an important pathogenic factor (Schneider et al., 2003;
Vermeer et al., 2003a), as is their location (Benisty et al., 2009; Carrera and Bogousslavsky,
2006; Saczynski et al., 2009). Moreover, this concept would advocate that the reason why
frontal executive functions are most prominently affected in VCI (Kramer et al., 2002; Prins
et al., 2005) is because of their dependency on complex neural nets (Bowler, 2005;
Cummings, 1995). In VCI, the neural nets involved in cognition, memory and behaviour will
be affected; these are thalamo-cortical, striato-subfrontal, cortico-subcortical and the
limbic systems (Jellinger, 2013a).
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Morphological substrates of vascular cognitive impairment
The increasing use of MRI has allowed the identification of markers of cerebral vascular
disorders that are linked with VCI; these are lesions related to atherosclerosis of large and
medium size arteries, small vessel disease and CAA (Ferrer, 2010). As a marker of small
vessel disease, lacunar strokes have been associated with an increased risk of cognitive
decline and dementia in longitudinal studies (Miyao et al., 1992; Samuelsson et al., 1996;
Yamamoto et al., 2002), and in a meta-analysis (Makin et al., 2013). Because they are part
of the spectrum of cerebral small vessel disease, they may carry a higher risk of cognitive
impairment than would be expected from their small size, and associated small vessel
disease may increase their impact on cognition (Makin et al., 2013). Silent cerebral infarcts
incidentally found by CT or MRI have also been linked with cognitive impairment (Vermeer
et al., 2007) and poorer long-term outcomes (Pantoni, 2003), suggesting that the term
‘silent’ may be misleading.
Likewise, it is well established that WML are associated with cognitive decline (Jokinen et
al., 2005) and dementia (Pantoni, 2010; Jokinen et al., 2009; Prins et al., 2004). In the LADIS
study, severe white matter hyperintensities independently and strongly predicted rapid
global cognitive decline of older adults with non-disabling complaints three years later
(Inzitari et al., 2009). A correlation was found between progression of white matter lesion
load and a decline in cognitive performance (Schmidt R, Stroke 2007), particularly affecting
information processing speed (van Dijk et al., 2008). These observations were recently
confirmed in a large pathological population-based study of 456 brains, including brains
with pathological features of AD, cerebral atrophy and vascular disease; pathology was
correlated to dementia status based on information obtained prior to death (Savva et al.,
2009). In this study, the presence of small vessel disease was associated with a more than
two-times increased risk of dementia at the age of 75 years. A threshold of vascular
damage, necessary for the expression of subtle cognitive deficits, was demonstrated in
elderly subjects who have otherwise a few cerebrovascular lesions without cognitive
deficits (Jellinger, 2013a; Pantoni, 2010).
Finally, there is increasing evidence that CAA is an important contributor to cognitive
impairment. CAA is clinically and pathologically associated with AD; the presence of the
amyloid protein is a pathological hallmark of the disease in which it is almost invariably
seen (Jellinger and Mitter-Ferstl, 2003). Population-based clinico-pathological studies have
shown that the presence of CAA is higher in demented compared with non-demented
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patients (Keage et al., 2009). Severe CAA was much more frequent in neuropsychiatric
patients (26.3%) than in general hospital patients (3.3%) in a comparative histopathological
study of a hospital-based population (Vonsattel et al., 1991), thereby suggesting that CAA
plays an important role in cognitive performance. CMBs, a radiological marker for small
vessel pathologies including CAA detected on gradient-echo T2* MRI sequences (Fazekas et
al., 1999) may play a key role in cognitive impairment. They are associated with executive
dysfunction in stroke patients (Werring et al., 2004) and with dementia severity in patients
with subcortical cognitive impairment (Seo et al., 2007). We have conducted 2 studies to
assess their cognitive impact in stroke patients which are detailed in Chapter 7. The close
relationship between CAA, coexisting AD and other age-related pathologies (e.g.
hypertensive arteriopathy) poses a challenge to the study of the independent effects of
CAA and CMBs on cognition. This will be further discussed in Chapter 7.
Clinical aspects
VCI is difficult to diagnose, due to moderate sensitivity and specificity of the multiple
published diagnostic criteria, and the lack of morphological criteria (Jellinger, 2013a). This
contrasts with the recently refined diagnostic criteria for AD (Jellinger, 2013b). Clinically,
vascular brain injury causes dysfunction in regions important for memory, cognition and
behaviour. The cognitive deficit in VCI differs from AD with greater executive and
attentional dysfunction (deficits in information processing speed and executive function)
and relatively intact episodic memory. White matter pathology in frontal-basal ganglia
circuits has frequently been invoked as an important cause of executive dysfunction. In
healthy subjects, large white matter hyperintensities were found to be associated with
impaired basic attention, visuo-constructive abilities, mental speed and executive control
(Almkvist et al., 1992; Au et al., 2006; Boone et al., 1992; Breteler, 2000). White matter
volume was also associated with urinary incontinence, the grasp reflex, and abnormal
motor behaviours in patients with AD (Hirono et al., 2000).
Interaction between vascular and degenerative pathologies
There is increasing evidence of an association between cerebrovascular disease and AD.
Dementia after stroke is very common (Henon et al., 2006; Leys et al., 2005), and related to
presence of pre-stroke AD pathology (Henon et al., 1998; Linden et al., 2004).
Cerebrovascular lesions often coexist with Alzheimer-type lesions: 25-80% of elderly
demented show mixed pathologies (Jellinger, 2013a), and they often have a large variety of
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different vascular lesions (Schneider et al., 2007). CAA, a vascular disorder of the small
vessels, is associated with cognitive impairment and is present in up to 100% in AD brains
(Greenberg et al., 2004b). It is possible that mild Alzheimer dementia pathology and small
vessel disease interact synergistically in promoting dementia (de la Torre, 2002; Barba et
al., 2000), and AD has even been considered a primary vascular disorder by some authors
(de la Torre, 2002). Common etiologic and reciprocally synergetic pathophysiological
mechanisms may promote both pathologies (Park et al., 2013; Yarchoan et al., 2012).
Several studies have observed that in patients with cerebrovascular disease and AD, for the
same severity of dementia, there were significantly fewer neurofibrillary tangles (one of
the major histopathological hallmarks of AD) in the brain, compared with patients with AD
only (Etiene et al., 1998; Zekry et al., 2002). This finding suggests that vascular lesions and
Alzheimer’s lesions have synergetic effects in the exacerbation of the clinical
manifestations of AD. None of the cases showed vascular disease without the presence of
Alzheimer’s lesions, suggesting that either AD or vascular lesions alone may be insufficient
to induce dementia. Likewise, cerebrovascular disease may play an important role in
determining the severity of AD symptoms, also in keeping with a possible synergistic
interaction between both pathologies (Snowdon et al., 1997). In elderly patients with
subclinical or mild AD, critically located vascular lesions or cortical watershed infarcts may
shorten the period of preclinical disease (Esiri et al., 1999; Pasquier and Leys, 1997) and
worsen cognitive impairment in established disease (Esiri et al., 1997; Miklossy, 2003). In
late stages of AD, vascular lesions have less impact on the progression of the cognitive
decline (Jellinger, 2007). Therefore, VCI is likely to have a multifactorial etiology; vascular
lesions, Alzheimer’s pathology and aging have a cumulative effect on the risk threshold of
damage required to induce dementia. The mechanisms by which these many factors
operate, and whether they are independent or synergistic, remain incompletely
understood.
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Chapter 2 - Introduction to Cerebral Microbleeds
The objectives of this chapter are to provide a historical overview of CMBs,
to understand the principles of their detection by MRI, to emphasize the
importance of standardised reporting and to describe their epidemiology
and risk factors in different populations.
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2.1 From microaneurysms and haemosiderin deposits to cerebral
microbleeds
CMBs are MRI-defined lesions representing previous small areas of blood-degradation
product deposition in the brain, usually considered to result from rupture of diseased small
vessels. They have generated intense interest as radiological markers for small vessel
diseases prone to bleeding, with the hope that they might contribute to our understanding
of the mechanisms of small vessel diseases, to non-invasively diagnosing small vessel
diseases in life, and to serving as a prognostic marker of larger ICHs. Understanding the
causes of spontaneous (‘primary’) ICH (or ICH without a clear cause) is of critical
importance because this type of stroke has devastating effects in terms of mortality and
morbidity. The underlying pathological processes of spontaneous ICH have been an
important topic of investigation for centuries. It is clear from many studies that
spontaneous ICH relates to characteristic pathological changes to the small vessels; these
are hypertensive arteriopathy and CAA (see Chapter 1). In addition to these, many old
histopathological studies have described small aneurysmal lesions or perivascular
haemorrhages in association with larger haemorrhages, which may be relevant in
understanding the origin of radiologically-defined CMBs. The term ‘microbleeds’ was first
coined in 1996 to describe small areas of bleeding in the brain (Offenbacher et al., 1996),
and many different terms have been used in subsequent years. We have chosen to use the
most commonly used term, cerebral microbleeds, in this thesis. After a brief historical
introduction, we will describe the histopathological lesions that underlie their characteristic
radiological appearance. We will then discuss the methods to detect, define and map CMBs
and their radiological characteristics in a second section, and will end this chapter with a
discussion on their prevalence among various populations and risk factors.
2.1.1 Charcot-Bouchard microaneurysms
In ‘Observationes anatomicae ex cadaveribus quos sustulit apoplexia’ published in 1658,
the Swiss pathologist Johann Jacob Wepfer (1620 – 1695), was the first to hypothesise that
the effects of a stroke were caused by bleeding in the brain (Compston, 2005). From post-
mortem studies, he found fragile, thickened vessels with degenerative changes secondary
to hypertension in relation to large cerebral haemorrhages, but was unable to identify a
point of rupture. The question of the primary site of bleeding in cases with no apparent
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ruptured major artery or vein had never been demonstrated until the research by Jean-
Martin Charcot and Charles-Joseph Bouchard opened new perspectives (Figure 18).
Figure 18. Left panel: Jean-Martin Charcot (1825-1893). Right panel:
Charles-Joseph Bouchard (1837-1915).
Jean-Martin Charcot was a French neurologist and professor of
anatomical pathology at the famous Salpêtrière Hospital in Paris for
more than 30 years. He is known as ‘the founder of modern neurology’
and his name is associated with several medical eponyms including
Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis (motor
neurone disease). One of his interests was research on the functions of
different parts of the brain and the role of arteries in cerebral
haemorrhage. Charles-Joseph Bouchard was a student of Jean-Martin
Charcot, and with Charcot he described the miliary aneurysms now
known as Charcot-Bouchard aneurysms. Bouchard wrote about these
aneurysms in his doctorate thesis ‘Étude sur quelques points de la
pathogénie des hémorrhagies cérébrales.’
In 1868, Charcot and Bouchard carefully examined the brains of 60 patients, mostly elderly,
who had died from ICH, and found what they interpreted to be miliary aneurysms on water
macerated vessels measuring 250-400 μm in diameter (Charcot and Bouchard, 1868). 
These microaneurysms, which still bear their names, were regarded as the potential cause
of cerebral haemorrhage as they were present in nearly 90% of patients who had suffered
a massive ICH. They were 200-2000 μm in diameter, saccular or fusiform dilatations 
attached to vascular filaments in the walls of the ICHs. They concluded that such changes
were the result of ‘periarteritis’ (rather than conventional arteriosclerosis) and suggested
that miliary aneurysms might be responsible for hypertension-induced ICH.
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aneurysms’ by Charcot and Bouchard (1868).
Left panel shows an aneurysm with adjacent
panel shows an aneurysm without leakage, and a collection of
blood without aneurysm.
However, despite their revolutionary findings, many scientists in subsequent years doubted
the authenticity of Charcot and Bouchard’s findings be
by several methodological issues: first, the details of the microscopic description were
lacking; second, rinsing the haemorrhage in water then microscopically examining teased
filaments might have precluded the reconst
exact composition of the walls of the vessels and aneurysms and the nature of the luminal
contents were not discernible because of the low magnification used. These issues
generated controversy about the tr
been any clinico-pathological confirmation that miliary aneurysm rupture caused cerebral
haemorrhages. Nevertheless, by the end of the nineteenth century, none of the possible
causes of cerebral haemorrhag
nervous tissues, haemorrhage into areas of infarction due to adrenalin, confluence of
petechial extravasations, bleeding due to rupture of cerebral veins) were widely accepted,
and Charcot and Boucha
changes (degenerative or inflammatory) in small calibre arterioles associated with
hypertension cause weakening of the wall and microaneurysm formation, which
subsequently ruptures to caus
mechanisms of hypertension
microaneurysms in association with hypertension and ICH is shown in
75
. Original illustration of ‘miliary parenchymal
leakage of blood; right
cause the original study was limited
ruction of the vascular anatomy; and finally, the
ue existence of miliary aneurysms. There had never
e other than arterial rupture (perivascular autolysis of
rd’s findings forged the generally accepted idea that pathological
e ICH. Their work generated exponential research into the
-induced ICH. A summary of selected studies on
Table 5.
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
76
Many subsequent studies suggested alternative explanations for microaneurysms,
including dissection of blood into a diseased segment of arterial wall, false aneurysms (also
referred to as ‘bleeding globes’) or even misinterpretation of complex arteriolar loops or
coils as aneurysms. In 1882, Charlewood Turner did not find microaneurysms in association
with ICH. He suggested that the dilatations found by Charcot and Bouchard resulted from
the accumulation of blood between the media and adventitia, and that microaneurysms
might be dissecting. This theory was later followed by Eppinger (1887) and Professor A.G.
Ellis (1909). In 1909, Professor A.G. Ellis found microscopic aneurysms in 20 cases of
hypertension-related ICH and attributed them to dissection of the vascular wall. He
sustained that miliary aneurysms arise from the rupture of the damaged intima allowing
intramural dissection of blood and subsequent medial degeneration. His findings suggested
for the first time a link between progressive degenerative changes of the vessel wall
following an initial intimal lesion as the cause of spontaneous hypertension-related ICH. In
some cases, perivascular haematomas in continuity with the intramural contents gave the
appearance of red, grape-like swellings which Ellis thought could have been mistaken for
true microaneurysms. Ellis’ work was interpreted as indicating that miliary aneurysms are
in fact periadventitial haematomas or pseudoaneurysms formed by blood clots adherent to
vessels. Several authors found similar lesions, resembling aneurysms but in reality
corresponding to masses of red blood cells adjacent to vessels in the walls of
haemorrhages. They were referred to as ‘bleeding globes’, a term introduced by Matsuoka
(Matsuoka, 1939), and were thought to result from small extravasations from arteries torn
apart by the main haemorrhage (Beitzke, 1936) or relate to functional rather than
mechanical circulatory disturbance (Wolff, 1937). In 1971, Miller Fisher (1971a) also clearly
demonstrated ‘bleeding globes’ at each site of arterial bleeding in microscopic sections of
ICHs, structures without outer walls and formed by fibrin envelopes, thereby artefactually
creating the appearance of true aneurysmal dilatations. He was not convinced there were
any aneurysms in the microscopic sections, and supported the idea that aneurysms are
nothing more than perivascular collections of blood clots, or tiny extravasations of blood
adherent to small arteries, or perhaps external dissections into the adventitia.
In 1930, F.H.K. Green made similar observations to Ellis. He took multiple blocks of brain
tissue from 10 hypertensive subjects and examined serial sections under the microscope
(Green, 1930). The brains had been hardened in formol saline for a few weeks prior to
cutting blocks into thick sections to preserve the course of visible arteries. Using this
technique, he found three microaneurysms consisting of a stretched and ruptured intima
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and media with distension of the adventitia and effusion of red blood cells in the
perivascular space. As such, he not only confirmed the existence of microaneurysms, but
was also the first to speculate that the cause of microaneurysm formation was
arteriosclerosis rather than ‘peri-arteritis’. However, one can question the authenticity of
these lesions given the few lesions found and the very limited method of investigation.
Favouring Charcot and Bouchard’s views on microaneurysms, Dr Ralph Ross Russell, who
had been working with Sir George Pickering in Oxford on the cause and effects of
hypertension, set out to confirm the presence of miliary aneurysms as the primary event in
ICH using a more comprehensive and systematic technique, the arteriolar X-ray micro-
angiography (Ross Russell, 1963). This consisted of a post-mortem angiography using
immediate perfusion of the carotid arteries with barium sulphate in gelatine followed by
cooling and formalin fixation. He found a strong correlation between hypertension and the
presence of intracerebral aneurysms, with 14 out of 15 hypertensive brains presenting
aneurysms compared with 10 out of 35 normotensive brains (Figure 20).
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Figure 20. Coronal radiographs of the lenticulo-striate arteries from a
young normotensive subject and from a hypertensive subject.
In the normotensive subject (left panel), the branches distribute evenly and
regularly without irregularity. Attenuation of small vessels and saccular
dilatations (arrowed) are visible in the hypertensive subject (right panel).
IC, internal capsule; P, putamen.
From Ross Russell, 1963
Up to 20 aneurysms were present in any one individual, and multiple aneurysms were seen
in hypertensive patients only. He found saccular dilatations along small lenticulo-striate
perforating arteries of 100-300 μm in diameter, especially at bifurcation points of arterial 
branches, and in well-defined sites of the brain (basal ganglia, centrum semi-ovale and
cortical grey matter) (Figure 21). Microaneurysms consisted of an internal layer derived
from the intima and an outer collagenous layer continuous with the adventitia of the
parent vessel. He interpreted this degeneration of the muscular and elastic component of
cerebral arteries as the result of the combined effects of age and hypertension.
Interestingly, there were often some red blood cells outside the aneurysms, with many
iron-containing macrophages and haemosiderin staining; an observation of definite
relevance for the understanding of the origins of CMBs. The aneurysms were present in the
absence of recent or past haemorrhage in the vicinity, strongly supporting the fact that
they were the cause and not the result of ICH.
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patients in multiple coronal sections. The brainstem and
cerebellum were not included
From Ross Russell, 1963
A few years later, Cole and Yates (1967) studied 200 brains, including 100 hypertensive and
100 normotensive brains, from age and sex
an injection technique similar to that used by Ross Russell. Forty
hypertensive brains showed aneurysms, compared with 7% of the normotensive brains.
Brains from 13 hypertensive subjects demonstrated small areas of bleeding outside the
vessel wall. The microaneurysms were surrounded by fresh blood and haemosiderin
pigment, once again providing a pathological lesion relevant to the study of CMBs.
Although the age of their population was slightly younger than that of Ross Russell, they
proposed that miliary an
haemorrhage, but were unlikely to cause the massive variety of ICH observed. Indeed, only
a minority of aneurysms occur on large vessels, and hypertensive haemorrhage can occur in
the absence of aneurysms. They further suggested that subclinical rupture of small arteries
and reabsorption of haemorrhages can form small cystic cavities where miliary aneurysms
later develop. However, the injection technique using barium sulphate had serious
drawbacks which led subsequent brain scientists to doubt Cole and Yates and Ross Russell’s
findings: first, small aneurysms are difficult to recognise in angiograms even when
magnified because this technique only demonstrates aneurysms that are above a certain
size and have relatively empty lumens; second, the exact aneurysm size is difficult to
measure due to large lesions sometimes being filled with thrombus; and third, it may
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-six percent of the
eurysms were the causal link between hypertension and minor
mortem study using
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overestimate the presence of aneurysms because the injection creates artificial bulges and
leaks due to injection pressures.
In subsequent years, the debate continued on whether arterial rupture resulted from
miliary aneurysms or from weakening of the arterial wall by arteriosclerosis. Further
studies looking specifically at the ruptured portion of the arterial wall were necessary. In
1972, Miller Fisher found miliary aneurysms in the necropsy brain from hypertensive
patients with a history of stroke including macroscopic ICH (Fisher, 1972). Blood coated the
outside of some aneurysms, and haemosiderin-laden macrophages were scattered in the
surrounding tissue suggesting chronic haemorrhage. All aneurysms were associated with
hypertension, and affected small arteries showing lipohyalinotic disorganisation. He
hypothesised that the microaneurysms could not individually cause macroscopic ICH due to
the small size of the parent artery, and that lipohyalinosis might be the common
pathogenic mechanism to miliary aneurysms and macroscopic ICH. Many of the lesions had
obliterated vascular lumens, and vascular weakening and rupture had to occur before the
formation of the well-developed lipohyalinotic aneurysm.
In 1983, Takebayashi and Kaneko provided the first investigation of surgical specimens as a
way to identify the cause of hypertension-induced ICH (Takebayashi and Kaneko, 1983).
They performed ultrastructural observations of 20 ruptured lenticulo-striate arteries
obtained from surgical material collected during emergency surgery for hypertensive ICH
and of 11 freshly removed brains of hypertensive patients who had died from ICH. They
found two ruptured miliary aneurysms and five non-ruptured aneurysms (Figure 22).
Arterial rupture was identified in 11 lenticulo-striate arteries measuring less than 300 μm, 
and in 10 autopsy cases each showing 2 to 11 ruptured sites on arteries of the large variety
(500-700 μm). Ruptured arteries characteristically showed hypertension-related 
degeneration of the medial smooth muscle cells and dilatation of the vascular lumen
indicating a weakening of the vascular wall due to a loss of elasticity. Their theory was that
aneurysms resulted from induced dissection at bifurcations, sites highly susceptible to
tensile forces. Whether rupture was complete or incomplete and resulted in bleeding,
depended on intravascular pressure, stress forces and the size of the arteries. In addition,
there was a positive correlation between the size of the haematoma and the size and
number of ruptured arteries, suggesting that miliary aneurysms are not likely to cause
rupture. At the sites of rupture, abrupt breakage of the arterial wall was more common
than microaneurysms. Therefore, they concurred that a large ICH is due to the rupture of
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large arteries, sometimes multiple ruptured arteries. The rupture of a single vessel gives a
variety of tensions to the adjacent arteries inducing rupture of unruptured arteries around
the large haematoma in an avalanche fashion. These findings were in agreement with
Miller Fisher’s emphasis on lipohyalinosis rather than microaneurysms as a common cause
of vessel rupture.
Figure 22. Non-ruptured military aneurysm and ruptured military
aneurysm.
The unruptured aneurysm (left panel) measures 500 μm in diameter. The 
wall of the aneurysm consists of dense layers of fibrin and plasma protein
mixed with a few haematogenous cells. The ruptured aneurysm (right
panel) measures 1000 μm in diameter. Its wall contains dense band-like 
deposition of fibrins. The connecting artery at the right upper corner
measures 180 μm in diameter and shows atherosclerotic changes  
From Takebayashi and Kaneko, 1983
In 1989, Wakai and Nagai provided a second investigation in which surgical specimens were
used to identify the cause of hypertension-induced ICH, which re-emphasised the role of
microaneurysms as a source of bleeding. They proceeded with a thorough investigation of
the haematomas and their walls under surgical microscopy in specimens from 14 patients
with spontaneous lobar ICH or cerebellar ICH. In the periphery of the haematoma, miliary
aneurysms were present in five cases and possible miliary aneurysms in two cases; possible
microaneurysms were identified in tissues in which the parent artery was not verified
histologically. There was contiguity between the masses of red blood cells and the
surrounding haematomas in all cases, and an arterial connection between the solid tissue
and the blood clot was found in all but one, suggesting that a vascular abnormality, likely a
microaneurysm, was the cause of bleeding.
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Favouring the idea that ICH results from other sources than microaneurysms, Mituzani and
coworkers provided beautiful illustrations of arterial dissections of lenticulo-striate arteries
from surgical specimens in 12 hypertensive patients with ICH (Mizutani et al., 2000). They
identified 6 arterial dissections of 15 arteries measuring 100-700 μm in diameter, 
suggesting that intracerebral arterial dissections may be a much more common cause of
hypertension-related ICH than previously thought.
A study using a new histochemical technique raised significant doubts about the
authenticity of miliary aneurysms in the early nineties. Challa and co-workers (Challa et al.,
1992) reassessed the existence of Charcot and Bouchard microaneurysms using Gomori’s
alkaline phosphatase to stain the endothelium lining of microvessels of post-mortem brain
specimens from 35 hypertensive and 20 age-matched normotensive patients. The sections
were examined using light microscopy and high resolution microradiography. This contrast-
free technique provided three dimensional perspectives with the enhanced ability to trace
vessels, and eliminated the artefacts of injection and maceration methods. The team also
sampled 2800 brains via routine paraffin sections. Charcot-Bouchard microaneurysms
were conspicuously absent in both groups which included four cases of hypertensive ICH.
The routine paraffin sections demonstrated only five examples of parenchymal aneurysms,
all in elderly patients with advanced arteriosclerotic changes and none were associated
with ICH. In contrast, the technique demonstrated tortuous vascular profiles and identified
complex coils and twists in arterioles, especially in old age (Figure 23).
Figure 23. Photomicrograph showing complex
microaneurysm-like vascular coils and twists
revealed using alkaline phosphatase staining.
From Challa et al., 1992
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These complex structures can mimic microaneurysms when assessed using old techniques
(paraffin and injection techniques) and lead to misinterpretation. Their impression was that
Charcot and Bouchard microaneurysms have little relationship to ICH for several reasons:
first, parenchymal aneurysms show chronic changes of fibrosis and thrombosis which
cannot be linked with acute events such as ICH; second, most sections when taken from the
edges of large haemorrhages do not usually show aneurysms; third, fibrinoid necrosis of
arterioles in the vicinity of ICH is a reaction to extravasated blood; and finally, the
drawbacks of previous methodological techniques of identification, namely overestimating
(injection technique) or underestimating (paraffin studies of thin slices) the presence of
microaneurysms.
However, the suggestion of such misinterpretation does not explain the preferential
location of microaneurysms in the basal ganglia (Ross Russell, 1963). Furthermore,
autoradiographic studies used systematic analysis of the full thickness of the sections
combined with histopathological analysis, making misinterpretation unlikely. It is also
possible that aneurysm frequency has been underestimated in Challa and coworkers’ study
(1992) because alkaline phosphatase is absent from severely damaged aneurysmal
arteriolar walls. Nevertheless, it appears from their study that microaneurysms are likely
much less common that previously thought, and that rupture of non-aneurysmal segments
of arterial walls damaged by hypertension, is the most likely mechanism of hypertension-
related ICH.
Only scarce reports have provided direct histological evidence for ruptured
microaneurysms as a clear source of bleeding, which may explain the continued
controversy on the existence of miliary aneurysms and their role in hypertensive
haemorrhage. In 2003, Miller Fisher reported the case of a thalamic haemorrhage which
had been sectioned serially in its entirety revealing a single site of bleeding. The ICH had
occurred in a hypertensive patient treated with pitressin for gastrointestinal bleeding-
related hypotension. Microscopical examination revealed that the ICH arose from an
elongated aneurysmal segment of a small artery measuring 180 μm in diameter. By 
following the aneurysmal outline in the serial sections, a 1 mm wide breech was identified
through the fibrillar material of the retaining wall which allowed continuity between the
lumen and the extravasated blood of the ICH. In the same year, Rosenblum provided an
example of a ruptured aneurysm within a pontine haemorrhage in an 83 year old male
patient, but in a very unusual context: the aneurysm had undergone dissection at its point
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of origin at a site of fibrinoid necrosis, and the outer wall of the dissection had ruptured,
causing parenchymal haemorrhage (Rosenblum, 2003). This was the first evidence of
dissection within an aneurysmal wall. The authors explained this phenomenon by the
fibrinoid necrosis that had weakened the wall of the parent arteriole leading to the
aneurysmal dilatation and dissection, with the haemorrhage resulting from the reduced
resistance to rupture of the thin outer wall of the dissection.
In conclusion, to date, many studies have not been able to consistently find true
microaneurysms at the site of macroscopic ICH. A combination of significant methological
issues and normal physiological events (e.g. destruction of microaneurysms during the
acute ICH) hindered the comprehensive assessment of microaneurysmal lesions as a cause
of bleeding. Rare reports have demonstrated the presence of microaneurysms at the core
of the arterial rupture. Nevertheless, many histopathological studies have demonstrated
that important structural changes, with or without microaneurysms, occur within and in
the vicinity of small perforating arteries of the brain exposed to chronic hypertension.
These changes are likely to play a key role in the pathogenesis of large symptomatic ICH.
Among these, blood degradation products possibly resulting from chronic extravasation
through damaged vessel walls can be seen in the perivascular space, and might be the
underlying substrate of radiologically-defined CMBs. Therefore, based on the best available
evidence to date, there is no doubt that Charcot and Bouchard microaneurysms occur, and
a significant role of microaneurysms in ICH cannot be rejected. However, many
fundamental questions remain regarding their cause, nature, prevalence and role in the
pathophysiology of ICH. To cite Miller-Fisher, haemorrhage entails not only the initial
rupture of a blood vessel, with or without microaneurysmal rupture, but also the secondary
mechanical shearing of surrounding blood vessels allowing the ICH to reach its full size
(Fisher, 1971a).
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Table 6. Summary of selected studies on microaneurysms (Charcot-Bouchard aneurysms) in
association with hypertension and ICH
Adapted from Werring, 2011
Study Year Technique
No. of
brains
Prevalence of microaneurysms
Controls Hypertension
Intracerebral
haemorrhage
Green 1930
Microscopic
examination of serial
frozen & paraffin
sections of blocks of
brain tissue
10 -
1/7
(14%)
1/3
(33%)
Ross Russell 1963
Arteriolar X-ray micro-
angiography with
barium-gelatin injection
54
10/38
(26%)
14/16
(88%)
5/5
(100%)
Cole and
Yates
1967
Arteriolar X-ray micro-
angiography with
barium-gelatin injection
200
7/100
(7%)
46/100
(46%)
18/21
(86%)
Fisher 1972
Microscopic
examination of formalin-
fixed blocks of brain
tissue
20 -
13/20
(65%)
NA
Takabayashi
and Kaneko
1983
Electron microscopy of
thin and semi-thin
consecutive sections of
Epon 812 embedded
arteries
61 - -
7/61
(11%)
Wakai and
Nagai
1989
Meticulous
microsurgical technique
followed by serial
sectioning and
microscopic
examination
14 - -
5/14
(36%)
Challa et al. 1992
Bells’ modification of the
alkaline phosphatase
technique
55 0/20 0/31 0/4
Mizutani et al. 2000
Microscopic
examination of surgical
specimens
12 - - 0/12
Overall prevalence
17/158
(11%)
74/174
(43%)
36/120
(30%)
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2.1.2 The first MRI reports of ‘microbleeds’
Although macroscopic ICH can be seen on non-contrast CT scans, the small aneurysmal
lesions and perivascular haemorrhages discussed above cannot be visualised on
conventional neuroimaging methods; even the gold standard of catheter angiography is not
sensitive enough to detect vascular lesions of this size. It has, therefore, been impossible to
visualise such lesions in vivo (Singh Alg and Werring, 2011). In vivo investigation of these
lesions has not been possible until the advent of MRI. Scharf et al. (1994) reported the
presence of small, intracerebral dots of marked signal loss using T2-weighted Fast Spin
Echo (FSE) MRI in patients with hypertensive cerebrovascular disease and ICH. These
seemed to be associated with ICH, lacunar infarcts and ischaemic white matter disease, and
they called them ‘haemorrhagic lacunes’. It is likely that these lesions were more
substantial haemorrhages (possibly secondary haemorrhagic transformation of lacunar
infarcts), since they used a T2 sequence at low magnetic field strength (1.0 tesla). Since the
mid-1990s, very small areas of bleeding have become detectable using a sequence highly
sensitive to haemosiderin, gradient-echo T2*-weighted MRI. These lesions appeared as
small, rounded dots of low signal intensity in patients with ischaemic and haemorrhagic
stroke, and in hypertensive and healthy elderly subjects (Fazekas et al., 1999; Roob and
Fazekas, 2000). In 1996, Greenberg et al. reported ‘petechial haemorrhages’ in 9 out of 15
patients with lobar haemorrhages consistent with CAA (Greenberg et al., 1996). In the
same year, Offenbacher and colleagues described similar intracerebral foci of MR signal
loss in 39 of 120 patients with spontaneous ICH (Offenbacher et al., 1996). The majority
consisted of homogeneous, rounded lesions with diameters of 2 to 5 mm, and they termed
these ‘microbleeds’. Figure 24 is taken from the same paper, and demonstrates the
difference in sensitivity for the detection of small and large haemorrhagic lesions between
non-contrast CT, T2-weighted fast spin echo (FSE) MRI and gradient-echo T2*-weighted
MRI (Figure 24). Both the studies by Greenberg and Offenbacher demonstrated a strong
association between ICH and CMBs on gradient-echo T2*-weighted MRI, suggesting that
CMBs may provide key information into the pathogenesis of ICH.
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A B
C D
Figure 24. CT and MR imaging of a 74 year old patient with a
putaminal spontaneous ICH showing the discrepancies between the
different imaging modalities.
A. CT scan shows an acute haematoma without any other parenchymal
abnormalities. B. and C. T2-weighted spin-echo MR images reveal another
clinically silent old haematoma in the left parieto-occipital region not
detected by CT. D. T2*-weighted GRE MRI permits better visibility and
shows many additional CMBs.
From Offenbacher et al., 1996.
In the same year, Chan reported multifocal hypointense cerebral lesions on gradient-echo
T2*-weighted MRI of patients with chronic hypertension. All seven patients in whom MRI
had shown small chronic haemorrhages had also been chronically hypertensive (Chan et al.,
1996). These small haemorrhages were located in the basal ganglia, thalamus, corona
radiata and subcortical white matter, brainstem, and cerebellum (although cortical foci
were not counted formally). Although other factors may have contributed to the apparent
lesions, this study demonstrated an association between multifocal hypointense lesions
found on MRI and a history of chronic hypertension. A correlation was established between
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the location of CMBs, and the areas involved in lacunar infarction, leukoaraiosis and
cerebral haemorrhage (Figure 25).
A B
Figure 25. MR imaging of a patient with chronic hypertension and worsening
dementia showing the overlap between white matter changes and CMB
distributions.
A. T2-weighted fast spin-echo MR image shows extensive white matter hyperintensity
suggestive of leukoaraiosis. No hypointense lesion is identified. B. T2*-weighted GRE
MR image shows multiple hypointense lesions (CMBs) with a predominantly deep
distribution. The distribution of white matter changes and CMBs clearly overlaps.
From Chan, 1996
2.1.3 Histopathological correlates of cerebral microbleeds
In 1999, the histopathological correlates of CMBs began to be reported. Histological-MRI
correlations demonstrated that the hypointensities detected on GRE T2* images reported
as CMBs correspond to focal deposits of paramagnetic blood break-down products,
especially haemosiderin, within macrophages. Tanaka and colleagues examined serial
sections of brain tissue from 3 patients with various causes of death (Tanaka et al., 1999).
The sections were examined at the site of small hypointense lesions detected on a T2*-
weighted echo plannar imaging (EPI) MRI undertaken prior to patients’ death. They found 3
CMBs corresponding to haemosiderin pigments contained within macrophages around
arteriosclerotic microvessels. Interestingly, one lesion also had an associated miliary
pseudoaneurysm with a structure similar to that of ‘bleeding globes’ described previously
(Matsuoka, 1939; Fisher, 1971b), which was connected to an arteriosclerotic vessel (Figure
26), while other vessels demonstrated the effects of hypertensive small artery disease with
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fibrinoid necrosis. An additional finding of this study was the presence of a small infarction
around the microaneurysm where macrophages had accumulated.
In the same year, Fazekas and colleagues undertook a histopathological analysis of MRI
hypointensities of 11 patients who had died from ICH and confirmed that CMBs
corresponded to collections of haemosiderin containing macrophages in the majority
(61.8%) of cases (Fazekas et al., 1999) (Figure 27). Haemosiderin deposits were also noted
without MR signal changes in two brains. The MRI-negative lesions (seen only on
histopathological analysis) were smaller and consisted of only a few macrophages. In the
CMBs without haemosiderin-laden macrophages, no specific pathology was found.
Figure 26. Pathological specimen from an autopsy case showing a miliary pseudoaneurysm
and haemosiderin deposits around arteriosclerotic vessels.
A. shows an organised miliary pseudoaneurysm (arrows) connected to an arteriosclerotic
microvessel. In D, haemosiderin pigments are contained within macrophages and are abundant
around the arteriosclerotic microvessels.
From Tanaka et al., 1999
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In both studies, all specimens with hypointense lesions showed moderate to severe
lipofibrohyalinosis of the adjacent arterioles, suggesting that these deposits result from the
rupture of these arterioles (Fazekas et al., 1999; Han et al., 2009; Tanaka et al., 1999; Naka
et al., 2004). Brains with fibrohyalinosis showed CMBs preferentially in the basal ganglia
and thalami. It was also noted that haemosiderin deposits were surrounded by gliosis and
incomplete ischaemic necrosis, therefore suggesting that systemic hypertension is
associated with both ischaemic and haemorrhagic lesions.
In Fazekas’ study, two types of vascular changes were observed (Fazekas et al., 1999).
Lipofibrohyalinosis related to hypertension was one of them, and patients with pure
lipofibrohyalinosis exhibited haemosiderin deposits in the deep regions (basal ganglia and
thalami) followed by infratentorial regions. However, CMBs were also observed in cortico-
subcortical regions in two specimens with additional CAA, the second type of vascular
changes observed. These findings suggested a different distribution of CMBs according to
the underlying arteriopathy. Further reports have confirmed a high frequency and
preferential occurrence of cortico-subcortical CMBs in CAA (Greenberg, 2006; Schrag et al.,
2010), whereas CMBs are usually found in the basal ganglia, deep white matter and
brainstem in patients with chronic hypertension (Greenberg et al., 2009b; Tatsumi et al.,
2008b) (Figure 28). In some cases, cortico-subcortical CMBs are found in patients with
Figure 27. Histological-MRI correlation of CMBs.
1B. Post-mortem GRE T2*-weighted MRI showing foci of signal hypointensity in the cerebellum and
pons. 1C. A CMB corresponding to the largest hypointensity is visible on the corresponding
histopathological section
From Fazekas et al., 1999.
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hypertensive microangiopathy, suggesting that both arteriopathies can coexist in some
patients causing an overlap in the distribution of CMBs.
Figure 28. Illustration of the relative frequency of CMBs in CAA and in
hypertensive arteriopathy.
The images represent different axial sections of the brain and the colours are
coded to represent the likelihood of encountering CMBs in all brain regions
with high likelihood (dark grey) and low likelihood (light grey). Data were
compiled from selected MRI studies of patients clinically diagnosed with CAA
or hypertensive arteriopathy (not on pathological confirmation).
From Werring, 2011
Subsequent histopathological studies of CMBs showed that the majority of lesions were
small foci of haemorrhage composed of haemosiderin-laden macrophages at the site of
radiological CMBs, in keeping with earlier studies.
In a post-mortem case report by Tatsumi et al. (2008b), almost all CMBs were found to be
haemosiderin laden macrophages and were frequently associated with hypertensive
microangiopathy. Schrag and colleagues reported 38 CMBs in 6 cases of AD in a
histolopathology study combined with susceptibility-weighted imaging (SWI) (Schrag et al.,
2010). Sixteen of the lesions were described as old haematomas which stained for iron, 10
lesions contained intact erythrocytes, 7 revealed cavitary lesions associated with a gliotic
capsule containing haemosiderin granules and haemosiderin-laden macrophages, 3
contained haemosiderin granules and haematoidin depositon, 1 was a microaneurysm and
another a dissected vessel. Most lesions contained evidence of CAA with vessel wall
thickening, Aβ replacement of smooth muscle cells and microaneurysms. 
In 2009, Greenberg and co-workers sought to explore the pathological changes that
predispose to bleeding in patients with CAA (Greenberg et al., 2009b). The
neuropathological analysis of six autopsied brains with high and low CMB counts showed
that CAA subjects with many CMBs demonstrate significantly thicker amyloid-positive
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vessels than those with few CMBs. This suggested that microbleeding may occur as a
consequence of the increased wall thickness of amyloid positive vessels reflecting more
severe CAA pathology. Vessel wall thickness might be a risk factor for microbleeding in
CAA. However, the mechanisms determining the degree of wall thickness are unknown,
and whether this mechanism holds true in hypertensive microangiopathy remains unclear.
MRI-histopathology correlations have also allowed further characterisation of the size of
CMBs. Recent studies have systematically compared the size of CMBs on MRI with the
actual diameter of the deposit assessed by histology. An autopsy imaging study of 38
lesions in 10 brains with CAA showed a range of 0.5-5 mm lesional (Schrag et al., 2010),
much smaller than the size on MRI which was consistently overestimated (‘blooming
effect’). The magnitude of blooming appears greater for smaller lesions.
As of 2010, the literature had reported the examination of two normotensive and two
hypertensive brains (Tanaka et al., 1999; Tatsumi et al., 2008b); 11 brains with spontaneous
ICH (Fazekas et al., 1999); 16 CADASIL brains (Dichgans et al., 2002; Yamamoto et al., 2009);
19 brains with CAA (Greenberg et al., 2009a; Schrag et al., 2010) and 8 patients with
vascular disease (Yamamoto et al., 2009), making a total of 58 brains. The findings of 10
such studies are summarised in Table 6. In 2011, Shoamanesh and co-authors published a
systematic review of studies combining MRI and histopathology of CMBs (Shoamanesh et
al., 2011). Only 5 studies met the inclusion criteria. From these, haemosiderin deposition
was the most common histopathological correlate of CMBs, followed by old haematomas,
no specific pathology, intact erythrocytes, vascular pseudocalcification, microaneurysm and
dissected vessel. Some of the lesions contained erythrocytes, suggesting that not all CMBs
are chronic in nature. In keeping with previous studies, lipofibrohyalinosis and CAA were
the dominant vascular changes associated with CMBs (Shoamanesh et al., 2011). CMBs
were cortico-subcortical among patients with documented CAA, in line with previous
reports. Shoamanesh et al. also commented on the fact that in many studies, CMBs are
often associated with a degree of surrounding tissue necrosis, which may be implicated in
their clinical effects. One might be tempted from these studies to calculate the sensitivity
and specificity of MRI for the detection of CMBs. This has been attempted in several
reports (De Reuck et al., 2011; Shoamanesh et al., 2011). However, the small sample sizes,
variation in the methods of detection and imaging parameters preclude a reliable
estimation.
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As these preliminary reports show, the number of CMBs detected depends on MRI
characteristics, such as pulse sequence, sequence parameters, spatial resolution, magnetic
field strength and image post-processing. This emphasizes the importance of taking into
account the MRI technique used in the interpretation of study results, as we will discuss
later in section 2.2, chapter 4 and chapter 9. Each of these factors has a potential effect on
conspicuity and detection of CMBs and may influence the reported prevalence of CMBs.
For example, increased magnetic field strength to 3 tesla or higher seems to improve CMB
conspicuity. The use of image post-processing techniques (e.g. SWI) gives a higher contrast
index between brain tissue and haemosiderin deposits that does conventional T2*-
weighted MRI. The use of three-dimensional T2*-weighted MRI at high resolution can
detect more CMBs than conventional two-dimensional GRE at lower resolution. We have
shown how echo times affect the detection of CMBs in one of our papers (Gregoire SM,
Clin Radiol 2009). However, limitations of MRI studies of CMBs are that they do not provide
microscopical evidence for the specific tissue changes. Histopathology might be more
sensitive for the detection of small vessel related changes, with the limitation that CMBs
are small and diffuse in the brain and that examination of the entire brain in microscopic
section is not possible. CMBs might be small enough to be fully contained within even a
thin (e.g. 5 mm) brain slice, which prevents them from being visible to the examining
pathologist. Future MRI developments, ie. ability to sample the whole brain at spatial
resolutions less than 1 mm, may ultimately allow the detection of CMBs with higher
sensitivity than histopathology. Further histo-pathological studies using these more
advanced techniques will be required to assess the relative sensitivities of MRI versus
pathology. Other limitations to the reporting of CMBs are the imaging analysis techniques
and reporting methods which have varied substantially across studies. CMBs have many
mimics which can be easily mistaken for CMBs by the inexperienced observer. The use of
standardised instruments to rate their presence may improve identification reliability. The
Microbleed Study Group published consensus criteria on the detection and reporting of
CMBs including recommended criteria for identification of CMBs (Greenberg SM, Lancet
Neurol 2009b). We also developed a rating scale for CMBs aiming at standardizing
identification and reporting, that will be discussed in Chapter 4.
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Table 7. Summary of publications correlating MRI findings and histology of CMBs as of 2009
Adapted from Werring, 2011.
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Correlation
/hypothesis Results and Conclusions
Schrag et al.,
2009
n/a HR 3D GRE
T2* SWI
(3T)
10 38 13 H&E amyloid: Aβ 
Macrophages: CD68
Complement: C6, IHC
Lymphocytes: CD3, CD20
Neurons: MAP2
Haemoxygenase ; HC ; Iron
CAA CAA and CMB correlation PM MRI and PM
histology
Size correlation MRI-histology
 The vast majority of lesions located near the cortical ribbon:
 2 main areas: beneath the grey-white matter junction and in the superficial cortex where pial
arterioles penetrate the grey matter
 In several haemorrhages it was possible to determine which vessel ruptured.
 One hypointensity was caused by a microaneurysm
 SWI consistently overestimates the diameter of small lesions (‘blooming effect’)
Greenberg et al.,
2009
46 6 181 H&E
Aβ IHC 
CAA  Comparison high and low CMB count
brains
 Comparison micro vs macrobleed
 Comparison CAA pathology with CMB
frequency
 Increased wall thickness of amyloid-positive vessels in high CMB-count brains relative to the
low CMB group
 No other qualitative pathological differences (frequency or type of amyloid-positive vessels)
 No correlation with dyshoric amyloid deposits, double barrel vessels
 In vivo study: haemorrhage size in bimodal distribution (mixture of 2 separate populations)
Yamamoto et al.,
2009
9 +co T2 FLAIR 9+ co n/a >9 H&E; CV; LFB
SMA; Coll IV
GLUT1
CADASIL  Pathological changes in WM of temporal
pole in CADASIL; correlation to histology
 Small vessel arteriopathic and perivascular space widening
 Perivascular space significantly widened in CADASIL compared to subcortical vascular
ischaemic dementia
Tatsumi et al.,
2008
1 GRE T2*
SWI (3T)
1 9 9 H&E
Iron
HTN  Correlation MRI-histology
 Case study
 All CMBs were haemosiderin deposits and frequently associated with hypertensive
microangiopathy
 Associated with lipohyalinosis or microaneurysms
Kikuta et al., 2007 1 GRE T2*
SWI (1.5T)
n/a 1 1/1 H&E
EvG
Factor VIII IHC
Moya-Moya  Hypointensity = CMB?
 Case study
 MRI CMB confirmed by histology (small haematoma)
Dichgans et al.,
2002 ;
Messori and
Salvolini, 2003
16 (+16
con)
GRE T2*
1.5T
7 94 H&E
Iron
CADASIL  Compare in vivo and PM imaging
 Compare PM imaging with PM histology
 All CADASIL individuals show hyperintense T2-weighted abnormalities on brain MRI
 Focal accumulations of haemosiderin-containing macrophages in 6/7 brains
 Significant correlation between age and number of CMBs
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Tanaka et al.,
1999
89 FSE T2, T2*
(1T)
3 108
(17
pts)
H&E
MTC
Myelin (KB)
HTN  Compare in vivo and PM imaging
 Compare PM imaging with PM histology
 Small hypointense lesions are foci of old haemorrhages, caused by rupture of arteriosclerotic
microvessels
 Incomplete ischemic necrosis in the surrounding areas
 Old haemorrhages = haemosiderin pigments
One case of organised pseudoaneurysm
Roob et al.,
1999b
GRE T2*
1.5T
7 34 34 H&E; MTC
Myelin (KB); Iron
Amyloid (CR)
HTN  Compare PM imaging with PM histology  Most CMBs were haemosiderin deposits and frequently associated with hypertensive
microangiopathy
 No detection of pathology in 13/34 regions
Roob et al., 1999a 280 GRE T2*
1.5T
n/a n/a n/a n/a HTN  Surveillance of elderly population
(prevalence of CMBs)
 CMBs in 18/280 neurologically normal patients
Fazekas et al.,
1999
n/a GRE T2*
(1.5T)
11 34 11 H&E; MTC
Myelin (KB)
Iron
Amyloid (CR)
HTN  Hypointensity = CMB = histology?  All brains examined showed moderate to severe small-vessel disease
 Areas of signal loss predominantly in basal ganglia, thalami, brain stem, or cerebellum
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2.1.4 The link between haemosiderin deposits and cerebral microbleeds
As discussed above, MRI-pathology correlations have shown that the majority of
radiologically detected CMBs relate to small foci of haemosiderin deposits in the vicinity of
pathologically damaged small vessels, in the context of widespread small vessel
vasculopathy, typically hypertensive arteriopathy or CAA. These may occasionally be
related to aneurysmal or pseudoaneurysmal lesions rather than well-defined extra-mural
bleeds. The alteration of the walls of small vessels may theoretically produce steady
extravasations of erythrocytes through the fragile vascular walls (Roob and Fazekas, 2000)
or tiny areas of frank haemorrhage (Werring, 2007). However, this mechanism as a cause
for CMBs remains speculative. MRI-pathology correlations are limited by technical factors
which hamper the understanding of the causes of CMBs. Firstly, CMBs are small
(radiologically <5 mm, and pathologically often much smaller than this) and widespread in
the brain, and can easily be missed by visual inspection of post-mortem material; their
identification requires careful and systematic examination of pathology specimens.
Secondly, correlation studies are descriptive and unable to establish a causal relationship
between the presence of vascular changes and of CMBs (Brandner, 2011) These technical
aspects probably account for the small number of brains with CMBs that have been
analysed in correlation studies.
To date, the pathological and radiological relationship between the haemosiderin foci and
radiologically-defined CMBs is not yet resolved. As discussed, the common view is that
CMBs arise from extravasation of red blood cells, resulting in pericyte erythrophagocytosis,
haemoglobin degradation and haemosiderin deposition. However, this hypothesis was
recently challenged. Alternative explanations to the origin of haemosiderin deposits have
been proposed based on evidence from CADASIL and peripheral injury. Perivascular
haemosiderin deposits are observed in CADASIL, a condition associated with severe
vascular fibrosis and no propensity for haemorrhage. Skin examination in the context of
chronic venous stasis of the leg shows perivascular deposits to be infrequent (Caggiati et
al., 2008). The hypothesis made by the group led by P. Ince is that haemosiderin deposits
may come from local iron sources within the brain, as opposed to haemoglobin
degradation (Janaway et al., 2013). Iron within the brain is normally stored within
oligodendroglial cells, especially in the basal ganglia (Morris et al., 1992). The damage to
tissue caused by small vessel disease related ischaemia causes release of the iron stores
from oligodendroglial cells, which exceeds the ability of the surrounding tissues to process
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it. The local excess of iron could therefore be processed by macrophages to haemosiderin
and result in perivascular accumulation. This hypothesis was tested in a population-based
neuropathology study correlated with post-mortem 3T MRI (Janaway et al., 2013). In the
study, greater putamen haemosiderin was significantly associated with age, markers of
small vessel disease related ischaemia (microinfarcts, arteriosclerosis and lacunes) and with
widespread CMBs, but not with measures of neurodegeneration. This suggests that the
ageing brain becomes more vulnerable to excessive release of iron from ischaemic damage
as the number of healthy cells able to process it (e.g. oligodendroglial cells) decreases.
CMBs may therefore also be a marker of focal haemosiderin deposition secondary to
parenchymal ischaemic damage. Furthermore, almost all patients (aged 65 and over) had
focal haemosiderin deposits, suggesting that histology is more sensitive for detecting
haemosiderin in post-mortem brain tissue than MRI analysis, and that their size needs to
be sufficient to be able to detect them on MRI. Other studies confirmed that the
overwhelming majority of subjects above the age of 70 have haemorrhages at the capillary
level (Cullen et al., 2005; Fisher et al., 2010). The presence of CMBs in the frontal lobe
white matter in patients with high amount of haemosiderin deposits in the basal ganglia
further suggests that CMBs reflect widespread small vessel disease.
To conclude, the literature on CMBs runs to less than 100 brains to allow the determination
of what the hypointensities observed on MRI mean. From these studies, there is no doubt
that CMBs correspond to pathology-defined haemosiderin deposits in the perivascular
regions. They are very common in the ageing brain, but only those of sufficient size, i.e. in
aggregates, will be detectable by MRI. From their association with small vessel
arteriopathies (hypertensive and CAA), it is clear that their presence may be a valuable
indicator of the presence and severity of cerebral small vessel disease. The latest research
suggests that their origin and implications might differ according to their distribution in the
brain. In the cortex, CMBs likely reflect the presence of CAA, a condition associated with
perivascular bleeds, microaneurysm formation and lobar haemorrhages (Maia et al., 2007).
Consequently, in CAA, it is likely that lobar CMBs are a biomarker for the risk of ICH. By
contrast, in the deep brain, the origins of CMBs are less clear, and may result from either
perivascular bleeding from damaged vessels, or from release of parenchymal iron stocks
following ischaemia. Therefore the relevance of deep CMBs as a marker for the risk of ICH
remains to be determined. Further large, well-designed histopathological studies combined
with MRI correlation are needed to characterise the range and threshold of haemosiderin
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pathology required to create a CMB on MRI and confirm the bleeding or ischaemic origin of
CMBs according to the underlying arteriopathy.
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2.2 Detection of cerebral microbleeds using magnetic resonance
imaging
2.2.1 Introduction to the principles of magnetic resonance imaging
Basic principles
Since this thesis contains a number of studies relating to MRI findings, an understanding of
the basic principles of MRI is necessary. MRI is a medical imaging technique based on
nuclear magnetic resonance (NMR) principles that uses the intrinsic magnetic properties of
the atoms within tissues and some extrinsic parameters to produce sophisticated images of
the human body (Faulkner, 1996). In contrast to CT, it does not involve ionising radiation. It
uses a powerful magnetic field to align the nuclear magnetisation of hydrogen atoms in the
body tissues (Lauterbur, 1973) and provides a much greater contrast between soft tissues
than CT.
NMR describes the application of a pulse of radiofrequency (RF) energy to a sample in the
presence of a magnetic field gradient, followed by the collection of a RF signal emitted by
the sample (Werring, 2001). The RF signal depends on the interactions that occur when
atomic nuclei are placed in an external magnetic field. Specifically, all tissues are composed
of atoms, and the nuclei of these atoms contain protons. Those nuclei with an odd nuclear
number (protons + neutrons = odd number) have two important intrinsic properties: first,
they have a special property to spin and second, because they are charged, they create a
local magnetic field. Each nucleus behaves like a magnetic dipole with a magnetic field. The
most important such atom in MRI is the hydrogen nucleus (which contains a single proton),
contained in water molecules of biological tissues. Each spinning proton may be
represented as a vector showing the direction of its magnetic moment (Figure 29).
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Figure 29. Schematic representation of a proton.
Protons are charged particles which have the property of spin
and have a magnetic moment which may be represented by a
vector.
In a resting state there is no net magnetisation because the sum of all the spin vectors of
protons is zero (Figure 30). However, when the tissue is placed in an external magnetic field
(conventionally designated B0), these protons absorb or emit energy and realign
themselves, and a net magnetisation is produced along the longitudinal axis of the
magnetic field. As the majority of protons adopt the parallel (lower energy) state, the
subject in the scanner is magnetised with a small net magnetic moment (M0). This magnetic
moment is also called longitudinal magnetisation, and is directly proportional to B0. In
clinical scanners, the magnetic field is commonly 1.5T (Tesla) in strength and is orientated
horizontally.
Figure 30. The proton magnetic moments (‘spins’)
(A) Proton magnetic moments are normally oriented randomly. (B) When
placed in an external field (B0), they become aligned in a parallel or
antiparallel state causing them to acquire a net magnetic moment, M0.
Protons placed in a magnetic field exhibit a type of motion called ‘precession’. The
precession can be conceptualised as a vector representing the magnetic dipole describing
the shape of a pole (Figure 31).
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Figure 31. Precession of a proton in an
external magnetic field.
The precession frequency, designated by ω, depends on the strength of the applied 
magnetic field (B0 given in Tesla) and the molecular species under consideration, and is
characterised by a gyromagnetic ratio (γ), according to the Larmor equation: 
ω = γ B0
In clinical MRI, the magnetic moment is manipulated to produce MR images. The simplest
manipulation is the application of a short burst of energy, called a RF pulse (usually a 90o
pulse). RF pulses are short duration oscillating magnetic fields with a specific frequency that
causes the protons to produce a rotating magnetic field (they ‘resonate’). The frequency
required to alter the alignment of the magnetisation is directly related to the precession
(Larmor) frequency, which for protons in a 1.5T magnetic field is approximately 64 MHz
(Werring, 2001). When the RF pulse is applied the precessing protons undergo re-
arrangement in two ways: firstly, some protons will gain energy and become realigned in
the higher energy anti-parallel state; and second, the protons will begin to precess in a
more coherent way (Figure 32). The former effect induces a reduction in the longitudinal
magnetisation of the sample, as they are less parallel orientated protons. The latter effect
causes the sample to acquire a transverse orientated magnetic moment, which is rotatory
due to the in-phase precession of the protons. These alignment changes generate a signal
which can be detected by the scanner and manipulated by additional magnetic fields to
provide more information and construct an image of the body.
N
+
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Figure 32. Application of a radiofrequency pulse
When a RF pulse is applied at the appropriate frequency (left)
protons lose their longitudinal magnetisation and gain
transverse magnetisation (right).
In this process, the protons are ‘tipped’ from their previously longitudinal alignment by an
angle, α. If this angle is 90°, then the RF pulse is commonly termed a ‘90° pulse’. The larger 
the amplitude and the longer the duration of the RF pulse, the larger the angle. NMR
measurements are made from the signal induced by the transverse magnetisation caused
by the RF pulse. Because transverse magnetisation is an oscillating magnetic field, it can
induce an electrical current in an appropriately placed receiver coil (Figure 33). The point
for creating an MR image starts from when the RF pulse is switched off because this causes
signal changes.
Figure 33. The net oscillating magnetic field
produced by protons precessing in phase.
This net oscillating magnetic field can induce a
signal in a receiver coil that can then be
detected.
z z
y y
x RF x
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When the RF pulse stops, the protons release the absorbed energy and immediately try to
return to their equilibrium position, a process known as relaxation (Brown and Semelka,
2003). The longitudinal magnetisation will increase back to its original size, M0, and the
newly acquired transverse magnetisation will diphase due to slight differences in the
precession rates of individual protons (Figure 34). The process of relaxation is described by
two time constants, T1 and T2, corresponding to the longitudinal and transverse relaxation,
respectively.
After the application of RF, the longitudinal magnetisation is lost, and the magnetisation of
the tissue is in the transverse plane. When the RF stops, the time required for protons to
achieve longitudinal magnetisation again (63% of its original value) by releasing the
absorbed energy is the T1 relaxation time. The released energy is transferred to its
surroundings (the ‘lattice’); therefore, the longitudinal relaxation is also referred to as spin-
lattice relaxation. In comparison, transverse relaxation occurs because each proton
experiences a slightly different magnetic field (due to inhomogeneities in the B0 field and to
interactions with surrounding protons), causing each one to naturally precess at a different
frequency. The net result is that when the RF pulse is switched off, protons lose their phase
coherence and the transverse magnetisation decays. The time required for the transverse
magnetisation to decay to 37% of its initial value and is the T2 relaxation time. The released
energy is transferred from an excited proton to a neighbouring proton; therefore, the
transverse relaxation is called spin-spin relaxation. If efforts are made to minimise the
external field inhomogeneities, then transverse relaxation is described by the constant T2,
and if inhomogeneities are present, then the dephasing will be more rapid, and the process
is described by a shorter constant termed T2* (‘T2 star’). Because dephasing is a very rapid
process, longitudinal relaxation (T1) takes much longer than transverse relaxation (T2)
(Brown and Semelka, 2003).
Diseased tissues can be identified on MRI because the protons in their tissues return to
their equilibrium at different rates. This is due to the physicochemical environment which is
different in different tissue types and is affected by pathological changes. Protons that are
tightly bound within large molecules such as lipids, proteins or carbohydrates, will not be
‘seen’ on conventional scans because they will lose their magnetisation to surrounding
molecules very quickly (i.e. they have a short T2). The unbound, ‘free’ water protons (with
a long T2), both intracellular and extracellular, are the protons whose movements are
detected by MRI.
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The Spin Echo experiment
The spin echo (SE) sequence is the most commonly applied sequence in neuroradiology
(Tress and Brant-Zawadski, 1985). It can be used to image tissues with different T1 and T2
relaxation properties resulting in T1-weighted and T2-weighted images and uses two RF
pulses. First, a 90° pulse is applied to create the detectable oscillating transverse
magnetisation which induces a signal in a receiver coil. This signal is rapidly lost due to
dephasing as a result of T2* decay. Next, a 180° pulse, called the refocusing pulse, is
applied and this refocuses the lost phase coherence. This pulse tips the protons by 180° in
the transverse plane. This has the effect of speeding up the protons which are precessing
more slowly, allowing them to ‘catch up’ with the faster precessing ones (Figure 34). At
this stage, protons again precess coherently, and this generates an oscillating magnetic
field, detectable by a receiver. The rephasing of protons and the detection of the signal is
termed the echo or echo collection.
Figure 34. Applications of the 90° and 180° RF pulses
After the RF pulse is switched off the protons diphase (A, B, C; top). The
180 pulse reverses their precession directions, restoring phase
coherence (D, E, F; bottom).
The time to echo (TE) is the time between the application of the 90° pulse and the peak of
the detected signal (Jackson et al., 1997; Scherzinger and Hendee, 1985). To create an
image, the experiment must be repeated many times; therefore the 90° and 180° pulses
are repetitively applied. The time between consecutive applications of the 90° pulse is the
time to repeat (TR). The SE sequence may be depicted by a pulse sequence diagram, as
shown in Figure 35.
90
A B C
180
D E F
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Figure 35. Pulse sequence diagram for a simple spin echo NMR experiment.
Consequently, TE and TR determine the resulting image contrast depending upon the
differences in T1 and T2 relaxation times (Jones et al., 1992). If a long TE is used, at the time
of echo collection protons with a short T2 will have dephased, whereas those with a longer
T2 (i.e. longer than the TE) will not. Therefore, tissues with a short T2 will return little NMR
signal and appear dark on T2-weighted images, whilst those with a longer T2 will return a
high signal and appear bright. If a T1-weighted image is required, then a short TR is chosen,
meaning that tissues with a long T1 will not have had the time to regain their original
longitudinal magnetisation, and will give a smaller NMR signal following their next
excitation. If the T1 is short, the signal is high (bright on the image); if the T1 is long, then
the signal is low (dark on the image).
The T1 and T2 properties of protons tend to vary together. In biological tissues, T1 is usually
of the order of 300 to 2000 ms, and T2 of the order of 30 to 150 ms. Tissues with very
mobile protons have longer relaxation times; e.g. CSF has a long T1 and a long T2. More
structured tissues have a shorter T1 and T2 because they contain less mobile protons that
readily exchange energy with their surroundings. Pathology usually increases the water
content in tissues and the mobility of protons; this causes lengthening of the T1 and T2 of
healthy surrounding tissues.
Creating an MR image
In order to create a meaningful image, additional information regarding the spatial location
of the NMR signals into the three dimensional space is required. To do this, magnetic field
gradients that convert information about physical position into frequency data are briefly
180 180
90 90
RF pulses
TE
TR
echo NMR Signal
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applied during the imaging sequence in order to localise the signal coming from each voxel
of tissue. These can induce protons in different positions along them to have different
precession frequencies. Three types of gradients are applied along the three orthogonal
axes of the scanner magnet coordinate system. These gradients are termed the slice-
selection (z axis), frequency-encoding (x axis) and phase-encoding (y axis) gradients.
The slice-selection gradient allows slices of tissues to be selectively excited, depending on
the range of frequencies of the RF pulse applied. This gradient is then switched off, and the
other two gradients are then applied. These latter gradients will help to determine where
the point on the slice from which the signal arises is located by altering this signal. The
frequency-encoding gradient is applied in the x axis direction resulting in different
precession frequencies along this axis. Each resulting signal of different frequencies
contributes to the net NMR signal emitted by the slice. After the frequency-encoding
gradient, a third y axis gradient, called the phase-encoding gradient, is very briefly applied
to finally localise a given tissue volume element. This results in a different precession
frequency along the y axis. The signal created by the dephasing of the protons in their new
y axis positions will be collected when this gradient is switched off. It should be noted that
the frequency- and phase-encoding gradients may each be applied to either the x or y axis.
The spatial resolution is determined by a factor called the gradient-time product, or κ. This 
corresponds to the achievable spatial resolution of the image and depends on the gradient
amplitude (G) and the time for which it is applied according to the equation:
Κ = Gt
This is because larger field gradients enable spins that are closer together to be
differentiated. Therefore, the larger the field gradient, the smaller the image features
received and the higher the resolution. Using digital sampling, a two-dimensional κ space 
matrix is created from the collection of the NMR signal at different time points on the x and
y axes.
The final MR image will therefore depend on two types of factors; the intrinsic parameters
(that are related to the tissue) and the extrinsic parameters (related to the scanner and set
by the physician or technologist). Changing the parameters of the scanner allows the
creation of contrast between tissues and allows them to be distinguished. It creates images
utilising the extrinsic scanning parameters (TE, TR, field of view, slice thickness, slice gap
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and resolution), and the intrinsic (physical and chemical) properties of atoms within tissues
(including spin angular moment, local magnetic field, spin-lattice relaxation and spin-spin
relaxation) (Jackson et al., 1997; Tress and Brant-Zawadski, 1985). Based on these
parameters, pulse sequences are selected which correspond to the manner in which the RF
pulses. A pulse sequence defines the manner in which the RF pulses and magnetic gradient
fields are applied (Jackson et al., 1997; Scherzinger and Hendee, 1985).
Echo planar imaging
In conventional SE, repetitive excitations are performed and echo collections are
successively performed to obtain an MR image. Echo planar imaging (EPI) is a technique
that was proposed to overcome the need for repetitive excitation pulses and to shorten the
time of image acquisition. This technique allows image data to be collected from a single
excitation pulse with an infinite TR. During this single excitation, the EPI collects the whole
of the κ matrix because it traverses the κ space rapidly (in the time taken for the NMR
signal to decay). For optimal resolution, large gradients in each spatial dimension are
required as these determine the gradient-time product.
However, rapidity is underpinned by serious disadvantages; mainly the vulnerability to
certain types of image artefact and distortion, especially at interfaces between tissue types
(e.g. air and bone), causing a magnetic susceptibility artefact. This results in signal dropout
and a geometric distortion of the image. The susceptibility artefact with specific reference
to CMBs and CMB mimics will be discussed in the next paragraphs.
Gradient-recalled echo principles
An important aspect of MR is that the magnetic field is never 100% homogeneous. This
inhomogeneity may arise from the main scanner magnetic field inhomogeneity (due to
nearby building walls and metals) and tissue-induced non-uniformity.
When a tissue is placed in a magnetic field, its different parts behave differently because of
their intrinsic paramagnetic properties. A paramagnetic effect on the local magnetic field is
called magnetic susceptibility. Interfaces between soft tissues, e.g. bone and air (which
have different magnetic susceptibility properties), also make the applied magnetic field
inhomogeneous (Roberts and Mikulis, 2007). The problem of susceptibility can be solved by
applying a second redirecting or refocusing RF pulse (Brown and Semelka, 2003). In cases
where the second redirecting RF pulse is not applied, ongoing dephasing of the protons
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
108
occurs and their vectors remain incompletely aligned. This results in low signal on MRI
(Brown and Semelka, 2003; Rajan, 1998).
Certain tissues, e.g. blood break down products (haemosiderin, deoxyhaemoglobin and
methemoglobin) have paramagnetic properties (positive magnetic susceptibility) and when
they are imaged by MRI, augmented spin dephasing and signal loss is observed. This effect
causes these tissues to appear as larger areas of signal loss on MR images than the original
size of the paramagnetic material, and is called the blooming or T2* effect (Koennecke,
2006; Roberts and Mikulis, 2007; Viswanathan and Chabriat, 2006). When imaging CMBs,
this T2* effect is critical, since they are only seen due to their susceptibility effect.
A gradient-recalled echo (GRE) sequence is a pulse sequence significantly faster than SE
sequences. As mentioned above, there is no 180° pulse (the refocusing pulse) and the
single RF pulse is less than 90°. This reduces the scan time, but increases the signal-to-noise
ratio. As the TE is increased, more artefacts are generated and signal loss becomes more
prominent (Jackson et al., 1997). The images obtained are termed as T2*.
Due to the absence of a redirecting RF pulse, the susceptibility-related signal loss increases
because of the field inhomogeniety, i.e. the T2* effect is emphasised, as discussed earlier.
Thus, this sequence positively exploits the magnetic field inhomogeneities. This type of
imaging protocol is termed a T2*-weighted GRE sequence (Brown and Semelka, 2003;
Jackson et al., 1997; Rajan, 1998; Scherzinger and Hendee, 1985) and is used in a variety of
clinical implications where paramagnetic blood breakdown products are to be detected
(Jackson et al., 1997; Roberts and Mikulis, 2007; Scherzinger and Hendee, 1985).
T2* GRE sequences are very sensitive to the inhomogeneity of the magnetic field produced
by the tissues. Each tissue has a specific way to respond to a magnetic field called the
magnetic susceptibility. At the interface between tissues, the inhomogeneity caused by the
magnetic susceptibility of the different tissues (soft tissues, bone, air) results in a local
disparity causing signal loss. This signal loss is called the magnetic susceptibility effect (fast
decay of the local MRI signal). Thus, when GRE T2* is applied to a tissue containing
materials with paramagnetic properties, signal loss can be detected. Based on these
properties, GRE T2* has a wide range of clinical applications (Roberts and Mikulis, 2007).
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2.2.2 Detection of cerebral microbleeds
Signal loss with cerebral microbleeds
The types of sequences used and tissue magnetic properties such as relaxation times and
proton density result in varying contrasts in MR images. Relaxation times are transverse
(T2) and longitudinal (T1), and vary for different types of tissue. Theoretically, tissues with a
long T1 will appear as a low signal on T1-weighted images and tissues with a long T2 will
show as bright on T2-weighted images. Two factors influence the relaxation times of a
tissue: the distribution of water within the tissue, and the surroundings. Among the
surroundings, paramagnetic substances such as metals, have a strong effect on the
relaxation times; they form a region of magnetic field inhomogeneity surrounding the
paramagnetic centre (Stankiewicz et al., 2007). One of the metals that is commonly present
in the human brain is iron, where it exists in the form of ferritin and haemosiderin and can
be visualised by MRI because it is present in sufficient quantity and in the right oxidation
state (Schenck, 2003; Schenck and Zimmerman, 2004). Histopathological studies have
demonstrated that CMBs contain haemosiderin deposits (Schrag et al., 2010; Tatsumi et al.,
2008a), a paramagnetic substance (Schenck and Zimmerman, 2004). Therefore, CMBs will
cause a decrease in the T1 and T2 relaxation times.
Sequences sensitive for the detection of cerebral microbleeds
MRI provides a unique opportunity to detect blood residues of ICH throughout life. CMBs
are composed of blood-breakdown products (haemosiderin, deoxyhaemoglobin and
methemoglobin) which are paramagnetic and hence have considerable internal
magnetisation when exposed to an MRI field (Greenberg et al., 2009b). This internal
magnetisation generates local inhomogeneity in the magnetic field that surrounds the
brain CMB and causes the susceptibility effect described above and concurrent signal loss
(Brown and Semelka, 2003). FSE pulse sequences had a relative lack of sensitivity to
magnetic susceptibility effects. T2*-weighted gradient recalled-echo (GRE) MRI enhances
the magnetic susceptibility (and resultant signal dropout) caused by haemosiderin, thus
increasing the sensitivity for haemorrhages (Atlas et al., 1988). The sequence has a high
sensitivity for differences in magnetic susceptibility, and shows a higher sensitivity than
conventional or FSE T2-weighted imaging for detecting previous small areas of bleeding
(Greenberg et al., 1996; Roob et al., 1999b; Chan et al., 1996). Because haemosiderin
remains stored at the site of a haemorrhage for many years, T2* GRE MRI is suitable to
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
110
assess the presence of past haemorrhages and is valuable in detecting chronic and small
haemorrhages (Atlas et al., 1988; Offenbacher et al., 1996; Schenck and Zimmerman,
2004). Nowadays, iron-sensitive MRI sequences (mainly GRE T2* MRI and susceptibility
weighted imaging [SWI]) are used to detect CMBs. As GRE T2* MRI has a greater sensitivity
to susceptibility variations than SE and FSE techniques (Atlas et al., 1988), it is commonly
used to detect blood-breakdown products resulting from haemorrhages and CMBs, and
using a 1.5T field strength, it is the most commonly used technique. However, technical
developments in this field are rapid, and it is likely that in the future, higher field strengths,
thinner slices, and newer sequences (including SWI) will make CMBs a very common
finding, especially in the elderly.
Because the blooming effect that characterises CMBs differs markedly with different MRI
parameters (field strength, slice thickness, TE, interslice gap, TR, flip angle [FA], and matrix
size), CMB detection may depend upon the specific MRI sequence used. Consequently,
longer TEs (Tatsumi et al., 2008a), increased magnetic field strength (3T versus 1.5T)
(Scheid et al., 2007), and new techniques such as thin section SWI (Nandigam et al., 2009)
enlarge the susceptibility effect and, hence, may increase the size and number of CMBs
detected compared to standard GRE T2* MRI sequences.
Susceptibility weighted imaging
SWI differs from GRE T2* images in that high resolution 3D gradient-recalled echo
sequence with a long echo time utilising both magnitude and phase are created (Sehgal et
al., 2005). These features make SWI more sensitive to detect CMBs than conventional
gradient-echo T2* sequences (Nandigam et al., 2009), and currently SWI is the most
sensitive technique to visualise CMBs in vivo (Ayaz et al., 2010). SWI can ‘magnify’ the size
of the smallest bleeds (<1mm) up to three-fold (Schrag et al., 2010), and up to four times as
many CMBs can be detected by SWI compared to conventional GRE T2* MRI (Nandigam et
al., 2009).
The MR signal after Fourier transform is a complex signal resulting in a formation of real
and imaginary images (Charidimou et al., 2013b). The combined real and imaginary parts
form the magnitude images, which are used in conventional MR images. Also derived after
the Fourier transform are phase images, which traditionally have been discarded as they
are sensitive to both local field inhomogeneities as well as unwanted magnetic field
inhomogeneities (Haacke et al., 2011) (Figure 36). By using high-pass filtering techniques to
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
111
remove large-scale inhomogeneities, the utility of the phase images is increased (Haacke et
al., 2004). Important information is contained within the phase images, including
differences in magnetic field strength in a particular voxel compared to the overall
magnetic field. Therefore, the combination of both the phase and magnitude images into a
single susceptibility-weighted image can be used to demonstrate blood products better
than using magnitude images alone (Ayaz et al., 2010).
An added advantage of using the phase information is the ability to differentiate between
blood products, which are paramagnetic, and calcification or mineralisation, which are
diamagnetic (Charidimou et al., 2013b). On SWI-filtered phase images, calcium carbonate
appears with the opposite-sign phase compared to haemosiderin (Wu et al., 2009). A
further component of SWI that aids in differentiating between CMBs and their mimics is
the use of minimum intensity projection (mIP) images. These images are taken over a
number of sections and so help to discriminate between CMBs and blood vessels, as they
are able to assess vessel continuity (Haacke et al., 2011).
Defining cerebral microbleeds: rationale
CMBs are an increasingly common radiological finding in stroke, neurological and general
medical practice. Finding CMBs in the brain can raise a number of clinical questions
regarding the safety of antithrombotic drugs, the risk of recurrent symptomatic ICH,
Figure 36. Post-processing steps to create a susceptibility-weighted image (SWI) in an elderly
patient with CAA.
Thin section magnitude images are multiplied by unwrapped phase images (usually to the power of 4)
to produce susceptibility-weighted images. This process increases the contrast between paramagnetic
substances such as CMBs and surrounding tissue. The visibility of CMBs and cerebral veins (which
contain paramagnetic deoxyhaemoglobin) is further enhanced by the generation of minimal intensity
projection (mIP) images. The final image shows multiple strictly lobar CMBs and cortical superficial
siderosis.
From Charidimou et al., 2013b
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cognitive decline and clinical deterioration. These risks may depend on the presence of
CMBs, but also their number and their anatomical distribution (e.g. lobar versus deep) in
the brain. These questions are of clinical relevance, particularly as CMBs may be helpful in
diagnosing small-vessel arteriopathies (including CAA) non-invasively in life. In order to
tackle these questions, it is important to be able to reliably define and map CMBs in the
brain. This may be challenging because of the many other lesions seen on MRI with similar
morphological or signal characteristics (CMBs mimics, discussed in more detail in section
2.2.3).
Although there has been general agreement on the radiological properties of CMBs, there
has until recently been a lack of standardised specific criteria with which to define them.
Many research units have used in-house CMB rating methods, and although reliability
(intra- and inter-observer agreement) has been reported, the exact methods used (detailed
CMB definition criteria, anatomical boundaries, etc.) have not usually been fully described.
A standardised approach with clearly described criteria for CMBs and their anatomical
location may be helpful in improving reliability and allowing results from different centres
to be compared. To date, there are two published CMB rating scales that have been
validated in hospital cohorts of stroke patients. One of these scales was developed as part
of this thesis (see Chapter 4). The radiological criteria for defining CMBs and an
introduction to these standardised rating scales will now follow. The potential for
automatically detecting and mapping CMBs in the future is discussed briefly at the end of
the MRI section on CMBs.
How should cerebral microbleeds be defined?
Since the emergence of MRI techniques allowing the detection of CMBs, definitions of the
MRI criteria for identifying CMBs have varied. However, all studies have used features
relating to shape (described variously as rounded, dot-like, ovoid, spherical), size (small)
and signal characteristics on MRI sensitive to susceptibility effects (dark or black, and of
homogeneous signal). Using these criteria, most radiological lesions defined as CMBs do
correspond to haemosiderin deposition in relation to pathologically abnormal small vessels
(Fazekas et al., 1999; Schrag et al., 2010), sometimes related to microaneurysms (see
section 2.1). Although many papers have described the various radiological features used
to distinguish CMBs, the first consensus criteria for their identification were not published
until 2009 (Greenberg et al., 2009a). On appropriate MRI sequences (typically GRE T2*or
SWI) CMBs are defined as round or ovoid (rather than linear or curvilinear) foci of
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homogeneous signal intensity loss. Irregularly shaped areas (e.g. linear, curvilinear, star-
like) of signal loss or hypointense lesions with a diameter greater than 10 mm are
considered old scars of ICH or ‘haemorrhagic lacunes’. This definition has the purpose of
excluding larger ICHs (‘macrobleeds’), subarachnoid blood or siderosis, specific secondary
causes of bleeding (e.g. arteriovenous malformations or tumours) and non-haemorrhagic
causes of low signal (e.g. mineralisation, regions of air-bone susceptibility-related signal
loss). These and other common mimics of CMBs are considered further in this chapter.
Examples of typical CMBs are shown in Figure 37 and Figure 38.
Figure 37. MRI example of a CMB (1)
GRE T2*-weighted MRI (left panel) and FLAIR sequence (right panel) of a 78 year old hypertensive
man who developed a sudden onset of weakness in the right side of his face, arm and leg. The GRE
T2*-weighted MRI shows a CMB (red arrow) in the left thalamus and several CMB mimics: vessel at
the bottom of the sulcus (white arrow) and hypointensities in the basal ganglia due to calcification or
iron deposition (black arrows). The FLAIR sequence (right panel) shows extensive white matter
disease and areas of previous infarction (but no CMBs).
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To date, there has been general agreement on a CMB cut-off size of 5-10 mm in diameter
on standard GRE T2*-weighted MRI sequences, although in some studies, the minimum
diameter used was 2 mm (Cordonnier et al., 2007). However, it should be appreciated that
the measurement used for a radiological lesion is not a true reflection of the actual size of
the CMB, due to the ‘blooming’ effect of the MRI signal at the lesion border (Greenberg et
al., 2009a) meaning that the actual tissue lesion size is usually considerably smaller, and
generally significantly less than approximately 5 mm (Schrag et al., 2010). Indeed,
haemosiderin deposits exert a high susceptibility effect on the local magnetic field, which
results in a larger area of signal loss (Greenberg et al., 2009b; Viswanathan and Chabriat,
2006). Some recent lines of evidence suggest that a rigid size definition for CMBs should
not be emphasised. First, CMB size may be affected by imaging parameters including
magnetic field strength and MR sequence characteristics, including the TE. Post-processing
techniques including SWI can further increase the size, conspicuity and number of CMBs
detected (Greenberg et al., 2009b). In fact, the smallest CMBs (< 1 mm) can be magnified
up to threefold on SWI or high-resolution three-dimensional GRE T2* sequences because of
the blooming effect (Greenberg et al., 2009b). Therefore, if an absolute size criterion is
applied, the definition of CMBs even in the same subject could markedly change depending
on which MRI sequence is used. Second, a recent study of lesion volumes in 46 patients
with probable CAA showed that brain haemorrhage volumes in this population did not
Figure 38. MRI example of a CMB (2).
T2-Weighted MRI (left panel) and GRE T2*-weighted MRI (right panel) from a patient with severe
hypertension who was admitted with a clinical lacunar syndrome due to a small subcortical
haemorrhage. She had stopped her antihypertensive medication before admission. Numerous CMBs
are visible in the brainstem on GRE T2*-weighted MRI but not on T2-weighted MRI.
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form a single continuum between CMBs and macrobleeds. Rather, they showed a clearly
bimodal distribution with a cut-off point of 5.7 mm, which interestingly falls within the
lower end of the most commonly used CMB upper cut-off size of 5-10 mm (Greenberg et
al., 2009b). Whether this finding holds true in other populations of patients with CMBs (e.g.
those with IS) requires further investigation. For the moment, it remains reasonable to
assume that radiological lesions much larger than approximately 5-10 mm should not be
considered to be CMBs. Based on these principles, consensus MRI diagnostic criteria for
CMBs have been proposed (Greenberg et al., 2009b) and are shown in Table 7. It should be
noted though that these criteria do not include any indication of size for CMB
identification.
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Table 8. Recommended criteria for the identification of CMBs
From Greenberg et al., 2009b
2.2.3 Cerebral microbleed mimics
The correct identification of CMB mimics is critical for the investigation of the prognostic
and therapeutic significance of CMBs. CMB mimics have similar characteristics as CMBs on
T1- and T2-weighted SE and GRE T2*-weighted MRI (Greenberg et al., 2009b). Common
mimics to consider are mainly of two types: mimics that do not contain blood products
(partial volume artefacts, paramagnetic substances: iron and calcifications) and mimics that
do contain blood products (traumatic CMBs, cavernous malformations, haemorrhage with
areas of infarction, flow voids from blood vessels, haemorrhagic metastases). Examples are
shown below. For each type, awareness of the imaging hallmarks and location
characteristics will reduce misinterpretation with true CMBs.
Mimics that do not contain blood products
Paramagnetic substances
Calcium, manganese and iron are paramagnetic substances that may appear as foci of low
signal on GRE T2* sequences. The most frequent mimic in older adults is mineralisation in
the basal ganglia, which may be associated with disorders of calcium metabolism,
extrapyramidal syndromes or neuropsychiatric disorders (Casanova and Araque, 2003). CT
Criterion Rationale
1. Homogeneous hypointense (black)
on T2*-weighted MRI or SWI
To ensure the lesion is paramagnetic and likely to contain blood
degradation products
2. Well-defined rounded or ovoid
lesions (rather than linear)
To exclude blood vessels and distinguish CMBs from cortical
subarachnoid blood or superficial cortical siderosis (the latter may have
separate relevance for diagnosing small vessel arteriopathies)
3. ‘Blooming’ effect on T2*-GRE MRI
and SWI compared to T1- or T2-
weighted sequences
Ensures that the lesion has susceptibility effect
4. Devoid of signal hyperintensity on
T1-weighted or T2-weighted
sequences
To avoid misclassifying some mimics, including cavernous
malformations (bright on T2), metastatic melanoma (bright on T1)
5. At least half of lesion surrounded by
brain parenchyma
To include very superficial cortical lesions which may be seen in CAA
6. Distinct from other mimics such as
iron or calcium deposits, bone, or
vessel flow voids
A reminder to consider these mimics
7. Clinical history excluding traumatic
diffuse axonal injury
To avoid mixing secondary traumatic CMBs with ‘primary’ CMBs
caused by small vessel disease
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may be helpful to distinguish susceptibility effects of calcification or iron deposits from
CMBs (Figure 39). In the posterior fossa, physiological iron deposits also occur in the
dentate nuclei.
Figure 39. Basal ganglia mineralisation mimicking CMBs.
GRE T2* MRI demonstrates bilateral hypointense foci in the basal
ganglia (right), corresponding to calcifications on axial CT brain (left).
Partial volume artefacts
In the brain, partial volume artefacts from adjacent bony structures can cause difficulties to
the inexperienced observer. Partial volume artefacts result from the loss of signal to noise
ratio secondary to the loss of contrast between different tissues. This may occur in
different areas of the brain, i.e. the petrous temporal bones, paranasal sinuses, frontal
bones, orbit and occipital bones (Figure 40). Problems from misclassifying CMB mimics can
be minimised by careful inspection of adjacent slices and reference to T2, FLAIR and
diffusion-weighted images.
Air embolism, iatrogenic devices and metallic embolism
A case of cerebral air emboli causing multiple, bilateral, small round foci of hypointensity
on GRE imaging has been reported (Jeon and Kang, 2007). There are several descriptions of
multifocal GRE hypointensities caused by embolization of metallic fragments from
prosthetic heart valves (Almansori et al., 2008). Non-metallic ventricular shunt tubes in
cross-section can also mimic CMBs (Tsushima and Endo, 2006).
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Figure 40. CMB mimic resulting from partial volume artefact on
axial GRE T2* MRI
The partial volume artefact is adjacent to the frontal (upper panels)
and occipital (lower panels) bones.
Mimics containing blood products
Blood vessels
Vascular flow voids in pial and leptomeningeal vessels in the cerebral sulci may be mistaken
for CMBs on GRE T2* MRI, especially when seen in cross-section. Flow voids from vessels in
the deeper structures of the brain can also be mistaken for CMBs. Keys to differentiate
them from CMBs are the absence of any ‘blooming’ effect when compared with T2 (CMBs
appear bigger on GRE T2 compared with T2-weighted MRI, whereas vessels do not), and
their linear shape on consecutive axial slices (Figure 41).
Haemorrhagic transformation of an infarct
Identification of this particular type of mimic is possible from the clinical history and review
of other MRI sequences (T2-weighted, FLAIR and DWI essentially). Small petechial
haemorrhages may be seen within, or along the margin of, the infarct.
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Figure 41. GRE T2* MRI (left) and T2-weighted MRI (right) of the
brain showing the flow void of a leptomeningeal vessel.
The leptomeningeal vessel is imaged in cross-section (white arrow),
and a petechial haemorrhage is visible within an area of infarction
(grey arrow).
Cavernous malformations
Cavernous malformations are well-circumscribed nodules compsed of clustered dilated
vessels without intervening neural tissue. They have been categorised into 4 types based
on their MRI appearances (Raychaudhuri et al., 2005). Larger cavernomas have a
characteristic hypointense rim of haemosiderin with a core of variable signal intensity
giving them a characteristic ‘popcorn’ appearance (Rigamonti et al., 1987). Smaller (type IV)
cavernomas appear as punctuate hypointense lesions on T2*-GRE images and can be
indistinguishable from CMBs. To what extent these punctuate lesions, especially in isolation
and without relevant family history or mutation, are distinct from CMBs is not clear.
Traumatic cerebral microbleeds
Traumatic brain injury causes rapid rotational acceleration and deceleration of the brain
leading to shearing of axons in susceptible regions (e.g. gray-white matter junction,
splenium of corpus callosum, internal capsule, dorsolateral brainstem) (Hortobagyi and Al-
Sarraj, 2008). Traumatic CMBs can form as a result, but these CMBs are considered as CMB
mimics as they are secondary to diffuse axonal injury rather than related to small vessel
disease. The presence of other traumatic lesions e.g. skull fracture, contusions should alert
the clinician of the correct diagnosis.
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2.3 Prevalence
2.3.1 In healthy individuals
Both high risk populations and community based studies have shown a high prevalence of
CMBs in the general population.
Overall prevalence
MRI studies using GRE sequences have demonstrated CMBs in 18% of individuals between
the ages of 60 to 69 years and in 38% of individuals older than age 80 (Vernooij et al.,
2008b). Earlier studies found CMBs in approximately 5-6% of the healthy elderly population
(Roob et al., 1999b; Jeerakathil et al., 2004b; Cordonnier et al., 2007; Koennecke, 2006),
and up to 11% in a community-based sample, a prevalence which further increased with
age (Sveinbjornsdottir et al., 2008). Recent studies report a generally higher prevalence of
CMBs than older studies, due to 2 factors: (1) advancements in imaging protocols with
increased sensitivity and rating scales (Greenberg et al., 2009b) (2) testing of older cohorts,
as with rising age, the incidence of hypertension, a strong risk factor for CMBs, increases
(Roob et al., 1999b; Vernooij et al., 2008b).
The reported prevalence of CMBs in community-based cohorts varies by age and MRI
methods used. Four population-based studies with reported prevalence on CMBs in normal
individuals are reported in Table 8. These studies are: (1) the Austrian Stroke Prevention
Study (ASPS); (2) the Framingham study; (3) the Age Gene/Environment Susceptibility
(AGES)-Reykjavik study; and (4) the Rotterdam Scan study.
Overall, roughly 20% of the population shows evidence of small, focal areas of brain
bleeding (Fisher, 2012), and by age 80, that prevalence is nearly 40% (Vernooij et al.,
2008b). Even if these numbers are impressive, there may well be an underestimation of the
actual prevalence of CMBs as the prevalence data are based on MR studies using a 1.5
Tesla field strength. If higher sensitive techniques (e.g., SWI, 3 Tesla MR) were used then
these would show an even more robust prevalence (Nandigam et al., 2009).
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Table 9. Prevalence of CMBs in normal individuals.
Cohort No Mean
Age
(years)
Prevalence
of CMBs [No
(%)]
MRI sequence Inter-rater
agreement
(kappa)
Definition
of CMB
Austrian Stroke
Prevention Study
280 60 18 (6.4) 1.5 T, TR 600-800 ms,
TE 16-20 ms, FA 20°,
slice thickness 5mm,
interslice gap 10%
0.4-0.65 2-5 mm
Framingham
Study
472 64.4 22 (4.7) 1.0 T, TR 760 ms, TE
26 ms, FA 30°, slice
thickness 5 mm,
interslice gap 0.5 mm
0.33-0.57 <10 mm
AGES-Reykjavik
study
1962 76 218 (11.1) 1.5 T, TR 3050 ms, TE
50 ms, FA 90°, slice
thickness 3 mm,
matrix 256 x 256, FOV
220 mm
0.71-0.73 No size limit
Rotterdam Scan
Study
1062 69.6 250 (23.5) 1.5 T, high-resolution
3-dimensional T2*-
weighted GRE
sequence; TR 45 ms;
TE 31 ms, FA 13°,
slice thickness 1.6
mm, matrix 320 x 224
0.85-0.87 <10 mm
Differences of prevalence among different ethnic groups
In relation to cerebrovascular disease
CMBs are common in all types of stroke, but are more common in ICH than in IS
(Cordonnier et al., 2007). Likewise, CMBs are more prevalent in patients with recurrent
ischaemic and haemorrhagic stroke than in first-ever strokes (Cordonnier et al., 2007;
Koennecke, 2006). Moreover, numerous studies have demonstrated that the frequency
and extent of CMBs are associated with the severity of the white matter hyperintensities
(Gorner et al., 2007; Jeong et al., 2004; Kato et al., 2002; Lee et al., 2005; Naka et al., 2004;
Roob et al., 2000). This suggests that CMBs may be a biomarker of the severity or degree of
progression of the underlying cerebrovascular disease. The development of CMBs is in
close relation to the severity of cerebral microangiopathy. Histopathological investigations
confirming this were detailed in section 1.3.1.
In a recent review of CMB studies, it was noted that in different stroke subpopulations,
Asian samples tended to have a higher prevalence of CMBs than those based on
presumably similar cases who were not of Asian ancestry (IS: 41.5% Asian versus 21.5%
non-Asian; ICH: 68% Asian versus 47% non-Asian) (Cordonnier et al., 2007; Koennecke,
2006). A small pilot study suggested significant black-white racial differences in the
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frequency and topography of CMBs in patients with ICH (Copenhaver et al., 2008), but it
was limited by the small numbers and retrospective design. Although the analyses were
adjusted for risk factors such as age and hypertension, other confounding factors may have
played a role and were not adjusted for (e.g socio-economic status). Variations in
prevalence among different ethnic and racial groups are difficult to interpret due to
variations in the samples and methodologies, lack of adjustment for important confounding
factors, and very scarce data.
In relation to Ischaemic stroke
The prevalence of CMBs in patients with IS varies widely, due to the heterogeneity of the
stroke subpopulations studied and the etiological mechanisms in IS. Three studies have
provided data on the detection rate of CMBs according to stroke subtype (Imaizumi et al.,
2004; Kato et al., 2002; Naka et al., 2004). In spite of substantial heterogeneity in these
three studies, the rate of CMBs in each subtype was as follows: 20% in atherothrombotic
stroke, 23% in cardio-embolic stroke, and 53% in small vessel occlusion. Based on a pooled
analysis of 1075 patients, the prevalence of CMBs among people with IS is 33.5% (range: 12
to 71%) (Cordonnier et al., 2007) and this prevalence increases with age (Imaizumi et al.,
2008). In patients with IS, differences in prevalence of CMBs are also observed among
different ethnic groups: CMBs are more prevalent among Asian subjects than non-Asian
(Cordonnier et al., 2007).
Non-traumatic intracerebral haemorrhage
The overall prevalence of CMBs in non-traumatic ICH is 60.4%, ranging from 47% to 97%,
which is considerably higher than in IS cohorts (Cordonnier et al., 2007). In patients with
deep ICH, the prevalence of CMBs increases with age (Kwa et al., 1998). Differences in the
prevalence of CMBs are also observed among different ethnic groups; CMBs are more
prevalent among Asian subjects than non-Asian, possibly due to confounding by the higher
prevalence of hypertension in Asian studies (Cordonnier et al., 2007) but in parallel with
the higher proportion of ICH in stroke in Asian populations (Koennecke, 2006). When
extrapolating data from black and white populations with ICH, blacks have a significantly
higher incidence of ICH than whites, being 17.5/100.000 versus 13.5, probably because of
the higher prevalence of hypertension among Blacks (Brott et al., 1986). However, in that
study, blacks were younger (mean age 58 versus 67 for whites) and more often
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hypertensive (74% versus 40%). The risk of ICH for hypertensive blacks was 4.4 times that
for normotensive blacks (Brott et al., 1986).
2.3.2 Cerebral microbleeds in other groups and diseases
Patients with memory impairment
In a memory clinic setting the prevalence of CMBs was found to be higher (17%) than
described in community samples, yet lower than in stroke patients (Cordonnier et al., 2006).
Interestingly, their incidence varied significantly according to diagnostic groups and
increased with increasing severity of cognitive impairment (10% of patients with subjective
complaints, 20% with mild cognitive impairment (MCI), 65% with vascular disease)
suggesting a possible link of CMBs with VCI. In AD, CMBs were reported in 26.8% of
subjects (Hanyu et al., 2003a) and another study of vascular disease also found a high
prevalence of CMBs in this population (Seo et al., 2007), thereby supporting this idea.
There is also some evidence that as the load of CMBs increases, brain function (e.g.
cognition) may be affected (Goos et al., 2009; Werring et al., 2004), though whether CMBs
directly and independently impact on brain function or are simply associated with the
general severity of small vessel diseases is not yet known. There are few prognostic studies,
but some data in a variety of different cohorts suggests that CMBs have a graded
relationship with VCI (Staekenborg et al., 2009) and functional decline or death (Greenberg
et al., 2004a; Henneman et al., 2009).
CADASIL
CMBs are also observed in some specific cerebrovascular conditions. Their overall
prevalence in CADASIL is 37.5%, ranging from 25 to 69% (Lesnik Oberstein et al., 2001;
Dichgans et al., 2002; Viswanathan and Chabriat, 2006; van den Boom et al., 2003). A large
two-centre cohort study of patients with CADASIL recently defined risk factors for CMB
which were detected in 35% of patients: the number of CMBs was independently
associated with systolic BP (Odds ratio [OR] 1.42 risk per 10 mmHg increase, p = 0.005), the
diagnosis of hypertension (OR 5.19, p<0.001), normalised white matter hyperintensities
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lesion volume (OR 1.16 risk per percent increase in volume, p < 0.001) and total normalised
lacunar infarct volume (OR 1.96, p = 0.004) (Viswanathan and Chabriat, 2006). These results
suggest that vascular risk factors such as hypertension may promote microhaemorrhage
from fragile small vessels prone to bleeding due to ultrastructural vessel wall modifications
caused by the NOTCH 3 mutation.
Moyamoya
CMBs are also very frequent in moyamoya disease, and are found in up to 44% of Asians
with this disease, depending on the type of MRI sequence used (Kikuta et al., 2005). CMBs
tend to occur in a periventricular distribution, in the temporal subcortical region, and basal
ganglia (Ishikawa et al., 2005). One study found that multiple CMBs may confer an
increased risk of subsequent ICH (Kikuta et al., 2008). Interestingly, a recent report
suggested that there is no association between CMBs and moyamoya-like vessels in
patients with atherosclerotic steno-occlusive disease (Tanaka et al., 2012).
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
125
2.4 Risk factors
With the growing interest in CMBs over the past decade, clinical and radiological risk
factors for CMBs are now reasonably well defined, the most important being increasing
age, arterial hypertension, neuroimaging correlates of cerebral small vessel disease (white
matter hyperintensities and lacunes), and APOE genotype (Koennecke, 2006; Werring,
2007). Ageing and chronic hypertension are the most consistent predictors of CMBs
(Cordonnier et al., 2007; Fiehler, 2006; Henskens et al., 2008; Jeerakathil et al., 2004b;
Koennecke, 2006; Kwa et al., 1998; Roob et al., 1999b; Tanaka et al., 1999; Vernooij et al.,
2008b; Werring et al., 2005; Greenberg et al., 2009a; Sveinbjornsdottir et al., 2008). Other
frequently reported risk factors include diabetes, cholesterol and antithrombotic drug use,
which have been shown in some, but not all, studies to increase the likelihood of CMBs.
2.4.1 Demographic factors
Most studies with a reasonable sample size and age distribution show CMB prevalence
increases with age (Cordonnier et al., 2006; Sveinbjornsdottir et al., 2008; Vernooij et al.,
2008b). An association with the male sex and increased CMB prevalence was found in two
studies (Jeerakathil et al., 2004b; Sveinbjornsdottir et al., 2008). Black-white and Asian-non
Asian differences in the frequency and topography of CMBs have been noted in various
studies, but such comparisons are difficult to interpret due to heterogeneity in samples.
2.4.2 Hypertension and other vascular risk factors
Hypertension is a recognised risk factor for CMBs. In patients with first-ever lacunar stroke,
high BP defined according to measures of ambulatory day and night BP was independently
associated with CMBs, with the association being the strongest for CMBs in the deep
regions of the brain (Staals et al., 2009). In the PROSPER study, only age and hypertension
distinguished elderly subjects with CMBs from those with no CMBs (van Es et al., 2008).
Again in this study, the association was the strongest for CMBs in the deep structures.
However, CMBs in the cortico-subcortical areas were also associated with an increased risk
of hypertension. In light of this it was suggested that CMBs may be a manifestation of
hypertensive-related microangiopathy that has reached an advanced stage in which blood
vessels are prone to bleeding (Kato et al., 2002; Werring, 2007). However, the close
correlation between ageing and hypertension itself may warrant further investigation into
this matter (Koennecke, 2006).
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Another way of looking at the association between CMBs and hypertension is to measure
target organ damage, i.e. cardiac ventricular wall thickness , aortic stiffness, glomerular
fitration rate (a measure of kidney function) or presence of retinopathy. Left ventricular
wall thickness, a marker of hypertension severity and duration, is associated with an
increased risk of CMBs (Lee et al., 2004b). In a study of patients referred for hypertension,
the presence of aortic stiffness (determined by aortic pulse wave velocity and central BP)
was not associated with CMBs but with imaging markers of CMBs (WML and lacunar
stroke) (Henskens et al., 2008). The risk of CMBs increases 1.8 to 1.9 fold with each
standard deviation (SD) rise in BP (Henskens et al., 2008). Likewise, a decrease in
glomerular filtration rate was significantly associated with CMBs in a study of 152 patients
with acute IS (Cho et al., 2009b).
There is increasing evidence that hypertension may influence the risk of developing new
CMBs over time. Excellent control of hypertension is advocated to avoid the risk of
developing CMBs; however, it has been seen that despite strict control of BP new CMBs
appear on follow up MRI scans in hypertensive patients with ICH (Imaizumi et al., 2003).
This topic will be developed further in Chapter 6.
CMBs are also associated with other vascular risk factors including smoking (Kwa et al.,
1998), diabetes (Cordonnier et al., 2007), previous ICH (Greenberg et al., 2004a), low total
serum cholesterol concentrations and low-density lipoprotein cholesterol (Lee et al., 2002).
In the population-based Rotterdam Scan study (Vernooij et al., 2008b), there was a
significantly increased likelihood that CMBs would be detected in users of any
antithrombotic drugs, with a slightly stronger association in those using platelet
aggregation inhibitors than in those using anticoagulant drugs. The risk associated with
these drugs had similar magnitude to that for WML (OR 1.6 and OR 1.7, respectively), after
controlling for age and sex. Risks were similar for strictly lobar and deep or infratentorial
CMBs. The study further suggested that aspirin use may increase the likelihood of CMBs
(Vernooij et al., 2009).
2.4.3 Pathological and radiological diagnoses underlying cerebral
microbleeds
There is robust evidence that imaging and pathological markers of hypertensive
arteriopathy and amyloid angiopathy increases the likelihood of CMBs. On pathology
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specimens, these bleeding-prone microangiopathies are termed lipofibrohyalinosis when
related to hypertension (Fazekas et al., 1999) and amyloid angiopathy when characterised
by the deposition of amyloid protein in the cerebral small vessels (Good et al., 1998). CMBs
have been associated with lacunes and extensive WML (leukoaraiosis) which have been
reported in both hypertensive arteriopathy and CAA (Cordonnier et al., 2007; Fiehler, 2006;
Greenberg et al., 2009b; Kato et al., 2002; Koennecke, 2006; Maia et al., 2006; Roob et al.,
1999b; Tanaka et al., 1999; Werring, 2007; Werring et al., 2005).
CAA is a major cause of lobar ICH and cognitive dysfunction in the elderly and is related to a
high prevalence of markers of small vessel disease, like WML and CMBs (Greenberg et al.,
1996; Viswanathan et al., 2008). As such, patients with possible or probable CAA (for which
the APOE ε4 allele is a marker) have been found to have significantly more often strict 
lobar CMBs compared to non-carriers (Sveinbjornsdottir et al., 2008; Vernooij et al., 2008b;
Werring, 2007). Conversely, cardiovascular risk factors, like hypertension, the presence of
lacunes and WML, are associated with CMBs in infratentorial (brainstem, cerebellum) or
deep (basal ganglia, thalamus) locations; and hence, CMBs in these regions may be
indicative of hypertensive/arteriosclerotic microangiopathy (Lee et al., 2004b; Roob et al.,
1999b; Vernooij et al., 2008b). However, trying to divide the distribution according to CAA
or hypertensive arteriopathy is likely to be an oversimplification as patients with CAA are
often hypertensive and may present with a mixed distribution of CMBs.
2.4.4 Genetic risk factors for cerebral microbleeds
Most genetic diseases exhibiting an increased susceptibility to CMBs are rare. Mutations
identified in CAA are characterised by misfolding of proteins, including Aβ, cystatin C, 
transthyretin and prions (Launer, 2011). CADASIL is a pure form of brain vasculopathy
caused by mutations in the NOTCH 3 gene (Chabriat et al., 2009) and CMBs are detected in
about a third of patients. Moyamoya is another example of genetic vasculopathy due to
mutations in genes responsible for encoding proteins in smooth muscle cells (Guo et al.,
2009), and is frequently associated with CMBs.
APOE is the only candidate susceptibility gene identified as risk for CMBs (Launer, 2011).
Associations of the APOE ε2 and APOE ε4 alleles with both ICH (particularly lobar) and CAA 
have been described (Biffi et al., 2010a; Rannikmae et al., 2013; Sudlow et al., 2006;
Tzourio et al., 2008). The mechanisms by which the APOE ε2 and APOE ε4 alleles cause CAA 
were developed in section 1.5. Strictly lobar CMBs are considered a diagnostic marker of
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CAA; they have been included in the modified Boston criteria for CAA (Linn et al., 2010).
There is now robust evidence that APOE ε4 carrier state is associated with CMBs 
(Cordonnier et al., 2007; Fiehler, 2006; Greenberg et al., 2009b; Kato et al., 2002;
Koennecke, 2006; Maia et al., 2006; Roob et al., 1999b; Vernooij et al., 2008b; Werring,
2007; Werring et al., 2005; Maxwell et al., 2011).. A recent metanalysis of the genetic
associations with CMBs suggested that APOE ε4 allele carriers are at higher risk of having 
CMBs, particularly in strictly lobar brain locations (Maxwell et al., 2011). The association
between ε2+ genotypes and strictly lobar CMBs was not significant in the analyses. Given 
the reported associations of APOE genotype with CAA and lobar ICH (Sveinbjornsdottir et
al., 2008; Vernooij et al., 2008b), this suggest that strictly lobar CMBs are a possible
biomarker of CAA. It is likely that with advances in technologies, more single nucleotide
polymorphisms will be identified.
CMBs have been reported in rare conditions caused by mutations that have been linked
with small vessel disease. Mutations in the genes encoding for some components of the
vascular basement membrane, such as type IV collagens, and forming the supporting
structure of the membrane, have recently been identified as risk factors for small vessel
disease in the brain. These mutations cause alterations to the vascular basement
membrane and may predispose to small vessel disease and haemorrhagic stroke. Type IV
collagens, and their most abundant types COL4A1 and COL4A2, are ubiquitous basement
membrane proteins. A novel COL4A1 mutation has recently been reported in a
normotensive patient with a history of infantile hemiparesis who later developed
spontaneous, recurrent ICHs (Vahedi et al., 2007). A brain CT at age 23 showed diffuse
leukoencephalopthy and multiple deep, hypodense lesions surrounded by calcifications
suggestive of vascular cavities and MRI showed numerous CMBs.
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Chapter 3 - Clinical Implications of Cerebral Microbleeds
The objectives of this chapter are to review the current knowledge on the
impact on CMBs on clinical factors including cognition, cerebrovascular
disease risk and on the safety of the use of antithrombotic and
thrombolytic treatments. It will also discuss other clinical manifestations
that have been associated with CMBs including transient attacks, and their
link with disability and death. At the end of this chapter the aims of this
thesis will be developed.
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3.1 Cognitive impairment
In this first section it will be discussed whether CMBs independently influence cognitive
functions. CMBs may be relevant in the study of cognition in healthy individuals, in patients
with AD and cerebrovascular disease, and in the study of VCI. A summary of the studies on
the impact of CMBs on cognition in different populations is given in Table 9 and these are
discussed in more detail below.
3.1.1 Cerebral microbleeds in normal populations
CMBs have been detected in about 5% of healthy individuals with no known neurological
disorder (Jeerakathil et al., 2004a; Roob et al., 1999b; Vernooij et al., 2008b). The
prevalence increases with age (Hachinski et al., 2006) and with the type of imaging method
used for CMB detection (Greenberg et al., 2009b). In one population-based study which
used an optimised SWI sequence, the prevalence of CMBs was about 40% in those over 80
years old (Vernooij et al., 2008b). However, studies of how CMBs could affect cognitive
function in healthy populations have been scarce. One recent study included 67% of adults
attending a self-funded screening examination in Japan, and CMBs were found in 6.8% of
these participants (Yakushiji et al., 2008), mainly in the cerebral lobes and deep white
matter, with a predilection for the frontal lobes. Lower scores on the mini mental state
examination (MMSE) were associated with the presence of CMBs, a shorter duration of
education and the presence of severe white matter hyperintensities. In particular,
‘attention and calculation’ subscores were lower in those individuals with CMBs than those
without. The authors speculated that CMBs may have direct effects of disrupting frontal-
subcortical circuits to account for this pattern of cognitive impairment. One criticism of this
study is that because participants were self-referring, the results may not be generalisable
to other populations. In another hospital-based study of 772 patients attending a memory
clinic, CMBs were detected in 10% of patients judged to have ‘subjective’ memory
complaints, but the authors found no difference overall in cognitive function between
patients with and without CMBs (Cordonnier et al., 2006). Of note, in this study, 54% of the
patients with CMBs had only a single lesion, which might not be as likely to be associated
with significant cognitive impairment as multiple lesions.
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Table 10. Associations between CMBs and cognitive function in different populations*
*Adapted from Werring et al., 2010
Study reference Design Clinical population Main associations Other MRI markers adjusted for in the study
Yakushiji et al., 2008 Cross-sectional Healthy self-funding adults (N=678) Lower scores on MMSE associated with
CMBs
WML
Cordonnier et al., 2006 Cross-sectional Memory clinic (N=772) None demonstrated -
Werring et al., 2004 Cross-sectional Stroke and TIA clinic (N=55) Executive dysfunction more common in
the group with CMBs compared with a
control group
WML (ARWMC rating scale)
Seo et al., 2007 Cross-sectional Memory clinic. Subgroup with subcortical
vascular dementia (N=86)
CMBs associated with MMSE score and
tests in a range of cognitive domains with
exception of language
WML (Scheltens scale), lacunes
Hanyu et al., 2003 Cross-sectional Memory clinic. Clinical diagnosis of AD
(N=59)
No association with MMSE -
Pettersen et al., 2008 Cross-sectional Memory clinic. Clinical diagnosis of AD
(N=80)
No association with MMSE or single test
of a cognitive test battery
-
Goos et al., 2010 Cross-sectional Memory clinic. Clinical diagnosis of AD Multiple CMBs associated with lower
MMSE (but few patients with multiple
CMBs)
WML. No independent association found.
Viswanathan et al.,
2008
Cross-sectional CADASIL (N=147) Association with global measures
(MMSE, Mttis Dementia Rating Scale)
WML, lacunes. No independent association
demonstrated except a small strategic effect for
caudate/internal capsule CMBs
Liem et al., 2009 Longitudinal, 7
year results
CADASIL (N=25) Increase in CMBs associated with
deterioration on CAMCOG
WML, lacunes. No independent association
reported.
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3.1.2 Cerebral microbleeds in Alzheimer’s disease
CMBs are commonly found in patients with AD, with a reported prevalence in hospital-
based cohorts of clinically diagnosed AD of between about 20 to 30% (Cordonnier et al.,
2006; Hanyu et al., 2003a; Pettersen et al., 2008). A mainly lobar distribution has been
found, with in one study reporting that they were particularly affecting the occipital regions
(Pettersen et al., 2008). This distribution is similar to that described in sporadic CAA,
suggesting that CMBs in AD are more likely to be related to CAA rather than hypertensive
arteriopathy. A recent MRI-post-mortem correlative study of the brains of eight patients
with AD found that in microhaemorrhages where the source vessel could be identified, Aβ 
was present in the vessel wall, thereby supporting this hypothesis (Schrag et al., 2010).
There are few studies investigating whether CMBs are associated with cognitive
dysfunction in AD. One study of 80 cases of probable AD found no relationship between the
presence of CMBs and cognitive impairment as assessed via tests of global cognition and
focal domains (Pettersen et al., 2008). Two other studies found no relationship, but used
the MMSE test, which may not be sensitive to subtle or focal cognitive deficits (Cordonnier
et al., 2006; Hanyu et al., 2003a; Pettersen et al., 2008). A more recent study investigated
63 patients with AD, and compared cognitive test results in those with multiple compared
to fewer CMBs (with a cut off set at 8 CMBs) (Goos et al., 2009). These results indicated
that patients with multiple CMBs performed worse on the visual association test, digit
spans and animal naming, when adjusted for other clinical and imaging confounding factors
(Goos et al., 2009).
3.1.3 Cerebral microbleeds in cognitive impairment
MCI is the preclinical age-related cognitive impairment and is likely more prevalent than
VCI. As part of the VCI entity, it represents a key healthcare challenge facing all aging
Western societies and is second only to AD as a cause of dementia (Hachinski et al., 2006).
Initial concepts of VCI invoked cortical or subcortical infarction – leading to the terms
‘multi-infarct dementia’ or ‘post-stroke dementia’ (Werring et al., 2010). However,
subcortical small vessel disease (often not causing acute or overt clinical symptoms) also
plays a critical role in VCI (Black et al., 2009; Bowler, 2007; van Dijk et al., 2008). MRI is the
most important tool for detecting and quantifying small vessel disease, and forms part of
the current diagnostic criteria for vascular disease (Hachinski et al., 2006). MRI
manifestations of small vessel pathology including white matter hyperintensities, lacunes
and perivascular spaces have been recognised for many years. Research on white matter
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hyperintensities and cognition has shown only modest correlation, particularly in patients
with symptomatic cerebrovascular disease (Sabri et al., 1999; van Swieten et al., 1996),
which may be a reflection of both the pathological heterogeneity of small vessel disease,
and the lack of pathological specificity of conventional MRI. The tissue water content
forming the MRI signal may be affected by many pathological processes including
infarction, ischaemic demyelination and gliosis, which may have different functional
effects. There is thus a need for a better understanding of the pathological basis of MRI
changes, and for more specific imaging markers to detect and quantify small vessel
pathology. CMBs are now recognised as a manifestation of small vessel pathology
(Greenberg et al., 2009b), but their clinical impact on cognition remains uncertain
(Koennecke, 2006). Chapter 7 presents the work addressing the question of how CMBs
might be related to cognition.
Cerebrovascular diseases
CMBs have been found in about 35% of patients with first-ever or recurrent IS, and about
60% of patients with first-ever or recurrent ICH (Cordonnier et al., 2007). A major challenge
in any study to investigate the potential relationship between CMBs and cognitive function,
particularly in stroke patient populations, is the strong association between CMBs and
other radiological markers of cerebrovascular disease. One study undertaken in a
neurovascular clinic population compared detailed cognitive function assessment in
consecutive patients with CMBs (N=25) to a non-CMB control group (N=30) carefully
matched for imaging and clinical factors likely to influence cognition, including white
matter hyperintensities. A marked difference in the prevalence of executive dysfunction
was found: 60% of patients with CMBs were impaired on tests sensitive to frontal
‘executive’ dysfunction, compared to 30% of patients without CMBs (Werring et al., 2004).
Frontal ‘executive’ impairment was also related to CMB location in the frontal lobes or
basal ganglia. This is consistent with the possible direct effect of CMBs on frontal-
subcortical circuits, although the cohort studied was small. More recently, CMBs have been
studied in cohorts of patients with a diagnosis of vascular disease. Seo et al. (2007)
investigated 86 subjects with subcortical vascular disease from a memory clinic with GRE
T2*-weighted MRI and neuropsychological testing, MMSE and a clinical dementia rating
scale. The authors reported that CMBs were found in 85% of these patients; CMBs were
related to the MMSE score, and to dysfunction in all cognitive domains except language,
which was borderline significant. In a memory clinic population, Cordonnier et al. (2006)
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found CMBs in 65% of patients with vascular disease, compared to 18% of patients with a
diagnosis of AD. However, in this memory clinic population as a whole, CMBs were not
related to cognition as assessed by the MMSE score. In CADASIL, a ‘pure’ form of cerebral
small vessel disease, CMBs were associated with lower MMSE scores, but had no
independent effects except for a possible strategic effect when located in the caudate
nucleus (Viswanathan et al., 2007). These cross-sectional studies suggest that CMBs may
play a role in VCI, either through direct structural or functional effects on surrounding
tissues including white matter tracts, or as a marker for the general severity of small vessel
damage.
Post-stroke dementia is an important subcategory of VCI, affecting about 10% of patients in
the months following first-ever IS, and about 30% of patients after recurrent IS (Pendlebury
and Rothwell, 2009). The possible mechanisms of dementia after stroke include either
further episodes of infarction, or deterioration in small vessel disease not associated with
clinical infarction. One hypothesis is that patients with pre-existing small vessel damage or
AD are at increased risk of cognitive decline after an incident of clinical stroke (Hennerici,
2009). CMBs may therefore play a role as a prognostic marker of future cognitive decline or
outcome in stroke patients. In support of such a hypothesis, data from a preliminary 5-year
follow-up study of patients from a neurovascular clinic suggest that baseline CMBs may
influence cognitive impairment at follow-up (Gregoire et al., 2009) (see Chapter 7). Another
study in a memory clinic setting found that CMBs (particularly in association with brain
atrophy) were an independent predictor of mortality (Henneman et al., 2009). Although
further larger prospective studies are required, if reliable MRI markers of small vessel
damage could identify a subgroup of patients at highest risk of subsequent cognitive
impairment, these patients could be offered targeted control of their vascular risk factors,
particularly hypertension (Birns et al., 2009; Hennerici, 2009).
Cerebral amyloid angiopathy
CAA is characterised by the vascular deposition of Aβ protein, mainly in cortical and 
leptomeningeal small calibre vessels, which provides a potential mechanism for vascular
and cerebral dysfunction (Iadecola et al., 2009). CAA is generally recognised in life by
symptomatic ICH, but at autopsy it is seen in up to 40% of the general elderly population,
and in over 80% of brains affected by AD. There is evidence that severe CAA may be
associated with cognitive impairment independently of lobar macrohaemorrhage
(Greenberg et al., 2004b). Furthermore, population-based autopsy studies have shown that
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CAA pathology is associated with cognitive impairment in life (Greenberg et al., 2004b).
Because CAA is so common in the ageing brain, regardless of symptomatic ICH, it could be
an important contributor to VCI. Population-based autopsy studies have shown that CAA is
associated with more severe cognitive impairment in life. In addition to lobar ICH, CAA is
increasingly suspected when lobar CMBs are detected on GRE T2*-weighted sequences.
The presence of strictly lobar haemorrhages in patients over 60 years with a symptomatic
lobar ICH has been reported to be highly correlated with severe CAA on histological analysis
(Knudsen et al., 2001), though it is unclear whether CMBs in deep regions should be an
absolute criterion. Moreover, the specificity of the Boston criteria for CAA in clinical
practice is not fully established, since the validation studies included small selected groups
of patients who did not undergo standardised imaging protocols (e.g. not routinely using
T2*-weighted MRI). Further studies are therefore needed to determine how generalisable
the Boston criteria are to other cohorts of patients with ICH. If CMBs are related to
cognitive dysfunction, then the question arises as to whether this is a direct effect on
surrounding tissues, an indirect effect (e.g. arteriolar narrowing causing hypoperfusion and
ischaemic damage), or simply a marker for severe small vessel pathology. One recent study
investigated pre-ICH cognitive impairment in 49 individuals with clinically probable CAA,
and found that the mean apparent diffusion coefficient (ADC) in the brain was strongly
correlated with cognition, whilst other MRI markers (white matter hyperintensities,
number of CMBs, atrophy measures) were not (Viswanathan et al., 2008). These data
suggest that in CAA, CMBs may exert any functional effects on cognition indirectly, perhaps
by chronic hypoperfusion or neuronal degeneration related to focal lesions.
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3.2 Cerebrovascular disease risk
3.2.1 Ischaemic stroke
The deep perforating arteries feeding the areas of the brain harbouring CMBs show
moderate to severe lipohyalinosis and ruptured arteriosclerotic microvessels secondary to
chronic hypertension (see Chapter 2). These changes form the substrate of the association
between CMBs with ischaemic vascular diseases which has been demonstrated in many
studies to date (Cordonnier et al., 2007). The prevalence of CMBs in patients with IS varies
widely suggestive of heterogeneity of pathology (mechanisms of stroke) and differences in
cohort studied (Lee and Roh, 2011). The prevalence of CMBs in patients with previous TIA,
cerebral infarction or recurrent IS is higher than that in healthy adults (Cordonnier et al.,
2007; Naka et al., 2004; Werring et al., 2004). Depending on studies, the overall prevalence
in first IS is about 20-30% and up to 44% in recurrent IS, suggesting that CMBs are
associated with the progression of small vessel cerebrovascular disease (Cordonnier et al.,
2007). CMBs seem to predominate in patients with small vessel occlusion-type IS compared
with patients with atherothrombotic and cardio-embolic strokes (Kato et al., 2002; Naka et
al., 2004; Ovbiagele et al., 2006).
Whether CMBs are a marker of increased future IS risk is a question of potentially major
clinical significance. An accurate estimation of risk is essential for the safe implementation
of treatment and prevention strategies such as antithrombotic agents in patients with
CMBs. Small prospective studies provide a partial answer to this question (Boulanger et al.,
2006; Thijs et al., 2010). In a study of 487 European patients with IS or TIA, patients with
CMBs had a higher risk of developing new IS but not ICH (Thijs et al., 2010). Recurrent ISs
occurred in 10% of patients with CMBs and 5% of patients without CMBs; this difference
almost reached significance (p=0.054). However, the association between CMBs and
recurrent stroke was not independent (Thijs et al., 2010). In line with these results,
Boulanger et al found an elevated risk of fatal and disabling cerebrovascular events, mainly
ischaemic, in patients with CMBs in a small prospective study of Canadian patients with IS
or TIA followed up over 14 months (Boulanger et al., 2006). There are a number of other
small prospective studies in Asian populations which report the associations between CMBs
and recurrent strokes (see section 3.3), but heterogeneity of the populations, differences in
outcome measures (haemorrhagic and ISs) and methodologies make their findings difficult
to compare. In most of these studies the exposure to antithrombotics was treated as a
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dichotomous variable, which gives less accuracy in assessment of risk than duration and
severity of exposure (e.g. type of antithrombotic) and represent another potential
limitation. Like in risk assessment for ICH (see section 3.2.2), results are not generalizable
across studies due to heterogeneity and differing ethnic backgrounds of populations
studied. In a recent meta-analysis of 10 prospective cohorts involving 3067 patients with IS
or TIA, there was a significant association between the presence of CMBs at baseline and
the risk of recurrent IS in Western, but not Asian cohorts (Charidimou et al., 2013a). The
presence of CMBs more than doubled the risk of recurrent IS (OR 2.23, 95%CI 1.29-3.85).
3.2.2 Intracerebral haemorrhage
CMBs have been associated with ICH in numerous studies. The overall prevalence of CMBs
in patients with ICH ranges from 47% to 97%, a higher prevalence than in IS (Lee et al.,
2005; Naka et al., 2004). Several cross-sectional and prospective studies indicated that the
presence and burden of CMBs is strongly related to the incidence or recurrence of
spontaneous ICH (Fan et al., 2003; Greenberg et al., 2004b; Lee et al., 2004c). They have
been associated with the severity of ICH (Lee et al., 2006). They have also been considered
to be pathogenetically related with ICH (see Chapter 2), and a regional association between
CMBs and macroscopic ICH was demonstrated in several studies, suggesting similar
underlying pathogenic mechanisms (Chen et al., 2008; Lee et al., 2004a). The spatial
distribution of CMBs in ICH may be of clinical interest in understanding the causes of
macroscopic ICH in vivo. Lobar CMBs are particularly frequent in patients with CAA, a
predominant cause of ICH in the elderly (Greenberg et al., 1996; van den Boom et al.,
2005). Analyses comparing hypertensive ICH and CAA-related ICH indicated that cortico-
subcortical CMBs are more frequent in the CAA group (Lee et al., 2007). A distinct genotype
for APOE was found in patients with lobar and non-lobar CMBs in a study of 414
consecutive stroke patients, suggesting a different pathogenesis between lobar and deep
CMBs (Kim et al., 2005). This support the hypothesis that, in ICH, lobar and deep CMBs are
attributable to different pathogenic mechanisms, CAA for lobar CMBs and hypertension for
deep CMBs, although a clear-cut distinction is unlikely due to overlap of risk factors for the
two processes in the elderly (e.g. hypertension).
As a marker of a bleeding-prone state in the brain, a major clinical question is whether
CMBs are associated with an increased risk of subsequent haemorrhagic stroke particularly
in relation to antithrombotic agents. In spite of the increasing interest and number of
published studies attempting to address this question, their significance as a risk factor for
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ICH remains unclear due to inconsistent study results. Studies showing an increased risk of
ICH in patients with CMBs after IS have mainly been performed in Asian populations (Fan et
al., 2003; Imaizumi et al., 2004; Naka et al., 2006; Soo et al., 2008) and might not be
generalizable to other study populations. In patients with ICH, Jeon and co-authors found
an elevated risk of haemorrhagic stroke due to CMBs in a prospective study of 112
survivors of ICH but the analyses could not be corrected for confounding factors due to
small sample size (Jeon et al., 2007). Similarly, the haemorrhagic burden at baseline (either
macro- or microhaemorrhages) predicted the appearance of new ICHs on repeat MRI after
a mean interval of 16 months in a prospective study of 94 survivors of spontaneous ICH
(Greenberg et al., 2004b). In patients with ICH and advanced WML, the presence and
burden of CMBs was higher than in patients with similar degree of WML but no ICH, with a
high positive predictive value of CMBs for ICH (Lee et al., 2005). The risk of recurrent
bleeding after symptomatic ICH seems to be higher for lobar ICH (often presumed due to
CAA) (Passero et al., 1995; Vinters, 1987) suggesting that lobar CMBs may be a stronger risk
factor for antithrombotic-associated ICH than deep CMBs but data are lacking. A recent
study of 104 survivors of spontaneous ICH attributed to CAA demonstrated that recurrent
ICH was associated with baseline lobar CMBs (Biffi et al., 2010b). A recent meta-analysis
demonstrated that CMBs are associated with a significant increased risk of ICH, especially
in Asian populations (OR 10.43, 95%CI 4.59-23.72) (Charidimou et al., 2013a). There was a
non significant trend towards a similar association in Western cohorts. However, the study
was limited by small sample sizes, short follow-ups, few outcome events and selection bias.
An overview of CMBs as risk lesions for ICH in the context of antithrombotic use will be
discussed in the next section.
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3.3 Antithrombotic treatment
ICH is one of the most important complications of long-term antiplatelet therapy (He et al.,
1998) and of anticoagulants (Hart et al., 1995), and carries the worst prognosis of all acute
cerebrovascular diseases (Broderick et al., 2007; Rosand et al., 2004). Identifying the risk
factors for antiplatelet- and warfarin-induced ICH is crucial to improving the risk-to-benefit
ratio of these drugs. CMBs, as a marker of subclinical cerebral damage due to small vessel
disease, may predict the future risk of ICH in patients with ICH or IS (Fan et al., 2003;
Greenberg et al., 2004a; Jeon et al., 2007; Naka et al., 2006; Soo et al., 2008). Studies have
assessed the association between ICH risk and CMBs and the potential influence of the use
of antithrombotic agents on the association. Antithrombotic drugs are often prescribed to
elderly patients for IS prevention but may place them at risk of CMBs and more major
bleeds. In addition to age, these patients often carry several risks factors for ICH and CMBs
including hypertension, AD, CAA and diffuse cerebrovascular disease. In such patients,
mortality from ICH may outweigh the benefits of antithrombotic agents. Anti-thrombotic
agents only offer a modest absolute risk reduction of recurrent IS estimated at 0.69-2.49%
per year for aspirin and 6% per year for warfarin (Antithrombotic Trialists Collaboration,
2002; Saxena and Koudstaal, 2004). Therefore, the benefit of anti-thrombotic agents has to
be weighed with the risk of ICH, especially in the presence of CMBs. In the Birmingham
Atrial Fibrillation Treatment of the Aged Study (BAFTA), patients with a mean age of 81.5
years followed up for a mean of 2.7 years and who received warfarin with a target
international normalisation ratio (INR) of 2 to 3 had a 0.5% risk per year of ICH (Mant et al.,
2007). The risks of major intracerebral bleeding associated with antithrombotic agents
might be reduced if patients are carefully selected.
3.3.1 Antiplatelet use
Recent data suggests that the use of antiplatelet agents may be associated with a higher
prevalence of CMBs in the healthy elderly population. In the Rotterdam Scan Study, which
is a population-based, cross-sectional MRI study in the general elderly community in the
Netherlands, the use of platelet aggregation inhibitors was significantly associated with the
presence of CMBs; the association persisted after adjustment for cardiovascular risk factors
and after excluding patients with a known history of cerebrovascular disease (Vernooij et
al., 2009). However, a recent study of 1452 asymptomatic elderly subjects aged 65 years
and above without cerebrovascular disease seems to challenge these results; in adjusted
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analyses, there was no association between aspirin and the presence of CMBs even after
prolonged aspirin use (Kim et al., 2012).
In patients with cerebrovascular disease, there has been some evidence that aspirin is
associated with CMBs (Ge et al., 2011; Lovelock et al., 2010; Vernooij et al., 2008b). In a
systematic review of antithrombotic use among European and Asian subjects, an excess of
CMBs in antiplatelet users versus non users with ICH (OR 1.7) was documented (Lovelock et
al., 2010). In patients with cerebrovascular disease stratified by specific antiplatelet agents,
antiplatelet use more than doubled the risk of having CMBs in patients with ICH but not in
patients with IS; the presence of CMBs was associated with the use of aspirin but not of
other antiplatelet agents (Naka et al., 2013). However, results of these analyses need to be
taken with caution. The systematic review mentioned is a case-case comparison study
pooling observational data from very heterogeneous populations. It is possible that the role
played by antiplatelet agents in such bleeds may have been overestimated, given variations
in risk factor load between populations and variations in the level of control of important
risk factors such as blood pressure. Furthermore the study was unable to establish causality
due to its cross-sectional design. Nevertheless, other reports have found an association
between antiplatelet use and CMBs (Jeong et al., 2004; Wong et al., 2003). Wong et al.
(2003) found CMBs in 19 out of 21 aspirin users with symptomatic ICH, compared to 7 out
of 21 matched aspirin users without ICH, but the study was limited by several factors: the
absence of a group of patients with ICH unrelated to aspirin and the lack of adjustment for
the presence of leukoaraiosis, a potentially important confounding factor. Another study
found that in patients with ICH, the prevalence of CMBs was higher among users of
antithrombotic agents, mainly antiplatelet medications (Jeong et al., 2004). Similarly, in
patients with ischaemic cerebrovascular disease only (i.e. IS or TIA), CMBs were more
frequent in aspirin users compared with non-users especially after long exposure to aspirin
(greater than 5 years) although a confounding effect of cerebrovascular disease could not
be completely eliminated (Ge et al., 2011). Likewise, Lovelock and co-authors found that
antiplatelet use increased the risk of CMBs in patients with IS or TIA, but to a lesser extent
than in patients with ICH (OR only of 1.4) (Lovelock et al., 2010). This confirmed the results
of an earlier study in patients with cerebral infarction showing that previous use of
antithrombotic drugs was independently associated with the presence of CMBs
(Nighoghossian et al., 2002).
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A major concern to physicians is whether patients with CMBs are more prone to ICH and
hence may affect their treatment choice when antiplatelet drugs are required in secondary
prevention of ischaemic cerebrovascular diseases. Several studies suggested that CMBs
may increase the risk of antiplatelet-related ICH (Lovelock et al., 2010; Soo et al., 2008).
Among 908 consecutive patients with acute IS admitted to a regional hospital in Hong Kong
and treated with a single antithrombotic agent (mainly aspirin), Soo et al. showed that both
age and CMBs were independent predictors of subsequent ICH (Soo et al., 2008). They
further demonstrated that, in patients with 5 or more CMBs and treated with aspirin, the
risk of ICH reached almost 8% and resulted in 4% mortality. As such, the risk of mortality
from ICH may outweigh the benefit of antiplatelet agents, although the analyses could not
be adjusted for severity of the white matter disease, another important contributor to ICH
risk. A recent randomised trial comparing the new antiplatelet drug cilostazol to aspirin
found that in the six patients who developed ICH, all had previous CMBs in the location of
the ICH (Huang et al., 2008). These observations are consistent with the hypothesis that
CMBs could be used to identify patients at the highest risk of antiplatelet-associated ICH,
but the small sample sizes and small number of outcome events makes it difficult to draw
firm conclusions with the available data.
The mechanisms implicated in the effects of aspirin exposure in patients with ICH and CAA
is unclear. As suggested in the Rotterdam Scan Study, exposure to aspirin may be
associated with increased prevalence of lobar CMBs, one of the hallmarks of CAA, and
consequently increase the risk of recurrent ICH by substantially increasing the number of
CMBs at risk for conversion into clinically manifest macrobleeds (Biffi et al., 2010b; Vernooij
et al., 2009).
How does the current knowledge translate into medical practice? Published data does not
provide sufficient evidence to withhold aspirin and platelet aggregation inhibitors in
patients with CMBs. In the healthy elderly population, although it may be associated with a
higher prevalence of CMBs, it is most likely to be safe. In the secondary prevention of
thrombotic events, antiplatelet use is justifiable and most likely beneficial assuming future
risk of ICH is low or can be reduced by controlling associated risk factors e.g. hypertension.
In patients with ICH, despite a strong association between CMBs and ICH, recent data
suggests that antiplatelet agent administration in patients with CMBs may not be as
harmful as previously considered. Certain groups of ICH survivors at high risk for ischaemic
cerebrovascular disease may benefit from antiplatelet agents without substantial increase
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of risk of ICH recurrence. In a prospective cohort study, the regular use of antiplatelets for
ICH patients was not associated with a substantial increase in risk of ICH recurrence
(Viswanathan et al., 2006). Although lobar ICH location has consistently been associated
with an increased risk of ICH recurrence (Bae et al., 1999; Douglas and Haerer, 1982),
survival rates were similar between survivors of either lobar or of deep haemorrhages
(Viswanathan et al., 2006). Similarly, in a prospective cohort study of 104 lobar ICH
survivors with CAA, the use of aspirin after ICH was associated with lobar ICH recurrence
when analyses were controlled for baseline predictors of ICH and CMB burden but the
study did not have sufficient statistical power to confirm this (Biffi et al., 2010b). Moreover,
in patients with ICH, pre-treatment with antiplatelet agents seems not to be an
independent risk factor of mortality and unfavourable outcome (Foerch et al., 2006). These
findings are consistent with the results of two large meta-analyses pooling the results of
trials in subjects without a history of ICH which found that aspirin conferred only a small
risk of intracranial bleeding (Antithrombotic Trialists Collaboration, 2002; He et al., 1998).
Interpretation of such studies is difficult due to the fact that exposure to antiplatelet drugs
is not randomly assigned but results from physician decisions based on individual patients.
Also confounding by indication for antiplatelet use may have occurred (Viswanathan et al.,
2006). For example, antiplatelets may have been avoided in patients at higher risk for ICH
recurrence (e.g. history of previous ICH, lobar location of ICH, number of ICHs on scan) or in
patients with higher numbers of lobar CMBs, leading to an underestimation of antiplatelets
ICH-associated risk. Another problem relates to the lack of blinding of the readers of the
MRI scans to the presence of ICH causing bias in reporting the number of CMBs. An ideal
study design will need to prospectively collect information on antiplatelet use in different
population categories comparing large groups of non-antiplatelet users and antiplatelet
users in which antiplatelet therapy will be randomly assigned, specifying the indication for
antiplatelet use, the duration of exposure to which particular agent, and recording the
rates of new ICHs over several years of follow-up. Adjustments for all potential
confounders including coexistent cerebrovascular disease and risk factors will be required
as well as total blinding of the readers of the MRI scans.
3.3.2 Anticoagulant use
Anticoagulant use has risen sharply over the past decade due to increased frequency of AF
in relation to aging of the population (Lip et al., 2012; Miyasaka et al., 2006). This has
caused an increase in incidence of ICH in the elderly population (Flaherty et al., 2007;
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Lovelock et al., 2010). Although highly effective in secondary prevention of ISs secondary to
AF (Anon, 1994), warfarin use is associated with a significant increase in the annual risk of
ICH, with devastating consequences including high disability and mortality (van Walraven et
al., 2002). Because oral anticoagulation-induced ICH is so often fatal or disabling, even a
small increase in the absolute risk of ICH can potentially outweigh the benefit of oral
anticoagulant treatment (Charidimou et al., 2012c; Gustafsson et al., 1992). Thus, the
prevention of ICH in patients on warfarin is critical and identification of risk factors remains
an important issue.
As suggested by the fact that many ICHs occur while anticoagulation intensity is within the
therapeutic range (Rosand et al., 2004), anticoagulant medications do not cause ICH on
their own. Anticoagulant-induced ICH is likely to result from an interplay of different factors
including the presence of an age-related underlying microangiopathy (mainly hypertensive-
related or CAA), vascular risk factors, genetic factors and the use of oral anticoagulation
treatments (Charidimou et al., 2012c). The Stroke Prevention in Reversible Ischaemia Trial
(SPIRIT) assessed independent predictors of haemorrhage in 651 anticoagulated patients
after cerebral ischaemia and pointed out that old age (>65 years), leukoaraiosis detected by
CT and intensity of anticoagulation predicted warfarin-related ICH (Anon, 1996; Gorter,
1999). The increased risk of warfarin-related ICH associated with leukoaraiosis on CT was
independent of age, BP and INR value (Gorter, 1999). In a case-control study of 26 patients
with warfarin-related ICH following IS and 56 controls, Smith et al. confirmed that the
presence and severity of leukoaraiosis detected by CT was an independent, dose-
dependent risk factor for post-stroke warfarin-induced ICH (Smith et al., 2002). However,
leukoaraiosis is a radiological definition which encompasses several disease mechanisms
not necessarily all related to previous ischaemia (Gouw et al., 2011; Schmidt et al., 2011)
and its predictive value for anticoagulation-related ICH is likely to be modest (Pantoni,
2010). Nevertheless, ischaemic leukoaraiosis is one of the two age-related damaging
processes of the small brain vessels that contribute to ICHs in the elderly, possibly
exacerbated by the use of anticoagulant treatments. We have indirect evidence that CMBs
may increase the risk of warfarin-induced ICH by the close association of CMBs with
leukoaraiosis (Hanyu et al., 2003b; Kato et al., 2002; Kwa et al., 1998; Naka et al., 2006;
Naka et al., 2004). As CMBs are a marker of more advanced cerebrovascular disease and
severe underlying microangiopathy, and presence of leukoaraiosis is a risk factor for
warfarin-related ICH (Smith et al., 2002), CMBs might contribute to increase the risk of
warfarin-related ICH.
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CAA accounts for another large proportion of ICHs in the elderly, especially lobar
(Charidimou et al., 2012b). It is likely implicated in the majority of the new lobar ICHs that
have shown a sharp increase in incidence over the past 2 decades among patients aged 75
years and older (Lovelock et al., 2007) and may also account for the increased incidence of
anticoagulation-associated ICH (Charidimou et al., 2012c). CAA was demonstrated in 7 of
11 lobar ICHs occurring on warfarin in a genetic and pathologic study (Rosand et al., 2000).
Genetic risk factors might also contribute to warfarin-related ICH risk. Carrying the apoE ε2 
or ε4 allele is associated with increased risk for lobar ICH and recurrent ICH resulting from 
CAA (McCarron and Nicoll, 2000; O'Donnell et al., 2000). Genetic polymorphisms may
predispose to increased risk for high INR levels on warfarin resulting in lower dose
requirements (Higashi et al., 2002).
CMBs detected on blood-sensitive MRI sequences, correspond to small collections of
blood-breakdown products next to diseased vessels affected by hypertensive-related
lipohyalinosis or CAA (see Chapter 2), and hence provide evidence of blood leakage from
these vessels (Charidimou and Werring, 2011). As a result of minor bleeding from advanced
microangiopathy, CMBs might serve as the substrate for large haemorrhagic strokes on
warfarin. The presence of warfarin could result in a tiny bleed enlarging even under normal
haemostatic mechanisms and would unmask an ICH that would have otherwise remained
self-limiting and asymptomatic (Hart et al., 1995). CMBs have been associated with ICH in
patients taking anticoagulant medications in cross-sectional case-control, case-case
comparisons and small case series studies (Lee et al., 2009; Lovelock et al., 2010; Ueno et
al., 2008) suggesting that they may be a stronger predictor of anticoagulant-associated ICH
than leukoaraiosis (Charidimou et al., 2012c; Ueno et al., 2008). In a small case-control
series comparing 24 patients with warfarin-related ICH versus 48 warfarin users who did
not develop an ICH, Lee and co-authors reported that the presence of CMBs increased the
risk of warfarin-associated ICH by 80-fold (Lee et al., 2009). In a systematic review of
antithrombotic use in European and Asian cohorts, the frequency of CMBs in ICH patients
treated with anticoagulants was reported to be 2.7-fold that in patients not treated with
anticoagulants (with ‘spontaneous’ ICH) (Lovelock et al., 2010). Furthermore, Lee and co-
authors suggested in a case-report that CMBs increase the risk of warfarin-related ICH
based on the development of large haemorrhages at the site of previously identified CMBs
(Lee et al., 2008a). However, these studies were small and unable to establish a causative
relationship between CMBs and warfarin-related ICH risk. Limited prospective studies are
available but suffer from serious methodological limitations mainly related to small sample
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size and lack of standardised imaging criteria (Fan et al., 2003; Soo et al., 2008). In the
largest prospective study to provide long-term clinical outcome in IS patients with CMBs
treated with antithrombotic agents, Soo and co-authors showed that age and presence of
CMBs were independent predictors of subsequent ICH (Soo et al., 2008). The risk of
subsequent ICH increased with the number of CMBs from 0.6% (no CMB) to 7.6% (≥5 CMB) 
and mortality resulting from ICH in patients with ≥5 CMB was 3.8%. The high risk and 
mortality of ICH seemed to outweigh the modest benefit of antithrombotic agents (3%
absolute risk reduction per year for aspirin, 6% absolute risk reduction for warfarin),
suggesting that antithrombotic agents may cause more harm than benefit in patients with
multiple CMBs. However, only 4% of patients in this study were treated with warfarin and
results are mainly driven by aspirin. In another Asian cohort study, Fan and co-authors
followed up 121 patients with IS over a mean of 27 months (Fan et al., 2003). Four patients
with CMBs (9.3%) and one patient without (1.3%) had ICH (p=0.05). Again, only a small
proportion of patients were using warfarin while the large majority were antiplatelet users
and these findings might not be generalisable to other populations.
Whether duration or intensity of anticoagIution plays a role in the development of
anticoagulation-induced ICH in patients with CMBs remains unclear. Duration of
anticoagulation and presence of CMBs were similar in 141 patients with IS on warfarin and
105 controls with IS not on warfarin, suggesting that warfarin treatment may not
contribute to CMBs and that other factors may play a role, e.g. a high prothrombin time
(Orken et al., 2009).
Based on the available data, there is no reason to suggest that the risk of warfarin-related
ICH is high enough to outweigh its benefit and that warfarin should be withheld in patients
with CMBs (Soo and Wong, 2011). However, one will be extremely cautious about initiating
anticoagulation therapy in patients with probable CAA as they are particularly prone to
warfarin-related ICH and ICH recurrence (O'Donnell et al., 2000; Rosand et al., 2004).
Anticoagulant therapy will be best avoided in these patients. Further data are required to
determine the risk of anticoagulants in patients with strictly lobar CMBs. Although studies
suggest a higher risk of anticoagulant-related ICH in these patients, CAA remains a
pathological diagnosis and its diagnosis cannot be solely made based on the presence of
strictly lobar CMBs. Therefore, care should be taken in controlling these patients’ risk
factors for ICH (e.g. strict BP control, close monitoring of INR) if anticoagulants are to be
initiated. One should hope that recent, large prospective studies will clarify the risks of ICH
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
146
associated with CMBs. The Clinical Relevance for Microbleeds in Stroke Study-2 (Cromis-2)
is a prospective, multicentre UK cohort study of patients anticoagulated after
cardioembolic stroke, aiming at understanding the contribution of CMBs in the occurrence
of ICH (www.ucl.ac.uk/cromis-2/).
To conclude this section, the association between CMBs and the use of antithrombotic
drugs remains controversial. The available evidence relies on retrospective, case-control,
observational or small prospective studies with insufficient power to reach definite
conclusions. Main limitations of available studies were the short follow-up periods and
insufficient number of outcome events. Other limitations are that most studies were
conducted in Asian cohorts in whom hypertension and CMBs are more common than in
Europeans and therefore may not be generalisable to other populations. Other limitations
arise from the fact that, when studying CMBs, it is difficult to exclude that CMBs existed
before the onset of use of these antithrombotic agents. This emphasises the need for
prospective data to study the association between antiplatelet agents and anticoagulants
in relation to CMBs and symptomatic ICH. In addition to safety of antithrombotic drugs,
one will also be interested to know whether antithrombotic agents increase the rate of
accumulation of CMBs over time and whether CMB distribution (i.e. lobar CMBs) plays a
role in antithrombotic-related ICH risk. Information from GRE imaging will be valuable
when deciding whether to prescribe antithrombotic medications, especially anticoagulants,
after IS. Before formal guidelines emerge, precautions should be taken to minimise the
risks of ICH in patients with CMBs, especially with a high load of CMBs. These include a
stringent BP control, maintaining cholesterol levels within the normal range, close INR
monitoring for patients on anticoagulants, and targeting a low INR window (2.0 to 2.5) in
patients with AF and without prosthetic heart valves.
It was recently highlighted that because anticoagulant-related ICH remains a rare adverse
event, randomised controls trials to investigate the safety and efficacy of anticoagulant
drugs might not be the most appropriate method (Charidimou et al., 2012c). Selection bias
related to patient’s bleeding risk profile and adherence are likely to occur causing an
underestimation of the bleeding risk. This is likely to hold true for antiplatelet-related ICH
too which has a lower incidence than anticoagulant-related ICH. In such assessments of
risk, correct estimates may be better provided by observational cohort studies (Charidimou
et al., 2012c; Vandenbroucke, 2011). Here in Chapter 5, we present the results of a case-
Part 1: Introduction to Small Vessel Disease and Cerebral Microbleeds
147
control hospital-based cohort study of the risk of antiplatelet-related ICH in patients with
CMBs.
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3.4 Thrombolysis
Several studies have addressed the role of CMBs in the prediction of ICH or haemorrhagic
transformation after thrombolysis in IS. Two initial observational studies indicated that
presence of baseline CMBs predicted incident haemorrhagic transformation in acute IS
patients after intra-arterial thrombolysis (Kidwell et al., 2009) and without thrombolysis
(Nighoghossian et al., 2002). However, subsequent prospective multicentre studies failed
to confirm the initial observation in patients receiving IV thrombolysis (Derex et al., 2004;
Fiehler et al., 2007; Kakuda et al., 2005). In the BRASIL study, MRIs from 560 patients with
acute IS recruited from 13 centres worldwide were analysed prior to thrombolysis. There
was no significant increase in the rate of symptomatic ICH among the 86 patients with
CMBs (Fiehler et al., 2007). The risk of symptomatic ICH among those with and without
CMBs was compared with benefit of thrombolytic therapy from the literature. The authors
concluded that risk of asymptomatic ICH would unlikely exceed the benefit of thrombolytic
therapy but the study lacked statistical power to conduct subanalyses on subgroups at
potentially higher risk (e.g. patients with numerous CMBs). Likewise, CMBs were not
associated with post-thrombolytic haemorrhagic transformation in an analysis of 70
patients with hyperacute stroke (Kakuda et al., 2005). A further study showed that baseline
CMBs were not associated with subsequent haemorrhagic transformation after acute
atherothrombotic stroke regardless of thrombolytic therapy (Lee et al., 2008b). These data
were pooled in a systematic review and meta-analysis of 790 patients, which revealed a
pooled relative risk (RR) of post-thrombolysis ICH associated with CMBs of 1.90 (95%
confidence intervals [CI] 0.92-3.93, p=0.082) (Charidimou et al., 2012b). In light of these
results, it appears that the presence of CMBs should not be a contra-indication for
thrombolysis in patients with acute IS.
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3.5 Other clinical manifestations of cerebral microbleeds
CMBs detected on GRE T2*-weighted MRI have generally been considered as not causing
overt clinical symptoms; indeed many reports have referred to them as ‘silent’ or
‘asymptomatic’ (Kato et al., 2002; Wong et al., 2003). Very few studies have investigated
whether they have any independent effect on brain function. This section considers first
the potential mechanisms by which CMBs could cause or be associated with neurological
dysfunction and then considers CMB in relation to transient neurological symptoms (mainly
in the context of CAA), and briefly discusses their association with disability and mortality.
3.5.1 How could cerebral microbleeds cause clinical symptoms?
Histopathological studies show that CMBs are associated with surrounding tissue damage
(Fazekas et al., 1999; Schrag et al., 2010; Tanaka et al., 1999; Tatsumi et al., 2008b), so they
might be expected to disrupt brain function. However, their absolute size is very small, of
the order of less than a millimetre, and at most a few millimetres, in diameter. As discussed
in chapter 2, the absolute size of a CMB is magnified by the blooming effect on T2*-
weighted or other iron-sensitive images, meaning that the radiological lesions are generally
larger than the true extent of the pathology (Schrag et al., 2010). Nevertheless, lacunes are
a clearly accepted cause of acute focal deficits (lacunar syndromes) and are generally
considered to be small: < 15mm, with the majority being 2-4 mm in diameter (Fisher,
1965). Absolute measurements of CMB size are scarce, but they seem to be rather smaller
than lacunes. One study of CAA showed that a cut-off of 5.7 mm best separated CMBs from
‘macrobleeds’ (Greenberg et al., 2009a), while another on CAA associated with AD showed
that CMBs were mostly around 1 mm in diameter (Schrag et al., 2010). Therefore, it might
be expected that the development of a single CMB would be less likely than the
development of a lacune to produce clinically evident symptoms. However, it is not
unreasonable that CMBs could do so if they form rapidly (as has been shown in a recent
study in acute stroke, Jeon et al., 2009), and in a functionally strategic location, for example
a small eloquent deep nucleus or white matter tract. The very limited evidence that this
can happen is discussed below. Another possibility is that rather than disrupting function
by direct destruction of tissue, microbleeding could disrupt the activity of surrounding
neurons, thus affecting local brain function or connectivity. This idea is supported by recent
experimental studies showing that small cortical CMBs can indeed adversely affect the
function of nearby neurons, as shown by a reduced or absent neural response adjacent to a
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small experimental haemorrhage (50-200 µm) (Cianchetti et al., 2009). Moreover, most
CMBs contain haemosiderin, a compound that may affect the electrical activity of the
cortex (Baumann et al., 2006). A further possibility is that CMBs are a marker of small
vessels with impaired vasoreactivity, which could impair brain function locally or even
cause small areas of ischaemia.
More likely perhaps than such local effects, is that the accumulation of multiple CMBs over
time could have a more insidious effect on the brain functions that depend on the integrity
of widespread anatomical networks, for example cognition or gait. This was discussed in
section 1.6.4. This hypothesis is analogous to the proposed mechanism for deficits
produced by ischaemic WML, including lacunes, of which the majority do not cause acute
stroke syndromes but can cumulatively disrupt cognition or gait (Baezner et al., 2008). This
idea is considered later in relation to CMBs and cognition.
A fundamental challenge in studying how CMBs could affect brain function is that they are
closely linked to many clinical and imaging manifestations of cerebrovascular disease,
including all types of IS and ICH, and WML and lacunes on MRI. It is therefore difficult to
determine whether CMBs have any independent functional effects, and well-designed large
studies addressing this remain extremely scarce.
3.5.2 Cerebral microbleeds and transient neurological symptoms
To date, only a limited number of case reports or case series addressing a possible link
between CMBs and transient neurological symptoms have been published. In these cases, a
causal link between the CMB and a transient event was usually suspected because of the
strategic location of the CMB in an anatomical area compatible with the focal symptoms.
Most of the cases described have been in patients with clinical features of CAA. As
discussed above, there are several ways in which CMBs could theoretically be associated
with or cause focal symptoms. First, they could form suddenly and by a direct tissue-
destructive effect cause neurological symptoms, analogous to the acute focal symptoms
caused by lacunar infarction. We recently published 2 cases of patients who developed
acute neurological symptoms presumably related to the formation of new CMBs (Teo et al.,
2011). In both patients, no acute ischaemic changes were visible on MRI and the new CMB
was anatomically correlated with the symptoms (Figure 42). In another report suggesting
this as a mechanism, Watanabe and Kobashi described a 72-year-old patient who
presented with a lateral gaze disturbance (Watanabe and Kobashi, 2005). A CMB was found
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in the contra-lateral pontine medial lemniscus when MRI was undertaken 6 months after
the onset of symptoms, with no other lesion seen to account for the clinical presentation
(Watanabe and Kobashi, 2005). An MRI 6 months prior to the symptoms had shown
ischaemic small vessel changes (multiple lacunar infarcts and leukoaraiosis), but no CMBs.
Although the development of the CMB after the onset of symptoms cannot be ruled out,
the anatomical correlation between the CMB and the symptoms suggests that a single CMB
lesion can cause focal neurological symptoms, but this is probably rare in comparison with
symptomatic lacunar infarcts.
A second way in which CMBs might be associated with focal symptoms is by their
association with small areas of ischaemia. This possibility has been considered mainly in
relation to CAA. Patients with CAA have a propensity to develop ICH, either macroscopic in
the form of lobar haemorrhages or microscopic (CMBs). However, recurrent transient
neurological symptoms without lobar haemorrhage have also been consistently reported.
These symptoms were attributed to recurrent TIAs, a label implying ischaemia as a
mechanism in various case reports (Chamouard et al., 1988; Okazaki et al., 1979; Smith et
al., 1985; Yong et al., 1992). In support of this possibility, there is histopathological
evidence of areas of infarction in severe CAA (Cadavid et al., 2000; Okazaki et al., 1979;
Olichney et al., 1995; Wattendorff et al., 1995). Increasing neuroimaging evidence with
advanced MRI techniques also suggests that small areas of acute infarction occur in a
substantial proportion of patients. Kimberly et al. recently described subclinical ischaemia
on diffusion-weighted MRI in 12 out of 78 patients with CAA (Kimberly et al., 2009), and a
case report has also described the dynamic evolution of ischaemic areas in CAA (Menon
and Kidwell, 2009). Ischaemic lesions were also noted in approximately 20% of patients
with CAA in a study that will be described in chapter 5. In the published reports, these
lesions seem mostly to be asymptomatic, so may not be a likely cause of acute focal
symptoms. The clinical significance of small areas of ischaemia in CAA clearly requires
further study.
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A B
Figure 42. Axial GRE T2*-weighted MR images of 2 patients with acute stroke syndromes
presumably caused by CMBs.
A. The image shows a round 6-mm well-circumscribed hypointense lesion in the right pons (white
arrow) in a 69 year old hypertensive patient who presented with sudden onset right UMN facial
weakness, ataxia and gaze-evoked nystagmus on right gaze. The MRI was performed on the day of
presentation. There was no area of restricted diffusion to suggest acute ischaemia. B. The sequence
shows a 2-mm solitary brain CMB in the ventral posterior nucleus of the right thalamus (white arrow).
The 78 year old patient was hypertensive and diabetic, and presented with sudden onset
paraesthesia over the left upper limb and cheek. There were no other lesions visible on MRI.
From Teo et al., 2011
A third, and perhaps the most likely possibility, is that CMBs may be associated with
‘electrical’ disturbances of nearby tissue; that is, they may cause cortical spreading
depression. Cortical spreading depression is more likely than seizures because seizures are
briefer. This possibility is supported by the clinical nature of the transient attacks described
in CAA. In a series reported by Greenberg et al. (1993), four patients subsequently
diagnosed with CAA presented initially with transient neurological symptoms. These
episodes were multiple, and mostly stereotyped, with focal weakness, paresthesias or
numbness and a spreading onset, with one patient reporting visual misperceptions.
Although in some respects these events resemble TIAs, the gradual onset and positive
neurological phenomena are atypical. Interestingly, three of these patients developed
subsequent large ICHs in the cerebral territory corresponding to the location of the
preceding transient deficits. The similar location involved in the original spells and in the
subsequent macrohaemorrhages suggests that in some cases a small lesion (e.g. a CMB)
may be a marker for an area of fragile abnormal vessels (perhaps with focal amyloid
deposition or microaneurysms) that heralds a larger lobar ICH. Although this hypothesis
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could not be tested at that time because CMBs as defined currently were not detectable on
the imaging available, T2-weighted and GRE imaging did reveal multiple cortical and
subcortical foci of signal loss that correlated anatomically with the symptoms described.
More recently, Roch et al. (2005) described six patients with cognitive complaints and
recurrent stereotyped episodes of transient motor or sensory symptoms. Imaging with GRE
T2*-weighted sequences showed multiple CMBs in three of these patients (of which two
were subsequently proven to have CAA on histopathological analysis), while the other
patients had a reduced signal in the cortical sulci compatible with haemosiderin deposition
and one patient had a thalamic infarct. Four of these patients responded to anticonvulsant
drugs, and two improved with the cessation of antiplatelet therapy. The hypothesis that
CMBs could cause seizures or seizure-like attacks is also compatible with the observations
that haemosiderin, a key component of CMBs on histopathological studies, can be irritant
and epileptogenic when close to the cortex (Baumann et al., 2006), and that experimental
cortical microhaemorrhages cause functional disturbance of adjacent neurons (Cianchetti
et al., 2009). The response of the transient neurological attacks in some patients to
anticonvulsant medication is further evidence of a seizure-like mechanism (Roch et al.,
2005). It should also be mentioned here that focal convexity atraumatic subarachnoid
bleeding is also increasingly recognised as a cause of recurrent stereotyped neurological
attacks, described in some cases as rather like migraine auras (Izenberg et al., 2009; Kumar
et al., 2010). This pattern of subarachnoid bleeding has also been recognised as a feature of
CAA in association with CMBs (Kumar et al., 2010).
In summary, in patients with transient neurological symptoms related to CAA, a seizure-like
mechanism may be likely when the symptoms are stereotypical, spread to contiguous
cortical regions or resolve with anticonvulsant drugs (Roch et al., 2005). By contrast, stroke-
like events with more typically ‘vascular’ symptoms (i.e. ‘negative’ phenomena including
weakness or sensory loss) and longer-lasting deficits may be more likely attributable to
acute ‘microinfarcts’ or the direct effects of new symptomatic CMBs. These presentations
may lead to considerable therapeutic dilemmas, because if microbleeding is causing the
problems, then antithrombotic treatment should presumably be avoided, whereas if
ischaemia is the dominant mechanism, then antithrombotic drugs may be warranted, and if
the attacks are caused by seizure activity then anticonvulsants are the most logical
treatment. We present in figure 43 the case of a patient posing such a diagnostic challenge
(Figure 43). However, it must be emphasized that these potential mechanisms suggested
for symptomatic CMBs are highly speculative: first, due to the nature and characteristics of
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CMBs, it has not been demonstrated that CMBs cause acute symptoms; second, the
ischaemic nature of the lesions causing acute symptoms cannot be entirely excluded;
finally, the acute symptoms observed could be due to other manifestations of small vessel
disease such as WML or CAA. It has to be acknowledged here that many of the
manifestations described above are similar to manifestations caused by WML or small
cortical infarcts. Spreading depolarisations are possible, as they can be detected using EcoG
or CASL, but are usually associated with major brain injury (e.g. trauma, malignant infarct
or large SAH). Imaging that precedes symptoms onset is lacking in many of the reports, and
even with pre-symptoms imaging, the nature of the lesion described is controversial. With
the use of modern MRI techniques, including GRE T2*-weighted, susceptibility-weighted
and diffusion-weighted sequences, it should be possible to differentiate symptomatic
ischaemic lesions from CMBs with more accuracy, which should increase understanding of
transient focal attacks in CAA and allow the most rational and safe management.
It is important to keep in mind that the limited evidence available suggests that new CMBs
do not usually seem to cause acute symptoms. This has been shown in a few longitudinal
MRI-correlated observational studies in different patient cohorts. New foci of haemosiderin
deposition were detected in 38% of patients with lobar haemorrhage (presumed from CAA)
followed up over 1.5 years, but all appeared to be clinically silent (Greenberg et al., 1999).
In the study reported in chapter 6 of this thesis a cohort of patients were followed up after
stroke and TIA at a mean interval of 5.5 years, and found that 50% of those with baseline
CMBs had developed new CMBs, compared with only 8% of the CMB-free matched
controls, despite most surviving patients remaining clinically stable (Gregoire et al., 2010a).
In a recent prospective observational study of 19 patients who underwent cardiac valve
surgery, 12 developed new lesions, seen by GRE T2*-weighted sequences, that
corresponded to CMBs (Jeon et al., 2010), and only two of these developed transient
neurological deficits. In one patient with generalised seizure, facial weakness, irritability
and confusion, diffusion-weighted image lesions were found and the relevance of the new
microbleeding was unclear. In two other longitudinal studies, no follow-up clinical
information about neurological events was reported; one of these studies was in a patient
cohort with consecutive IS (Jeon et al., 2009), the other in a longitudinal study of patients in
a memory clinic (Goos et al., 2010).
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Figure 43. Axial GRE T2*-weighted MR
image from a patient who presented with
recurrent TIA-like events despite
increasingly aggressive antithrombotic
treatment.
When antithrombotic therapy was reduced in
intensity, the frequency of events was also
reduced, suggesting that the antithrombotic
treatment may have exacerbated symptoms
related to microbleeding. There are multiple
lobar and deep CMBs.
Courtesy of Dr Rolf Jäger, National Hospital
for Neurology and Neurosurgery, London,
UK.
3.5.3 Cerebral microbleeds, disability and death
The accumulation of CMBs (as well as other cerebrovascular disease markers, including
leukoaraiosis or lacunes) might reflect progressive small vessel pathology and so could
result in the development of progressive disability (including cognitive dysfunction or
reduced mobility) or even be associated with an increased risk of death. Data on this are
limited, but a prospective study of 94 patients with spontaneous lobar ICHs showed that
the higher the number of baseline CMBs, the higher the 3-year cumulative risk of disability
or death (Greenberg et al., 2004b). In individuals with more than six CMBs (detected by
GRE T2*-weighted imaging), the cumulative risk of the combined endpoint of cognitive
impairment, functional dependence or death was 52% (Greenberg et al., 2004b). The
occurrence of CMBs has also been associated with clinical disability in the hereditary small
vessel disease CADASIL (Lesnik Oberstein et al., 2001; Viswanathan and Chabriat, 2006).
The OR for functional dependence (defined as a modified Rankin score of ≥3) per additional 
CMB was 1.16 (95% confidence internal, 1.01-1.34, p = 0.034) after adjustment for
confounding variables (Viswanathan and Chabriat, 2006). In a memory clinic population,
CMBs had a strong positive predictive value with respect to mortality in adjusted analyses,
particularly when numerous CMBs were present (Henneman et al., 2009).
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3.6 Conclusions
To summarise, although there are plausible mechanisms by which CMBs cause clinical
symptoms, the evidence that CMBs independently affect brain function remains limited.
Case reports suggest that CMBs may be a cause of transient neurological attacks,
particularly in patients with CAA. These can mimic TIAs or ISs, but often seem to be
atypical, with gradual onset similar to that seen in partial seizures; they may, therefore,
result from ‘electrical’ activity related to CMBs. The evidence that CMBs directly cause focal
neurological symptoms through associated tissue damage is even scarcer, but the
increasing ability to detect CMBs, together with other advanced neuroimaging methods,
should help to determine how important this is as a cause of cerebrovascular events. Some
prospective data indicates that new CMBs do not cause obvious symptoms, yet CMBs have
been shown to have an independent prognostic significance for disability and mortality in
different cohorts of patients, including CADASIL, spontaneous lobar haemorrhages and
memory clinic populations. The independent contribution of CMBs to disability and death
in other groups, including stroke patients, requires further investigation.
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3.7 Thesis aims
Despite the high prevalence of CMBs and the increasing number of publications on the
subject, there remains significant uncertainty about the question of whether CMBs have an
effect on the human brain and if so, about the mechanisms of this effect. Their discovery in
clinical practice causes clinicians anxiety about a number of important questions, for
example, what is (1) the reliability of one’s ratings of CMB presence and number, and the
relative power of the method used to detect them, (2) the clinical significance of their
number and distribution in regard to the underlying vasculopathy, (3) the risk of CMB
accumulation over time and (4) the risks of subsequent stroke or cognitive impairment in
relation to other risk factors of cerebrovascular disease. The answers to these questions
will help in increasing our understanding of CMBs, and beyond this, help to disentangle
small vessel disease mechanisms and clinical implications. Moreover, it is possible that
CMBs as a biomarker of the presence of small vessel disease, may contribute to monitoring
the severity of small vessel diseases in the brain, and the impact of preventive measures on
small vessel disease progression.
The main objective of this thesis is to provide new insights into the detection of CMBs and
their clinical impact in patients with stroke and TIA using neuroimaging studies in a
hospital-based setting. This is accomplished by
(1) developing and validating a standardised method of rating CMBs on clinical MR images;
this method will be compared with existing method of rating CMBs. Rating CMBs in the
brain may be difficult because of the many other lesions seen on MRI with similar
morphological or signal characteristics (CMB ‘mimics’). The use of a standardised rating
method and an appreciation of the distinctive radiological characteristics of CMBs should
make this process more reliable. In Chapter 4, we developed a new visual rating scale – the
Microbleed Anatomical Rating Scale (MARS) – to address some of the challenges of defining
and mapping CMBs in the brain.
(2) investigating the important question of the risk of ICH associated with the presence of
CMBs. In Chapter 5, we explore whether the burden or distribution of CMBs are associated
with antiplatelet-related ICH in a case-control and case-case comparison study. This risk
could overweight the benefits of antiplatelet therapy in certain categories of patients,
especially those taking antiplatelet agents in primary prevention, and those with numerous
and lobar CMBs.
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(3) examining the dynamic evolution of CMBs in a stroke clinic population and assess risk
factors for development of new CMBS. Among these factors, hypertension may play a
crucial role and this would suggest a possible role of CMBs as a biomarker of hypertensive
injury to the brain and a way to monitor new treatment strategies. In Chapter 6, we report
the findings of a serial GRE T2* MRI study conducted in a cohort of IS and TIA patients over
more than 5 years of follow-up.
(4) investigating whether and how CMBs relate to cognition in a hospital ischaemic stroke
and TIA cohort. At the time of writing, the role of CMBs in ischaemic cerebrovascular
disease remained largely unexplored. The findings of a large, hospital-based cross-sectional
study of the association between CMBs and cognitive impairment are presented in Chapter
7.1.
(5) assessing whether CMBs are associated with future cognitive impairment in a cohort of
patients with IS and TIA. In Chapter 7.2, we formulated the hypothesis that CMBs, as a
marker of small vessel pathology, are associated with executive impairment in a stroke
clinic cohort and compare the result of their detail cognitive assessment at baseline and 5.7
years follow-up.
(6) exploring how CMBs relate to ‘silent’ ischaemic lesions in ICH. Emerging data suggest
that CAA, a common cause of lobar haemorrhage, is associated with small microinfarctions.
CMBs and other markers of ischaemic small vessel diseases might predict silent ischaemia
after ICH, especially after lobar ICH secondary to CAA, with implications for the
understanding of the mechanisms of small vessel disease. There is increasing evidence that
ischaemia and haemorrhage both occur in small vessel disease in a dynamic interplay
(Chapter 8).
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PART 2 – CEREBRAL MICROBLEEDS: NEW INSIGHTS
FROM NEUROIMAGING AND CLINICAL STUDIES
Chapter 4 - Exploring Ways of Improving Microbleed
Identification, Detection and Reporting
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4.1 Cerebral microbleed quantification and mapping
CMBs on gradient-recalled echo (GRE) T2*-weighted MRI may be a useful biomarker for
bleeding-prone small vessel diseases, with potential relevance for diagnosis, prognosis
(especially for antithrombotic-related bleeding risk), and understanding mechanisms of
symptoms, including cognitive impairment. To address these questions, it is necessary to
reliably measure their presence and distribution in the brain. At the time of writing, some
previous studies had reported information on the reliability of their CMB ratings, but only
one had provided the characteristics of the instrument used in a study that validated the
first published visual CMB rating scale (Brain Observer Micro Bleed Scale [BOMBS],
Cordonnier et al., 2009). We designed and systematically validated our own scale, the
MARS. We measured intra-rater and inter-rater agreement for presence, number and
anatomic distribution of CMBs using MARS across 2 different MRI sequences (TE = 40 ms
and TE = 26 ms) in a representative stroke population. We compared the characteristics of
MARS and BOMBS, and tested their inter-rater agreement on the same population sample
to compare their reliabilities. We finally made recommendations for future users of visual
CMB rating scales, to allow the combination of reliable data across different centres, and
develop clear imaging standards for CMB rating.
4.2 Rationale for the use of standardised visual rating scales for
cerebral microbleeds
Like WML (leukoaraiosis) (Hachinski et al., 1987), CMBs are recognised as an MRI correlate
of small vessel pathology. Over many years, WML on MRI have been extensively
investigated, and a number of rating scales have been developed to assess their severity
and location (Scheltens et al., 1998). These have been shown to have good inter-rater
reliability and continue to be widely used. While volumetric quantification of WML is
considered superior to rating scales in assessing the burden of disease, rating instruments
continue to be used because of their practicality and applicability to standard clinical
datasets. Since awareness of CMBs is much more recent, few standardised instruments
have yet been developed, and there has been great inconsistency in the methods and
reporting of reliability in CMB studies to date. Investigators have used a wide variety of MRI
sequences and rating methods for CMBs, the characteristics of which varied greatly or were
inconsistently reported. The level of observer agreement varies considerably across recent
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studies. A summary of the differences in MRI specifications, brain CMB size definitions and
reports of inter- and intra-observer reliability in recent cohort studies (published in 2009) is
shown in Table 10. In 13 out of 21 studies (62%), there was no report of the reliability of
their CMB measures. Variations in methods included differences in the properties of the
rating scales, in MRI sequences characteristics, in CMB defining criteria and in observers’
training background (e.g. neurology or radiology) or MRI rating experience (Cordonnier et
al., 2007; Greenberg et al., 2009b). MRI sequence characteristics, especially the TE, can
affect the number of lesions classified as CMBs (Gregoire et al., 2010b). The inter-observer
agreement varied from a kappa factor of 0.68 to one of 0.97 in these studies. In general,
agreement about the number of CMBs is higher than that for presence of CMBs (data not
shown). Because of the heterogeneity in these studies, the data cannot be easily compared
and interpreted (Gregoire et al., 2009). A CMB rating scale would be a useful tool to
overcome these issues; it would provide a uniform rating methodology (including clear
definitions of CMB criteria and anatomical regions) and enable reliable (reproducible) data
collection to allow more informative cross-study comparisons.
Part 2 – Cerebral Microbleeds: New Insights from Neuroimaging and Clinical Studies
162
4.3 Presentation of the Microbleed Anatomical Rating Scale
4.3.1 Study design and methods
We developed MARS, an anatomically detailed scale designed to be reliable, easy to use
and generalisable across MRI sequences and observers with various imaging experience
(Figure 44). We specifically included a categorisation of CMBs into individual brain lobes,
since this anatomical information may be important to assess their contribution to VCI or
diagnosing CAA (Cordonnier et al., 2006; Hachinski et al., 2006; Werring et al., 2004; Seo et
al., 2007). Indeed, the MARS was developed from earlier basic rating schemes originally
employed in studies of cognition (Werring et al., 2004). We systematically measured the
intra- and inter-rater reliabilities of the scale for CMB presence and number in lobar, deep
and infratentorial regions, in a representative stroke population.
Population
We considered unselected, consecutive patients (N=426) admitted to the Stroke Service at
the National Hospital for Neurology and Neurosurgery (NHNN) from July 2004 to October
2007. The Stroke Service takes all suspected stroke patients admitted from the surrounding
district and has a policy of performing MRI with GRE T2* sequence in all of them unless
there is a contra-indication (e.g. too medically unstable, severe claustrophobia, metallic
implants). Patients who did not have an MRI were excluded. We excluded patients without
GRE T2*-weighted MRI of sufficient quality for analysis (e.g. due to motion artefact).
Standard protocol approvals
This study on human subjects received approval from the NHNN and Institute of Neurology
Joint Research Ethics Committee (approval number 07/Q0512/39; date of approval 22
October 2007).
Imaging protocols
All MRIs were carried out at 1.5 Tesla field strength using two MRI systems. The majority of
patients (N=271) was imaged on GE Medical Genesis Signa system using a TE of 40ms for
the T2*-weighted sequence. The parameters of the sequences were as follows: axial T2-
weighted FSE (TR 6000, TE 105, FA 90, matrix 256x224, FoV 24x18, slice thickness 5 mm,
slice gap 1.5mm, NEX 2); axial GRE T2* (TR 300, TE 40, FA 20, FoV 24x18, matrix 256x160,
slice thickness 5mm, slice gap 1.5mm, NEX 1). A smaller number of patients (N=30) were
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imaged on a Siemens Avanto system using a TE=26ms for the T2*-weighted sequence. The
parameters of the sequences were as follows: axial T2-weighted FSE (TR 4320, TE 106, FA
150, matrix 448x392, FoV 24x18, slice thickness 5mm, slice gap 1.5mm, NEX 2); axial GRE
T2* (TR 800, TE 26, FA 20, FoV 24x18, matrix 512x448, slice thickness 5mm, slice gap
1.5mm, NEX 1).
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Table 11. Variations in MRI specifications, brain CMB size and results of inter- and intra-rater reliabilities in cohort studies published in 2009
IE = Inter-rater; IA = intra-rater; MCI = mild cognitive impairment; CAA = cerebral amyloid angiopathy; IS = Ischaemic stroke; HCHWA-D = hereditary cerebral haemorrhage with amyloidosis-Dutch type; TBI =
Traumatic brain injury; Neu = Neurologist; NRa = Neuroradiologist; NSu: Neurosurgeon; Ra: Radiologist; NR = not reported
Study Samplesize Demographics
MRI Parameters CMBs Agreement
TE
(msec) TR (msec)
Magnet
Strength
(Tesla)
Slice
thickness
(mm)
Slice
gap
(mm)
MB
size (mm) Raters IE IA Characteristic
Lee et al., 2009 24 Warfarin users 15 500 1.5 6 2 <5 2 Neu 0.88 - Presence
Henneman et al., 2009 1138 Memory clinic 15-22 600-800 1.0/1.5 5 1 <10 3, trained >0.90 >0.90 Number
Nandigam et al., 2009 20 CAA 24-25 750-763 1.5-3.0 1.5-5 0-1 NR 2 raters 0.97 0.8-0.9** Number
Igase et al., 2009 377 Healthy NR NR 3.0 NR NR <5 2 Neu ‘very good’ - -
Staekenborg et al., 2009 152 MCI 22 800 1.0 5 1.5 2-10 NRa - - -
Henskens et al., 2009 192 Hypertensive 23 736 1.5 5 0.5 <5 2 Neu 0.68 - Presence
Kirsch et al., 2009 73+33 MCI+healthy 18 500 1.5 4 NR <=10 4 ‘readers’ - - -
Tang et al., 2009 519 Acute IS 30 350 1.5 5 0.5 2-10 1 Neu 0.78 0.85 Presence + Number
van Rooden et al., 2009 27 ICH with HCHWA-D 45-48 2593-3070 1.5 6 0.6 <5-10 1 NRa - - -
Nishikawa et al., 2009 698 No previous clinical event 23 889 1.5 6 1 <10 1 NRa, 1 NSu - - -
Cho et al., 2009a 152 Acute IS 20 700 1.5 5 2 <10 2 Neu 0.881 0.881 -
Staals et al., 2009 123 First-ever lacunar stroke 23 shortest 1.5 5 0.5 <10 2 Neu 0.68 - Presence
Ishikawa et al., 2005 106 ICH 23 889 1.5 6 1 <10 1 Ra, 1 NSu - - -
Lim and Kim, 2009 234 Primary ICH 20 425 3.0 5 2 <5 1 NRa - - -
Sun et al., 2009 998 Acute IS 30 300 1.5 5 0.5 2-10 NRa - - -
Jeon et al., 2009 237 Acute IS 30 400 1.5 5 2 ≤5 2 raters - - - 
Klein et al., 2009 60 Infective endocarditis 17.3 750 1.5 5 0.5 ≥5, >5 - ≤10 2 NRa - - - 
Orken et al., 2009 141 IS on Warfarin 15 640 1.5 NR NR <5 2 raters - - -
Goos et al., 2009 63 Alzheimer disease 22-25 415-800 1 + 1.5 5 1-1.5 ≤10 NRa - - - 
Park et al., 2009 21 Mild TBI without ICH 26 800 1.5 5 2 <5 NRa - - -
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Brain cerebral microbleed rating
We tested the reliability of the scale for CMBs presence and number in all individual
cerebral regions in the patients scanned at TE=40ms. The images of the patients scanned at
TE=26ms were studied in a secondary analysis for presence of CMBs only. Images were
displayed using the Agfa IMPAX picture archiving and communications system (PACS) (Agfa,
Mortsel, Belgium) on 3-megapixel premium diagnostic grayscale displays (Barco [Kortrijk,
Belgium] Coronis 3MP MDCG-3120-CB), and assessed by a clinical neurologist (SMG) and
trainee neurologist (UJC) in semi-dark conditions. Rater 1 (SMG) had five years’ experience
in neuroimaging; rater 2 (UJC) had one year’s experience. Rater 2 rated the MRIs twice at a
4 week interval, chosen as the minimum time likely to be used in prospective studies.
Rater 1 rated the MRIs twice at a 1 year interval on a subsample of the first 100
consecutive patients. Both raters had received training sessions in CMB detection from a
senior neuroradiologist (HRJ). Each rater was blinded to clinical data and the other rater’s
ratings. Cases of disagreement were reviewed by a consultant vascular neurologist (DJW)
and consultant neuroradiologist (HRJ), both with extensive experience in CMB rating.
Appropriate guidance was incorporated into instructions for future users of the scale.
The microbleed anatomical rating scale
We classified CMBs into ‘definite’ and ‘possible’ categories because a previous study
suggested that such classification improves reliability (Cordonnier et al., 2009). Definite
CMBs were defined as small, rounded or circular, well-defined hypointense lesions within
brain parenchyma with clear margins ranging from 2 to 10 mm in size on GRE T2*-weighted
images; possible CMBs were less well-defined, less hypointense, or not strictly rounded or
circular. The 2-10mm size range includes the highest upper limit defined in previous studies
(Table 10) (Cordonnier et al., 2007). We included a lower size limit in accordance with
consensus guidelines on standards for neuroimaging in VCI (Hachinski et al., 2006). CMB
mimics were carefully excluded using all available imaging. In the basal ganglia we
considered strictly unilateral lesions without evidence of corresponding infarction (on T2-
weighted and FLAIR images) or calcification (on CT scans) to be definite.
CMBs were classified into deep, lobar and infratentorial categories. Lobar MRI landmarks
were defined according to Stark and Bradley (1999), and included cortical and subcortical
regions (including subcortical U-fibres). Deep regions included the basal ganglia, thalamus,
internal capsule, external capsule, corpus callosum and deep and periventricular white
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matter (DPWM); infratentorial regions included the brainstem and cerebellum. All regions
were presented for easy reference in an anatomical diagram (drawn by SMG using
representative axial MR images) adjacent to the scale. DPWM was defined as white matter
adjacent to or within approximately 10 mm of the lateral ventricular margin. Definite and
possible CMBs were reported at each location on the MARS rating form (Figure 44). The
sum of definite and possible CMBs was recorded as total CMBs.
Statistics
Intra- and inter-rater agreements for the presence or absence of CMBs were calculated
using the non-parametric un-weighted κ measure of agreement. κ results were interpreted 
as poor (0-0.20), fair (0.21-0.40), moderate (0.41-0.60), good (0.61-0.80) or very good
(0.81-1) agreement as per Landis and Koch (1977). We used the intraclass correlation
coefficient to assess the intra and inter-rater reliabilities for the number of CMBs. The
intra-rater reliabilities of each rater were compared. All statistical tests were conducted
using the Statistical Package for the Social Sciences (SPSS) for Windows version 16.0 (SPSS
Inc., Chicago, IL).
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The Microbleed Anatomical Rating Scale
Figure 44. Microbleed anatomical rating scale rating form
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4.3.2 Results
Demographic findings
MRI was performed in 355 consecutive patients (83%) admitted to the stroke unit. Fifty-
four patients were excluded from the final analysis for insufficient quality MRI due to
motion artefact (N=43), or absence of GRE T2*-weighted MRI sequence (N=11). The final
cohort consisted of 301 patients, including 271 patients scanned at TE=40ms and 30
patients scanned at TE=26ms. This is summarised in the patient flow diagram (Figure 45).
The radiological findings of our patients included ischemic stroke (N=109, 36%), small
vessel disease with acute infarction (N=106, 35%), small vessel disease without acute
infarction (N=28, 10%), ICH (N=15, 5%), ICH with small vessel disease (N=12, 4%) and SAH
(N=9, 3%). Thirteen subjects (4%) had a normal intracranial MRI scan; 9 subjects (3%) had
another pathology. One hundred seventy-two were male, 129 were female; mean age was
65.2 years (range 18-97). CT was available in the majority of patients (94%, N=283).
Figure 45. Patient flow diagram of MARS study
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Cerebral microbleeds in any location of the brain
CMBs were most prevalent in the lobar region (17-22%) followed by deep (14-15%) and
infratentorial regions (6-12%). Results of intra- and inter-rater reliabilities for the presence
and number of definite, possible and total CMBs in the brain are shown in Table 11. Raters
disagreed on the presence or absence of one or more definite CMBs in 69 cases (25%), of
which 28 (41%) were thought to have a single definite CMB by at least one of the raters.
Because the clinical and pathophysiological significance of a single CMB is uncertain, we
investigated the effect of excluding patients with one definite CMB from the analysis. After
excluding these patients, there was a substantial improvement of the inter-rater
agreement for the presence of definite CMBs in any location (κ = 0.91 [95% CI 0.85-0.97]). 
The intra-rater reliability of rater 1 for the presence of CMBs in all locations at a 1-year
interval was good (κ = 0.75 [95% CI 0.61-0.89], but lower than that of rater 2 at a 4 week 
interval (κ = 0.89 [95% CI 0.79-0.99]). 
Cerebral microbleeds in lobar, deep and infratentorial regions
CMBs were most prevalent in the lobar region (17-22%) followed by deep (14-15%) and
infratentorial regions (6-12%). Intra- and inter-rater reliabilities for the presence and
number of definite CMBs in lobar, deep and infratentorial regions were good to very good
(Table 11).
Cerebral microbleeds in individual anatomical regions
For the presence of CMBs, intra-rater agreement was good to very good in all individual
regions. Inter-rater agreement was good to very good for the presence of CMBs in
individual lobes, in the thalamus and brainstem; moderate inter-rater agreement was
obtained in the cerebellum and basal ganglia. All inter- and intra-rater reliabilities for CMB
presence and number are shown in Table 11. We could not calculate the reliability for
CMBs in the insula and in deep locations other than thalamus and basal ganglia because of
the small number of patients with CMBs in these regions.
The reliability of the scale for possible and total CMBs was lower than that for definite
CMBs in all regions of the brain (Table 11).
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Table 12. Reliability of MARS at TE=40ms for presence and number of CMBs (kappa
agreements and correlation coefficients)
Presence of CMBs* Number of CMBs**
CMBs N (%),rater 1
N (%) rater
2
IA
(95% CI)
IE
(95% CI)
N (range)
rater 1
N (range)
rater 2
IA
(95% CI)
IE
(95% CI)
Any location
Definite 67 (25) 87 (32) 0.85 †(0.77-93)
0.68 †
(0.58-0.78) 266 (0-23) 360 (0-29)
0.98
(0.97-0.99)
0.93
(0.91-0.94)
Possible 52 (19) 63 (23) 0.72 †(0.62-0.82)
0.31 §
(0.17-0.45) 109 (0-14) 147 (0-22)
0.86
(0.83-0.89)
0.58
(0.49-0.65)
Total 84 (31) 105 (39) 0.84 †(0.78-0.90)
0.61 †
(0.51-0.71) 375 (0-35) 507 (0-49)
0.98
(0.97-0.98)
0.91
(0.89-0.93)
Lobar, deep and IT
Definite
Lobar 46 (17) 60 (22) 0.85 †(0.77-0.93)
0.72 †
(0.62-0.82) 156 (0-14) 209 (0-22)
0.98
(0.97-0.98)
0.91
(0.89-0.93)
Deep 37 (14) 40 (15) 0.94 †(0.88-1)
0.71 †
(0.59-0.83) 83 (0-8) 97 (0-9)
0.97
(0.96-0.98)
0.92
(0.90-0.94)
IT 16 (6) 32 (12) 0.85 †(0.75-0.95)
0.64 †
(0.48-0.80) 27 (0-8) 54 (0-6)
0.91
(0.88-0.93)
0.73
(0.67-0.78)
Possible
Lobar 32 (12) 40 (15) 0.76 †(0.64-0.88)
0.39 §
(0.23-0.55) 66 (0-14) 95 (0-20)
0.89
(0.86-0.91)
0.72
(0.66-0.78)
Deep 19 (7) 20 (7) 0.56
§
(0.36-0.76)
0.20 §
(0-0.40) 34 (0-12) 23 (0-2)
0.47
(0.37-0.56)
0.16
(0.05-0.28)
IT 9 (3) 22 (8) 0.54
§
(0.34-0.74)
0.22 §
(0.02-0.42) 9 (0-1) 29 (0-3)
0.97
(0.97-0.98)
0.145
(0.03-0.26)
Total
Lobar 60 (22) 74 (27) 0.84 †(0.76-0.92)
0.64 †
(0.54-0.74) 222 (0-28) 304 (0-42)
0.96
(0.94-0.96)
0.91
(0.89-0.93)
Deep 49 (18) 50 (18) 0.87 †(0.79-0.95)
0.67 †
(0.55-0.79) 117 (0-17) 120 (0-10)
0.85
(0.81-0.88)
0.88
(0.85-0.91)
IT 23 (8) 46 (17) 0.80 †(0.70-0.90)
0.56 §
(0.42-0.70) 36 (0-8) 83 (0-6)
0.85
(0.81-0.88)
0.66
(0.58-0.72)
Individual lobes and regions (definite
CMBs)
Frontal 24 (9) 24 (9) 0.89 †(0.79-0.99)
0.77 †
(0.63-0.91) 41 (0-4) 53 (0-7)
0.95
(0.93-0.96)
0.84
(0.80-0.87)
Temporal 22 (8) 36 (13) 0.87 †(0.77-0.97)
0.73 †
(0.59-0.87) 53 (0-5) 80 (0-9)
0.96
(0.95-0.97)
0.81
(0.77-0.85)
Parietal 21 (8) 26 (10) 0.98 †(0.94-1)
0.74 †
(0.60-0.88) 35 (0-7) 49 (0-5)
0.93
(0.92-0.95)
0.75
(0.69-0.79)
Occipital 13 (5) 15 (6) 0.70 †(0.50-0.90)
0.62 †
(0.40-0.84) 24 (0-4) 19 (0-3)
0.75
(0.69-0.79)
0.65
(0.58-0.72)
Insula 3 (1) 7 (3) 0.85 †(0.65-1) ND 3 (0-1) 8 (0-2)
0.89
(0.87-0.92) ND
Thalamus 20 (7) 27 (10) 0.96 †(0.90-1)
0.84 †
(0.72-0.96) 44 (0-6) 57 (0-8)
0.95
(0.94-0.96)
0.91
(0.88-0.93)
Basal ganglia 18 (7) 16 (6) 0.87 †(0.75-0.99)
0.44 §
(0.22-0.66) 23 (0-4) 26 (0-4)
0.88
(0.85-0.91)
0.59
(0.51-0.66)
Other deep locations ⁫ 13 (5) 8 (3) ND ND 16 (0-2) 14 (0-3) ND ND
Brainstem 7 (3) 11 (4) 0.95 †(0.85-1)
0.77 †
(0.55-0.99) 8 (0-2) 15 (0-4)
0.96
(0.95-0.97)
0.76
(0.71-0.81)
Cerebellum 11 (4) 27 (10) 0.81 †(0.69-0.93)
0.55 §
(0.43-0.67) 19 (0-7) 39 (0-5)
0.86
(0.83-0.89)
0.73
(0.66-0.78)
* un-weighted kappa statistic, ** intraclass correlation coefficient
† = Good/very good agreement §= Moderate agreement ⁫ Internal capsule, external capsule, corpus callosum, deep and periventricular
white matter
MARS = Microbleed Anatomical Rating Scale; TE = echo time; CI = confidence interval; IA: intra-rater; IE: inter-rater; IT: infra-tentorial; ND:
not done
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Agreement for cerebral microbleed rating at TE=26 ms
At TE=26ms (N=30), we obtained very good intra- and inter-rater agreements for the
presence of definite CMBs (intra-rater κ = 1 and inter-rater κ = 0.87 [95% CI 0.61-1]) in any 
location of the brain.
4.3.3 Discussion
With the increasing interest in the clinical relevance of CMBs in individuals with
cerebrovascular disease or dementia and in normal ageing, there is a need for a reliable
instrument to rate their presence, number and distribution throughout the brain. Although
some previous studies have reported information on the reliability of CMB rating
(Copenhaver et al., 2008; Gorner et al., 2007; Henneman et al., 2009; Henskens et al., 2008;
Lee et al., 2008b; Lee et al., 2009; Nandigam et al., 2009; Pettersen et al., 2008; Yakushiji et
al., 2008), only one (Cordonnier et al., 2009) clearly described the characteristics of the
instrument used, and most did not report the intra- and inter-rater reliabilities for all
relevant anatomical regions. Here, we have shown that MARS has good-to-very-good intra-
and inter-reliability for the presence and number of definite CMBs in individual cerebral
lobes, deep and infratentorial regions. There was only moderate agreement for the
presence of possible CMBs.
The particularity of MARS is to assess CMBs in individual cerebral lobes, as well as deep
regions. Lobar anatomical information may be important for studies investigating the
impact of CMBs on cognitive functions in cerebrovascular and degenerative diseases
(Hachinski et al., 2006; Schneider, 2007; Werring et al., 2004; Liem et al., 2009; Seo et al.,
2007) or for the diagnosis of CAA, in which a preferential parieto-occipital distribution for
CMBs has been reported (Greenberg et al., 1996). Indeed, our classification is based partly
on the theoretical potential for CMB distribution to help distinguish CAA from hypertensive
small vessel disease (Vernooij et al., 2008b). The deep category includes brain structures
potentially affected by hypertensive disease of the small penetrating arteries; lobar regions
include the cortico-subcortical regions (cortex and subcortical white matter), more likely to
be affected by CAA. The use in MARS of a similar lobar scheme to previously validated age-
related white matter change scales (Hachinski et al., 2006; Wahlund et al., 2001) allows the
investigation of regional correlations between WML, CMBs and clinical factors. MARS has
other features designed to maximise ease of use: the rating form includes a convenient
summary of the total CMB counts for the whole brain and each anatomical region, and a
Part 2 – Cerebral Microbleeds: New Insights from Neuroimaging and Clinical Studies
172
clear guide to anatomical boundaries of the cerebral lobes and regions (Figure 44). MARS
does not subclassify CMBs according to their size, which in another recently published scale
(BOMBS) (Cordonnier et al., 2009) may unnecessarily complicate the ratings without adding
extra useful information. A full comparison of the two scales is available in the next section.
The present study has strengths in comparison to some previous reports on CMB rating.
First, we systematically tested MARS in a representative stroke population; many previous
studies have included healthy populations (Jeerakathil et al., 2004b; Roob et al., 1999b;
Yakushiji et al., 2008) or patients with a single cerebrovascular diagnosis (ICH (Greenberg et
al., 2004a; Lee et al., 2005; Roob et al., 2000), CAA (Lee et al., 2005; Nandigam et al., 2009).
Second, intra-rater reliability has not been addressed with an adequate interval in most
previous studies (Sveinbjornsdottir et al., 2008; Vernooij et al., 2008b) but is critically
important for longitudinal cohort studies. MARS has shown high agreement with up to a 1
year intra-rater interval, suggesting that it may be useful for such follow-up studies. The
lower intra-rater reliability for rater 1 is probably due to the longer interval between ratings
compared with rater 2. Third, our study investigated the reliability of quantifying the
number of CMBs, which may be relevant in exploring their relationship with other
quantitative imaging or clinical data; most previous studies tested the reliability of rating
CMB presence but not number (Jeerakathil et al., 2004b; Lee et al., 2009; Lemmens et al.,
2007; Seo et al., 2007). Fourth, our results suggest that MARS may be reliable when
applied to a range of MRI sequences, in particular across different TE values. The inter-rater
reliability in our cohort studied at TE=26ms was better than at TE=40ms; this may be
because some CMBs or CMB mimics are missed at TE=26ms, therefore paradoxically
increasing the apparent reliability of the scale despite reduced sensitivity. However, we did
not repeat MRI studies with different TE on the same patients to investigate this possibility.
Previous studies on CMBs reported TE values from 15 to 50ms (Table 10) (Jeerakathil et al.,
2004a; Roob et al., 1999b), which may substantially affect the reported prevalence of CMBs
(Greenberg et al., 2009b) Long TEs may increase the number and size of CMBs detected
(Tatsumi et al., 2008a) but could also reduce image quality and increase unwanted
susceptibility artefacts (Greenberg et al., 2009b). Many other MRI acquisition
characteristics influence CMB detection, including magnetic field strength, slice thickness,
FA and post-processing techniques (including SWI), but the optimum MRI protocol for
detecting CMBs needs further study (Greenberg et al., 2009b; Haacke et al., 2007; Scheid et
al., 2007; Thomas et al., 2008; Vernooij et al., 2008a). The use of a validated scale could
help to identify the MRI acquisition strategy with highest reliability. Finally, our scale had
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good reliability for raters with different levels of experience in neuroimaging. Our less
experienced rater documented the highest number of CMBs, suggesting that stringency in
rating might increase with experience, even when both observers undergo similar training
(as in our study). This suggests that to maximise the reliability of CMB rating the same
observer should be used for all ratings if possible, even where training is standardised; for
multicentre studies, a single rating centre for analysis may also improve reliability. In future
studies, automated methods of CMB detection may help to further improve agreement for
CMB number.
Regions of the brain that caused discrepancies among our raters and with reduced
reliability included the basal ganglia, cerebellum and occipital lobes. In the basal ganglia,
susceptibility effects from calcification or iron deposits can mimic CMBs; CT may be helpful
to distinguish calcification. In the posterior fossa, causes of disagreement include
physiological iron deposits in the dentate nuclei and partial volume artefact from adjacent
bony structures. Air-bone interfaces can cause susceptibility artefacts elsewhere, e.g., in
the inferior frontal or temporal lobes. Problems from misclassifying CMB mimics can be
minimised by careful inspection of adjacent slices and reference to T2, FLAIR and diffusion-
weighted images. Because of the lower agreement for possible CMBs, including only
definite CMBs may improve the reliability of CMB rating for research studies. Patients with
only 1 potential CMB accounted for most cases of disagreement, and inter-rater reliability
substantially improved when these patients were excluded. We therefore suggest caution
in rating a single CMB as a definite lesion. More work is required to establish whether only
patients with multiple CMBs should be included in research studies, and how this affects
CMB prevalence in different diseases. This issue is further complicated because the
classification of patients into those having single versus multiple CMBs may vary with the
MRI technique used: e.g. higher field strengths, thinner slices or SWI seem to increase the
conspicuity and number of CMBs detected (Greenberg et al., 2009b).
Our study has some limitations. First, the number of scans at TE=26ms was small (N=30),
which may increase the CI for our reliability measures. Second, we chose to investigate the
effect of TE on reliability (because TE is likely to have a marked effect on CMB detection),
but did not investigate the effect of changing other relevant MRI sequence characteristics
(Greenberg et al., 2009b). Both of our observers were neurologists, and it would be of
interest to test the reliability of the scale in other types of rater (e.g. radiologists). Finally,
there were limitations related to our assessment of reliability. We conducted a limited
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assessment of reliability between two raters, and only assessed the reliability of the scale.
Other domains of validity need to be established.
4.4 Other standardised cerebral microbleed visual rating scale
4.4.1 BOMBS
At the time of publication of MARS, another visual rating scale had just been published,
BOMBS (Cordonnier et al., 2009). In the BOMBS study, pilot evaluations (not using a
standardised scale) showed inter-rater agreement for ‘certain’ CMBs with a kappa value of
0.44, which improved with modifications and standardisation as the BOMBS scale to one of
0.68, tested in a different population to the pilot study. The BOMBS approach did not
improve agreement about total CMB counts (certain and uncertain). The BOMBS includes a
sub-classification of CMB size as >5 mm or 5-10 mm, although the value of this information
in distinguishing CMBs remains unclear (Greenberg et al., 2009a). The BOMBS rating form is
presented in Figure 46.
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Figure 46. Brain observer microbleed scale (BOMBS)
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4.4.2 Comparison between MARS and BOMBS
We performed a limited comparison between BOMBS and MARS by using BOMBS to rate
MRI scans from our population to provide a comparison of reliabilities. Both our raters
evaluated the first consecutive 100 patients using BOMBS to calculate the inter-rater
reliability. The second MARS ratings of both raters were then used to re-calculate its inter-
rater reliability for the same sample.
On the sample of the first consecutive 100 patients, the inter-rater reliability of BOMBS for
the presence of definite CMBs in all locations was κ = 0.64 [95% CI 0.48-0.80]; the inter-
rater reliability of MARS was κ = 0.75 [95% CI 0.61-0.89]. Both MARS and BOMBs have 
good-to-very-good intra- and inter-rater reliability for CMB presence and number in the
brain. Although the 95% CI overlapped, our raters had a higher inter-rater reliability in
favour of MARS compared to BOMBS when tested in the same population. The inter-rater
reliability for the presence of ≥1 CMB for BOMBS and MARS was generally very similar, 
though MARS had higher reliability for rating deep CMBs (κ = 0.71; 96% confidence interval 
[CI] 0.59-0.83 for MARS versus κ = 0.54; 95% CI, 0.25-0.83 for BOMBS), albeit with 
overlapping CIs. The MARS system was also shown to have very good intra-rater reliability
over a 1-year interval (κ = 0.85 for presence of at least one CMB), and high reliability was 
found using two MRI sequences with different TE values. The testing of rating scales on
images collected using different MRI sequences is important because these affect the
conspicuity and size of CMBs, which have been shown to influence CMB identification
(Nandigam et al., 2009). We acknowledge that the comparison of reliabilities between the
two scale was not a validation measure of MARS and was open to inadvertent bias because
the same raters undertook the comparisons.
The main difference between BOMBS and MARS is that the latter classifies CMBs into
individual lobar anatomical regions, as well as deep structures, with the hypothesis that the
lobar location of CMBs is likely to be an important factor in how they might affect brain
function (particularly cognition). Both scales provide guidance for use, definition criteria for
CMBs and CMB mimics and a table for anatomical categorisation of the CMBs. In each of
these scales, there are two steps: first to identify whether a given lesion is likely to be a
CMB or not and, second, to record the distribution of CMBs in the brain according to an
anatomical scheme. These scales give the option of including ‘definite’ or ‘certain’, as well
as ‘possible’ or ‘uncertain’ CMBs. The inclusion of less certain lesions has been shown in
both studies to lower the agreement between raters, so it is recommended that, at least
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for research studies, only ‘definite’ CMBs are reported. Furthermore, the clinical relevance
of having a single CMB compared with multiple CMBs is not yet determined, though it
seems likely that a single CMB has less relevance for clinical impact on brain function or
prognosis (Goos et al., 2009). Consequently, in research studies, it is recommended that a
distinction is made between patients with just one CMB and those with multiple (>1) CMBs.
Also the classification of patients into those having single versus multiple CMBs may vary
with the MRI technique used , since MRI acquisition characteristics (including field strength,
slice thickness or SWI) have a great influence on CMB detection and identification
(Greenberg et al., 2009b).
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4.5 Conclusions
There is increasing interest in the use of biomarkers to detect and measure the risk of
developing diseases, and to measure disease progression and responses to treatment.
Since CMBs can be readily quantified, they may be a valuable imaging biomarker in the field
of cerebrovascular disease. We have shown that the MARS scale has generally good intra-
and inter-rater reliability for definite CMBs, and hope that it will prove to be a useful
contribution to efforts to reliably map brain CMBs. Further studies are needed to establish
optimal and standardised MRI protocols for CMB identification; investigate the clinical and
diagnostic significance of single (or few) versus multiple CMBs; and develop clear standards
for CMB rating. This should allow the combination of reliable data from different centres
for effective investigation of the many remaining important clinical questions.
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Chapter 5 - Cerebral Microbleeds and Intracerebral
Haemorrhage Risk: Exploring the Risk Factors for
Intracerebral Haemorrhage in Patients on Anti-platelet
Treatment in a Case-Comparison Study
5.1 Summary
ICH is an uncommon but devastating complication of regular antiplatelet use: identifying
high risk patients before treatment could potentially reduce this hazard. Brain CMBs on
gradient-recalled echo (GRE) T2*-weighted MRI are considered a biomarker for bleeding-
prone small vessel diseases. We hypothesised that patients with CMBs are more prone to
ICH if they are treated with antiplatelet agents, especially if the CMBs are numerous and
lobar. We investigated this in a hospital-based matched case-comparison study. Cases of
spontaneous ICH were ascertained using overlapping methods, from a prospective
database of 1017 consecutive unselected patients referred to our stroke unit and
associated clinics. For each case of antiplatelet-associated ICH, 2 controls matched for age,
sex and hypertension without history of ICH on antiplatelet therapy were selected. We
found that CMBs were more frequent in antiplatelet users with ICH than in matched
antiplatelet users without ICH (13/16[81%] versus 6/32[19%], p=0.004) and patients with
non-antiplatelet-associated ICH (13/16[81%] versus 15/33[45%], p=0.03). The frequency of
lobar CMBs was 11/16[69%] in antiplatelet-associated ICH versus 11/33[33%] in non-
antiplatelet-associated ICH (p=0.032). CMBs were more numerous in antiplatelet users with
ICH compared to controls (p=0.016). The number of CMBs was associated with the risk of
antiplatelet-associated ICH (adjusted OR 1.33 per additional CMB, 95%CI 1.06-1.66,
p=0.013). We concluded that brain CMBs are associated with ICH in patients on anti-
platelet treatment. In patients with a large number of lobar CMBs, the risk of ICH could
outweigh the benefits of antiplatelet therapy. Due to our small numbers and lack of proven
causal association, larger prospective studies to investigate the prognostic significance of
CMBs in regular antiplatelet users are warranted.
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5.2 Study design
Since CAA is radiologically characterised by CMBs in a lobar distribution in the brain
(Vernooij et al., 2008b) we hypothesised that brain CMBs – especially lobar - are associated
with antiplatelet-associated ICH. We used a case-comparison study design to compare CMB
prevalence and distribution in antiplatelet users with symptomatic ICH compared with
matched ICH-free antiplatelet users. Because CMBs are known to be associated with ICH
regardless of antiplatelet use, we also conducted a case-case comparison study between
antiplatelet users with ICH and patients with spontaneous ICH unrelated to antiplatelets.
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5.3 Study methods
5.3.1 Study population
We studied a population of 1017 unselected consecutive patients referred to the Stroke
Unit and associated neurovascular clinics at the NHNN from December 2000 to February
2008. The Stroke Unit takes all patients with suspected stroke admitted from the
surrounding district and has a policy of performing MRI with gradient-recalled echo (GRE)
T2*-weighted sequence in all patients with ICH and IS unless contra-indicated, allowing us
to minimise selection bias. MRIs are performed within 5 days of admission or on the day of
the clinic. All patients have standard questions including questions about antithrombotic
use recorded onto a written proforma.
Cases were patients with spontaneous symptomatic ICH occurring during regular
antiplatelet treatment. All patients with ICH were ascertained with overlapping methods
including MRI images, reports and medical records. The intake and duration of antiplatelet
treatment at the time of admission or visit were ascertained from hospital and GP records.
Cases of spontaneous ICH unrelated to antiplatelet agents or other antithrombotic
treatment were ascertained from MRI images and medical records. Due to small numbers,
all cases of spontaneous ICH unrelated to antiplatelet agents were included and therefore
these were not matched with cases of antiplatelet-associated ICH. For each antiplatelet
user with ICH two controls matched for age, sex and hypertension and without any history
of ICH were selected randomly (blinded to other clinical details or CMB ratings) from
prospective databases of consecutive patients admitted to the stroke unit and associated
neurovascular clinics. Controls were patients using antiplatelet agents admitted to the
department due to suspected IS or TIA.
We recorded the BPs taken at the time of admission or visit. Patients were considered
hypertensive when they were on antihypertensive drugs or when their BP was ≥140/90 for 
more than 7 days after admission. We compared baseline demographics, prevalence of
leukoaraiosis and presence, number and distribution of CMBs between cases and controls.
We also performed a case-case comparison between antiplatelet users and non-
antiplatelet users with ICH.
5.3.2 Standard protocol approval
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The study received ethics approval by The NHNN & Institute of Neurology Joint Research
Ethics Committee (approval number 07/Q0512/39; date of approval 22 October 2007).
5.3.3 Imaging analysis
MRIs were carried at 1.5T field strength. GRE T2* sequences were obtained in the axial
plane on a Genesis Signa Scanner [TR 300 milliseconds, TE 40 milliseconds, FA 20°, FoV
24x18, matrix 256x160, slice thickness 5mm, slice gap 1.5mm, NEX 1]. A minority of
patients was scanned on a Siemens Avanto Scanner [TR 800 milliseconds, TE 26
milliseconds, FA 20°, FoV 24x18, matrix 512x448, slice thickness 5mm, slice gap 1.5mm,
NEX 1]. CMBs were identified by a neurologist trained in CMB identification (SMG) and
blinded to all clinical information, who rated CMB presence, number and distribution on
GRE T2* images using MARS, a validated scale for CMB reporting in all brain locations
(Gregoire et al., 2009). Leukoaraiosis was defined as the presence of early confluent or
confluent WML, corresponding to a Wahlund score equal or above 2 (Wahlund et al.,
2001). Lacunes were defined as brain infarcts measuring between 3 and 20mm in size and
mostly present in the deep brain structures (Bryan et al., 1999). According to previous
descriptions, they were characterised as being hypointense in T1-weighted and FLAIR
images, and surrounded by a hyperintense rim in FLAIR images (Kwon et al., 2006; Naka et
al., 2006). ICHs were classified as deep, lobar and posterior fossa. According to MARS, CMB
distribution was classified as deep, lobar and posterior fossa.
5.3.4 Statistical analysis
Blinded analysis of the data was performed with the Data Analysis and Statistical Software
STATA Intercooled version 8.0 and SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL).
Conditional logistic regression analysis was used for the comparison of characteristics
between the case group (antiplatelet users with ICH) and matched control group
(antiplatelet users without ICH). A two-sided independent groups t-test was used for
variables that are normally distributed in each group, Fisher’s exact test for comparison of
proportions, and Mann–Whitney U test for comparison of variables that are not normally
distributed in at least one of the two groups. We investigated the effects of the number of
CMBs in predicting antiplatelet-associated ICH, with adjustment for leukoaraiosis. The
variables entered into the regression analysis model were variables that were significant in
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univariate regression. For the case-case comparison study, we used two-sided independent
t-test, Fisher’s exact tests and non-parametric Mann-Whitney U tests to compare
demographics and radiological features between the two groups. Statistical significance
was declared if p<0.05.
5.4 Results
5.4.1 Demographic results
We identified a total of 164 subjects (N=16%) with ICH admitted during the study period. Of
these, we excluded patients with structural and secondary causes of ICH (aneurysms,
tumours, cavernomas, arterio-venous malformations, coagulation disorders or use of oral
anticoagulants, venous thrombosis or head injuries) (N=69). We then excluded patients in
whom the MRI images were not of satisfactory quality (N=3), did not include a GRE T2*
sequence (N=8) or were not performed (N=35). Of the remaining 49 patients (30%), we
identified 16 cases (patients on regular antiplatelet therapy) and 33 non-antiplatelet users
with ICH (Figure 47).
Patients included in the study were slightly older than patients excluded due to a lack of
MRI (p=0.043). However, there was no significant difference between the 2 groups for any
of the other vascular risk factors: hypertension, systolic BP, diastolic BP, statin use, median
cholesterol total, smoking history, diabetes, previous history of stroke, history of AF,
ischaemic heart disease (IHD) and antithrombotic use. The proportion of patients scanned
on the Siemens Avanto scanner was small: antiplatelet-associated ICH (N=1, 6%), controls
(N=2, 6%), non-antiplatelet-associated ICH (N=3, 9%).
We selected 32 matched controls from the database of antiplatelet users without ICH.
Cases and controls were well matched for all clinical characteristics and potential
confounding factors including previous history of IS, IHD, lacunar infarcts, median dose of
aspirin and duration on antiplatelets (Table 12). Antiplatelet agents used by patients and
controls were: aspirin (N=43), clopidogrel (N=3), aspirin plus dipyridamole (N=1), or
clopidogrel plus aspirin (N=1).
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Among patients with ICH related and unrelated to antiplatelet agents, the groups were
similar for most clinical characteristics (Table 13), but as expected, previous IHD and stroke
were more prevalent among antiplatelet than non-antiplatelet users (p=0.003 and <0.001).
Figure 47. Patient flow diagram of antiplatelet-associated ICH study.
5.4.2 Incidence and location of the intracerebral haemorrhages
The majority of subjects had single ICHs (N=14 [87.5%] and N=28 [85%] in antiplatelet users
and non-antiplatelet users). The ICHs were most often located in the cerebral lobes (Table
13). Multiple acute ICHs were seen in 2 antiplatelet users (12%) and 5 non-antiplatelet
users (18%). Two patients had prior ICH, one on long-term antiplatelet therapy (6%) and
Structural or
secondary
causes of ICH
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one non-antiplatelet user (3%). Examples of GRE T2* images of an antiplatelet user who
developed two acute lobar haemorrhages are shown in Figure 48.
5.4.3 Comparison between cases and controls
Thirteen (81.2%) antiplatelet users with symptomatic ICH had CMBs compared with six
(18.8%) antiplatelet users without any history of ICH (p=0.004) (Table 14). CMBs were more
numerous in subjects with ICH compared with controls (median: 6.0, range 0-28, versus
median: 0, range 0-15; p=0.016). In both groups, CMBs were most common in the lobes
than in the deep or posterior fossa regions. The prevalence of leukoaraiosis was higher in
antiplatelet users with ICH compared with controls (50% versus 22%, p=0.069).
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Table 13. Characteristics of antiplatelet users with and without history of ICH
NS: not significant; IQ range: interquartile range
*p<0.05
† Plus–minus values are means+/-SD
With ICH
(N=16)
Without ICH
(N=32) P value
Clinical characteristics†
Mean age in yrs (range) 70+/-10.5 (52-86) 67.25+/-9.9 (53-94) NS
Men, N (%) 10 (62.5) 20 (62.5) NS
Hypertension (%) 12 (75) 24 (75) NS
Systolic blood pressure (mmHg) 165+/-26 154.85+/-25 NS
Diastolic blood pressure (mmHg) 87+/-12 81.5+/-15.51 NS
Diabetes (%) 4 (25) 7 (22) NS
Cholesterol total >6mmol/L (%) 1 (6) 3 (9) NS
Statin use (%) 5 (31) 14 (52) NS
Ischaemic heart disease (%) 6 (37.5) 13 (40.6) NS
Atrial fibrillation (%) 2 (12.5) 6 (18.7) NS
Previous stroke (%) 8 (50) 16 (50) NS
Smoking (%) 10 (62.5) 17 (53) NS
Duration, months (%) 41.6+/-48.4 37.7+/-43.4 NS
Number taking aspirin (%) 15 (94) 30 (94) NS
Median dose of aspirin in aspirin users in mg (range) 75 (75-300) 75 (75) NS
Median interval stroke-MRI in days (range) 11 (2-115) 17 (0-131) NS
Imaging characteristics
CMBs
Presence (%, range)
Median (range)
13 (81.2, 0-28)
6.0 (0-28)
6 (18.8, 0-15)
0 (0-15)
0.004*
0.016*
Lobar
Presence (%)
Median (range)
11 (69)
3.0 (0-15)
5 (15.6)
0 (0-8)
0.004*
0.016*
Deep (basal ganglia and thalamus)
Presence (%)
Median (range)
9 (56.2)
1.0 (0-11)
3 (9.4)
0 (0-3)
<0.001*
NS
Posterior fossa (brainstem and cerebellum)
Presence (%)
Median (range)
6 (37.5)
0 (0-2)
4 (12.5)
0 (0-5)
NS
NS
Lacunes
Presence (%)
Median (range)
12 (80)
2.0 (0-9)
27 (84)
2.5 (0-10)
NS
NS
Leukoaraiosis
Presence (%) 8 (50) 7 (22) NS
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Table 14. Characteristics of subjects with symptomatic spontaneous ICH
Antiplatelet users
(N=16)
Non-antiplatelet users
(N=33) P value
Clinical characteristics†
Mean age in yrs (range) 70+/-10.5 (52-86) 66+/-10.6 (41-87) NS
Men, N (%) 10 (62.5) 18 (54.5) NS
Hypertension (%) 12 (75) 27 (81.8) NS
Systolic blood pressure (mmHg) 165+/-26 151+/-32 NS
Diastolic blood pressure (mmHg) 87+/-12 83+/-16 NS
Diabetes (%) 4 (25) 2 (6.1) NS
Cholesterol total >6mmol/L (%) 1 (6) 2 (6) NS
Statin use (%) 5 (31) 4 (13) NS
Ischaemic heart disease (%) 6 (37.5) 1 (3) 0.003*
Atrial fibrillation (%) 2 (12.5) 3 (9.1) NS
Previous stroke (%) 8 (50) 2 (6.1) <0.001*
Smoking (%) 10 (62.5) 10 (30.3) NS
Median interval stroke-MRI in days (range) 11 (2-115) 7 (0-222) NS
Imaging characteristics
CMBs
Presence (%, range)
Median (range)
13 (81.2, 0-28)
6.0 (0-28)
15 (45.4, 0-31)
0.0 (0-31)
0.030*
0.012*
Lobar
Presence (%)
Median (range)
11 (69)
3.0 (0-15)
11 (33)
0 (0-12)
0.032*
0.016*
Deep (basal ganglia and thalamus)
Presence (%)
Median (range)
9 (56.2)
1.0 (0-11)
9 (27.3)
0 (0-17)
NS
0.032*
Posterior fossa (brainstem and cerebellum)
Presence (%)
Median (range)
6 (37.5)
0 (0-2)
5 (15)
0 (0-8)
NS
NS
Lacunes
Presence (%)
Median (range)
12 (80)
2.0 (0-9)
24 (75)
2.0 (0-7)
NS
NS
Leukoaraiosis
Presence (%) 8 (50) 8 (24) NS
NS: not significant; IQ range: interquartile range
*p<0.05
† Plus–minus values are means+/-SD
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Figure 48. GRE T2* MRI of an antiplatelet user who developed two lobar intracerebral
haemorrhages
GRE T2*-weighted MRI of a patient with antiplatelet
CMBs (white arrows) and three lobar haemorrhages (temporal left, parieta
arrows). Cerebral amyloid angiopathy is likely to be the underlying cause of the CMBs and multiple
ICHs in this patient.
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Table 15. Logistic regression analyses testing the factors predicting the likelihood of ICH in
antiplatelet users with ICH and antiplatelet users without ICH matched for age, sex and
hypertension
Odds Ratio 95% CI P value
Number of CMBs
Total number of CMBs 1.27 1.04-1.55 0.016*
Total number of CMBs adjusted for leukoaraiosis1 1.33 1.06-1.66 0.013*
Distribution of CMBs
Number of Lobar CMBs 1.35 1.06-1.72 0.016*
Number of Lobar CMBs adjusted for leukoaraiosis2 1.42 1.07-1.89 0.016*
Number of Deep CMBs 5.86 0.96-35.69 0.055
Number of Deep CMBs adjusted for leukoaraiosis3 5.69 0.95-34.22 0.057
*p<0.05
1Hosmer-Lemeshow goodness of fit: Chi-Square 15.532, sig. 0.004
Positive predictive value:38 %
Negative predictive value: 77%
2Hosmer-Lemeshow goodness of fit: Chi-Square 11.310, sig. 0.023
Positive predictive value: 42%
Negative predictive value: 75%
3Hosmer-Lemeshow goodness of fit: Chi-Square 55.535, sig. 0.016
Positive predictive value: 36%
Negative predictive value: 76%
5.4.5 Comparison between cases of intracebral haemorrhage differing in
the use of antiplatelets
CMBs were more frequent in antiplatelet users with ICH compared with patients with non-
antiplatelet-associated ICH (13/16 [81.2%] versus 15/33 [45.4%]; p=0.030). CMBs were
more numerous in antiplatelet users (range 0-28, median 6.0 versus range 0-31, median 0;
p=0.012) and lobar CMBs more prevalent (69% versus 33%, p=0.032). Both deep and lobar
CMBs were more numerous in antiplatelet users than in non-antiplatelet users (p=0.032 for
deep and p=0.016 for lobar CMBs). Finally, leukoaraiosis was more prevalent in antiplatelet
users with ICH compared with subjects with ICH unrelated to antiplatelets, but the
difference was not statistically significant (50% versus 24%, p=0.106).
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5.5 Discussion
In this study we found that CMBs were more prevalent and numerous in antiplatelet users
who developed symptomatic ICH compared with matched antiplatelet-users who did not
develop ICH. The CMB number was strongly associated with ICH risk even after controlling
for the presence of leukoaraiosis and other potential confounding factors. Our study
suggests that the association of ICH with CMBs may be more powerful than that with
leukoaraiosis, although CMBs and leukoaraiosis may reflect similar pathological damage to
small vessels (Naka et al., 2006). In separate regression analyses adjusted for the presence
of leukoaraiosis, lobar (but not deep) CMBs were a statistically significant predictor of ICH
in patients on anti-platelet treatment. These data support a potential role for brain CMBs,
particularly in a lobar distribution, as a risk factor for antiplatelet-associated ICH.
We have confirmed previous observations of a predominance of lobar CMBs in patients
with ICH (Roob et al., 2000; Tsushima et al., 2003); we also found that lobar CMBs were
more common in antiplatelet-associated ICH than in ICH unrelated to antiplatelet agents
(p=0.032). Moreover, regression analyses indicated that lobar CMBs were significantly
associated with antiplatelet-associated ICH. These observations suggest that lobar CMBs
may be more strongly related to antiplatelet-associated bleeding than deep CMBs,
although our sample size is too small to confirm this hypothesis, which requires
confirmation in larger studies. Previous autopsy and MRI studies suggest that lobar CMBs
are related to CAA (Greenberg, 1998; Rosand et al., 2000). In CAA, Aβ-protein is deposited 
in the walls of superficial cortical and leptomeningeal vessels, causing them to become
brittle and prone to bleeding. CAA may account for a large proportion of spontaneous ICH
in older people (Wong et al., 2000) and has been suggested as a risk factor for ICH
associated with warfarin (Rosand et al., 2000) and aspirin (Wong et al., 2000) as well as
with ICH after thrombolysis for IS (McCarron and Nicoll, 2004). These data are consistent
with the hypothesis that CAA is an important risk factor for ICH related to antiplatelet use,
and suggest that patients with clinical and imaging findings suggestive of CAA should be
treated with antiplatelet agents only if there are compelling reasons to treat to reduce
their overall risk of ischaemic vascular events.
Very few previous studies have investigated the association between CMBs and
antiplatelet-associated haemorrhage (Huang et al., 2008; Wong et al., 2003). Moreover,
these were in Chinese patients in whom hypertension and CMBs are more common than in
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Europeans, so may not be generalisable to all stroke populations. Nevertheless, Wong et al
found CMBs in 19 of 21 aspirin users with symptomatic ICH, compared to 7 of 21 matched
aspirin users without ICH, a result consistent with our findings. In contrast with our study,
no cases of ICH unrelated to aspirin were included, and no adjustment was made for the
presence of leukoaraiosis, a potentially important confounding factor. A recent randomised
trial comparing the new antiplatelet drug cilostazol to aspirin found that in the 6 patients
who developed ICH, all had previous CMBs in the location of the ICH (Huang et al., 2008);
this observation is also consistent with the hypothesis that CMBs could be used to identify
patients at the highest risk of antiplatelet-associated ICH, but the small number of outcome
events makes it difficult to draw firm conclusions.
Our study has a number of methodological strengths. First, our data were prospectively
collected, with standardised clinical data and MRI imaging sequences; because of our policy
of performing routine GRE MRI on all patients unless contra-indicated, we were able to
minimise selection bias. Second, we matched our cases with our controls, which is a
powerful way to identify risk factors for rare outcome events. Given the very low absolute
risk of antiplatelet-associated ICH (about 0.1-0.2% per year), prospective studies would
require large number of patients and long follow-ups: indeed, the few prospective studies
so far available failed to reach definite conclusions because of small sample sizes and low
statistical power (Boulanger et al., 2006; Fan et al., 2003; Naka et al., 2006). Third, we were
able to specifically investigate the independent effect of CMBs on ICH risk because
important known confounding factors (age, sex, hypertension, duration on antiplatelets,
and previous history of stroke and presence of leukoaraiosis) were controlled for in the
matching process and logistic regression analysis. We adjusted for leukoaraiosis which is a
risk factor for warfarin-associated ICH and is associated with CMBs (Algra et al., 1997;
Diener et al., 2004; Jeong et al., 2004; Roob et al., 2000; Smith et al., 2002). Fourth, we
used a reliable anatomical CMB rating scale with good intra- and inter-observer agreement
(Gregoire et al., 2009). Finally, we included patients with ICH unrelated to antiplatelet
treatment, ascertained from the same population as our main case group, making it less
likely that our finding is confounded by the well-described association of CMBs with ICH
overall. However, in this case-case ICH comparison, a greater proportion of patients with
ICH taking antiplatelet agents had a history of previous IS, which could contribute to the
higher CMB prevalence in this group.
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The main limitations of our study include the small cohort and retrospective design. We
obtained large CI in the estimation of ICH risk for the number of deep CMBs, likely to be
due to the small number of deep CMBs in our cohort overall. We could only include
patients who had MRI, which biased the study towards including slightly older and less
severe cases of ICH. Our overall prevalence of CMBs might therefore be a bit
overestimated. Another limitation comes from the fact that our ‘controls’ presented with
non-ICH stroke symptoms, and therefore were not ‘true’ controls. However, this should not
have biased our study towards positive results as our controls are likely to have more CMBs
than ‘true’ controls. Also, there was a possible lack of comparability between our cases,
because these were not matched. Therefore, comparison between their baseline
characteristics (e.g. blood pressure) may have failed to reach significance due to small
numbers. Finally, like all case-control and case-comparison studies, ours can only provide
evidence of an association between CMBs and ICH in patients on anti-platelet treatment,
and not that CMBs are causally associated. For these reasons, our results need to be
confirmed in other prospective studies.
The study also has a limitation due to the delay of a few days before performing MRI after
the ICH, which may lead to survival bias in this condition associated with high early
mortality (Leys and Cordonnier, 2010).
Part 2 – Cerebral Microbleeds: New Insights from Neuroimaging and Clinical Studies
193
5.6 Conclusions
In summary, we have demonstrated an association between CMBs and ICH in patients on
antiplatelet treatment. The predominance of lobar CMBs in patients on antiplatelets who
develop an ICH suggests that CAA may be an important underlying risk factor for ICH in
patients taking antiplatelets. Our findings suggest that patients with numerous CMBs,
particularly in a lobar distribution, may be at higher risk of ICH, which could outweigh the
benefits of antiplatelet therapy in these patients (Soo et al., 2008). Therefore, CMB
screening may be an important component in the design of future antiplatelet trials,
especially in primary prevention where the risks of ICH are more likely to outweigh the
benefits than in secondary prevention. Large prospective studies and systematic analyses
are needed to further clarify the risks and benefits of antiplatelet therapy in patients with
CMBs.
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Chapter 6 - Exploring Cerebral Microbleed Dynamics in a
Case-Control Study
6.1 MRI detection of new cerebral microbleeds in patients with
ischaemic stroke
Some recent studies indicate that CMBs have a dose-related effect on the risk of ICH,
cognitive dysfunction and mortality (Greenberg et al., 2004a; Greenberg et al., 1999;
Werring et al., 2004). Furthermore, the burden of CMBs in the brain may be a useful
biomarker to monitor the progression of cerebrovascular disease affecting small vessels;
indeed, in CAA, CMBs have been shown to accumulate over time, and to predict recurrent
ICH and clinical decline (Greenberg et al., 1999). By contrast, very little is known about
whether CMBs develop over time in patients with IS, in whom CMBs are increasingly
detected because of the routine use of GRE T2*-weighted MRI in neurovascular clinics
(Werring et al., 2005). It has been suggested that the development of CMBs – which cause
surrounding tissue damage on histopathological studies – may have important cumulative
effects on brain function including cognition (Werring et al., 2004). Thus, CMB development
over time, and the factors which may influence this process, is of potentially significant
clinical interest in stroke medicine. Although the presence of hypertension, and left
ventricular hypertrophy on echocardiography (a marker of hypertension severity and
duration) (Henskens et al., 2008) are associated with CMBs in cross-sectional studies, it is
not known whether hypertension influences the risk of developing new CMBs over time.
Studies on CMBs using serial MRI largely relate to patients with a symptomatic lobar
haemorrhage and probable or possible CAA. Two studies on patients with lobar
haemorrhages suspected of CAA showed that 38% to 46% of patients developed new CMBs
at follow-ups of 1.5 and 1 year, respectively (Greenberg et al., 1999; Chen et al., 2006). In
the first study, the development of new CMBs was related to the number of CMBs at
baseline; in the second, it was related to the volume of WML at baseline. In another study,
the number of MRI-detected CMBs increased after the onset of ICH in patients with
symptomatic spontaneous deep ICH (Imaizumi et al., 2003).
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We studied the incidence of new CMBs in a cohort of patients with IS or transient
ischaemic attack (TIA) screened for CMBs at baseline. Predictors of new CMBs were tested
in logistic regression. At the time of conducting this research, there had been no studies
that had investigated how CMBs accumulate over time in patients with IS and the factors
influencing this process. It was not known whether vascular risk factors e.g. hypertension
or the use of antithrombotic agents influence the rate of accumulation of CMBs. We
discuss the rationale for attempting to answer this particular question.
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6.2 Study design
We assessed the development of new CMBs in patients with IS and TIA screened for CMBs
on GRE T2* MRI at baseline and at 5 year follow-up, with detailed clinical assessments at
both time points. We hypothesised that CMBs and higher BP at baseline increase the risk of
developing new CMBs.
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6.3 Study methods
6.3.1 Study population
Consecutive individuals referred to the neurovascular clinic at the NHNN with suspected IS
or TIA from 2001-2002 underwent detailed clinical assessment by a consultant stroke
neurologist, and GRE T2* MRI on the same day. On the basis of the results from GRE T2*-
weighted MRI, 25 patients with cerebral CMBs and a CMB-free control group (N=30)
matched for age, gender and other clinical and radiological characteristics were selected
from a previously published study of cognition in patients with CMBs (Werring et al., 2004).
Patients with confirmed IS or TIA (N=48) were invited for repeat MRI and clinical
assessment. Clinical follow-up assessment included a neurological examination, detailed
medical questionnaire, validated disability scales (National Institute of Health Stroke Scale
(IHSS), Modified Rankin Scale, Barthel Index) and standardised quality of life measurements
(EuroQoL).
6.3.2 Standard protocol approval
The study was approved by the Institute of Neurology and NHNN Joint Research Ethics
Committee (approval number 07/Q0512/39; date of approval 22 October 2007). All
participants gave written informed consent.
6.3.3 MR imaging and reporting
All baseline and follow-up MRIs were carried out on a GE Medical Genesis Signa 1.5Tesla
system using the following imaging protocol: axial T2-weighted FSE (TR 6000, TE 105, FA 90,
matrix 256x224, FoV 24x18, slice thickness 5 mm, slice gap 1.5mm, NEX 2); axial GRE T2*
(TR 300, TE 40, FA 20, FoV 24x18, matrix 256x160, slice thickness 5mm, slice gap 1.5mm,
NEX 1). Similar patient positioning was ensured between studies by a standardised
radiographic protocol. Images were assessed by SMG blinded to clinical details using
validated rating scales for WML (Wahlund et al., 2001) and CMBs (MARS, Gregoire et al.,
2009) in the same conditions as described previously (see chapter 4 and 5). T2-weighted
MRI and FLAIR images were used to help exclude common CMB mimics (Gregoire et al.,
2009).
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6.3.4 Statistical analysis
Statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) and
the Data Analysis and Statistical Software Stata (Statacorp, 1985) version 10.0.
Comparisons between groups at each assessment were carried out using Fisher’s exact test
for categorical variables, the independent sample T-Test for normally distributed
continuous variables, and the Mann-Whitney U test for non-normally distributed
continuous variables. Univariate and multivariate analyses using binary logistic regression
analysis were used to look for the predictors of new CMBs. The variables entered into the
multivariate regression analysis model were variables that were significant in univariate
regression. We used penalised maximum likelihood regression and likelihood ratio tests to
test the mean systolic BP at baseline as a predictor of new CMBs. Significance was declared
at p<0.05 (two-sided).
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6.4 Results
6.4.1 Demographic findings
The overall prevalence of CMBs in patients with IS or TIA in our neurovascular clinic is
30.2%, similar to that of previous studies (Cordonnier et al., 2007). Of the original cohort
(N=48: N=21 with CMBs, N=27 CMB-free) 11 patients (23%, N=7 with CMBs [33%]; N=4
CMB-free [15%], p=0.164) died between original study enrolment and follow-up. The only
vascular death was a myocardial infarction in the CMB group. Four patients (8%) were lost
to follow-up. Of the remaining 33 patients, a final cohort of 21 patients (64%, N=8 with;
N=13 without CMBs) underwent repeat MRI and clinical assessment. The two groups were
still well matched for clinical characteristics at follow-up (Table 15). The mean interval
between assessments was 5.6 years (SD=0.44). All patients were on antihypertensive
therapy except two without CMBs.
6.4.2 Imaging findings
At baseline 8 patients had a total of 62 microhaemorrhages (87% lobar, median 4.0, range
1 to 36; Table 15). At follow-up, five patients (23%) had developed 56 new CMBs (all lobar).
Among patients with CMBs at baseline, 4 of 8 (50%) developed new CMBs compared with
one of 13 (8%) CMB-free patients (p=0.047). Examples of new CMBs are shown in Figure
49. The number of new CMBs in patients with baseline CMBs was significantly higher than
in patients without (54 [range per patient 0 to 34, median 1] versus 2 [range per patient 0
to 2, median 0], p=0.025).
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Table 16. Baseline patient characteristics
CMBs (N=8) CMB-free (N=13) p
Clinical characteristics
Female gender (%) 3 (37) 5 (38) 1.000
Median age: years (range) 65 (45-87) 65 (36-76) 1.000
Hypertension (%) 8 (100) 8 (62) 0.111
Median systolic BP: mm Hg (range) 150 (110-165) 135 (120-160) 0.131
Median diastolic BP: mmHg (range) 80 (60-105) 80 (64-94) 0.581
Diabetes (%) 2 (25) 3 (23) 1.000
On antiplatelets (%) 7 (87) 12 (92) 1.000
On anticoagulants (%) 1 (12) 0 0.400
Median time on antiplatelet agents in
months (range) 72 (24-108) 78 (48-144) 0.852
On antihypertensive treatment (%) 8 (100) 11 (85) 0.505
History of previous stroke (%) 3 (37) 2 (15) 0.325
Index event: TIA (%) 0 1 (8) 1.000
Presence of lacunar infarcts (%, median,
range) 7 (87, 1.5, 0-3) 12 (92, 1.0, 0-3) 0.826
Anterior circulation stroke/TIA (%) 2 (25) 2 (15) 0.618
Posterior circulation stroke/TIA (%) 0 1 (8) 1.000
Imaging characteristics
White matter changes
Median total WML score (range) 5 (0-11) 2 (0-5) 0.100
† p<0.05
TIA indicates transient ischaemic attack
6.4.3 Predictors of new cerebral microbleeds
The results of the regression analyses are shown in Table 16. CMB presence at baseline
predicted the formation of new CMBs at 5 years (OR 12, 95% CI 1.02 to 141.34, p=0.048);
the association with the number of CMBs was weak (OR 1.51, 95% CI 0.99 to 2.30,
p=0.055). Mean baseline systolic BP predicted new CMBs at follow-up (OR 1.28 per unit
increase, 95% CI 1.23 to 1.33, p<0.001) even after adjustment for the presence of CMBs at
baseline (OR 1.18, 1.01 to 1.38, p=0.002). All patients who developed new CMBs had a
baseline systolic BP >150mmHg. The mean systolic BP at follow-up was higher in patients
with new CMBs compared with those without (163+/-20 mmHg versus 141+/-16 mmHg,
p=0.020). We found no association between antiplatelet use, presence or number of
lacunar infarcts, and new CMBs.
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Table 17. Study patients with ≥1 CMB at baseline, follow-up, or both and with corresponding 
number of CMBs at baseline and follow up and associated clinical events
Light grey columns are values at baseline. Non bolded columns are values at follow-up. Dark grey columns are
differences between baseline and follow-up.
(+) indicates no. of additional CMBs at follow-up compared with baseline for the same region of the brain
(-) indicates no. of CMBs less at follow-up compared with baseline for the same region of the brain
*Patient without CMBs at baseline
‡ One parieto-occipital CMB could not be seen on follow-up images because of artefacts in that region
B = baseline; FU = follow-up; D = difference
6.4.4 Clinical follow-up
There were few vascular outcome events among the survivors in this cohort: ICH not at the
site of a CMB (N=1, CMB group); non-fatal myocardial infarction (N=1, CMB-free group).
The other surviving patients were clinically stable; there was no difference between the 2
groups at follow-up in median Barthel index (100, range 80 to 100 versus 100, range 95 to
100, p=0.190), median total EQ-5D score (80, range 55 to 98 versus 75, range 20 to 90,
p=0.228) and median NIHSS (0 in both groups, p=1.000). Median Rankin scores were
slightly worse in CMB patients than CMB-free patients at follow up (1, range 1 to 3 versus
1, range 0 to 2, p=0.040).
Patient
Number
Frontal
Parieto-
occipital
Temporal
Basal
ganglia
Infraten-
torial
Total
Any clinical
event
during
follow-up
B
F
U
D B
F
U
D B
F
U
D B
F
U
D B
F
U
D B
F
U
D
1 0 9 +9 1 2 +1 1 7 +6 0 0 = 1 1 = 3 19 +16 None
2 0 0 = 0 0 = 0 0 = 1 1 = 0 0 = 1 1 = None
3 2 3 +1 0 0 = 1 2 +1 1 1 = 1 1 = 5 7 +2 None
4 5 5 = 1 3 +2 3 3 = 1 1 = 0 0 = 10 12 +2 ICH
5 0 0 = 1 1 = 0 0 = 0 0 = 0 0 = 1 1 = None
6 0 0 = 3 2 -1 1 1 = 0 0 = 0 0 = 4 3 -1‡ None
7 7 9 +2 20 39
+1
9
9 16 +7 0 0 = 0 0 = 36 64 +28 None
8 1 1 = 0 0 = 1 1 = 0 0 = 0 0 = 2 2 = None
9* 0 1 +1 0 1 +1 0 0 = 0 0 = 0 0 = 0 2 +2 None
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Patient Baseline Follow-up
1
3
4
Figure 49. GRE T2*-weighted MRI of patients who developed new CMBs without
clinical events over 5-year follow-up.
New CMBs (white arrows) are detected on follow-up images (right panel) but not at
baseline (left panel).
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Table 18. Univariate and multivariate logistic regression analysis
Factor Odds Ratio 95% CI p
Univariate regressions
Presence of CMBs at baseline 12 1.02-141.34 0.048
Number of CMBs at baseline 1.51 0.99-2.30 0.055
Total score of WML at baseline 1.19 0.83-1.72 0.334
Systolic BP at baseline 1.28 1.23-1.33 <0.001
Multivariate regression*
Presence of CMBs at baseline
Systolic BP at baseline
4.27
1.18
0.15-122.73
1.01-1.38
0.396
0.002
*Hosmer-Lemeshow goodness of fit: Chi-Square 10.246, sig. 0.175
Positive predictive value: 100%
Negative predictive value: 70%
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6.5 Discussion
In this study, 50% of surviving patients with CMBs at baseline developed new CMBs over
5.6 years compared with only 13% of matched CMB-free patients. The presence of CMBs at
baseline predicted new CMB development. The risk of developing new CMBs was
significantly associated with the mean baseline systolic BP. At the time of conducting this
research, no similar data were available in IS cohorts.
We found that baseline systolic BP predicted the development of new CMBs and was above
150 mm Hg in all patients in whom new CMBs developed. Hypertension is an established
risk factor for CMBs in cross-sectional studies (Henskens et al., 2008), but we are not aware
of previous longitudinal data on whether hypertension increases the risk of developing new
CMBs. Therefore, rigorous BP control in patients with IS with CMBs may prevent the
progression of small vessel damage and new CMB formation.
Many new CMBs were detected despite patients remaining clinically stable with few clinical
events and retention of independence in their daily activities. This suggests that the rate of
CMB accumulation may exceed that of clinical vascular events. CMBs in patients with IS
may therefore be a more sensitive marker for the progression of small vessel pathology in
the brain than clinical outcomes; this could have implications for clinical trials (e.g.
investigating the effects of antihypertensive agents) or observational studies.
Previous published data on CMBs using serial MRI largely relates to patients with a
symptomatic lobar haemorrhage and probable or possible CAA. A previous study in CAA
showed that 38% of patients with lobar haemorrhage developed new CMBs at a follow-up
of 1.5 years (Greenberg et al., 1999); the development of new CMBs was related to the
number of CMBs at baseline. A subsequent study in CAA patients reported that 46% of
patients developed new CMBs after 1 year (Chen et al., 2006); in the latter study, the
development of new CMBs was related to the volume of WML at baseline. In our cohort
the presence and number of CMBs at baseline (but not the extent of WML) were associated
with new CMB formation. Our results support the idea that CMBs in IS patients are a
marker for more severe and potentially progressive small vessel pathology, requiring active
treatment including careful control of BP and other vascular risk factors.
There is currently no clear evidence to suggest that finding CMBs on MRI should influence
the use of antithrombotic agents. There was no association between antiplatelet usage and
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new CMB formation in our small study. Recent data suggest that the use of antiplatelet
agents may be associated with a higher prevalence of cerebral CMBs in a healthy elderly
population (Vernooij et al., 2009) but there are no other data on whether the use of
antiplatelet agents increases the rate of accumulation of CMBs over time. We found that
antiplatelet-users with large numbers of CMBs may have a substantially higher rate of ICH
than those without CMBs, which could cancel out the benefit of these treatments in
preventing occlusive vascular events in some patients (Gregoire et al., 2010c) but this
hypothesis needs to be tested in other populations (see Chapter 5 for full study details).
CMBs are often considered to be clinically silent; indeed, in our cohort some patients
developed many new CMBs despite no apparent clinical deterioration. Nevertheless, CMBs
have been associated with neurological symptoms including transient motor or sensory
disturbances (Greenberg et al., 1993; Roch et al., 2005) or cognitive dysfunction (Werring
et al., 2004). There are very few follow-up studies investigating CMBs and neurological
function, but one recent study found that in patients with CADASIL mutations followed up
over 7 years, an increased number of CMBs was associated with cognitive decline (Liem et
al., 2009). Other studies suggest that CMBs have an independent prognostic significance for
mortality or the risk of subsequent ICH in patients with stroke (Soo et al., 2008)or in a
memory clinic population (Henneman et al., 2009). Clearly, further follow-up studies are
needed to establish how CMBs are related to the development of neurological impairments
in stroke patients over time.
Strengths of our study include the use of a long follow-up period, with standardised MRI
sequences and a single observer using a validated CMB rating instrument. The main
limitation of our study is the small sample size which may affect the generalizability of our
findings to the general population of patients with IS, and limits the precision of our
estimates of rates of new CMB development. The selection of patients with ischaemic
strokes may have excluded asymptomatic patients with potentially larger number of CMBs
(e.g. CAA). However, the overall prevalence of CMBs in patients with IS in our
neurovascular clinic is 23% (Werring et al., 2005), in line with other estimates (Cordonnier
et al., 2007), suggesting that our findings are generalizable. The small sample size also
affected the power of our analysis of baseline CMBs as a risk factor for new CMBs. The
small p value (p=0.048) suggests that the association found may have not been a real
finding and that our results may have been different in a larger population sample. Most
CMBs detected at baseline were lobar as were all new CMBs. Although lobar CMBs are
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suggested to reflect CAA, whereas deep CMBs are due to hypertensive arteriopathy, the 2
pathologies may interact or coexist (Fazekas et al., 1999). In our study, patients with deep
CMBs were overrepresented in patients who died or were lost to follow-up, which may
have introduced bias towards detecting new lobar CMBs. We used one-off BP
measurements - which are recognised to be of limited value in comparison to more
sophisticated techniques including ambulatory BP monitoring, so we could not relate CMB
accumulation or clinical events to control of BP during follow-up. Finally, although care was
taken to ensure accurate repositioning of patients between MRI studies, it is possible that
some of the apparently new CMBs were found because of a change in head position
between scans. However, if this was a significant problem we would expect a significant
number of ‘disappearing’ CMBs at follow-up, which was not the case.
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6.6 Conclusions
CMBs may be a useful quantitative method for objectively monitoring the progression of
small vessel pathology in patients with IS in observational or therapeutic studies (e.g. of
antiplatelet or antihypertensive agents). Larger prospective studies are needed to
determine whether specific treatments (e.g. aggressive treatment of hypertension) can
reduce CMB formation, and how CMB accumulation relates to long-term clinical outcomes.
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Chapter 7 - Cerebral Microbleeds and Cognitive Function
7.1 Strictly lobar cerebral microbleeds are associated with
executive impairment in patients with ischaemic stroke or
TIA
7.1.1 Summary
CMBs are a marker of small vessel diseases, including hypertensive arteriopathy and CAA,
and may be associated with cognitive impairment. The relationship between CMBs and
cognitive function in ischaemic cerebrovascular disease remains uncertain. We therefore
investigated the cognitive impact of CMBs in a cohort of patients with IS or TIA. All patients
underwent detailed and comprehensive neuropsychological testing and standardised MRI
including FLAIR, T1, T2 and gradient-recalled echo T2*-weighted sequences. CMBs, WML,
lacunes and territorial cortical infarcts (defined by standardised criteria) were identified,
and associations with cognition assessed. Three hundred and twenty patients with a
diagnosis of IS or TIA were included. Of these, 72 (22.5%) had at least one CMB. Of all the
cognitive domains tested, only executive impairment was more prevalent in patients with
CMBs than without (38% versus 25%; p=0.039). In univariate analysis, the presence of
strictly lobar (but not deep) CMBs was associated with executive impairment (OR 2.49,
95%CI 1.16-5.36, p=0.019). In adjusted multivariate analyses, the presence (OR 2.34, 95%CI
1.08-5.09, p=0.031) and number (OR1.33, 95%CI 1.04-1.69, p=0.022) of strictly lobar CMBs
were significantly associated with executive impairment. CMBs were not associated with
impairment in other cognitive domains. In conclusion, strictly lobar CMBs are
independently associated with executive dysfunction in patients with IS or TIA. Our findings
suggest that a microangiopathy related to strictly lobar CMBs (e.g. CAA) contributes to
cognitive impairment in this population.
7.1.2 Rationale
Cognitive impairment after stroke is associated with significant functional impact and high
risk of dementia (Wentzel et al., 2001), which might be preventable with improved
understanding of the underlying mechanisms. Cerebral small vessel disease plays a key role
in cognitive dysfunction (Anon, 2012). CMBs, detected on gradient-recalled echo (GRE) T2*-
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weighted MRI, are an important marker of small vessel pathology; they correspond to small
perivascular haemosiderin deposits related to vessels affected by hypertensive
arteriopathy and CAA, and are presumed to represent focal areas of previous bleeding
(Fazekas et al., 1999). Recent evidence suggests that CMBs are linked to cognitive
impairment (Cordonnier et al., 2006; Goos et al., 2009), particularly executive function or
processing speed (Seo et al., 2007; Werring et al., 2004; Yakushiji et al., 2008). There is
indirect evidence that CMB location reflects the underlying small vessel disease process
(strictly lobar CMBs being a marker for CAA; deep CMBs for hypertensive arteriopathy)
(Poels et al., 2010), but the importance of CMB location with regard to cognition remains
uncertain.
Some previous studies of CMBs and cognition have been limited by not considering a full
spectrum of cerebrovascular lesions (Fisher, 2010) or using insensitive cognitive screening
instruments. The role of CMBs in ischaemic cerebrovascular disease without dementia
remains largely unexplored. We therefore investigated the association of CMBs with
detailed neuropsychological measures of cognition, taking account of other MRI markers of
cerebrovascular disease, in a hospital-based IS or TIA population. We hypothesised, based
on observations in our previous preliminary report (Werring et al., 2004) that CMBs are
independently associated with domain-specific executive impairment in a larger cohort of
patients with IS or TIA, and investigated whether lobar or deep CMBs were most strongly
associated with cognitive dysfunction.
7.1.3 Methods
Patients
Patients referred to the stroke service at the NHNN, London, UK, and referred for detailed
cognitive testing were considered. During the study period the NHNN received all stroke
referrals from the surrounding healthcare districts. Neuropsychological testing is
performed routinely in all patients with adequate English, unless they are too unwell (e.g.
reduced conscious level) or have severe cognitive impairment (e.g. severe dysphasia or
dementia). Inclusion criteria were: standardised adequate quality MRI, including GRE T2*
T2-weighted and Fluid Attenuation Inversion Recovery (FLAIR); and complete
neuropsychological data (including at least one measure of both executive function and
speed and attention processing) within 3 months of the MRI scan. Exclusion criteria
included: previous traumatic brain injury or ICH; or known cause of cognitive impairment
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other than cerebrovascular disease. All patients had detailed standardised clinical
diagnostic assessment including neurological examination, BP measurement, ECG and
echocardiogram. We ascertained stroke mechanism using the Trial of Org 10172 in Acute
Stroke (TOAST) criteria (Adams et al., 1993). The study was approved by the NHNN and
Institute of Neurology joint research ethics committee (approval number 07/Q0512/39;
date of approval 22 October 2007).
Imaging
All patients had MR imaging according to a standardised protocol on a 1.5 Tesla scanner:
Signa Echospeed (General Electric, Milwaukee, WI, USA), including the following sequences:
sagittal T1; axial T2-weighted FSE; axial T2*-weighted GRE (TR 300ms, TE 40ms, FA 20, FoV
24x18, matrix 256x160); and coronal FLAIR (TR 9895ms, TI 2473ms, TE 140ms). For all these
sequences, slice thickness was 5 mm and slice gap 1.5 mm. Image analysis for CMBs was
conducted by a neurologist trained in neuroimaging (SMG) blinded to clinical details. CMBs
were categorised as lobar, deep or infratentorial using the MARS (Gregoire et al., 2009), an
instrument with good intrarater and interrater reliability for the presence of definite CMBs
in all brain locations using different MRI sequences and observer experience (Gregoire et
al., 2009). CMBs in the insula were classified as lobar. WML were rated on axial T2-
weighted and coronal FLAIR images using a validated scale (Wahlund et al., 2001) by SMG
and another trained observer (GS). Interobserver agreement for WML showed intraclass
correlations between 0.84-0.96. Images were assessed for the number of lacunes, defined
as CSF-containing spaces, between 2-20 mm diameter, with high signal on T2-weighted or
FLAIR images, or with a perilesional halo on FLAIR images (Vermeer et al., 2007). Territorial
cortical infarcts were defined as involving the cortical territory of a large cerebral artery
(not suggesting a perforating vessel occlusion), with a diameter above 15 mm.
Neuropsychological data
Neuropsychological assessment (blinded to CMB status) comprised a standardised battery
evaluating 7 cognitive domains: current intellectual functioning, speed and attention,
verbal and visual memory, naming skills, perceptual functions, speed and attention and
executive functions. Executive functions were examined using two or more of the
following: Stroop test (Trennary et al., 1989), Word fluency (Spreen and Benton, 1969),
Trail Making Test Part B (U.S. Army, 1944), Weigl Colour Form Sorting Task (Weigl, 1941),
and Modified Card Sorting Test (Nelson, 1976). The tests used to evaluate the other
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cognitive domains are described in detail elsewhere (Werring et al., 2004). Derived scores
were calculated for each test based on published normative data from a sample of
individuals of comparable age. Each patient’s performance in each cognitive domain was
classified as impaired or unimpaired, according to predefined criteria (Werring et al., 2004).
Statistical analysis
Statistical analysis was performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA). The
characteristics of patients with and without CMBs were compared using two-sided
independent t-test for normally distributed variables, Fisher’s exact test for comparison of
proportions when the expected number of counts was less than 5 (otherwise Chi-Square
test was used), and Mann–Whitney U test for comparison of non-normally distributed
variables. Factors associated with executive impairment were investigated in unadjusted
logistic regression analysis. Significant variables were subsequently entered into
multivariate binary logistic regression analysis. Other variables entered into the
multivariate regression models were variables potentially playing a significant role as
confounders in the association tested. Significance was declared at p<0.05.
7.1.4 Main findings
Of 1335 patients considered, 320 patients with a final diagnosis of IS or TIA were included
(Table 18; Figure 50). Of the 320 patients, 254 (79%) had an IS and 66 (21%) had a TIA. At
least one CMB was identified in 72 patients (22.5%). The CMB group included a higher
proportion of men, a higher prevalence of hypertension, diabetes, antithrombotic use and
previous IS or TIA, a greater number of lacunes, and more severe WML compared to the
group without CMBs.
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Table 19. Characteristics of the patients
Patients with
CMBs
(N=72)
Patients without
CMBs
(N=248)
p
General characteristics
Gender: females (%) 20 (28) 110 (44) 0.012*
Age in years, mean (SD) 67 (12) 63 (15) 0.091
Pre-morbid IQ score, median (range) 98 (50-124) 97 (56-131) 0.843
Number years of education, median (range) 10 (5-18) 10 (0-20) 0.844
Hypertension (%) 63 (88) 175 (72) 0.008†
Systolic blood pressure, mean in mmHg (SD) 149 (23) 146 (26) 0.404
Diastolic blood pressure, mean in mmHg (SD) 84 (13) 82 (14) 0.494
Diabetes (%) 23 (32) 40 (16) 0.004†
Previous ischaemic stroke/TIA (%) 28 (40) 63 (26) 0.033*
Antithrombotic use (%) 36 (50) 89 (37) 0.044*
Clinical classification
Stroke diagnosis (%) 59 (82) 195 (79) 0.540
Anterior circulation stroke/TIA (%) 52 (74) 184 (78) 0.481
Posterior circulation stroke/TIA (%) 18 (26) 50 (21) 0.434
TIA diagnosis (%) 13 (18) 53 (21) 0.540
Ischaemic stroke/TIA mechanism
Atherothrombotic (%) 12 (17) 42 (18) 0.859
Cardioembolic (%) 7 (10) 48 (20) 0.043*
Small-artery occlusion (%) 34 (47) 81 (34) 0.040*
Undetermined (%) 16 (22) 52 (22) 0.933
Other determined cause (%) 3 (4) 16 (7) 0.580
Imaging classification
Median number of lacunes (range) 1 (0-6) 0 (0-3) <0.001†
Presence of territorial cortical infarct (%) 26 (36) 117 (47) 0.096
Median N cortical infarcts (range) 0 (0-3) 0 (0-5) 0.196
Large Vessel Infarct
Anterior circulation: ACA (%) 3 (4) 2 (0.8) 0.083
Anterior circulation: MCA (%) 8 (11) 33 (14) 0.546
Bilateral (%) 5 (7) 17 (7) 0.995
Median WML Scores
Total (range) 10 (0-22) 7 (0-26) <0.001†
IQ = intelligence quotient; ACA = anterior cerebral artery; MCA = middle cerebral artery; SD = standard
deviation; TIA = transient ischaemic attack; WML = white matter lesions.
*p < 0.05; †p < 0.01
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Figure 50. Flowchart describing patient selection for study 7.1
Stroke clinic
(2001-2006)
Stroke ward
(1999-2007)
Initial cohort
N=1335
Total cohort with GRE T2* MRI
sequence and neuropsychology
N=535
Study cohort
N=445
Patients with a diagnosis of
ischaemic stroke or TIA
N=320
With CMBs
N=72
Without CMBs
N=248
No GRE T2* MRI
sequence N=294
Limited or no
neuropsychology N=363
Previous history of traumatic
brain injury N=12
No medical information
N=6
Poor quality imaging
N=3
English as second
language N=8
Previous history or ICH or current
admission for ICH N=28
Known cause of cognitive
impairment other than vascular
disease N=4
Interval between MRI and
psychology >1 year N=29
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Lobar CMBs were found in 51 patients (71%), deep CMBs in 37 (51%) and infratentorial
CMBs in 21 (29%) patients. Lobar CMBs were most common in the temporal (N=31, 61%)
followed by parieto-occipital (N=27, 53%) and frontal lobes (N=24, 47%). Thirty patients
(42%) had strictly lobar CMBs; 16 (22%) had strictly deep CMBs. Among patients with
strictly lobar CMBs, 6 had ≥5 CMBs. Of the domains tested, only executive impairment was 
more prevalent in patients with CMBs compared to those without (38% versus 25%,
p=0.039). There was no significant difference (P>0.10) between the CMB and non-CMB
groups in the proportion impaired in the other cognitive domains (Table 19).
Table 20. Proportions of patients impaired in each cognitive domain
Cognitive domains Patients with CMBs
(N=72)
Patients without CMBs
(N=248)
p
Global cognitive (%) 9 (22) 50 (32) 0.209
Verbal memory (%) 8 (11) 28 (12) 0.894
Visual memory (%) 11 (16) 58 (24) 0.161
Naming skills (%) 8 (11) 28 (12) 0.894
Perceptual function (%) 13 (18) 38 (15) 0.586
Executive function (%) 27 (38) 62 (25) 0.039*
Speed and attention (%) 39 (63) 129 (59) 0.624
Median number of domains impaired (range) 2 (0-5) 1 (0-7) 0.403
Chi-Square test (2-sided) used to test each domain; Mann Whitney U test for mean number of domains.
*p<0.05
In unadjusted binary logistic regression, executive impairment was associated with the
presence of ≥1 strictly lobar CMBs and with ≥5 strictly lobar CMBs (Table 20). The number 
of lacunes and mean WML severity were not associated with executive impairment.
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Table 21. Unadjusted univariate binary logistic regression analyses testing the factors
associated with executive impairment
Factors Odds ratio 95% CI p
Age 1.01 0.99-1.02 0.456
Gender (male) 1.02 0.62-1.68 0.945
Hypertension 1.51 0.83-2.78 0.180
Diabetes 1.12 0.61-2.04 0.721
Number of lacunes 1.13 0.82-1.56 0.440
Antithrombotic use 1.06 0.64-1.75 0.826
Previous stroke/TIA 1.29 0.76-2.21 0.334
CMBs
Overall presence 1.79 1.03-3.13 0.040*
≥ 1 lobar CMB 1.86 0.99-3.48 0.052
≥ 1 deep CMB 0.95 0.44-2.06 0.900
≥ 1 strictly lobar CMBs 2.49 1.16-5.36 0.019*
≥ 5 lobar CMBs 13.63 1.57-118.38 0.018*
WML
Mean total 1.02 0.97-1.07 0.535
*p < 0.05
In multivariate analysis adjusted for age, WML severity and hypertension, the presence of
≥1 strictly lobar CMB and of ≥5 strictly lobar CMBs remained significantly associated with 
executive impairment (≥1: OR 2.34, 95%CI 1.08-5.09, p=0.031; ≥5: OR 13.72, 95%CI 1.55-
121.57, p=0.019) (Table 21). The number of strictly lobar CMBs was associated with an
increased likelihood of executive impairment (OR 1.33 per additional CMB). CMB presence
in the parieto-occipital lobes (adjusted OR 3.05, 95%CI 1.33-6.96, p=0.008) and insula
(adjusted OR 5.55, 95%CI 1.58-19.53, p=0.008) was associated with executive impairment;
the presence of infratentorial CMBs showed a non-significant trend towards association
with executive function (OR 2.39, 95%CI 0.94-6.05, p=0.067). In other brain regions, CMBs
presence was not associated with executive impairment.
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Table 22. Multivariate binary logistic regression analyses testing the factors associated with
executive impairment
Predictors Odds ratio 95% Confidence
interval
p
MODEL 1
Presence of strictly lobar CMBs (versus none)
Age
Hypertension
Mean total score of WML
2.34
1.00
1.38
0.99
1.08-5.09
0.98-1.02
0.69-2.74
0.94-1.05
0.031*
0.743
0.357
0.818
MODEL 2
Presence of ≥5 strictly lobar CMBs (versus none) 
Age
Hypertension
Mean total score of WML
13.72
1.00
1.56
0.99
1.55-121.57
0.98-1.02
0.78-3.11
0.93-1.05
0.019*
0.998
0.206
0.715
MODEL 3
Number of strictly lobar CMBs
Age
Hypertension
Mean total score of WML
1.33
1.00
1.45
0.99
1.04-1.69
0.98-1.02
0.73-2.88
0.93-1.05
0.022*
0.822
0.284
0.647
*p < 0.05
MODEL 1
*Hosmer-Lemeshow goodness of fit: Chi-Square 9.147, sig. 0.330
Positive predictive value: 60%
Negative predictive value: 72%
MODEL 2
*Hosmer-Lemeshow goodness of fit: Chi-Square 7.532, sig. 0.481
Positive predictive value: 17%
Negative predictive value: 73%
MODEL 3
*Hosmer-Lemeshow goodness of fit: Chi-Square 10.084, sig. 0.259
Positive predictive value: 50%
Negative predictive value: 72%
7.1.5 Discussion
In patients with IS or TIA, CMBs were associated with impairment in executive functions,
but not other cognitive domains. Strictly lobar (but not deep) CMBs were associated with
executive impairment, independent of age, hypertension and the severity of WML. The
presence of at least one strictly lobar CMB more than doubled the likelihood of executive
impairment, with evidence of a graded increase in the risk of impairment with an increasing
number of strictly lobar CMBs.
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CMBs have been reported to be common in various populations. However, links between
CMBs and cognitive function have been inconsistent, probably because of the great
variability in populations, MRI techniques and cognitive rating instruments used
(Cordonnier et al., 2006; Goos et al., 2009; Poels et al., 2012a; Qiu et al., 2010; Seo et al.,
2007; van Norden et al., 2011; Werring et al., 2010; Yakushiji et al., 2008). Nevertheless,
consistent with our findings, a large recent study in community-based elderly subjects
showed that CMBs were independently associated with lower scores in processing speed
and executive functions (Qiu et al., 2010). Another study in a large European population-
based cohort (Poels et al., 2012a) reported robust associations between strictly lobar CMBs
and cognitive function (information processing speed and motor speed), but only weak
associations for deep or infratentorial CMBs.
The association between CMBs and cognitive function in stroke cohorts (Werring et al.,
2005) is largely unknown. In a small case-control study of 55 patients referred to a
neurovascular clinic, we found that executive impairment was twice as common in patients
with CMBs as in matched CMB free controls, independent of WML (Werring et al., 2004).
These effects were hypothesised to be mediated by CMBs in frontal and basal ganglia
regions. In the current study, executive dysfunction was associated only with strictly lobar
CMBs, with no significant association with deep or infratentorial CMBs. The different
findings in the present study may be explained by the inclusion of only outpatients with
less severe cerebrovascular disease and mainly deep CMBs in the previous report (Werring
et al., 2004). A study in patients with neuroimaging evidence of small vessel disease
reported that frontal and temporal lobe CMBs were related to global cognitive function,
psychomotor speed, and attention (van Norden et al., 2011). Finally, a hospital-based study
of 411 patients with IS, haemorrhagic stroke and non-stroke (Yamada et al., 2012) found
that ‘dementia’ was associated with CMBs in the IS subgroup, but the study did not report
adjusted analyses, nor the criteria used to define dementia.
Our study provides evidence for a link between a process associated with strictly lobar
CMBs and executive function in ischaemic cerebrovascular disease. Strictly lobar CMBs are
a putative marker for CAA (Vernooij et al., 2008b), making this a possible risk factor for
cognitive impairment, even in patients in whom CAA was clinically not suspected. Our
finding of frequent CMBs in the temporal and parieto-occipital regions is in keeping with
the anatomical predilection of CAA (van Norden et al., 2011; Vernooij et al., 2008b). CAA,
although most often clinically recognised as a cause of lobar ICH in the elderly, is also
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associated with dementia (Charidimou et al., 2012b). CAA pathology is more prevalent at
autopsy in the brains of individuals who were previously demented than those who were
not demented (Pfeifer et al., 2002). The severity of CAA may also increase the risk of future
cognitive decline: in a prospective cohort study of patients with lobar ICH, the risk of
cognitive impairment at 2 years increased with increasing baseline CMB burden (hazard
ratio [HR] 1.9, 95% CI 1.2 to 2.8, for each increase in CMB category) (Greenberg et al.,
2004b). Community-based pathological studies including the Honolulu-Asia Aging Study
(HAAS) and MRC Cognitive Function and Aging Study (CFAS) found CAA to be associated
with cognition even after controlling for age and neurodegenerative pathology (Pfeifer et
al., 2002; Wharton et al., 2011). The Religious Orders study showed that moderate-to-
severe CAA was linked to impairment in specific cognitive domains, particularly ‘perceptual
speed’, assessed with the Symbol Digit Modalities Tests and Number Comparison tests
(Arvanitakis et al., 2011); however, we found no association between CMBs and ‘speed and
attention’ functions, also assessed by the Symbol Digit Modalities test. Possible
explanations include the following: first, our patients all attended hospital with IS or TIA,
while the Religious Orders study included community-based subjects, whom only 36% had
cerebral infarction at autopsy; and second, the Religious Orders Study found associations
with moderate-to-severe CAA pathology, whereas our patients with strictly lobar CMBs
probably have less severe CAA pathology. Indeed, without pathological data, we do not
know the true prevalence or severity of definite CAA pathology. Nevertheless, we suggest
that our data add to emerging evidence that CAA has an independent association with
cognitive function in a range of populations.
It is unclear whether CMBs are a direct cause of cognitive impairment or are a general
marker for the severity of microangiopathic disease (Werring et al., 2010); our finding that
CMBs in the parieto-occipital lobes and insula were associated with executive impairment
most favours an indirect link. Mechanisms by which lobar CMBs (reflecting CAA) could be
linked with cognitive impairment include vascular Aβ damaging the neurovascular unit 
(Iadecola C et al, Stroke 2009), hypoperfusion from small vessel stenosis, or even small
areas of ‘microinfarction’ (Gregoire et al., 2011). Some CMBs may have a direct effect on
surrounding or connected brain regions, a notion supported by tissue necrosis seen in
histopathological studies (Fazekas et al., 1999; Schrag et al., 2010). Precise mapping of
CMBs throughout the brain, with assessment of damage to surrounding tissues and the
whole brain using quantitative MRI techniques (e.g. diffusion tensor imaging) may be a
helpful future approach (van Norden et al., 2011).
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The pattern of CMBs we observed (prevalent in the temporal, parieto-occipital and frontal
lobes) has previously been associated with cognitive dysfunction in different populations
(Pettersen et al., 2008; Seo et al., 2007). A recent study of non-demented elderly subjects
also noted that frontal and temporal CMBs were associated with poor cognitive
performance (van Norden et al., 2011) although this cohort was restricted to patients with
small vessel disease, with a much lower prevalence of cortical infarcts than ours.
Strengths of our study include: the standardised, detailed neuropsychological battery; the
standardised MRI protocol tailored to the detection of cerebrovascular disease; and the use
of validated rating scales by trained raters blinded to clinical details. We considered a range
of cerebrovascular lesions (lacunes, WML, cortical infarcts), and adjusted analyses for
potential confounding factors. Despite this, we cannot exclude an effect of other
unmeasured confounders (e.g. cerebral volume loss). There may have been selection bias
because of our inclusion criteria: patients with very severe stroke who died soon
afterwards will not have had MRI or neuropsychology, and patients with severe dementia
are unlikely to have been referred to our outpatient service. However, the routine use of
neuropsychology means that our results are likely to be generalisable to other stroke
service cohorts of stroke survivors able to undergo neuropsychological testing. The use of a
routine clinical MRI without optimised sequence parameters or advanced post-processing
may have underestimated the prevalence of CMBs, although such technical factors do not
seem to markedly affect the relationship between CMBs and cognition (Goos et al., 2011).
Nevertheless, it remains possible that highly optimised sequences (e.g. high field strength)
could affect the relationship between CMBs and cognition (Conijn et al., 2011). Finally, we
were not able to definitely confirm that strictly lobar CMBs were correlated with
histopathological or in vivo amyloid imaging evidence of CAA.
7.1.6 Conclusion
Our findings suggest that strictly lobar CMBs may be an independent risk factor for
executive impairment in patients with ischaemic cerebrovascular disease. They support the
hypothesis that a microangiopathy related to strictly lobar CMBs (e.g. CAA) contributes to
cognitive impairment in this population. With increasing knowledge of the pathophysiology
and clinical-radiological spectrum of CAA (Charidimou et al., 2012b), our findings may have
implications for the diagnosis, treatment and prevention of cognitive impairment in stroke
populations.
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7.2 Cerebral microbleeds and long-term cognitive outcome:
longitudinal cohort study of stroke clinic patients
7.2.1 Summary
Cognitive impairment causes significant disability in the elderly, and is common following
IS. Although the underlying mechanisms and prognostic factors remain unclear, small
vessel diseases are known to contribute. CMBs are a MRI manifestation of small vessel
diseases and may contribute to VCI, particularly executive functions. We hypothesised that
baseline CMBs would predict long-term cognitive outcome, specifically executive function.
A cohort of consecutive patients found to have CMBs when first referred to a stroke clinic,
together with a CMB-free control group matched for age, gender and clinico-radiological
characteristics, were invited for follow-up cognitive assessment a median of 5.7 years later.
MRI and detailed cognitive assessment (including current intellectual function, verbal
memory, visual memory, naming skills, perceptual functions, executive function and speed
and attention) were performed at baseline and follow-up. Patients were classified (blinded
to MRI and clinical data) as impaired or unimpaired in each domain using pre-defined
criteria. We compared the prevalence of cognitive impairments in each domain at baseline
and follow-up and investigated clinical and radiological predictors (including baseline CMBs
and WML) of executive cognitive impairment.
Of the original cohort of 55 patients, 13 died without follow-up. Twenty-six of the surviving
patients (9 with, 17 without baseline CMBs) agreed to follow-up neuropsychological
assessment; 21 of these patients had a repeat MRI scan. The median number of cognitive
domains impaired increased, regardless of the presence of baseline CMBs (with baseline
CMBs: median = 3 [0-5] at follow-up vs median 2 [0-2] at baseline, p=0.016; without CMBs:
median 1.0 [0-5] at follow-up vs median 0 [0-5] at baseline, p=0.035). Frontal-executive
impairment at follow-up was more prevalent in patients with baseline CMBs than without
(78% vs 29%, p=0.038). The presence of baseline CMBs predicted executive impairment at
follow-up (OR 8.40, 95%CI 1.27-55.39, p=0.027). Fifty percent of patients with CMBs versus
8% of patients without baseline CMBs developed new CMBs (p=0.047). The severity of
WML increased; the difference was statistically significant only in patients without baseline
CMBs (p=0.027). There were no new cortical infarcts.
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The conclusion is that in stroke clinic patients, CMBs are consistently associated with
executive impairment; baseline CMBs are associated with executive impairment at follow-
up after 5.7 years. The presence of CMBs has prognostic relevance for long-term cognitive
outcome in stroke clinic patients, and may help to optimally target preventive strategies in
individuals at highest risk of cognitive decline.
7.2.2 Rationale
VCI causes significant disability in the elderly, and is a common outcome following IS.
Although the underlying mechanisms and prognostic factors remain unclear (Bowler,
2005), small vessel diseases including hypertensive arteriopathy or amyloid angiopathy are
known to contribute (Schneider, 2007). Optimising control of vascular risk factors may
prevent the progression of cognitive impairment (Purandare, 2009), but these strategies
require the identification of individuals most at risk of deterioration. To identify individuals
at particular risk for cognitive decline, it is critical to understand the mechanisms and
prognostic factors for long term cognitive impairment after stroke.
CMBs are an imaging biomarker of small vessel pathology with potential relevance for
cognitive outcome (Seo et al., 2007): some studies suggest an association between CMBs
and executive function (Liem et al., 2009; Qiu et al., 2010; Werring et al., 2004), yet their
prognostic relevance for long-term cognitive outcome in stroke patients has not been
investigated. Indeed, very few studies have explored the detailed profile of cognitive
impairment in different cognitive domains in stroke survivors: although executive
dysfunction is a common early feature (Ballard et al., 2002), few data are available on
longer term cognitive dysfunction. In this study, we undertook detailed neuropsychological
assessments to test the hypothesis that baseline CMBs (a marker of small vessel pathology)
are associated with executive impairment after 5.7 years of follow-up in a cohort of stroke
clinic patients.
7.2.3 Study methods
Consecutive patients referred to a stroke clinic (at the NHNN Queen Square, London) found
to have CMBs were matched to a non-CMB control group for clinico-radiological
characteristics when they first attended the clinic (2001-2002), as previously described
(Werring et al., 2004). These patients were invited to attend a follow-up examination as
part of this research (2007-2008). All patients had a detailed neuropsychological
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assessment and MRI (unless contraindicated) at baseline and follow-up (Werring et al.,
2004). The initial cohort consisted of 55 patients (N=25 with CMBs, N=30 without CMBs).
Baseline and follow-up MRIs were assessed for CMBs and WML using validated rating
scales (Gregoire et al., 2009; Wahlund et al., 2001), and for cortical infarcts, by a trained
observer (SMG) blinded to clinical details. A standardised comprehensive
neuropsychological test battery was used at baseline and follow-up [see reference 5 for a
detailed description], and included assessments of cognitive function in 7 domains: current
intellectual functions, verbal memory, visual memory, naming skills, perceptual functions,
executive functions; and speed and attention. All these areas of cognition were evaluated
using standard neuropsychological tests. Executive functions were examined using two or
more of the following tests: Stroop Test (Trennary et al., 1989); Word fluency (Spreen and
Benton, 1969), Trail Making Test Part B (U.S. Army, 1944), Weigl Colour Form Sorting Task
(Weigl, 1941) and Modified Card Sorting Test (Nelson, 1976). The neuropsychologist was
blinded to clinical details and MRI data at the time of assessing the patients. Patients were
classified (blinded to MRI and clinical data) as impaired or unimpaired in each domain using
standardised pre-defined criteria as described elsewhere (Werring et al., 2004). We
recorded cortical territorial infarcts, CMBs, and WML, at baseline and at follow-up.
Statistical analysis was performed using SPSS version 17 (SPSS Inc., Chicago, IL, USA). The
study was approved by our research ethics committee (approval number 07/Q0512/39;
date of approval 22 October 2007). All patients provided written informed consent.
7.2.4 Results
Thirteen out of the original 55 patients died between the baseline examination and the
follow-up study. Of the 42 surviving patients, 9 (6 male) with baseline CMBs and 17
patients without (10 male) consented to follow-up (Figure 51). The median time between
assessments was 5.67 years (4.75-7.08) (Table 22). Baseline CMBs were present in lobar
regions in 8/9 (89%) and in deep regions in 3/9 (33%) patients.
Part 2 – Cerebral Microbleeds: New Insights from Neuroimaging and Clinical Studies
223
Figure 51. Flowchart describing patient selection for study 7.2
55 patients
(original cohort, 2001-2002)
With microbleeds
(N=25)
Without microbleeds
(N=30)
Excluded from follow-up
(N=15)
Died (N=8) of
Sepsis (N=3); Cancer (N=3),
MI (N=1); Suicide (N=1)
Declined (N=4) because
Severe disease (N=2); Lack
of interest of motivation
(N=2)
Lost to F-U (N=3)
Not reassessed (N=1)*
Excluded from follow-up
(N=14)
Died (N=5) of
Sepsis (N=1); Cancer (N=1),
Renal failure (N=1);
Unknown (N=2)
Declined (N=4) because
Severe disease (N=2); Lack
of interest of motivation
(N=4); Hospital anxiety
(N=1)
Lost to F-U (N=1)
Consented
(N=9)
Consented
(N=17)
26 patients
(follow up cohort, 2008)
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Table 23. Baseline characteristics of CMB and CMB-free patient groups in the 5.7 year follow-
up cohort
With CMBs
(N=9)
Without CMBs
(N=17)
p
Demographics
Male gender (%) 6 (67) 10 (59) 1
Median age at first assessment (range) 65 (44-86) 62 (35-75) 0.560
Median education in years (range) 13 (9-24) 11 (0-20) 0.230
Median NART score (range) 95 (73-116) 105 (86-126) 0.132
Median interval between assessments
in years (range) 5.67 (4.75-6) 5.67 (5.17-7.08) 0.244
Hypertension (%) 8 (89) 9 (53) 0.087
Median systolic BP (range) 150 (120-160) 135 (110-165) 0.100
Median diastolic BP (range) 80 (60-105) 80 (64-94) 0.738
Smoking (%) 3 (33) 8 (47) 0.683
Median cholesterol in mmol/L (range) 5 (3.8-6.8) 6 (1-8.3) 0.324
Diabetes (%) 2 (22) 4 (23) 1
Previous history of stroke (%) 3 (33) 3 (18) 0.628
Diagnosis
Ischaemic stroke (%) 9 (100) 13 (77) 0.263
Lacunar (%) 7 (78) 13 (77) 1
TIA (%) 0 1 (6) 1
Non stroke diagnosis (%) 0 2 (12) 0.529
Anterior stroke (%) 2 (22) 2 (12) 0.591
Posterior stroke (%) 1 (11) 1(6) 1.000
Effect of baseline cerebral microbleeds on long-term cognitive outcome
Baseline CMBs were associated with the prevalence of executive impairment at both
baseline and follow-up, but not with impairment in other cognitive domains (Table 23). At
follow-up, there were 7/9 [78%] patients with baseline CMBs impaired in executive
functions vs 5/17 [29%] of patients without CMBs (p=0.038). Patients with CMBs had more
domains impaired at follow-up compared to baseline, as did patients without CMBs (with
CMBs: median 3 [0-5] at follow-up vs median 2 [0-2] at baseline, p=0.016; without CMBs:
median 1.0 [0-5] at follow-up vs median 0 [0-5] at baseline, p=0.035). Comparisons
between CMB and CMB-free groups at baseline and follow-up did not show differences in
the median number of impaired domains (Table 23).
The presence of baseline CMBs was a predictor of executive dysfunction at follow-up, as
were hypertension and premorbid intellectual functioning (Table 24). Baseline executive
function was not a predictor of impairment in this domain at follow-up.
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Table 24. Imaging and cognitive results for the original baseline cohort and the 5.7 year follow-
up cohort
Baseline (full cohort) [5] Follow-up cohort
With
CMBs
(N=25)
Without
CMBs
(N=30)
p-value With
CMBs
(N=9)
Without
CMBs
(N=17)
p-value
Imaging analyses
Presence of cortical infarct (%) 6 (24) 5 (17) NS 3 (33) 3 (18) NS
Median total score of WML
(range)
3 (0-16) 3 (0-22) NS 9 (4-19) 6 (0-14) NS
Cognitive impairment
Current intellectual functioning
(% impaired)
6 (24) 4 (13) NS 2 (22) 5 (29) NS
Verbal memory (% impaired) 2 (9) 3 (10) NS 2 (22) 2 (12) NS
Visual memory (% impaired) 1 (4) 5 (17) NS 1 (11) 3 (18) NS
Naming skills (% impaired) 3 (12) 6 (20) NS 2 (22) 1 (6) NS
Perceptual functions (%
impaired)
3 (12) 1 (3) NS 1 (11) 2 (12) NS
Frontal executive functions (%
impaired)
15 (60) 9 (30) 0.030 7 (78) 5 (29) 0.038
Speed and attention functions
(% impaired)
10 (42) 13 (45) NS 8 (88) 10 (59) NS
Median N of cognitive domains
impaired
2 (0-5) 0 (0-5) NS 3 (0-5) 1 (0-5) NS
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Table 25. Regression analyses (unadjusted binary logistic regression) testing the effect of
baseline variables including CMBs on executive impairment at the 5.7-year follow-up
OR 95%CI p
Age 1.10 0.99-1.22 0.056
Presence of CMBs 8.40 1.27-55.39 0.027*
Any new CMBs at follow-up 6.67 0.59-74.51 0.123
Hypertension 6.67 1.05-42.43 0.045*
Total score of WML 1.11 0.93-1.33 0.247
Years of education 0.91 0.77-1.08 0.277
Frontal-executive impairment at baseline 6.50 0.61-68.96 0.120
Premorbid intellectual functioning (NART) 0.90 0.82-0.99 0.034*
OR = Odds ratio; CI = confidence interval; NART = National Adult Reading Test.
Asterisks indicate statistically significant p values.
Changes in MRI findings over time
Of the 26 patients, 21 (8 with CMBs, 13 without) had follow-up MRI. Fifty percent of
patients with CMBs [4/8] versus 8% [1/13] of patients without baseline CMBs developed
new CMBs (p=0.047). The severity of WML increased in both groups; the difference was
statistically significant only in patients without baseline CMBs (p=0.027). There were no
new cortical infarcts.
7.2.5 Discussion
Our main findings were: (1) the finding of CMBs on first attendance at a stroke clinic
predicted executive impairment at follow-up 5.7 years later; (2) patients with or without
CMBs had more cognitive domains impaired at follow-up; (3) we observed worsening of
MRI markers of small vessel disease (WML and new CMBs), but no new cortical infarcts.
CMBs have been found to be more common in patients with cognitive disorders including
in a memory clinic cohort (Cordonnier et al., 2006), Alzheimer disease (Pettersen et al.,
2008) and vascular dementia (Seo et al., 2007) than in healthy populations, but evidence of
an independent effect of CMBs on the risk of cognitive impairment is limited. A case-
control study of the full baseline data of the present cohort suggested that CMBs are
selectively associated with executive impairment (Werring et al., 2004). The follow-up
findings of the present study are consistent with these previous findings, although the
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mechanisms remain speculative. The effect of CMBs on cognitive progression has been
evaluated in CADASIL (Liem et al., 2009) and in MCI (Ayaz et al., 2010). To the best of our
knowledge, no previous studies have investigated the prognostic value of CMBs and long-
term cognitive outcome in stroke patients.
Both the CMB and CMB-free patient groups developed more impaired domains over the
follow-up period. In parallel, we found MRI evidence of progressive small vessel damage:
WML scores increased in both groups, whilst in those with baseline CMBs, 50% developed
new CMBs. These observations suggest that cognitive deterioration after ischaemic stroke
can result solely from progressive small vessel pathology rather than new cortical territorial
infarcts, which did not occur in our cohort.
The strengths of our study are the use of a standardised neuropsychological battery by
blinded neuropsychologists, of standardised MRI protocols and validated CMB and WML
scales. The main weakness is the small sample size, meaning that our estimates of risk have
wide CI, and our results must be considered to be preliminary rather than definitive. We
did not have sufficient statistical power to investigate change in executive function over
time or adjust our analysis of risk of follow-up cognitive impairment; nor could we
investigate any association between imaging changes and cognitive progression.
Furthermore, we were unable to characterise the subtype of cognitive disorder as no
concomitant analysis using Pittsburgh Compound B-Positron Emission Tomography (PIB-
PET) or single-photon emission computed tomography (SPECT) was presented.
7.2.6 Conclusions
In conclusion, our data support the hypothesis that CMBs are consistently associated with
executive dysfunction, and may have prognostic relevance for long-term cognitive
outcome, in stroke clinic patients. Further studies of the prognostic significance of CMBs for
long term cognitive outcome in larger cohorts of stroke patients are warranted.
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Chapter 8 - Cerebral Microbleeds and Acute Silent
Ischaemia: Detection of acute silent ischaemia in a
multi-centre cross-sectional MRI study of patients with
intracerebral haemorrhage
8.1 Summary
Subclinical acute ischaemic lesions on brain MRI have recently been described in
spontaneous ICH, and may be important to understand pathophysiology and guide
treatment. The underlying mechanisms are uncertain. We tested the hypothesis that
ischaemic lesions are related to MRI markers of the severity and type of small vessel
disease (hypertensive arteriopathy or CAA) in a multicentre, cross-sectional study. We
studied consecutive patients with ICH from 4 specialist stroke centres, and age-matched
stroke service referrals without ICH. Acute ischaemic lesions were assessed on MRI (<3
months after ICH) using diffusion-weighted imaging. WML and CMBs were rated using
validated scales. We investigated associations between DWI lesions, clinical and
radiological characteristics. We included 114 patients with ICH (39 with clinically-probable
CAA); and 47 age-matched controls. The prevalence of DWI lesions was 9/39 (23%) in
probable CAA-related ICH versus 6/75 (8%) in other types of ICH (p=0.024); no DWI lesions
were found in controls. DWI lesions were mainly cortical and were associated with mean
WML score (OR 1.14 per unit increase, 95% CI 1.02-1.28, p=0.024) and the presence of
strictly lobar CMBs (OR 3.85, 95% CI 1.15-12.93, p=0.029). Acute, subclinical ischaemic
brain lesions are frequent but previously underestimated after ICH, and are three times
more common in CAA-related ICH than in other ICH types. Ischaemic brain lesions are
associated with WML and CMBs, suggesting that they result from an occlusive small vessel
arteriopathy. DWI lesions contribute to the overall burden of vascular-related brain
damage in ICH, and may be a useful surrogate marker of ongoing ischaemic injury from
small vessel damage.
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8.2 Rationale
ICH is the most disabling form of stroke, for which acute treatments are limited. There is an
urgent need to better understand the pathophysiology of ICH to help enhance the
development of new treatments. Most ICH (>75%) are classified as primary (spontaneous),
due to rupture of small arteries of the brain, affected by two main disease processes:
hypertensive arteriopathy and CAA. Hypertensive arteriopathy, characterised by
lipohyalinosis and fibrinoid necrosis of small deep perforating arteries, is an important
cause of ICH, particularly in deep brain structures, including the basal ganglia, brainstem
and thalamus. CAA is defined by Aβ deposition in the media and adventitia of cortical and 
leptomeningeal small- to medium-sized arteries, arterioles and capillaries (Attems, 2005;
Vinters, 1987) and is considered an important cause of lobar ICH, especially in the elderly.
DWI detects acute brain ischaemia with sensitivity approaching 100% (Davis et al., 2006).
Recent studies using DWI have detected clinically unsuspected areas of acute ischaemia in
ICH (Kidwell and Greenberg, 2009; Menon and Kidwell, 2009; Prabhakaran et al., 2010), but
the mechanisms underlying these lesions are not clear. Ischaemia could, for instance, be
due to an active occlusive small vessel arteriopathy (e.g. CAA); or due to cerebral
hypoperfusion due to reduced BP in the context of a failure of autoregulation. It is of
practical importance to establish the underlying mechanism because one of the few
promising treatments currently under investigation for ICH is aggressive BP lowering to
reduce haematoma expansion (Anderson et al., 2008; Delcourt et al., 2010). We reasoned
that if ischaemic DWI lesions in ICH are due to occlusive small vessel damage, then they
should be related to the severity of the underlying small vessel disease. We tested this
hypothesis using MRI to detect acute ischaemic brain lesions and relating them to two MRI
markers of cerebral small vessel disease: WML and cerebral CMBs. Since neuropathological
analyses have identified asymptomatic ischaemic infarction as a common finding in the
brain of patients with advanced CAA (Cadavid et al., 2000; Haglund et al., 2006b; Okazaki et
al., 1979; Olichney et al., 1995; Soontornniyomkij et al., 2010), we also hypothesised that
ischaemic lesions would be most common in ICH attributed to probable CAA, and in
association with strictly lobar CMBs, a radiological marker for CAA.
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8.3 Methods
8.3.1 Participants
We included patients within 3 months of spontaneous ICH consecutively referred to 4
specialist stroke centres in the United Kingdom and Belgium. The hospitals were: The
NHNN, Queen Square (London), Addenbrookes’ Hospital (Cambridge); Cliniques
Universitaires Saint Luc (Brussels) and Cliniques Universitaires UCL de Mont Godinne
(Yvoir). All centres have a policy of routine MRI for investigating the cause of spontaneous
ICH. We identified all cases with spontaneous lobar ICH and appropriate MRI data available.
Probable CAA was defined according to the Boston criteria: patients with two or more
spontaneous strictly lobar ICH over the age of 55 years, without any other identified cause
(Knudsen et al., 2001). The remaining patients with spontaneous ICH not fulfilling the
criteria for CAA (e.g. one strictly lobar haemorrhage, mixed [deep and lobar]
haemorrhages, and strictly deep haemorrhage[s]) were classified as non-CAA related. All
cases were ascertained using overlapping methods from prospective clinical databases and
radiological reports. Clinical information (demographics, vascular risk factors, use of
antithrombotics) was obtained from prospective databases and medical records. A total of
422 patients with ICH were screened, of whom 129 were excluded because of diagnosis of
non-spontaneous ICH (e.g. secondary to haemorrhagic infarction, aneurysms, tumours,
cavernomas, arterio-venous malformations, coagulation disorders or use of oral
anticoagulants, venous thrombosis or head injuries), and 179 because MRI with the
necessary sequences of adequate quality was not available within 3 months of the acute
ICH.
Age-matched controls were ascertained from a database of consecutive patients with
suspected stroke attending the neurovascular clinic at NHNN but with a final non-
stroke/TIA diagnosis for their presenting symptoms after full investigation. They were
matched for age with the CAA-related ICH patients using an unbiased group matching
process blinded to their final diagnoses and imaging findings.
8.3.2 Standard protocol approvals
The study received ethical approval by the NHNN and Institute of Neurology Joint Research
Ethics Committee (approval number 07/Q0512/39; date of approval 22 October 2007), the
Commission d’Ethique Biomédicale Hospitalo-facultaire of the Faculté de Médecine
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(Cliniques Universitaires St Luc)(approval number 2008/lSJUIN/I 76; date of approval 23
June 2008), and of the Comité d’Ethique médicale of the Cliniques Universitaires UCL de
Mont Godinne (approval number 53/2008; date of approval 08 July 2008).
8.3.3 MRI protocols
The MRI stroke protocol was standardised in each hospital. Imaging was at 1.5T field
strength for the majority of patients (105/114, 92%) and included T1-weighted, T2-
weighted, FLAIR, DWI and GRE T2* sequences.
National Hospital for Neurology and Neurosurgery, Queen Square
MRIs were carried at 1.5T field strength. Axial GRE T2* images were obtained using a
General Electric Genesis Signa Scanner (GE Medical Systems, Milwaukee, WI) [TR 300 ms,
TE 40 ms, FA 20°, field of view (FoV) 24 x 18, matrix 256 x 160, slice thickness 5 mm, gap 1.5
mm, number of excitations (NEX) 1] for 38 patients. Four patients were scanned on a
Siemens Avanto Scanner (Siemens, Erlangen, Germany) [TR 800 ms, TE 26 ms, FA 20°, FoV
24 x 18, matrix 512 x 448, slice thickness 5 mm, slice gap 1.5 mm, NEX 1]. Axial DWI
sequences were acquired using the following parameters: TR 1000 ms, TE 98.5 ms, b =
0/1000 s/mm2 , slice thickness 5 mm, gap 0.5 mm, FoV 250 mm, matrix 256 x 256, NEX 1
(GE); TR 3200 ms, TE 78 ms, slice thickness 5 mm, gap 1.5 mm; FoV 250 mm, matrix 256 x
256, NEX 1 (Siemens).
Addenbrookes’ Hospital, Cambridge
Twelve patients were scanned on a 1.5T GE Medical Systems Signa Excite scanner. GRE T2*
sequences were obtained in the axial plane using the following parameters: TR 460-660 ms,
TE 15 ms, FoV 22 cm, matrix 256x192-224, slice thickness 6 mm, gap 7mm, NEX 2. Four
patients were scanned on a 3T GE Medical Systems Signa HDX scanner, with GRE
parameters as follows: TR 600 ms, TE 15 ms, FoV 22cm, matrix 256x192, slice thickness 6
mm, gap 7 mm, NEX 1. Axial DWI sequences were acquired with the following parameters:
at 1.5T, TR 10 000 ms, TE 61.6 ms, b = 0/1000 s/mm2, slice thickness 5 mm, no gap, FoV 280
mm; at 3T, TR 6000 ms, TE 61.6 ms.
Cliniques universitaires Saint Luc, Brussels
At St Luc, axial GRE T2* sequences were acquired, with parameters as follows: 3T, TR 230
ms, TE 16 ms, slice thickness 4 mm, gap 0.4 mm; 1.5T, TR 230-240 ms, TE 50-70 ms, slice
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thickness 5 mm, gap 1 mm. Axial DWI was acquired using the following parameters: TR
4500 ms, TE 94 ms, b = 0/1000 s/mm2, slice thickness 5 mm, gap 0.5 mm; FoV 240 mm2,
matrix 256 x 256; TR 3312 ms, TE 93 ms, b = 0/1000 s/mm2 , slice thickness 5 mm, gap 1
mm, in-plane resolution 1.88 x 2.33 mm2 reconstructed to 0.94 mm2; and TR 2907 ms, TE
55 ms, FA 90°, b = 0/1000 s/mm2 , slice thickness 4 mm, gap 0.4 mm, in-plane resolution 1.8
x 2.27 mm2 reconstructed to 0.9 mm2.
Cliniques universitaires UCL de Mont Godinne
All MRIs were carried at 1.5T field strength. GRE T2* sequences were obtained in the axial
plane on a Siemens Magnetom Symphony System [TR 921 ms, TE 22 ms, FoV 230 mm,
matrix 256 (1.2 x 0.9 x 0.4 mm), slice thickness 4mm, slice gap 10%]; and an EPI sequence:
TR 4750 ms, TE 46 ms, FoV 250, matrix 128 (2 x 2 x 3 mm), slice thickness 3mm, slice gap
10%. Axial DWI sequences were acquired with the following parameters: TR 4900 ms, TE 93
ms, b = 0/1000 s/mm2 , slice thickness 4 mm, gap 0.4 mm, FoV 250 mm, matrix 256 x 256.
8.3.4 Imaging analysis
All images were analysed by a clinical neurologist (SMG), blinded to clinical information.
Acute ischaemic lesions were identified as bright areas on DWI sequences and
corresponding dark areas on ADC maps by SMG and reviewed by a senior vascular
neuroradiologist (HRJ) to reach consensus, blinded to other imaging sequences and clinical
details. DWI lesions in close proximity (<20mm) to an ICH were excluded. The locations of
DWI lesions were classified as cortical or cortical-subcortical (including cerebellum) or deep
(including brainstem). We recorded the presence and measured the number of acute
symptomatic ICHs and the median total number of ICH on MRI. ICH distribution was
classified as lobar (including cerebellum) and deep (including brainstem). SMG rated the
presence, number and distribution of CMBs on GRE T2* images using the CMB anatomical
rating scale (MARS) (Gregoire et al., 2009). WML were rated on a 4-point scale, with scores
ranging from 0 to 3 (Wahlund et al., 2001) on sagittal T1, coronal FLAIR and axial T2-
weighted MR images. The presence of subarachnoid blood, intraventricular haemorrhage
and superficial siderosis were also recorded.
8.3.5 Statistical analysis
We compared the characteristics of patients with probable CAA-related ICH and the
remaining patients with spontaneous ICH. Population characteristics were compared using
Part 2 – Cerebral Microbleeds: New Insights from Neuroimaging and Clinical Studies
233
the Chi-square test and Fisher’s exact test for categorical variables. Continuous variables
were analysed using independent samples t-test (when the data distribution was normal)
and the Mann-Whitney U tests (when the distribution was non-normal). We used
univariate binary logistic regression to test for the factors associated with DWI lesions. The
variables entered into the multivariate regression analysis model were variables thought to
be potential confounders (age, sex) and had been significant in univariate regression. The
threshold of statistical significance was set at p<0.05 for all analyses.
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8.4 Results
The final cohort consisted of 114 patients with ICH, 39 of whom fulfilled the criteria for
probable CAA; and 47 age-matched controls. The clinical and radiological characteristics of
the ICH cohort are reported in Table 25. The ICH patients excluded from the study were not
significantly different from those included in measures of ICH severity including: median
ICH volume 17.7 cm3 [range 0.40-73.56 cm3] in patients excluded versus 10.5 cm3 [range
0.31-50.00 cm3] in patients included, p = 0.93; median GCS on admission: 14 [range 9-15] in
patients excluded versus 15 [range 6-15] in patients included, p = 0.691. Patients excluded
had a higher prevalence of symptomatic lobar ICH (excluded: 82% lobar versus included
54% lobar, p = 0.002).
In our age-matched control group, the following prevalences of vascular risk factors were
found: hypertension 83%, diabetes 13%, previous history of stroke 29%, use of
antithrombotics 46%. Controls had the following final diagnoses: syncope (N=7 [17%]),
vestibular disturbance (N=7 [15%]), asymptomatic carotid stenosis (N=6 [13%]), transient
global amnesia (N=4 [9%]), functional (N=4 [9%]), small vessel disease without acute stroke
(N=4 [9%]), migraine (N=4 [9%]), memory problems (N=2 [4%]), incidental cerebral
infarction (N=1 [2%]), other (N=7 [15%]).
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Table 26. Characteristics of patients with probable CAA compared with patients with other
causes of spontaneous ICH
BP = blood pressure; TIA = transient ischaemic attack; WML = white matter lesions; SAH = subarachnoid
haemorrhage; IVH = intraventricular haemorrhage
*p< 0.05; **p< 0.01
‡ Possible CAA and non-CAA
Examples of GRE T2* MRI studies of two non-CAA patients are shown in Figure 52: one with
a mixed distribution of haemorrhages (a large deep symptomatic haemorrhage with both
deep and lobar cerebral CMBs); and one with exclusively deep haemorrhages. There were
33 patients with multiple (≥2) ICHs (29%). In these, all ICHs identified on MRI (apart from 
the symptomatic lesion) occurred at previous remote times, except in 2 patients with
simultaneous multiple ICHs at presentation.
Probable
CAA
(N=39)
All other
ICH‡
(N=75)
p
Clinical demographics
Median age in years (range) 74 (49-90) 69 (49-93) 0.094
Sex, female (%) 14 (36) 30 (40) 0.669
Hypertension (%) 24 (62) 64 (85) 0.013*
Smoking history (%) 11 (28) 23 (31) 0.884
Diabetes (%) 6 (15) 13 (17) 0.859
Statins on admission (%) 8 (21) 16 (21) 1.000
Previous history of ischaemic stroke or TIA (%) 5 (13) 7 (9) 0.549
On antithrombotics (%) 11(28) 26 (35) 0.537
First ever ICH (%) 20 (51) 61 (81) <0.001**
Median interval between ICH and MRI in days
(range) 8 (0-76) 5 (0-84) 0.300
Radiological characteristics
Median total score of WML (range) 9 (2-26) 9 (0-20) 0.505
Presence of cortical infarcts (%) 2 (9) 4 (10) 1.000
Presence of lacunar infarcts (%) 9 (41) 21 (55) 0.284
Presence of CMBs (%) 35 (90) 42 (56) <0.001**
Presence of multiple ICH (%) 19 (49) 14 (19) <0.001**
Median total number of ICH on MRI (range) 1 (0-5) 1 (1-3) 0.002**
Presence of SAH or IVH (%) 15 (38) 11 (15) 0.004**
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8.4.1 Prevalence of DWI lesions
The prevalence of DWI lesions was as follows: ICH patients overall = 15/114 (13%);
probable CAA = 9/39 (23%); all other ICH = 6/75 (8%); controls = 0/47(0%). Two patients
had two DWI lesions; the rest had a single DWI lesion. Representative examples of DWI
lesions are shown in Figure 53. DWI lesions were more common in patients with probable
CAA compared with patients with other causes of ICH (p = 0.024). DWI lesions were most
commonly found in lobar cortical-subcortical areas (N = 12, 75%), especially the frontal
lobes (N = 6, 38%). DWI lesions were all round or ovoid; their size was 0.42-1.46 cm
diameter in patients with probable CAA, and 0.25-1.50 cm in patients with other causes of
spontaneous ICH (p = 0.328). Half of the MRI scans were done within 1 week of the
presenting ICH (63/114 [55%]); and 99/114 [87%] within 1 month. The longest interval
between presenting ICH and MRI was 84 days. About one-third of DWI lesions were
detected within 1 week (6/17 [35%]); 14/17 (82%) were detected within 1 month. The
latest DWI lesion detected was at 64 days after the presenting ICH. No DWI lesions were
associated with any new clinical symptoms.
Figure 52. GRE T2* images of non-CAA cases.
A. Bleeds with mixed distribution. The GRE T2* image shows a deep ICH in the right basal ganglia (grey
arrow), and CMBs in the left internal capsule and right occipital lobe (white arrows). B. Deep bleeds only.
The GRE T2* image shows an ICH in the right thalamus (grey arrow).
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Figure 53. Examples of positive DWI lesions
Top panels (A) and (B) show probable CAA related ICH: (A) DWI sequence showing presence
of small ischaemic lesion in the right parietal lobe (white arrow) in the presence of 2 lobar ICH,
frontal and parietal, suggestive of CAA; (B) corresponding T2-weighted sequence. Bottom
panels (C) and (D) show non-CAA related ICH: (C) DWI sequence showing presence of small
lacunar ischaemic lesion in the left lentiform nucleus (white arrow) in presence of deep ICH; (D)
a small infarct is visible on the corresponding T2- weighted sequence (white arrow).
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Patients with DWI lesions had more severe WML (mean total score 12 [range 3-17] versus 8
[range 0-26], p = 0.007), and a higher prevalence of lobar CMBs (14/15 [93%] versus 57/99
[58%], p = 0.008), but not deep CMBs (4/15 [27%] versus 28/99 [28%]) (see Table 26). There
was no difference in admission systolic or diastolic BP between patients with and without
DWI lesions.
Table 27. Characteristics of patients with and without DWI lesions
BP = blood pressure; SD = standard deviation; TIA = transient ischaemic attack;
WML = white matter lesions; SAH = subarachnoid haemorrhage;
*p< 0.05; **p< 0.01
DWI (+) lesion
(N=15)
DWI (-) lesion
(N=99) p
Clinical demographics
Median age in years (range) 73 (49-88) 71 (19-93) 0.973
Sex, female (%) 4 (27) 10 (10) 0.308
Hypertension (%) 10 (67) 78 (80) 0.307
Median interval between ICH and MRI in days
(range) 10 (0-64) 4 (0-84) 0.471
Mean SBP in mmHg (SD) 162 (37) 161 (29) 0.840
Mean DBP in mmHg (SD) 85 (21) 87 (16) 0.693
Smoking history (%) 8 (53) 26 (27) 0.067
Diabetes (%) 4 (27) 15 (16) 0.284
Statins on admission (%) 4 (27) 20 (21) 0.736
Previous history of ischemia or TIA (%) 3 (20) 9 (9) 0.202
On antithrombotics (%) 3 (20) 34 (36) 0.229
Diagnosis of probable CAA (%) 9 (60) 30 (30) 0.024*
Radiological characteristics
Median total score of WML (range) 12 (3-17) 8 (0-26) 0.007**
Presence of cortical infarcts (%) 0 (0) 6 (11) 1.000
Presence of lacunar infarcts (%) 4 (80) 26 (47) 0.353
Presence of multiple ICHs (%) 5 (33) 28 (29) 0.764
Median total number of ICH on MRI (range) 1 (1-3) 1 (0-5) 0.581
Presence of SAH or IVH (%) 5 (33) 21 (21) 0.327
Presence of strictly lobar CMBs including
cerebellum (%) 14 (93) 57 (58) 0.008**
Presence of deep CMBs including brainstem
(%) 4 (27) 28 (28) 1.000
Median total number of strictly lobar CMBs
(range) 4 (0-14) 1 (0-294) 0.028*
Median total number of deep CMBs (range) 0 (0-14) 1 (0-14) 0.983
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8.4.2 Estimated incidence of DWI lesions
Assuming that DWI lesions remain detectable for about ~10 days after stroke (Burdette et
al., 1998), then the estimated annual incidence can be calculated as:
Estimated annual incidence =
௡௢௢௙஽ௐ ூሺାሻ௟௘௦௜௢௡௦
௡௢௢௙௣௔௧௜௘௡௧௣௢௣௨௟௔௧௜௢௡௙௢௨௡ௗ
x
ଷ଺ହሺௗ௔௬௦௣௘௥௬௘௔௥ሻ
ௗ௨௥௔௧௜௢௡௢௙஽ௐ ூ௟௘௦௜௢௡௦(ௗ௔௬௦)
For a consistent incidence of DWI lesions per year, the estimated annual incidence in the
whole cohort of ICH patients would be (16/114) x (365/10) = 5.1 silent infarctions per
person-year; in probable CAA-related ICH the estimated annual incidence = (9/39) x
(365/10) = 8.4 silent infarctions per person-year.
8.4.3 Factors associated with DWI lesions
In univariate regression analysis, significant predictors of DWI lesions were smoking history,
diagnosis of probable CAA, total score of WML, and the presence of strictly lobar CMBs
(Table 27).
Table 28. Univariate regression analysis testing the factors associated with DWI lesions
OR 95% CI p
Clinical characteristics
Age in years 1.00 0.96-1.05 0.941
Sex, male 0.54 0.16-1.80 0.314
Hypertension 0.49 0.15-1.59 0.234
Number of BP medications at time of ICH 0.88 0.51-1.53 0.648
Smoking history 3.08 1.01-9.33 0.047*
Diabetes 1.96 0.55-6.99 0.298
High cholesterol 0.77 0.39-1.49 0.438
On antithrombotics 0.45 0.12-1.70 0.238
Classification of ICH mechanism
Diagnosis of probable CAA 3.45 1.13-10.56 0.030*
Radiological characteristics
Total score of WML 1.13 1.02-1.26 0.019*
Presence of multiple ICH 1.23 0.39-3.93 0.724
Presence of lacunar infarcts 4.46 0.47-42.5 0.194
Presence of CMBs
Presence of CMBs 8.00 1.01-63.38 0.049*
Presence of strictly lobar CMBs, including cerebellum 10.32 1.31-81.55 0.027*
Presence of deep CMBs, including brainstem 0.92 0.27-3.14 0.897
*p< 0.05; **p< 0.01
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In multivariate analysis, DWI lesions were associated with both mean WML score (OR 1.14
per unit increase, 95% confidence interval [CI] 1.02-1.28, p = 0.024) and the presence of
strictly lobar CMBs (OR 3.85, 95% CI 1.15-12.93, p = 0.029) (Table 28). These associations
remained significant after adjustment for age and gender. Adjusting the analysis for
variation in magnetic field strength (1.5 or 3T) did not substantially weaken the association
between lobar CMBs and the presence of DWI lesions (adjusted OR 3.73, 1.11-12.57, p =
0.034).
There was no statistically significant difference in the median ICH volume between DWI-
positive and DWI-negative groups: for DWI-negative patients, median ICH volume was
10.25cm3 [range 0.31-37.63], whilst in DWI-positive patients, median ICH volume was
12.09cm3 [range 0.58-50.00] (p=0.892).
Table 29. Multivariate regression analysis showing the factors associated with DWI lesions*
O.R. 95% CI p
Characteristics
Mean white matter change score 1.14 1.02-1.28 0.024
Strictly lobar CMBs 3.85 1.15-12.93 0.029
Age (years) 0.97 0.92-1.03 0.374
Sex 0.62 0.17-2.29 0.469
* Hosmer-Lemeshow goodness of fit: Chi-Square 4.986, sig. 0.759
Positive predictive value: 100%
Negative predictive value: 88%
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8.5 Discussion
In this study, we frequently detected subclinical acute ischaemic brain lesions in ICH
patients; they were about three times as common in probable CAA-related ICH compared
with the other cases of ICH. We found no DWI-hyperintense lesions in our age-matched
controls despite them having a similar or higher prevalence of conventional vascular risk
factors to the ICH patients. DWI lesions were associated with markers of small vessel
damage including total WML and the presence of lobar CMB, but not with admission BP.
Overall, DWI-positive lesions were predominately located in lobar areas, mainly in the
cortical-subcortical areas of the frontal and temporal lobes. They were small and mostly
ovoid or round in shape. The distribution and morphology of the detected DWI lesions
correlates well with the ‘icroinfarcts’ identified in neuropathological studies of patients
with CAA (Cadavid et al., 2000; Haglund et al., 2006b; Okazaki et al., 1979). Since these
lesions were associated with markers of small vessel damage severity (WML and CMBs),
rather than conventional risk factors, they probably represent acute small vessel infarcts
related to small vessel arteriopathy, especially CAA. About a third of silent ischaemic
lesions were detected within one week after ICH, and ~80% of them within one month,
which suggests a possible early peak followed by a descending incidence over time, but we
were unable to investigate this further as we did not acquire repeat imaging studies in this
cohort.
To our knowledge, only one imaging study has investigated the presence of silent ischaemic
lesions in CAA (Kimberly et al., 2009); DWI-hyperintense lesions were identified in 12 out
78 subjects (15%) with probable or definite CAA, while no lesions were found in a control
group of 55 subjects with Alzheimer disease or MCI (p=0.001). In agreement with our
findings, the authors did not find an association between DWI lesions and conventional risk
factors. In contrast to our results, they found no association between DWI lesions and
WML, but this study did not include any ICH cases not attributed to CAA so was not
representative of the full spectrum of spontaneous ICH. Another recent study found DWI
lesions in 23% of patients in a cohort of 118 patients with ICH scanned within one month,
and found that DWI lesions were associated with aggressive BP lowering (Prabhakaran et
al., 2010), but this study did not investigate the relationship of DWI lesions to MRI markers
of small vessel disease and did not use formal criteria to define CAA.
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What are the implications of our findings on the understanding of ICH pathophysiology?
We demonstrated a high prevalence of silent acute ischaemic events within the first 3
months after CAA-related ICH at a mean time of 8 days. More than 80% of the lesions
occurred within 1 month post-ICH. Since DWI lesions are positive only for about ~10 days
(Burdette et al., 1998) and were still detectable in our study up to about ~2 months (Table
26), these lesions are likely to be a dynamic persisting phenomenon in ICH patients, and a
common feature of the underlying arteriopathy. Ischaemia may therefore be a previously
unrecognised cause of progressive disability with possible relevance for clinical outcome
after ICH. The lack of association with admission BP suggests that hypoperfusion resulting
from low systemic BP is unlikely to have caused these ischaemic lesions, although we do
not have detailed information on BP control. Imaging data suggest that autoregulation is
largely preserved in acute ICH, supporting this conclusion (Reinhard et al., 2010). Indeed,
lowering BP is one of the most promising available treatments in acute ICH, having been
shown to reduce haematoma expansion in a randomised trial (Anderson et al., 2008); a
further large study is underway (INTERACT 2) (Delcourt et al., 2010). Antihypertensive
treatment is also an important chronic treatment for patients following ICH (Arima et al.,
2010; Progress Collaborative Group, 2001), but the effects on vascular damage from silent
ischaemic lesions is unknown.
Our finding of a significant association between DWI lesions and lobar CMBs, and WML
severity adds to the evidence that, although generally considered to be a haemorrhagic
disorder, CAA is also characterised by frequent small infarcts (Menon and Kidwell, 2009;
Soontornniyomkij et al., 2010). Since WML severity increases with increasing CMB burden
in CAA cohorts and thus with the severity CAA-related microvasculopathy (Greenberg et al.,
2004a), infarcts seem to relate to the severity of the underlying small vessel damage.
Furthermore, the relation between DWI lesions and presence of CMBs suggests shared
pathophysiological pathways for haemorrhagic process and ischaemia. In CAA, amyloid-β is 
deposited in small arteries and arterioles, causing thickening of the vessel wall and lumen
restriction (Olichney et al., 1995), and endothelial/vascular smooth muscle dysfunction
(Dotti and De Strooper, 2009). These changes can not only cause vessels to become brittle
and prone to microaneurysm formation and blood leakage (Attems et al., 2011), but also to
impaired local regulation of cerebral blood flow and thus small-vessel or capillary occlusion
(Smith and Greenberg, 2009). The use of PET with amyloid-binding ligands (such as
Pittsburgh B compound) will help to determine whether a regional correlation exists
between amyloid deposition and ischaemia, as in CAA-related haemorrhage (Dierksen et
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al., 2010). Other mechanisms such as blood-brain barrier disruption and active
inflammation could also contribute to this active vasculopathic process. Taken together
with recent reports of the development of CMBs after IS, our data suggest a previously
unsuspected and intriguing interplay between the haemorrhagic and ischaemic
components in small vessel diseases (Kidwell and Greenberg, 2009), suggesting a dynamic
continuum between ‘microbleeding’ and ‘microinfarction’.
DWI lesions were found in only 8% of patients with ICH who did not fulfill the criteria for
probable CAA. This group had a higher prevalence of hypertension and a mixed pattern of
CMBs (lobar and deep) suggesting that microinfarction can also result from hypertensive
arteriopathy. The association between asymptomatic acute infarcts and hypertensive small
vessel disease was suggested in previous studies, although no definite correlation with
hypertension was found (Jouvent et al., 2011; Kang et al., 2004; O'Sullivan et al., 2003). In
our study, it is possible that some of the ischaemic lesions in the non-CAA ICH group may
have in fact been due to the presence of CAA, hypertensive arteriopathy and CAA often co-
exist. Moreover, although the Boston criteria have been shown to have excellent specificity
for CAA, the sensitivity is low, with a negative predictive value of 39%, so that some lobar
ICH patients not fulfilling the Boston criteria are likely to have a degree of CAA pathology
(Knudsen et al., 2001); this could have weakened the association we found between
probable CAA and DWI-lesions.
The association between DWI lesions and WML burden suggests that at least some WML
could be due to accumulated microinfarcts (Smith, 2010), or chronic hypoperfusion.
Another potential mechanism through which CAA-affected cortical and leptomeningeal
vessels can damage white matter is by the entrapment of amyloid-β in perivascular spaces, 
impairing interstitial drainage pathways from white matter otherwise not directly affected
form CAA pathology (Roher et al., 2003).
Our study has several strengths: the systematic evaluation of MRI scans by one trained
rater using validated scales, the concomitant use of DWI and ADC maps to assess the
presence of silent ischaemia and the review of all positive scans by an experienced
neuroradiologist. It suffers from limitations due to the lack of pathological confirmation of
the ischaemic nature of the DWI lesions and of the CAA pathology as a cause of ICH. In all
hospital-based ICH MRI studies, it is not possible to completely rule out bias as the most
severe cases will suffer early mortality or be unable to tolerate an MRI examination. Thus,
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in the present study, there is likely to be ascertainment bias towards a less severely
impaired cohort. However, we found no significant differences in measures of ICH severity
(including hematoma volume and GCS scores on admission) between included and
excluded subjects. Patients excluded had a higher prevalence of symptomatic lobar ICH,
which could lead to an underestimation of the association between DWI lesions and CAA-
related ICH. Finally, we could not rule out the confounding effect of a direct influence of
the acute ICH in causing ischaemia as we did not include a group of patients with CAA
without symptomatic lobar haemorrhage, but we excluded any DWI lesions in close
proximity to the symptomatic ICH, and found no relationship between ICH volume and the
presence of DWI lesions, making this unlikely.
Our findings raise clinical questions, especially the dilemma about the use or avoidance of
antithrombotics in patients with ICH. Although the risk of anticoagulation likely overweighs
the benefit in most patients with ICH due to CAA, the risk versus benefit of antiplatelet
agents is less clear (Biffi et al., 2010b; Rosand et al., 2000). The presence of DWI lesions
may identify a subgroup of ICH patients who might have greater benefit from
antithrombotic treatment, but clinical studies are needed to address this question.
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8.6 Conclusions
Our study clearly points to a previously unsuspected high prevalence of acute ischaemia in
patients within 3 months of ICH, but longitudinal studies with serial clinical examinations
and imaging are also needed to further characterise the dynamics, associations and clinical
impact. Further studies will determine whether the detection of DWI positive lesions in
CAA can be used as a surrogate marker with value in diagnosis or assessing the severity and
progression of the disease.
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Chapter 9 - Discussion and Conclusions
9.1 Discussion
CMBs were first described in the mid-1990s as small hypointense dots detected in vivo on
T2*-weighted MR sequences (O'Sullivan et al., 2002; Schrag et al., 2010), and with a
physical size of less than a millimetre they were thought to be clinically silent However,
they have emerged as an important new imaging marker of cerebral small vessel diseases
(Greenberg et al., 2009b; Offenbacher et al., 1996) and their impact is increasingly
recognised; they may be associated with an increased risk of haemorrhagic stroke, IS and
dementia (Charidimou et al., 2013a; Cordonnier and van der Flier, 2011; Werring et al.,
2004). The sequences sensitive to CMBs are now used in routine clinical settings, and the
sophisticated detection methods and ageing population mean that CMBs are encountered
in an ever-increasing number of patients: from population-based samples of healthy elderly
people, to stroke populations and patients with cognitive impairment. Therefore, there is
an urgent need to establish their pathophysiology and clinical significance.
In the first three chapters I covered the historical context of CMBs and the mechanisms
underlying CMBs from histopathological studies, thereby demonstrating their close
association with two underlying pathological processes, hypertensive arteriopathy and
CAA. I described the technical aspects of their detection, definition and mapping in the
brain and showed that they are readily detected on iron-sensitive MRI sequences. I
reviewed the epidemiology of CMBs and discussed their association with clinical and
imaging factors in different populations, including patients with cognitive impairment or
users of antithrombotic medications. In the later chapters I reported the findings of our
main studies.
In this chapter I first summarise our main findings and discuss their relevance in the context
of current knowledge, before raising the questions that are the most relevant in CMB
research, and attempting to provide answers in the perspective of our findings and the
available literature. Finally, I highlight points and areas where knowledge in CMBs is lacking
and suggest directions for future research studies.
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9.1.1 Summary of our main findings
Our studies resulted in some novel observations which are summarised below.
Development of an optimal rating method
CMBs have been studied increasingly often over the past decade, and when we started this
work there was a need for a standardised assessment of CMBs in order to compare study
results and pool data across studies and centres. To address this issue we developed a new
CMB rating scale (see Chapter 4). We designed and tested the MARS on a population of 301
patients referred to our stroke service and performed reliability assessments for two raters
with different levels of experience in neuroimaging and across two different MRI sequences
(TE 26 ms and TE 40 ms). We found that MARS had good-to-very-good inter- and intra-rater
reliability in most locations of definite CMBs in the brain. However, in regions where CMB
mimics are most frequent (basal ganglia, cerebellum), reliability was slightly lower. We also
compared our scale with the only other existing scale (BOMBS) on a subsample of 100
patients taken from the same cohort. Slightly different reliabilities were obtained for MARS
and BOMBS, with a trend towards a better reliability of MARS (kappa 0.69 versus 0.68, with
overlapping CI). The main focus of our scale was to detail the anatomical distribution of
CMBs in order to assess their clinical significance in relation to their location in specific
brain lobes and regions. The anatomical distribution of CMBs is crucial for studies
investigating the relevance of CMBs in cerebrovascular diseases (CAA, hypertensive small
vessel disease) and in cognitive dysfunction. Our ‘deep’ and ‘lobar’ boundaries were based
on the potential to differentiate hypertensive small vessel disease and hypertensive
haemorrhage (likely deep distribution) from CAA (likely lobar distribution). The other main
focus of the scale was to provide a set of criteria by which to define CMBs because at the
time their radiological characteristics for reporting had not been standardised.
Furthermore, we provided a range of MRI criteria allowing CMBs to be categorised as
‘definite’ or ‘possible’, the latter being extremely frequent (up to 1/3 of all scored CMBs)
and recommended for maximal reliability reporting definite CMBs only. An increasing
number of studies show that quantification of CMBs may be of clinical relevance, in terms
of the risk of recurrent ICH and subsequent cognitive impairment. We therefore assessed
the reliability of our scale not only for CMB presence, but also for CMB number. However,
we may have underestimated the number of CMBs on our scans due to the fact that we
used radiological methods routinely used in most centres (GRE T2* at 1.5T in 2D, no post-
processing techniques). Although we used standardized MRI parameters, the majority of
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patients were scanned using low resolution sequences, without post-processing
techniques. Also there was heterogeneity in the MRI parameters between centres.
However, only a few patients were scanned on a higher resolution scanner at each centre,
and we do not think that this would have influenced the results. Using higher resolution
scanner may have introduced potential bias towards an overestimation of the reliability of
MARS, as suggested by the slightly improved reliability using a sequence with a lower TE.
New MRI methods with better resolution (including higher field strength and 3D images)
will improve the depiction of CMBs, although whether these techniques will improve the
reliability in CMB rating remains to be determined. Recent evidence suggests that SWI has
greater reliability and sensitivity for detecting CMBs than GRE T2* MRI (Cheng et al., 2013).
Methods based on automatic detection will help to increase the reliability of CMB ratings
compared with manual ratings. Finally, our assessment of MARS was a limited validation of
the scale only, due to the fact that only reliability was assessed, and that we had only 2
raters from the same department. We recommend the use of standardized imaging and
clear definition of definite CMBs when rating CMBs in studies. These should involve two
experienced raters and cases of disagreement should be reviewed by a senior
neuroradiologist.
Antiplatelet-associated intracerebral haemorrhage risk
In Chapter 5 we demonstrated a strong independent association between CMBs and
increase risk of ICH when on antiplatelet treatment, which has potential implications for
the use of antiplatelet agents in patients with CMBs. The number of CMBs was significantly
associated with ICH in patients on anti-platelet treatment, suggesting that the risk of ICH
could outweigh the benefit of treatment with aspirin in patients with numerous CMBs. The
novel aspect of our study was in showing that CMBs are more common in antiplatelet-
related ICH compared to a matched antiplatelet user group without ICH, and in a second
case group of patients with spontaneous ICH unrelated to antithrombotic agents. We were
the first group to include these two comparison groups (a control group of aspirin users
without ICH and a second case group of spontaneous ICH). Because CMBs are known to be
associated with ICH and aspirin use is also associated with ICH, these two comparison
groups allowed us to control for the effect of these confounding associations in the link
between CMBs and ICH in patients on anti-platelet treatment. Another important
contribution of our study is that it was the first to highlight CMBs as a potential risk factor
for ICH in a non-Asian cohort. It is likely that patients with non antiplatelet-associated ICH
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had a higher prevalence of CMBs because they had underlying CAA which might have
contributed to the incidence of ICH without the use of antiplatelets. Although our study did
not completely eliminate selection bias, mainly related to the fact that patients with more
severe ICH did not have an MRI and might have been excluded, it is the closest that any
ethical study can get to including a representative ICH population. Our study design of
matching cases to controls for all potential confounding factors is a powerful way to
investigate how CMBs relate to ICH in aspirin users. Critics may comment that we did not
fully investigate the potential interaction between CMBs and aspirin use for ICH because
there were no controls with neither ICH nor aspirin use. However, it would have been
impossible to find non aspirin using controls that could be matched with our case group for
age, hypertension and other vascular risk factors. Finally, we could not prove causality
between antiplatelet therapy, and anti-platelet associated ICH. Due to these limitations and
also to our small sample size, we acknowledge that our study does not make a strong
enough case to recommend completely avoiding antiplatelet agents in patients with IS, or
even in patients with CAA – who are at even greater risk of ICH. Given the limitations of
methodology, our findings need to be investigated further before advocating a change in
practice. However, our data did suggest that caution is advisable when prescribing
antiplatelet agents in such patients, and that the finding of CMBs should be considered as
part of the clinical decision making process.
Temporal changes of cerebral microbleeds
In Chapter 6 we presented the results of a five year clinical and imaging follow-up study in a
small sample of patients with TIA and IS. We assessed the incidence of new CMBs and
predictors of new CMBs in this specific population. Our results showed that half the
patients with CMBs developed new lesions after five years, and that the main risk factors
for developing new CMBs was the presence of CMBs at baseline and baseline systolic BP.
All the patients who developed new CMBs had a baseline systolic BP of above 150 mmHg.
Our findings suggest that CMBs are a dynamic process, with a burden that increases over
time in relation to increased baseline BP. This observation had not been made in stroke
cohorts prior to publication, nor had a link been made between a high baseline systolic BP
and CMB accumulation. Our findings are consistent with other markers of small vessel
disease progression, which strengthen the role of CMBs as another marker of small vessel
disease. They emphasises the need to vigorously treat hypertension in patients with CMBs,
as uncontrolled hypertension may contribute to the multiplication of CMBs and cause
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potentially devastating effects, including ICH and further ischaemic events. Another striking
finding was that most patients who developed new CMBs remained clinically stable over
the follow-up period, suggesting that CMBs could be used as a marker to monitor the
progression of small vessel pathology in the brain. Lacunar infarcts and WML were not
associated with the development of new CMBs in this study. Our conclusions were drawn
from a small cohort (only 8 patients had new CMBs) which limits the power of our study.
Also, lobar CMBs were predominant in our cohort, and in a higher proportion than in other
IS cohorts (Han et al., 2009), which might have biased our findings towards detecting more
lobar CMBs at follow-up. However, our study was the first to show a relationship between
hypertension and further CMB formation in patients with ischaemic cerebrovascular
disease. If confirmed in larger cohorts then this observation has considerable implications
for the treatment of stroke patients.
Contribution of cerebral microbleeds to cognitive impairment
The effects of CMBs on cognition have been studied in various population groups, from
healthy elderly community subjects to subjects with memory impairment (Cordonnier et
al., 2006; Poels et al., 2012a; Yakushiji et al., 2008). Their prognostic relevance for future
cognitive impairment in stroke patients is uncertain due to the paucity of studies
undertaken within this population group, and to the fact that the majority of the previous
studies were cross-sectional and did not look at the effects of CMBs on cognitive functions
over time. The first preliminary report by Werring et al. (2004) demonstrated an
independent association of CMBs with executive impairment in a small (55 patients) cohort
of stroke patients against matched controls. In Chapter 7.1 we confirmed this observation
in a larger cohort of 320 patients. We demonstrated that this effect is largely driven by
lobar CMBs, a marker for the presence of CAA. We found that patients with strictly lobar
CMBs were more than twice as likely to have impaired executive functions. The presence of
more than five CMBs in a strictly lobar distribution increased the risk of executive
impairment by a factor 13, suggesting a role for CAA in VCI. At the time of submitting our
paper, further reports were published supporting our preliminary hypothesis linking lobar
CMBs and CAA with cognitive impairment, although the methods of assessing
neuropsychological functions differed (Arvanitakis et al., 2011). In the absence of data from
large prospective cohorts this was the best study model to test CMBs for cognitive
impairment as we included all available data and used standardised imaging and
comprehensive neuropsychological protocols. We believe that our population is similar to
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other populations of stroke patients with ischaemic cerebrovascular disease. Patients with
a non-stroke diagnosis were excluded for clarity and generalizability of the findings to other
stroke cohorts. The study was undertaken in a stroke population with a high burden of
vascular disease; in the absence of comparisons between representative matched
population samples, this does not make our findings generalizable to non stroke
populations. We do not know if stroke populations behave differently in terms of cognitive
deficits than non stroke populations with similar CMB load. It is possible that using
optimised imaging sequences (higher resolution with 3D, higher magnetic field strength [7T
versus 1.5T], improved image processing techniques such SWI) we would have detected
more CMBs but we would not expect these to alter associations with cognition.
In Chapter 7.2 we demonstrated that CMBs are consistently associated with executive
impairment after six years in a small longitudinal study. Our findings demonstrated a trend
towards a greater proportion of patients exhibiting a deterioration of their executive
functions over time. None of the patients with CMBs recovered normal executive functions;
they either remained impaired or developed new impairments. Likewise, there was an
increase in the number of cognitive domains impaired at follow-up compared with baseline
for both patients with and without CMBs, suggesting that cognitive impairment extends
beyond executive functions over time and becomes more severe and widespread in the
long term. This was the first longitudinal study testing detailed cognitive functions in stroke
patients at baseline and follow-up. Several limitations weaken our paper, including the lack
of follow-up imaging analyses to further specify the type of cognitive disorder, investigate
the role of CMB distribution (lobar versus deep) on cognitive function, and study the
causative link with CMBs. The small sample size (only 9 patients with CMBs had
neuropsychological follow-up) precluded analyses controlling for all confounding factors,
such as premorbid intellectual functioning, and resulted in wide CIs. Furthermore, we could
not use continuous data, which would have given more power to our analyses and would
have allowed an analysis of change of cognition. However, we believe that our findings are
generalisable and that they will be replicated in other, larger stroke cohorts.
Association with acute ischaemia
In CAA, a disease strongly associated with ICH and the presence of lobar CMBs, several
neuropathological studies have demonstrated that asymptomatic ischaemic infarction is a
key pathological feature, especially in patients with advanced disease (Vinters, 1987). In
Chapter 8 we investigated the presence of acute ischaemia on DWI MRI in patients with
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acute ICH consistent with a diagnosis of CAA. We described the presence of lesions
exhibiting diffusion restriction (acute ischaemic lesions) in 114 patients with acute ICH and
assessed their relation to markers and severity of small vessel disease. We found DWI
positive lesions to be most frequent in CAA-related ICH and to be related to the severity of
WML and CMBs. We concluded that the presence of acute ischaemic lesions in patients
with CAA-related ICH is secondary to the underlying CAA pathology rather than
hypertension-related arteriosclerosis. We also found that the incidence of DWI lesions is
not constant over time; it peaks shortly after the ICH (especially within three months) and
is later followed by a lower incidence. Over the period of one year the estimated incidence
of acute ischaemic infarction might reach 10 per person affected by CAA-related ICH. Our
main limitation in this study was the robustness of the diagnosis of CAA as pathological
confirmation was not available. In addition, there was possible selection bias in obtaining
the MRI scans, although our analyses demonstrate that patients excluded from analysis
were similar to patients included in terms of ICH severity (ICH volume) and GCS on
admission. The median ICH volume and GCS scores were comparable to previously
published data on symptomatic ICH from population-based studies (van Beijnum et al.,
2009), thereby suggesting that our population was representative in terms of ICH severity.
Our findings suggest that subclinical ischaemic lesions detected on MRI are a marker of the
presence of an active underlying vasculopathy (CAA) leading to both ischaemia and
haemorrhage. DWI positive lesions could be used as a surrogate marker with value in
diagnosing or assessing the severity and progression of the disease.
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9.1.2 Critical appraisal of our studies
Below we propose a critical appraisal of our studies against a set of criteria for ideal study
design of CMBs (Cordonnier et al, 2007) and based on the recommendations for CMB
mapping in research studies (Greenberg et al., 2009) (Table 30). These criteria were
published following the principles of the Cochrane Collaboration, Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) (Whiting et al., 2003).
Based on the ideal study design for CMBs, our studies did not assess CMBs as predictors of
prognosis. Such objective would require prospective study designs, with predefined and
validated outcome measures, outcomes assessed blind to prognostic factors of interest,
stratification of outcome by differences in treatment and satisfactory levels of follow-up
(Cordonnier et al., 2007). Our studies were studies of the association of CMBs with clinical
and/or radiological features (except for the study on the reliability of the MARS scale,
chapter 4). They also evaluated the prevalence of CMBs in particular disease groups
(hospital-based population, the majority of patients were white Caucasians, with ischaemic
stroke/TIA or ICH cohort). As such, they could not assess causality in the relationship
studied. According to these principles, such studies should include a specification of MRI
parameters, a suitable GRE 2* sequence, a clear definition of CMBs size and appearance, a
clear definition of participtants clinical and radiological diagnosis, independent of risk
factors (Table 29). Other desirable study attributes are generalizability of the population
and findings, exempt of selection bias. When assessing CMBs’ association with other
radiological features or clinical findings, an appropriate comparison group should be
chosen. Each group should have clearly defined risk factors and assessment of CMBs should
be blinded to clinical features of interest (Cordonnier et al., 2007). Depending on the
question being addressed (mainly assessment of risk or assessment of association), the
ideal studies on CMBs will include the above characteristics to ensure adequate reporting
of CMBs, minimise selection bias and ensure generalizability of the findings. In this thesis,
our main limitations related to the use of retrospective study designs and small sample
sizes, limiting the power of our analyses of associations between CMBs and clinical and
radiological characteristics. We were only able to provide a limited assessment of validity
and reliability of regression analyses, which were limited because of small sample sizes.
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Table 30. Critical appraisal of our studies against a set of criteria for ideal study design of CMBs
Studies Study aim Clear
specification
of MRI
parameters
Clear
definition
of CMBs
Participants
diagnosis
clearly
defined
Participants generalizable Risk factors
clearly
defined
Assessment of
CMBs blinded
to clinical and
radiological
data
Comparison group(s) chosen
appropriately
Chapter 5. CMB
and the risk of ICH
in patients on anti-
platelet treatment
Prevalence of CMBs
in the ICH population
and association of
CMBs with
clinical/radiological
features
√ √ √ No
Small sample size and
potential selection bias:
1/ Non Asian cohort
2/ Possible high prevalence of
CAA in ICH groups
3/ Selection of less severe ICH
cases
√ (age, sex,
HTN, WML)
Not fully
(readers were
not blind to the
presence of ICH,
the severity of
the WML, the
pt’s age)
No
1/Controls were not truly
controls
2/There were no controls with
neither ICH nor aspirin use
3/Cases not perfectly matched
for HTN and previous history of
stroke
Chapter 6.
Exploration of CMB
dynamics
Prevalence of CMBs
in an IS/TIA
population and
association of CMBs
with
clinical/radiological
features
√ √ √ No
1/ small sample size
2/ Symptomatic IS only
3/ Overrepresentation of
deep ICH in patients who
died
√ (systolic
BP at
baseline,
baseline
CMB)
Not fully
(readers were
not blind to the
severity of WML
in some
patients and to
pt’s age)
√ but groups were not entirely
comparable for hypertension,
history of previous stroke and
WML
Chapter 7.1. CMBs
are associated with
executive
impairment
Prevalence of CMBs
in a population with
IS/TIA and association
of CMBs with
clinical/radiological
features
√ √ √ No
Large cohort but with
selection bias:
1/ very severe strokes were
excluded
2/ patients with severe
dementia were excluded
√ (age, HTN,
WML) but
other
factors not
measured
(e.g. volume
loss)
Not fully
(readers not
blind to the
severity of WML
in some
patients, and to
pt’s age)
√ but groups not entirely
comparable in several
characteristics (gender, HTN,
diabetes, previous hx of
stroke/TIA, use of
antithrombotics, prevalence of
lacunes and WML)
Chapter 7.2. Strictly
lobar CMBs are
associated with
long term executive
impairment
Prevalence of CMBs
in a population with
IS/TIA and association
of CMBs with
clinical/radiological
features
√ √ √ No
1/ small sample size
2/ subsample of original
study with significant drop
out
No (not able
to fully
assess risk
factors due
to small
sample size)
Not fully
(readers not
blind to severity
of WML in some
patients and to
pts’ age)
√ (but differences in age,
gender, HTN, previous history
of stroke and premorbid
intellectual functioning
although differences not
significant)
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Chapter 8. Lobar
CMBs are
associated with
acute silent
ischaemia
Prevalence of CMBs
in a population with
ICH and association of
CMBs with
clinical/radiological
features
√ √ √ No
1/ only symptomatic ICH
were included
2/ most severe ICH cases
were excluded
3/relatively small sample
√ (age, sex,
WML and
strictly lobar
CMBs), but
we cannot
exclude an
effect of
HTN, and
ICH on
ischaemia)
Not fully
(readers not
blind to
presence and
location of ICH,
patient’s age,
and WML
burden)
√ but populations and imaging
characteristics were slightly
heterogeneous
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9.1.3 Remaining questions and areas for future research
Can cerebral microbleeds be reliably mapped in the brain?
Rating and mapping CMBs is a challenge which we have attempted to provide practical
solutions to through the development of a new scale (MARS) and recommendations for
rating and mapping CMBs in research studies that have been incorporated in the scale (see
Chapter 4). As discussed, CMB prevalence in research studies is influenced by the rating
and imaging methodologies, and these should be systematically reported. Future studies
should follow the standards for study design and recommendations for reporting of CMBs
(Cordonnier et al., 2007; Greenberg et al., 2009b) in order to allow comparability and data
pooling between studies. These include the use of a standardised rating instrument, and
MARS could be used for this purpose. For full recommendations, the guidelines of the CMB
study group are reported in Table 29 (Greenberg et al., 2009b). As a marker of bleeding
prone angiopathies, CMBs are closely associated with other markers of small vessel
diseases, and the reporting of these should follow the recently published STRIVE standards
(Wardlaw et al., 2013).
To the best of our knowledge, no other rating scales of CMBs have been proposed to date
other than those reported in this thesis, MARS and BOMBs. We recommend using MARS
over BOMBs because MARS has marginally better reliability, and its anatomical
categorisation of CMBs into lobes better reflects the potential clinical relevance of CMBs
and their effect on brain function depending on the question being addressed and the
population studied. For example, patients with CAA have CMBs predominantly in the
Table 31. Recommendations for CMB mapping in research studies
from Greenberg et al., 2009
 Use standardised MRI parameters (field strength, spatial resolution, slice thickness, TE, post-
processing, etc.) – especially relevant if studies are carried out in multiple centres
 Apply clear definition of CMBs and mimics – rigid size criteria are probably not needed
 Use a standardised rating instrument with clearly defined anatomical regions, appropriate to the
research question (e.g. deep vs. lobar, or individual lobes)
 Scale should have good inter- and intra-rater reliability applied to sequences and used by the
observers in the study
 Use trained observers (ideally a single observer for all analysis in a study)
 Observers should be blinded to clinical details relevant to the study hypothesis
 Images rated on diagnostic quality workstations in semi-dark conditions
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posterior lobar regions (temporal and occipital lobes) (Ayaz et al., 2010; Rosand et al.,
2005), whilst patients with AD have a predominance of cortico-subcortical CMBs with
occipital lobes accounting for 57% of these CMBs (Pettersen et al., 2008). However, these
manual rating scales, although simple, reliable and inexpensive, are very time consuming
and operator-dependent. Although they produce reliable and reproducible information,
they may not be practical in research settings outside routine clinical practice.
Alternative imaging methods to GRE T2* MRI for CMB detection are currently under
evaluation and should ultimately help to better depict and quantify CMBs. Some of these
techniques, e.g. SWI, are currently being implemented in routine clinical settings, marking
substantial progress in the routine diagnosis of brain vascular diseases. SWI increases the
tissue contrast of CMBs (Sehgal et al., 2005), can detect smaller lesions (Schrag et al., 2010)
and reveals more CMBs than conventional T2* GRE (Nandigam et al., 2009). In line with
this, it was recently shown that SWI confers greater reliability and sensitivity in CMB
detection than GRE T2* MRI (Cheng et al., 2013). SWI creates more complex images due to
high sensitivity to other iron-containing structures (Mittal et al., 2009), and for example,
reveals many flow voids from small blood vessels. However, in the study by Mittal et al.
(2009), the increase in sensitivity of SWI did not come at the expense of a reduction of
inter-rater reliability. In contrast with our study, there was a significant effect of rater
experience in the sensitivity and reliability of SWI for CMB detection. This suggests that
appropriate training is paramount when using sophisticated sequences. Similar to manual
ratings using GRE T2*, the authors found that reliabilities were affected by the number of
CMBs, as larger numbers are more time consuming and represent a challenge to the rater.
Studies of populations with relatively large numbers of CMBs may have reduced rating
reliability, which may affect CMB prevalence in these studies. The increased sensitivity and
reliability of SWI in this study suggests that SWI might be better in these populations
(Cheng et al., 2013). Further research is needed to establish whether SWI should be the
best standard for CMB detection in research and clinical practice.
Further methods for detecting and measuring CMBs are in development. Similar to fully
automated evaluations for white/grey matter and white matter lesion volumes (de Boer et
al., 2009), automated methods for other measures such as CMBs are under investigation
(Seghier et al., 2011). Automated methods represent a new opportunity for quickly and
reliably mapping CMBs by detecting various properties of CMBs (e.g. signal characteristics,
size, shape) in order to distinguish them from other tissue types. They potentially have
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major benefits in terms of reliability and speed: they are quick, reliable, not operator
dependent, and aim to reduce processing time and increase consistency over manual rating
methods (Gregoire and Werring, 2011). They may allow the comparison of CMB anatomical
distribution between patients groups using group overlap or probabilistic maps in standard
stereotactic space, and also the automated quantification of CMB size and volume.
However, the drawbacks of these methods are the difficulty of distinguishing mimics – with
similar signal and morphological characteristics – from true CMBs, resulting in a relatively
high prevalence of false positives, and the need for some observer intervention and
research-quality rather than standard clinical scans.
Reports on automated methods have mainly used standard MR images (Seghier et al.,
2011) but post-processing techniques (SWI) were recently proposed (Barnes et al., 2011).
The technique with SWI relies on a statistical thresholding algorithm to identify
hypointensities (Barnes et al., 2011), but its sensitivity appears lower than that of the
standard manual review and consensus agreement. Therefore, for the moment we
recommend using visual rating scales as they offer a simple and practical solution to assess
the presence, number and distribution of brain CMBs on standard clinical-quality brain MR
images without the need for sophisticated post-processing methods.
Ultimately, the most appropriate type of rating scale used will depend upon the particular
clinical question(s) being addressed (for further reading, see Chapter 4, and Gregoire and
Werring, 2011). For example, some studies may need to consider CMBs in specific arterial
territories (e.g. investigations of arterial recanalisation interventions), whilst others may
require classification into the cerebral lobes (e.g. cognitive correlations), and some will
concentrate on deep versus lobar distributions of CMBs (e.g. diagnosis of CAA and other
small vessel arteriopathies). The use of standardised rating scales in CMB studies should
allow more informative cross-study comparisons, and if the rating method is fully
standardised then this may also help to identify other sources of variation in CMB
evaluation, including MRI acquisition strategies. Standardised rating instruments and CMB
definition criteria will be essential in determining the value of newer MRI acquisitions
techniques including SWI. It seems reasonable that CMB research studies wherever
possible should use a standardised rating system with central rating by a single observer.
These, and as many other study factors as possible, should be kept constant when
longitudinal CMB data are collected in prospective studies. In the coming years more
sophisticated automated or semi-quantitative methods for detecting CMBs are likely to
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emerge, but there will remain a need for simple, practical rating scales that can be applied
to routinely-collected clinical datasets.
What is the etiology of cerebral microbleeds?
To date, the exact etiology of CMBs remains unclear. Histopathological data of CMBs
remains scarce which limits our understanding of their potential causes. Most studies have
included the MRI analysis of living patients and a separate histopathological analysis of
post-mortem brains. Only a few studies have conducted an analysis of pre- and post-
mortem brains and the number of brains studied was small. Nevertheless, CMBs have
usually been attributed as resulting from an increased vascular fragility in patients with
various types of small vessel disease. Theoretically, CMBs may be caused by the steady
extravasation of erythrocytes through the damaged vessel walls of small brain arteries. An
increased vascular fragility of the vessel wall due to chronic lipofibrohyalinosis or CAA
causes their rupture. It is possible that these underlying microangiopathies lead to the
formation of the microaneurysms or pseudoaneurysmal lesions that were originally
described by Charcot and Bouchard. However, we do not yet know how these lesions relate
to CMBs and their clinical significance is remains to be verified.
There is insufficient data from the current literature to tell us whether CMBs are a primary
event, an ICH at a very small scale, or whether they represent a general marker of
increased small vessel fragility. In keeping with the ‘bleeding’ hypothesis, it is possible that
they develop from tiny areas of frank haemorrhage in a similar way to large spontaneous
haematomas. If this is the case, then the factors preventing further extension of the
bleeding to cause larger haematomas remain unknown. Certain circumstances (e.g. the use
of antithrombotics) may play a role and some facts come to support this hypothesis: (1)
incident symptomatic ICHs have been reported at the site of a previous CMB (Fan et al.,
2003; Huang et al., 2008); and (2) patients with CMBs have been found to have a similar
pattern of vasculopathy to those with ICH (Rosand et al., 2005; Ayaz et al., 2010). The
association of age-related cerebrovascular ischaemic disease and lobar CAA-related and
deep hypertensive haemorrhages suggests the occurrence of small haemorrhages in the
development of CMBs. However, some facts from CAA patients suggest that CMBs and ICH
represent distinct pathophysiological events: (1) the volumes of the haemorrhagic lesions
fall into two distinct peaks of CMBs and macrobleeds, rather than forming a single
continuous distribution; and (2) CMBs are associated with increased vessel thickness in
amyloid-laden vessels, which is not observed in areas with macrobleeds and fewer CMBs
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(Greenberg et al., 2009a). These findings suggest that particular properties of the diseased
vessel may predispose to the formation of CMBs rather than macrobleeds or vice versa,
and that lobar CMBs and lobar ICH represent independent vascular rupture events (Khan et
al., 2011).
Possible explanations of the mechanisms leading to the formation of CMBs come from the
close interplay between the ischaemic and haemorrhagic processes associated with the
underlying vasculopathies. There is a preliminary but important indication that CMBs
detected as a hypointense focus on T2*-GRE weighted imaging may pathologically
correspond to a more diverse spectrum of pathology, including microhaemorrhages and
microinfarcts (Janaway et al., 2013; Shoamanesh et al., 2013). After ICH some lesions
exhibiting restricted diffusion on DWI MRI have imaging characteristics that can be
attributed to either infarct or haemorrhage (Shoamanesh et al., 2013). We found a high
prevalence of DWI positive lesions in patients who recently sustained a CAA-related ICH,
suggesting the presence of active ischaemia (Gregoire et al., 2011). Further reports have
confirmed that incident microinfarcts and microhaemorrhages occur concurrently after ICH
(Menon et al., 2012; Shoamanesh et al., 2013). A sequence of events has been
hypothesised to explain this phenomenon in the setting of a diseased microvasculature,
one of which leads to the formation of CMBs. Firstly, the increasing intracranial BP results
in a rise in systemic BP that causes the rupture of remote fragile vessels and CMBs; then,
aggressive BP lowering causes a haemodynamic insufficiency which the diseased
microvasculature cannot compensate, resulting in the development of microischaemic
infarcts (Menon et al., 2012; Shoamanesh et al., 2013). These data suggest that after ICH,
and possibly IS, for reasons that are still unknown, the activity of the cerebral small vessel
diseases flares up, resulting in new microischaemic and microhaemorrhagic lesions. CMBs
are one of the manifestations of the close interplay between the active ischaemic and
haemorrhagic processes occurring in cerebral vasculopathies.
Recent data challenges the hypothesis that CMBs result from microbleeding from diseased
vessels. The hypothesis made by the group led by Paul Ince is that haemosiderin deposits in
the brain come from local iron sources that are released after ischaemia (Janaway et al.,
2013). The ischaemic processes caused by small vessel diseases causes a release of the iron
stores which exceeds the ability of the tissues, especially ageing tissues, to process it. In
elderly patients with small vessel disease, the excess of iron accumulates in perivascular
macrophages, which are seen in histopathological studies. CMBs may therefore be a
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marker of focal haemosiderin deposition secondary to parenchymal ischaemic damage,
rather than the result of microbleeding. In their histopathological study, most patients had
haemosiderin deposits, suggesting that standard MR techniques underestimate the
presence of CMBs. These findings will need to be confirmed in other studies.
Advances in the understanding of CAA have the promise to determine where CMBs fit in
the pathogenesis of the disease and elucidate the mechanisms leading to their formation.
New non-invasive techniques capable of detecting amyloid deposition in the brain in vivo,
e.g. Positron Emission Tomography (PET) imaging with amyloid Pittsburgh compound B
(PiB) have been developed (Johnson et al., 2007; Klunk et al., 2004; Mathis et al., 2003).
This agent has the ability to detect CAA before it causes symptomatic ICH or CMBs
(Charidimou et al., 2012b), which might provide useful insights into CMB formation. A
recent study using PET-PiB in clinically probable CAA found that CMBs correspond to areas
with a high concentration of amyloid, e.g. lobar (Dierksen et al., 2010), and PiB retention
declined with increasing distance from the CMBs (Johnson et al., 2007). PET-PiB also
provides useful insights in the pathogenesis of deep and lobar CMBs. In a recent study of
patients with AD and subcortical VCI, it was shown that subcortical small vessel disease and
amyloid-related pathologies (e.g. CAA) both contribute to their pathogenesis with a
synergistic effect (Park et al., 2013). Other recently introduced techniques, such as SWI, a
three-dimensional T2*-GRE technique, enables visualisation of CMBs with much increased
sensitivity, resulting in higher lesion counts (at least 67% more compared with conventional
T2*-GRE) with potential implications in the understanding of their pathogenesis (Nandigam
et al., 2009). Further recent developments in the field of high resolution MR imaging enable
the detection of small vessels in vivo, and should shed light into the mechanisms of CMBs,
but these techniques are yet to be integrated into clinical practice (Harb et al., 2013).
A full understanding of the pathogenesis of CMBs will require a large prospective cohort
study of patients with ischaemic and haemorrhagic small vessel diseases, compared with
age-matched controls, and combine longitudinal clinical and multimodal radiological data.
Pre-mortem and post-mortem brain examination correlated with post-mortem brain scans
will be needed to allow comparisons and correlation with vascular risk factors,
demographic and radiological characteristics using validated tools. The feasibility of such a
study is limited, which explains why numerous questions on the etiology of CMBs remain
incompletely answered.
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Temporal changes of cerebral microbleeds: are they static or dynamic?
From studies demonstrating the temporal changes of CMBs (Chen et al., 2006; Goos et al.,
2010; Greenberg et al., 1999; Orken et al., 2013; Poels et al., 2011), it seems clear that they
are a dynamically changing phenomenon rather than a static marker of small vessel disease.
CMBs present a rapid evolution within the first few days after an acute IS, suggesting a
widespread small pathological process associated with acute ischaemia. In addition, they
generally do not disappear over time (Poels et al., 2011), and our findings also support the
idea that CMBs are a dynamic process (Gregoire et al., 2010a). We demonstrated that one
in two patients with previous IS or TIA develops new CMBs in the following five years after
their stroke/TIA (Gregoire et al., 2010a). The main risk factor associated with new CMB
formation was a high baseline BP. The potential benefit of more aggressive BP lowering is
currently being tested in the PRESERVE trial. Further research is needed to determine the
temporal changes of CMBs over longer term periods and to understand the long-term
clinical implications of acute CMB development after acute ischaemia and ICH, with
potential implications for treatment. There is already good reason to treat hypertension
and other risk factors aggressively in small vessel disease but CMBs may strengthen the
case.
Are cerebral microbleeds useful diagnostic markers of brain small vessel
diseases?
There is no doubt from neuroimaging and neuropathological studies that CMBs are a
marker of CAA, hypertensive small vessel disease and other small vessel diseases.
Histopathological correlation has shown that CMBs occur in association with small vessel
diseases (Fazekas et al., 1999). In CAA, the sensitivity of the Boston criteria increased when
CMBs were included as haemorrhagic lesions (Charidimou et al., 2012b), and an increasing
body of evidence suggests that the spatial distribution of CMBs may allow the differential
diagnosis of the underlying bleeding-prone arteriopathy. We have indirect (but not proven)
evidence that CMBs in an exclusively deep distribution result from hypertensive
arteriopathy, whilst those at the cortico-subcortical boundaries of the cerebral lobes are
related to CAA (Poels et al., 2010). Lines of evidence supporting this hypothesis come from:
(1) the study of the genetic polymorphisms associated with CMBs suggesting that strictly
lobar CMBs are an imaging biomarker of CAA (Maxwell et al., 2011); (2) neuroimaging
studies in clinically probable CAA using PiB-PET showing that CMBs correspond to areas
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with a high concentration of amyloid (Dierksen et al., 2010); and (3) neuroimaging studies
of CMBs in patients with ICH, where patients with hypertensive ICH are more likely to have
deep CMBs, whereas patients with lobar ICH tend to have strictly lobar CMBs (Lee et al.,
2004c; Roob et al., 2000; Smith et al., 2010). However, this dichotomic distinction between
deep and lobar CMBs has limitations, as hypertensive arteriopathy (lipofibrohyalinosis) has
been shown to affect superficial perforating vessels arising from pial arteries (Werring,
2011), whereas conversely, amyloid deposits have been detected in deep regions in AD
(Ogomori et al., 1989).
If their spatial distribution can be mapped, CMBs may be more specific for the underlying
pathology than some other imaging manifestations of small vessel diseases (e.g. WML).
More sensitive imaging techniques using ‘high-end’ sequences (e.g. higher field strength,
higher resolution, or use of advanced post-processing) compared with conventional T2*-
weighted imaging, may contribute to more accurately identifying persons with underlying
small-vessel pathology, with potential relevance for subsequent management (Poels et al.,
2012b). Studies using PET-PiB may provide new data concerning the associations between
deep and lobar CMBs and the underlying small vessel processes. A recent study using PET-
PiB and MRI in patients with cognitive impairment showed that WML and lacunes
contribute to both deep and lobar CMBs, whereas amyloid deposition was associated with
the likelihood of having lobar (but not deep) CMBs (Park et al., 2013). Thus, CMBs may have
the promise to detect and quantify the effects of small vessel disease and amyloid
deposition.
Are cerebral microbleeds a prognostic marker of increased future stroke risk?
There is increasing evidence that CMB formation contributes to new clinical events and a
higher stroke risk in stroke patients:
(1) Their contribution to transient neurological disturbance has been mostly studied in
cross-sectional studies (Greenberg et al., 1993; Roch et al., 2005) and in a meta-analysis
(Charidimou et al., 2012a). We described two cases of neurological dysfunction in patients
with acute symptomatic CMBs, but these are not reported in this thesis because of space
limitations (James et al., 2011)
(2) A recent meta-analysis suggested that CMBs increase the risk of any recurrent stroke,
especially ICH (O.R 8.52, 95%CI 4.23-17.18) and to a lesser extent IS (OR 1.55, 95%CI 1.12-
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2.13) (Charidimou et al., 2013a). This recent meta-analysis confirms the hypothesis of an
increased stroke risk associated with CMBs that was previously suggested in small
longitudinal and prospective studies. This risk varies among ethnic groups, with a greater
risk of ICH among Asian populations, and a greater risk of recurrent IS in Western
populations (Charidimou et al., 2013a). CMB distribution may also influence stroke risk, as
lobar CMBs are a stronger risk factor for ICH than deep CMBs. More data are required to
assess the effect of CMB distribution on stroke risk.
Large prospective data for patients with CMBs compared to CMB-free controls and testing
their prognostic relevance for the risk of new clinical events (including transient
neurological events, subsequent TIA, IS and ICH), cognitive decline and mortality, are
required to confirm these findings. We need to understand the influence of CMB burden
and distribution, and crucially whether CMBs affect the future balance of risk between ICH
and IS. Large meta-analyses will be essential to elucidating these aspects.
Do cerebral microbleeds contribute to cognitive impairment?
Cross-sectional and small longitudinal studies suggest that CMBs impact on executive
cognitive functions in stroke patients (Gregoire et al., 2013; Werring et al., 2004). We found
a strong independent association between CMBs and executive impairment in stroke
patients that persist over time (Gregoire et al., 2012) and that is largely driven by CMBs in a
strictly lobar distribution (Gregoire et al., 2013) (see Chapter 7). These findings are
consistent with the results of other studies showing a direct contribution of CAA-related
CMBs to cognitive impairment (Ayaz et al., 2010; Viswanathan et al., 2010). Although these
results need to be confirmed in larger longitudinal and prospective studies, they suggest an
independent role for CMB-associated vasculopathy in cognitive impairment.
The mechanism(s) by which CMBs might influence cognitive function remain speculative.
They may reflect focal damage of brain tissue and may interfere with cognitive processes
when located in strategic areas. A more likely explanation is that they are a more general
marker for the severity of small vessel disease, and as such may influence cognition
(Werring et al., 2010). This last hypothesis is of significant interest as it may help to unravel
the potential key link between vascular and neurodegenerative pathologies (Cordonnier
and van der Flier, 2011). Vascular damage induced by Aβ has been suggested to be a key 
step in the pathogenesis of AD (Ferrarese and Piazza, 2012). In patients with cognitive
impairment due to subcortical small vessel disease or CAA, small vessel disease and
Discussion and Conclusions
265
amyloid burden interactively affect cognitive functions (Park et al., 2013). Such an
interaction between vascular disease and amyloid was demonstrated experimentally and
suggests a magnifying effect of amyloid on ischaemia (Hachinski, 2011; Whitehead et al.,
2007). In clinical trials of immune therapies directed against Aβ for the treatment of AD 
(Piazza et al., 2013; Sperling et al., 2012), some patients developed complications resulting
from the anti-amyloid drugs characterised by amyloid-related imaging abnormalities (ARIA)
on MRI. These MRI abnormalities were similar to those of CAA-related inflammation (CAA-
ri) and seem to be immune-mediated (Piazza et al., 2013). Further trials of Aβ 
immunotherapy correlating anti-Aβ dosage to MRI data (and identification of amyloid in
vivo using PET- PiB) will help to better understand the pathogenic mechanisms linking CAA
and AD, and the role that CMBs play in the development of cognitive impairment in these
patients.
Are antiplatelets and anticoagulants safe in patients with cerebral microbleeds?
The limited prospective data are consistent with the hypothesis that CMBs increase the risk
of ICH as a complication of antithrombotic use. On the other hand, CMBs are also
associated with recurrent IS, creating a clinical dilemma concerning the use of
antithrombotic drugs in patients with CMBs. In certain population groups (e.g. patients
with a high vascular risk and numerous lobar CMBs, and patients diagnosed with CAA), the
risk/benefit ratio of antithrombotic drugs may shift towards an increased risk of ICH. We
found an independent association between CMBs and ICH in patients on anti-platelet
treatment in a small case-control study (see Chapter 5). We observed a predominance of
lobar ICH and lobar CMBs in the antiplatelet and non-antiplatelet users, suggesting a
possible overrepresentation of patients with CAA compared with other studies.
Nevertheless, clinicians should cautiously weigh the risks and benefits of antiplatelet
treatment in individuals diagnosed with CAA, especially since recurrent ICH with aspirin use
in CAA appears to be moderated by CMB burden. Further studies evaluating the relative
effects of CMB burden on future ICH and IS risk are warranted to determine whether a
certain CMB load might tip the risk-benefit balance in favour of avoiding antithrombotic
treatment (Charidimou et al., 2013a). Although data continues to accumulate, no definite
answer has yet emerged.
Several key questions regarding the use of antithrombotic drugs in patients with CMBs
remain unanswered, including the underlying pathophysiology mechanisms for the
associations between antithrombotic agents with CMBs, the possible cause-effect link
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between antithrombotic agents and CMBs, the relationship between dosage and duration
and the prevalence and lesion load of CMBs, the risks specific to different ethnic groups,
and whether the risk is related to a specific distribution of CMBs. CAA, characterised by the
presence of strictly lobar CMBs, is increasingly recognised as a cause of anticoagulant-
related ICH (Greenberg et al., 2009b). Therefore, we need more data on CMB distribution
in studies evaluating the impact of antithrombotic agents in ICH.
With regard to anticoagulant use, there are no large prospective studies of CMBs in IS
cohorts treated with anticoagulants for AF. We only have indirect evidence of an
association between lobar CMBs, reflecting CAA and the risk of anticoagulant-related ICH
(Charidimou et al., 2012b; Rosand et al., 2000). Future studies will need to prospectively
follow patients anticoagulated after IS associated with AF and we look forward to the
results of the CROMIS-2 trial.
9.1.4 Implications for future clinical trials
In the coming years more prospective data from large clinical trials will contribute to
answering the remaining questions on CMBs. The majority of current knowledge is based
on data that was cross-sectionally acquired, precluding the understanding of cause and
effect relationships between CMBs and clinical events. Large cohorts will be needed to
study the genetic contribution to the development of CMBs and ICH in stroke patients. In
the analysis of their observations, researchers will need to prioritise the use of continuous
over dichotomous outcomes, as continuous data provides more sensitive and powerful
analyses. Studies will also need to ensure that raters are blinded to all clinical data. In
studies evaluating the impact of CMBs on cognitive functions, repeated cognitive screening
is required and analyses will need to take into account possible learning effects. With
regard to the critical question of the safety of antithrombotic drugs in patients with CMBs,
valid prospective data is required to determine the causes, incidence and risk factors of
CMBs and ICH in bleeding-prone populations (e.g. with numerous lobar CMBs and in the
presence of previous ICH). Stratification of populations and CMB carriers according to
ethnicity, specific agent and duration of therapy will inform the safety of use of
antithrombotic agents, and risk-benefit analyses will allow physicians to make informed
decisions. These studies will need to ensure that risk factors (e.g. BP) are adequately
controlled for as this may influence outcomes. Long follow-up times in prospective studies
will be needed to reliably investigate the relationship between CMBs and clinical outcomes.
The standardised use of imaging methods and rating scales will facilitate the pooling of
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data from different centres and studies, allowing an optimised study of their clinical effects
in large cohorts. This will be especially important in studying the risk of anti-thrombotic
related ICH associated with CMBs, as the number of clinical events remains small and the
population size required to study such events is large. Because of the strong association
between CMBs and other markers of cerebrovascular disease, bias should be minimised by
adjusting for all potential confounders that may influence the associations tested. In
particular, the possible association between CMBs and antithrombotic drugs is potentially
confounded by the indications for which the drugs are prescribed: antithrombotics are
more likely to be prescribed to patients at higher risk of developing CMBs; and there is a
strong relationship between CMBs and cerebrovascular diseases which is independent of
the use of antithrombotic agents. Therefore, future studies addressing the question of the
safety of antithrombotic agents in patients with CMBs will require a strict matching process
in homogeneous populations.
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9.2 Main conclusions
The discovery of CMBs over the past decade has revealed that presymptomatic small vessel
pathology due to chronically increased BP or CAA is a factor associated with an increased
risk of future symptomatic cerebrovascular disease, including larger haematomas, IS and
cognitive impairment. Nowadays, following substantial advances in imaging techniques,
areas of signal abnormalities in the brain, including silent WML and CMBs, have allowed the
evidence of the underlying small vessel changes that were previously only visible at autopsy
to be highlighted (see Chapters 1 and 2). As a surrogate marker of the underlying bleeding-
prone microangiopathies, these abnormalities have generated significant clinical interest as
potential predictors of future neurological decline and vascular risk (see Chapter 3).
Because these microangiopathies are associated with an increased ICH risk, CMBs have
generated increasing interest as potential predictors of ICH, especially related to the use of
antithrombotics. CMBs may have potential in helping to assess the risk-benefit ratio of
administering antithrombotic drugs following a stroke. A growing literature, including our
work, shows that they have numerous other clinical implications including a role in
recurrent IS, cognitive decline, disability and death.
CMBs are a marker of vascular vulnerability secondary to age-related microvessel changes,
including lipohyalinosis and CAA. Questions remain on the mechanisms leading to their
formation which should be answerable through studies using the emerging detection
techniques (e.g. PET-PiB, SWI), ideally correlated with results from definite pathology.
These new techniques will shed light on the pathogenesis of the underlying
microangiopathies. Ultimately, the early detection of small vessel diseases may allow more
effective interventions to reduce the burden of stroke, cognitive impairment and other
major challenges facing our ageing societies.
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